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ABSTRACT 
 
Streptococcus pneumoniae (pneumococcus) is among the commensal bacteria species that 
asymptomatically colonise the human nasopharynx. However, this species may occasionally 
invade the host’s sterile sites (lungs, blood, middle of the ear and cerebral spinal fluid) and 
cause severe life-threatening disease, such as pneumonia, meningitis, acute otitis media and 
bacteraemia (bloodstream infection).  Invasive pneumococcal disease (IPD) is especially 
common among children under the age of five, the elderly (>65 years) and among individuals 
with compromised immunity, such as asplenia and among individuals with 
immunosuppressive illness, particularly those infected with HIV. 
 
Each year, IPD accounts for one fifth of these deaths and more than 150 million episodes of 
pneumococcal pneumonia in children under five years, most of which occur in sub-Saharan 
Africa (SSA). 
 
Although the population genetics and evolutionary biology of pneumococci is well 
understood, it still remains unclear why some pneumococci strains are associated with 
meningitis more than others, and whether there are virulence factors that are associated with 
the tendency to cause meningitis. This thesis explores the differences in genetic diversity 
among meningitis and bacteraemia associated (blood sepsis) pneumococci to establish 
whether such differences exist among invasive pneumococcal isolates collected from 
Malawian patients. It also examines the differences in likelihood and direction of genetic flux 
(gene acquisition or loss), which mainly occurs by recombination, among meningitis-
associated and bacteraemia-associated pneumococcal isolates. Furthermore, the prevalence of 
the pneumococcal pilus, which greatly enhances initial pneumococcal adhesion at the 
 V 
nasopharynx, thereby providing a colonisation advantage; and has been identified as a highly 
immunogenic potential vaccine candidate was examined for the period prior to the 13-valent 
pneumococcal conjugate vaccine (PCV13) introduction into the childhood immunisation 
programme of Malawi, in order assess the impact of PCV13 introduction on pilus prevalence. 
 
Various innovative, robust and high-throughput bioinformatics techniques, some of which 
were newly developed, were used to interrogate the genome sequences of these invasive 
pneumococcal disease isolates. 
 
Here, by comparing the differences in the composition of genomic antigen diversity among 
isolates associated with bacteraemia and meningitis, I provide some evidence from human 
disease that meningitis causing pneumococci have a distinct “core genome”, which encodes 
for both known and previously undescribed proteins that are likely to be essential for 
meningeal invasion and survival. Furthermore, I present evidence suggesting that meningitis-
associated pneumococci undergo less genetic flux and have a more conserved genome than 
those associated with bacteraemia. I also show for the first time in SSA that there is a low 
prevalence of invasive piliated pneumococci (16.43%), and that these piliated pneumococci 
are all covered by the PCV13. Interestingly, it was noted that most of the piliated 
pneumococci were resistant to cotrimoxazole. However, this antibiotic resistance can also be 
attributed to the widespread use of sulphadoxine pyrimethamine (Fansidar TM), an 
antimalarial drug that also has the same targets as cotrimoxazole (that is the dihydrofolate 
reductase and dihydropteroate synthase genes) that has resulted in drug resistance conferring 
mutations in Plasmodium falciparum, and more conclusive studies that include carriage 
isolate datasets are required. 
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CHAPTER 1 
 
Introduction 
 
1.1: Pneumococcal disease 
 
The human nasopharynx is colonised by multiple commensal bacterial species that include 
Streptococcus pneumoniae, Staphylococcus species, Haemophilus influenzae, Moraxella 
catarrhalis and Neisseria meningitidis [1]. These species may invade the host’s sterile sites 
and cause severe life-threatening disease. The confined environment of the nasopharynx 
allows close interactions among bacterial strains within and between species. S. pneumoniae 
(the pneumococcus) is the causative bacterial pathogen associated with life-threatening 
disease, such as pneumonia, meningitis, acute otitis media and bacteraemia (bloodstream 
infection) [2, 3]. Pneumococcal disease is preceded by asymptomatic colonisation of the 
human nasopharynx, which is highest among young children [4, 5].  Pneumococcal disease 
occurs rarely, when commensal pneumococci invade normally sterile sites of the body (lungs, 
blood, middle of the ear and cerebral spinal fluid) (Figure 1.1) [6].  
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Figure 1.1: Pathogenic routes of pneumococcal infection. The different host tissue sites 
are infected through the airborne and haematogenous routes. This may result in different 
disease outcomes (highlighted in boxes). The main route for pneumococcal meningitis 
infections is also highlighted using bold arrows (reproduced from Bogaert et al. [5]). 
 
It is estimated that 1 child in 8 under the age of five years dies annually in sub-Saharan 
Africa (SSA), and this childhood mortality rate is almost 20 times higher than that in 
developed nations (1 in 143) [7, 8]. Pneumonia accounts for one fifth of these deaths. There 
are more than 150 million episodes of pneumococcal pneumonia annually in children under 
five years, with the majority of deaths occurring in developing and least developed countries 
(Figure 1.2) [9-12]. It has therefore been referred to as the serious “forgotten child killer” by 
the United Nations Children's Fund (UNICEF) and the World Health Organisation (WHO) 
[10, 11]. 
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Figure 1.2: Global distribution of pneumococcal deaths in children under the age of 5 
years. This is a distribution per 100,000 children of HIV-negative IPD deaths only 
(reproduced from O’Brien et al. [13]). 
 
The populations most at risk of IPD are children under the age of 5 years, the elderly (> 65 
years) and those with compromised immunity, such as asplenia and among individuals with 
immunosuppressive illness, particularly those infected with HIV. Pneumococci are classified 
into more than 92 distinct serotypes based on the immunohistochemistry of their 
polysaccharide capsules, with several serotypes just recently identified [14-16]. The 
prevalence of carriage serotypes is much higher compared to those associated with invasive 
disease, consequently pneumococcal carriage is more common [17]. Although all 
pneumococci are capable of causing invasive disease, only a small proportion of 
pneumococcal serotypes are most frequently associated with the majority of severe invasive 
disease, and these serotypes are rarely carried at the nasopharynx [17-19]. The burden of 
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pneumococcal disease is significantly higher in developing and least developed countries (up 
to 99.9% of the global pneumococcal disease burden), compared to developed countries, with 
the majority occurring in sub-Saharan Africa and South Asia [11, 13, 20]. 
 
1.2: Bacteriology  
 
1.2.1: The bacterium  
 
The pneumococcus was first isolated from rabbits independently by George Sternberg and 
Louis Pasteur in 1880, and both scientists were able to grow the bacteria in vitro and 
described its morphology similarly [21]. All antigens were widely regarded to be proteins in 
nature, but in 1917 Oswald Avery and colleagues identified polysaccharides and substances 
composing the pneumococcal capsules as virulence determinants [21]. In 1928 Fred Griffith, 
demonstrated that hereditary molecules are composed of DNA in experiments using type 2 
pneumococci. Griffith’s experiment entailed injecting mice with live noncapsulated type 2 
pneumococci together with heat killed capsulated type 2 pneumococci. He observed that the 
noncapsulated pneumococci become virulent and were capsulated [21]. However he failed to 
draw conclusions on the interesting discovery of genetic transformation, which was 
highlighted in 1944 by Avery, MacLeod and McCarthy [22]. S. pneumoniae is a Gram-
positive, lancet-shaped coccus. It is bile soluble, α-haemolytic when cultured on blood agar, 
and usually occurs in pairs (so-called diplococci), which may form chains (Figure 1.4). They 
grow optimally when cultured in 5% CO2 at 37oC and have a doubling time of 20 - 30 
minutes. They typically have a polysaccharide capsule but may be uncapsulated [23]. Pilus, a 
cell surface organelle that extends beyond the polysaccharide capsule, has been reported to be 
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present in up to 30% of pneumococci [24-26]. Two types of pneumococcal pili have been 
identified (type I and II), each assembled from distinct subunits [24, 27]. 
 
1.2.2: Diagnosis and laboratory typing schemes 
 
Pneumococcal disease may be presumed on clinical (e.g. features of a lobar pneumonia or 
typical CSF findings particularly in the context of an otitis media) or radiological grounds 
(for which there are standardised WHO criteria [28]) but requires laboratory investigation for 
confirmation. Otitis media may be confirmed by middle ear aspiration and culture; 
pneumonia may be confirmed by lung or pleural fluid aspirate, and/or blood culture; 
bacteraemia may be confirmed by blood culture or pneumococcal DNA using polymerase 
chain reaction (PCR) [29]; and meningitis may be confirmed by CSF gram stain, culture or 
pneumococcal PCR, or blood culture in the context of typical CSF findings. Sputum culture 
is poorly predicative of pneumococcal pneumonia but pneumococcal DNA quantification of 
nasopharyngeal samples by PCR is currently attracting considerable attention, particularly as 
a research tool [29-32]. Pneumococci retrieved from blood, CSF and other sterile fluids are 
grown on selective media, blood agar with gentamycin (an antibiotic that allows only 
pneumococci to grow), at 37oC and 5% CO2 overnight. Their identity is further confirmed by 
optochin sensitivity. Pneumococci are soluble in bile; a feature that distinguishes them from 
genetically closely related competitive nasopharyngeal commensal Streptococcus viridans.  
 
Latex agglutination is used to characterise pneumococci into serogroups, and it entails 
binding of bacteria with polyclonal antibodies, which are initially bound to latex. The 
presence of pneumococci is indicated by formation of agglutinations. A more accurate 
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serological technique is the Quellung reaction that is considered the “gold standard” [33]. It is 
based on the binding of the polysaccharide capsule to a homologous monoclonal antibody. It 
entails further characterisation to the serotype level using monoclonal antibodies after latex 
agglutination.  More recently, multiplex PCR reactions have been used for pneumococcal 
serotyping [34]. E-tests are used to determine antibiotic minimum inhibitory concentrations 
(MICs), and consequently resistance profiles of the bacterial isolates. Multi-locus sequence 
typing (MLST) is used to classify pneumococci in to evolutionarily related clones referred to 
as sequence types (STs) [35, 36]. MLST has contributed greatly in molecular epidemiology 
and provided a better understanding of bacterial diversity and evolution [37-42]. 
 
1.3: Epidemiology of pneumococcal disease 
 
1.3.1: Geographic distribution of pneumococcal disease 
 
The distribution of pneumococcal serotypes associated with invasive disease varies both by 
age of individuals and geographically [18, 19]. Understanding the geographic distribution of 
pneumococcal disease is critical for the development of optimal vaccine formulations with 
increased coverage. Currently, the widely implemented, licensed 7-valent polysaccharide 
conjugate vaccine (PCV7) has a reported coverage of approximately 40% in Asia and 60% in 
Africa and Latin America compared to above 80% in North America and Oceania [18, 43]. 
The vaccine has greatly reduced the burden of pneumococcal infections in developed 
countries [44, 45]. The overwhelming disease burden remains in developing countries where 
the pneumococcal conjugate vaccines have just begun to be introduced into routine childhood 
vaccination schedules. Although geographic IPD burden has been estimated, the burden 
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evaluations still underestimate IPD cases and are unlikely to be representative of all 
pneumococcal diseases. This is especially true in SSA, where not all patients present to 
hospitals and not all cases are fully investigated.  
 
The efficacy of the PCV7 is evidenced by a great decline in overall pneumococcal infections 
after vaccine introduction in the USA [44-46]. Efforts have been made to reproduce this 
effect in other populations, especially those with a high disease burden. This is supported by 
the successful introduction of the Haemophilus influenzae type B (Hib) vaccine, which 
greatly reduced the number of pneumonia infections attributed to Haemophilus influenzae 
[47, 48].  However, there are high cases pneumococcal disease in SSA, and a different 
distribution of invasive disease serotypes compared to those in Europe and North America 
[18, 49]. Thus, the pneumococcal conjugate vaccine formulations being introduced in Africa 
are different from the one introduced in the USA and Europe (PCV7). These formulations are 
capable of protecting against additional invasive serotypes that are most prevalent in the host 
populations. An example is serotype 1, which is a predominant cause of IPD in Africa [18, 
50, 51]. The 13-valent pneumococcal conjugate vaccine (PCV13) is currently being 
introduced across Malawi, a SSA country, since November 2011 and is anticipated to provide 
better coverage (88%) for invasive serotypes [50]. Developing countries, where the vaccine 
has just begun to be introduced, have also been urged to conduct suitable pneumococcal 
disease surveillance to establish baseline levels of disease and to monitor the effects of 
vaccination [52].  
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1.3.2: The burden of pneumococcal disease in Africa 
 
Each year, an estimated 14.5 million episodes of severe IPD is caused by S. pneumoniae 
globally [13, 53]. Almost a million deaths occur in children under five years, a tenth of whom 
are HIV positive, and more than 61% of the majority of deaths in HIV negative children 
occurred in ten African and Asian countries (Figure 1.3) [13].  
 
 
 
Figure 1.3: The estimated incidence and mortality rate in children under the age of 5 
years in Africa. (A). Shows the estimated incidence of childhood pneumonia per child per 
year in Africa for the year 2004. (B). Shows the estimated pneumococcal deaths per 100,000 
HIV negative children under the age of 5 years. There is high morbidity and mortality due to 
pneumococcal disease in children under the age of 5 years in Africa (reproduced from 
UNICEF/WHO [10] and O’Brien et al. [13], respectively). 
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Approximately 50% of children under the age of 9 years have been reported to be 
asymptomatic carriers of pneumococcus in East Africa [4]. In West Africa about half of the 
cases of pneumococcal disease in children have been reported to occur in the first year of life, 
with 20% before the age of 6 months [54, 55]. Still, clinical surveillance in developing 
countries, greatly underestimates the cases of pneumococcal disease. A large number of 
deaths are due to poor diagnosis and are often not fully investigated because most health 
centres lack the capacity to perform microbiology assays, resulting in very limited data on 
invasive disease. Incidence may also be underestimated due to the poor sensitivity of 
diagnostic tests, such as blood cultures; improper handling and transportation of samples; and 
use of unsuitable media [56]. The use of antibiotics also greatly compromises the sensitivity 
of blood cultures [12, 56, 57]. There is limited access to care given that most health 
institutions are remotely located, and not all patient present to hospitals [12, 13, 58]. This is 
especially true in rural areas where most infant deaths occur outside the hospital [12].  
 
1.3.2.1 Pneumococcal Disease in Malawi 
 
Malawi, a poor developing country in southern Africa (Figure 1.4), has a high disease burden 
manifested by a high mortality rate and an average life expectancy of 52 years [59]. Malawi 
has a population of 15.4 million, and HIV seroprevalence is estimated at 12.7% among the 
population aged 15 - 49 years [59, 60].  
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Figure 1.4: Location of Malawi on the African continent. The location of Malawi on the 
African map and the location of Blantyre in Malawi, where pneumococcal isolates used in 
this study were collected.  
 
S. pneumoniae is the most common cause of bacterial meningitis and substantially 
contributes to bacteraemia among adults and children [61, 62]. In Malawi, bacterial 
infections, and specifically pneumococcal pneumonia and meningitis, are high especially 
among HIV infected individuals [62-64]. These bacterial infections also exhibit seasonality 
with high prevalence in the cold and dry seasons followed by a reduction in the rainy season 
[63]. Treatment and prevention of pneumococcal infection in the developing world, which 
has the majority of cases, is paramount, particularly with the high burden of 
immunocomprising conditions such as malnutrition, malaria and HIV [60, 65]. Limited 
health care resources and access to suitable treatment, late presentation for treatment and 
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increasing antimicrobial resistance have further complicated the situation resulting in high 
case fatality regardless of HIV status [66]. However, the introduction of the PCV13 vaccine 
into the childhood immunisation schedule has begun in Malawi. PCV13 is anticipated to 
provide a coverage of 88% in children, based on serogrouping data from invasive isolates 
[50]. 
 
1.3.3: Invasive pneumococcal disease (IPD) and human immunodeficiency virus (HIV) 
 
HIV infected individuals are at a higher risk of acquiring respiratory disease [66]. HIV 
infection with or without progression to AIDS significantly increases the risk of IPD [67]. 
Individuals with HIV are 30 to 100 times more at risk to IPD compared to age-matched HIV 
negative counterparts; with rates increasing with decrease in CD4 T cell count [6, 64, 66, 68, 
69]. There is a higher IPD incidence among HIV infected intravenous drug users and smokers 
compared to HIV uninfected current or former intravenous drug users [6, 68]. HIV disease is 
characterised by a continuous loss in the numbers and function of CD4 T cells, as well as 
functional defects in other immune cells, including B cells, macrophages, dendritic cells and 
natural killer cells [70]. Bacterial diseases due to S. pneumoniae, Mycobacterium tuberculosis 
and non-typhoid salmonellae (NTS) are among the major pathogens associated with serious 
complications of HIV infection and are responsible for high morbidity and mortality rates 
associated with HIV infection in SSA [66, 71]. The high prevalence of NTS and S. 
pneumoniae bacteremic illness in advanced HIV positive patients is well established in HIV 
endemic regions of Africa [71-73]. HIV infected individuals are 30 to 100 times more likely 
to develop IPD, and this is especially true in Africa, where 67% of the global HIV infected 
individuals reside [60, 64]. Disease manifestations due to these bacterial infections occur 
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early in the course of HIV infection. The incidence of IPD increases proportionately with 
immune-suppression in HIV infected individuals. Close exposure to children is also a risk 
factor for IPD in HIV infected adults, who commonly have serogroups that are most common 
in children compared to HIV uninfected adults [74]. Recurrent IPD is particularly common in 
HIV infected individuals, with additional reinfection episodes of up to 25% in patients within 
the following year [68]. Nasopharyngeal and/or oropharyngeal colonisation with 
pneumococci is a prerequisite for IPD, but it is still unclear if HIV increases the risk of this 
colonisation at these mucosal surfaces [75-78]. However, in healthy HIV infected adults there 
is no association between HIV infection and increased bacterial colonisation of the normally 
sterile distal airways (trachea and bronchi) by an excess of nasal flora, predisposing them to 
elevated bacterial pneumonia [79].  
 
Highly active antiretroviral therapy (HAART) has led to a dramatic reduction in the 
incidence of IPD and prolonged the time to the first IPD incident in HIV infected individuals 
compared to the period before HAART or in the absence of HAART [68, 69]. However, 
individuals with lower CD4 T-cell count are still at a higher risk of developing IPD [68, 69]. 
HAART has been a major success in suppressing IPD and other bacterial infections, 
however, it has limitations that include: cost, lifelong adherence, unknown side effects of 
continuous drug use in the long-term and it does not seem to improve immune response to 
vaccination against pneumococcal disease, especially among children [74].  
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1.4: Pneumococcal disease interventions 
 
Interventions that inhibit specific invasive bacterial strain growth and colonisation may 
disturb the niche co-colonisation balance, thereby allowing increased niche occupation by 
previously outcompeted but highly virulent strains [80]. Interventions that target a particular 
bacterial species may also elicit non-specific or cross-reactive immune responses, resulting in 
inhibition of other non-targeted bacteria [1]. Other interventions, such as antibiotics, may 
result in alteration of bacterial defence mechanisms resulting in more tolerant bacterial strains 
[81, 82]. Careful considerations must be made when administering certain interventions to 
ensure they are highly effective but do not result in drastic detrimental alterations in 
microbial population structures.   
 
1.4.1: Antibiotics  
 
Antibiotics have long been in use for the treatment against pneumococcal infection. An 
example is penicillin, which has had a remarkable impact on bacterial chemotherapy, and is 
still used to treat bacteremic and non-bacteremic pneumococcal pneumonia, reducing the 
overall case fatality [21]. However, increased penicillin use was accompanied by a 
concomitant increase in the recovery of fully adapted, penicillin resistant pneumococcal 
mutants from patient’s blood and CSF [83, 84]. Resistance is due to mutations in the genes 
that encode the penicillin binding proteins (PBPs) [85-87]. Horizontal transfer of these 
altered PBPs led to spread of penicillin resistance among closely related species. An example 
is penicillin resistance in viridans group streptococcus (e.g., S. sanguis and S. oralis), which 
is thought to have arisen from horizontal transfer of altered PBP from penicillin resistant 
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pneumococci [86]. Similar bacterial drug resistance mechanisms have been observed for 
other antibiotics used for IPD case management [88, 89]. There has been a marked increase 
in the prevalence of pneumococci with decreased multi-drug (penicillin, erythromycin, 
tetracycline, chloramphenicol, ceftriaxone, clindamycin and cotrimoxazole) susceptibility 
worldwide [84, 90-93]. Acquisition of drug resistance provides a selective advantage among 
pneumococci making antibiotic prophylaxis difficult, highlighting the need for new antibiotic 
agents.   
 
 In SSA, cotrimoxazole prophylaxis has been shown to significantly decrease the proportion 
of bacterial pneumonia [68]. However, there are serious concerns over increased use of 
cotrimoxazole on antimicrobial resistance patterns on all bacterial populations and the 
unexpected negative repercussions on public health [66, 93]. An example is Malawi, where 
one third of patient pneumococcal isolates are multi-drug resistant and 92% of these isolates 
are resistant to cotrimoxazole [93]. 
 
The global spread of multi-drug resistant strains necessitates the urgent development of novel 
intervention strategies against highly invasive, multi-drug resistant pneumococci. Functional 
characterisation of pneumococcal genes is required to understand the process of resistance 
acquisition, which greatly challenges the ability to treat infection. In regions with high 
disease burden, such as SSA, antibiotic prophylaxis against bacterial infections although 
effective, has huge limitations that include: the high cost of drugs, poor drug delivery and 
high risk wide spread antimicrobial resistance due to high antimicrobial resistance at baseline 
levels [61]. Consequently more efforts are being directed towards disease prevention 
interventions. 
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1.4.2: Vaccines 
 
Vaccines are an effective intervention strategy used for prevention of the first episode of 
disease and disease recurrence, and when efficacious significantly reduce disease incidence 
and severity.  The first pneumococcal vaccine trial was conducted among South African 
miners in 1911 using heat-killed pneumococci [91]. Subsequently, capsular antigens were 
used as vaccines based on the finding that the capsular polysaccharide could induce immune 
responses in humans [21]. 
 
Currently, two classes of pneumococcal vaccines are licensed; the 23-valent polysaccharide 
pneumococcal vaccine (PPV) and the pneumococcal conjugate vaccine (PCV). The 23-valent 
polysaccharide pneumococcal vaccine (PPV), which is based on the polysaccharide capsule 
of 23 serotypes most commonly associated with disease in the USA [94]. In developed 
countries, where there is access to antiretrovirals, PPV has been shown to be efficacious in 
case control studies of HIV infected adults and particularly those with higher CD4 T cell 
counts. In patients with less than 200 CD4 T cell counts antimicrobial prophylaxis is more 
effective in the reduction of pneumonia [68]. Although PPV elicits capsule specific 
antibodies in HIV infected individuals, albeit of much lower magnitude compared to that in 
immunocompetent individuals. Post-vaccination antibody levels do not show marked 
differences when compared by CD4 T cell counts. However, in patients with higher counts 
(>500/µl), immunisation soon after seroconversion may elicit more robust immune responses 
[68]. A randomized, double-blind placebo-controlled vaccine trial among HIV infected adults 
in Uganda without access to antiretrovirals showed an increase in pneumonia among 
vaccinees, however, a six year follow-up showed reduction in mortality among the 
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vaccinated group [66, 68, 74, 95]. In general, PPV does not protect against either pneumonia 
or IPD in HIV infected adults in SSA. Moreover, PPV fails to induce an immune response, 
and to reduce pneumococcal carriage and transmission among children under the age of 2 
years and the elderly (65 years and older), who constitute a sizeable proportion the 
populations most at risk of IPD [6]. 
 
More recently, pneumococcal conjugate vaccines (PCVs) have been developed. Initially a 7-
valent conjugate pneumococcal vaccine (PCV7) was tested and then introduced that is based 
on 7 serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) that are commonly associated with disease 
in North America conjugated to protein vaccine carriers [96]. The protein vaccine carrier 
CRM197, a non-toxic mutant of diphtheria toxin, was incorporated in the PCV7 due to its 
ability to elicit a T-cell mediated immune response, which is present in humans from birth [3, 
97]. PCVs have been shown to be capable of inducing antibody levels that are detectable at 
the nasopharyngeal mucosa, thereby diminishing nasopharyngeal pneumococcal carriage and 
transmission, providing herd immunity among unvaccinated children and adults [3, 44, 45]. 
The 9-valent, 10-valent and 13-valent pneumococcal vaccines were later developed. These 
vaccines cover additional serotypes that are not included in the PCV7 (serotypes 1 and 5 for 
PCV9; serotypes 1, 5, and 7F for PCV10; and serotypes 1, 3, 5, 6A, 7F and 19A for PCV13) 
(Table 1.1). Phase III clinical trials on the PCV10 and PCV13 vaccines were recently 
successfully completed, and these vaccines have now been licensed for introduction into 
national immunisation programmes [98, 99]. 
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Table 1.1: Pneumococcal conjugate vaccines. Shows a summary of the different 
pneumococcal conjugate vaccines, their manufacturing companies, the serotypes covered by 
each PCV. 
 
Vaccine 
name 
Name of the manufacturing 
company 
No. of serotypes 
covered 
Serotypes covered 
Prevnar 
(PCV7) 
Wyeth (now Pfizer) 7 4, 6B, 9V, 14, 18C, 19F, and 23F 
Prevnar 
(PCV9) 
Wyeth (now Pfizer) 9 1, 4, 5, 6B, 9V, 14, 18C, 19F, and 23F 
Synflorix 
(PCV10) 
GlaxoSmithKline 10 
1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 
23F 
Prevnar 
(PCV13) 
Pfizer 13 
1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 
19A, 19F, and 23F 
 
 
PCV7 has been shown to protect individuals against IPD, and to reduce pneumococcal 
carriage and transmission of vaccine type serotypes (VTs) [3, 45, 100]. However, the vaccine 
is not able to protect against non-vaccine type serotypes (NVTs) that are not included in the 
formulation [101]. An increase in the number of NVTs that were mostly associated with 
carriage, after PCV7 vaccination resulted in serotype replacement disease [101, 102]. 
Although vaccination with PCV7 led to a decrease in VTs and a concomitant increase in 
NVTs, the incidence of IPD due to NVTs is trivial compared to that by VTs in HIV 
uninfected individuals [103-106]. This is probably due to low invasive potential of NVTs 
[107]. However, significant increase in invasive disease by NVTs in HIV infected adults 
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suggest susceptibility in this group due to repressed immune responses, are less competent at 
opsonophagocytosis of pneumococcal serotypes that are otherwise considered to have a low 
propensity to cause IPD [108]. PCV7 has been shown to be immunogenic in HIV infected 
adults from Uganda who were previously vaccinated with PPV, which was ineffective among 
these individuals [95, 109]. PCV7 also protects against subsequent re-infections in HIV 
positive adults and reduces 65% of vaccine type IPD in HIV infected children [64, 74]. A 
PCV prime-PPV boost strategy is recommended to overcome the limitation of using PPV 
alone and has a higher efficacy of vaccination breadth; magnitude and sustainability of 
antibody responses among HIV infected adults with CD4 T cell counts between 200 - 500 
[110]. Although, the levels of PCV7 antibody induction are similar quantitatively in both 
HIV negative and positive infants, qualitative differences have been suggested in HIV 
positive infants, who are less competent at opsonophagocytosis of pneumococci compared to 
those in HIV negative peers [74]. 
 
PCV7 introduction exerted selection pressure on pneumococci and resulted in changes in the 
pre-existing population structures. An example is serotype replacement disease, characterised 
by a decrease in the prevalence of vaccine type (VT) pneumococci and a corresponding 
increase in IPD due to non-vaccine type (NVT) pneumococci that increased in number to 
occupy the empty niche left by VT serotypes, after vaccine introduction [111-114]. Another 
example is capsular-switching as a vaccine escape mechanism [114]. In the post vaccine 
period, circulating vaccine type pneumococci switched their capsules for non-vaccine type 
capsules in order to escape the vaccine [53, 114]. Pneumococcal conjugate vaccines with 
higher serotype formulations have been developed to offer broader coverage against invasive 
pneumococci and to curb vaccine escape. The efficacy of these vaccines has been established 
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and those that provide better coverage have been recommended, especially in regions of high 
disease burden [98, 99, 115-118]. Development of new protein vaccines capable of eliciting 
protective immune response regardless of the pneumococcal capsular type is paramount. A 
better understanding of protein antigens that are universal to all pneumococci and play a 
significant role during the disease process is required for vaccine development.    
 
1.5: Pneumococcal virulence factors and vaccine candidates 
 
Invasive pneumococcal disease is preceded by nasopharyngeal colonisation and is a complex 
multistep process that involves the interaction of specific bacterial virulence factors with the 
host. The antiphagocytic polysaccharide capsule was for a long time considered essential for 
pneumococcal invasion [119]. This was based on previous observations that all virulent 
pneumococcal isolates from patients were encapsulated, compared to their noncapsulated 
avirulent derivatives [119]. Pneumococcal polysaccharide capsules are major virulence 
factors that are capable of eliciting specific protective antibody dependent immune responses 
in humans and different serotype capsules have been used in various vaccine formulations 
[120]. The antigenicity of each capsule is serotype specific, but cross-protective immunity 
may be elicited between capsules with similar polysaccharides [120]. However, recent studies 
have implicated pneumococcal proteins as major contributors to the pathogens disease 
process [119, 121-125]. These proteins are able to act indirectly as mediators of inflammation 
or directly by invading host tissues [119, 121, 124, 126]. 
 
Proteins elicit a T cell mediated immune response and have been used as carriers in conjugate 
vaccines [3, 127]. Major efforts have been made to identify potential pneumococcal protein 
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vaccine candidates that induce immunologic memory and are present all pneumococci thus 
eliciting a serotype independent immune response [5, 120, 125, 128-130].  
 
Tissue culture and different animal models at a variety of anatomical locations have been 
used to identify individual novel pneumococcal virulence factors and potential vaccine 
candidates [24, 131-135]. Although multiple pneumococcal virulence factors have been 
determined, the combination of these factors that determines the propensity to cause IPD is 
still not well understood. More recently, computational analysis of pneumococcal genomes 
has been used to cumulatively identify potential protein vaccine candidates and their role in 
pathogenesis [122, 136, 137].  
 
A variety of proteins that enable pneumococci to effectively invade and colonize hosts have 
been characterised (Figure 1.5). Some of these proteins have been proposed as next-
generation pneumococcal protein vaccine candidates. The most well studied proteins can be 
broadly categorised as: cytoplasmic proteins, choline-binding proteins, metal-binding 
lipoproteins, sortase dependent surface proteins and pneumococcal histidine triad proteins.   
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Figure 1.5: Some key virulent pneumococcal antigens that have been considered as 
potential protein vaccine candidates. These include: cytoplasmic proteins (pneumolysin); 
choline-binding proteins (Choline binding protein A (CbpA or PspC), autolysin, and 
pneumococcal surface protein A (PspA)); metal-binding lipoproteins (pneumococcal surface 
antigen A (PsaA)); and sortase dependent surface proteins (Neuraminidase and hyaluronate 
lyase) (reproduced from Rigden et al. [138]). 
 
1.5.1: Choline binding proteins (Cbp’s) 
 
Choline binding proteins are surface proteins that are attached to the pneumococcal cell wall 
[121, 138]. Examples include pneumococcal surface protein A (PspA), pneumococcal surface 
protein C (PspC or CbpA or SpsA), choline binding protein D (CbpD), choline binding 
protein E (CbpE), and choline binding protein G (CbpG), autolysin (also known as N-
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acetylmuramoyl-L-alanine amidase) (LytA), β-N-acetylglucosamidase (LtyB), β-N-
acetylmuramidase (LytC) [121, 124, 132, 139-142].  
 
Pneumococcal surface protein A (PspA) is found on the cell surface of virtually all 
pneumococcal strains [121, 143], and elicits an immune response in mice that protects against 
invasive infection more than 100 fold the 50% lethal dose [121, 134, 144-146]. PspA 
subverts immune responses by inhibiting complement binding [121]. However, PspA exhibits 
high polymorphism at both the DNA and protein level [147], which undermines its use as a 
universal immunogenic antigen.  
 
Choline binding protein A (CbpA or PspC) binds to and blocks the polymeric 
immunoglobulin receptor (pIgR) that transports secretory IgA across the respiratory 
epithelium [148]. PspC facilitates pneumococcal adhesion to human epithelial cells during 
initial colonisation, and has also been shown to be essential in the penetration across the 
blood brain barrier (BBB) during CSF invasion [132, 133, 139, 149]. PspC facilitates 
bacteraemia by binding to the pIgR receptor on the host’s epithelium, thereby allowing 
pneumococcal transcytosis across the mucosal epithelium into blood [124]. Once 
pneumococci are in blood circulation, on reaching the BBB, PspC binds to endothelial 
laminin receptors, facilitating transcytosis across the BBB into the CSF [124]. PspC plays a 
major role in pneumococcal pathogenesis and is under consideration as a potential vaccine 
candidate. 
 
Autolysin (LytA) is normally present in inactive form and is activated when cell wall 
biosynthesis stops as a result of nutrient starvation or antibiotic treatment [119]. LytA is 
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involved in separation of daughter cells and cell lysis during stationary phase and in the 
presence of antibiotics, and plays a role in virulence by activating the release of cytoplasmic 
protein pneumolysin, which causes cell lysis releasing pneumococcal antigens in to the host 
and further aggravating disease [119, 121]. LytA also is also involved in the induction of 
cytokine release and cellular immunity, and LytA mutants have been associated with reduced 
severity of host tissue inflammation [150]. LytB is also involved in daughter cell separation, 
while LytC has lysozyme activity at 30oC and mutants of LytB and LytC poorly colonize the 
nasopharynx in murine models [122].  
 
CbpG facilitates adherence to mucosal surfaces and virulence at both mucosal surfaces and 
blood, and immunisation with recombinant CbpG is protective in murine models of 
colonisation and bacteraemia [151]. 
 
1.5.2: Cytoplasmic proteins 
 
Numerous pneumococcal cytoplasmic proteins have been identified, most of which are 
involved in metabolism and other house keeping activities. Pneumolysin (Pln) is the best-
characterised virulent cytoplasmic protein and considered one of the most promising potential 
protein vaccine candidates. It is a single 53-kDa polypeptide chain produced by all 
pneumococci and is a released by autolysin activity [121, 141]. It acts by forming 
transmembrane pores in the target membranes resulting in cell lysis and can directly impede 
the host's ability to opsonise, phagocytose and eliminate invading pneumococci, and also 
disrupts the humoral immune responses to infection by binding to the Fc region of IgG [119, 
121, 132, 152-154].  
                                                                                                                Chapter 1: Introduction 
 24 
1.5.3: Metal-binding lipoproteins 
 
Metal-binding lipoproteins play important roles in bacterial transport and fitness. Examples 
include pneumococcal surface antigen A (PsaA), pneumococcal iron acquisition A (PiaA), 
pneumococcal iron uptake A (PiuA) and zinc metalloproteinases [121, 155, 156]. PsaA is 
bound to an ABC transport protein complex that transports manganese ions and plays a role 
in host cell adhesion, while PiaA and PiuA mediate pneumococcal iron uptake [155, 156]. 
Vaccination with PiaA and PiuA elicits protective immune response, and Pia-Piu double 
mutant strains have significantly reduced growth on iron deficient medium as well as reduced 
virulence in animal models of pneumonia and bacteraemia [148]. Genomic analysis has 
revealed the presence of zinc metalloproteinases in pneumococci [157]. Zinc 
metalloproteinase B (ZmpB) and zinc metalloproteinase C (ZmpC) have been shown to be 
virulent in mice models of colonisation and bacteraemia [158-160]. 
 
1.5.4: Sortase dependent surface proteins 
 
Sortase dependent surface proteins are surface proteins and include: Neuramidases (Nan), 
immunoglobulin A1 protease (Iga1), hyaluronidase (Hyl) and putative proteinase maturation 
protein A (PpmA) [121, 124, 161]. Hyl lyses hyaluronic acid mostly associated with host 
connective tissue and extracellular matrix, thereby allowing host tissue invasion [119, 121, 
124]. NanA and NanB deglycosylate mucus glycoconjugates, consequently preventing 
pneumococcal mucus entrapment and prolonging nasopharyngeal colonisation [124].   
 
 
                                                                                                                Chapter 1: Introduction 
 25 
1.5.5: Pneumococcal histidine triad proteins (Pht’s) 
 
The Pht is a family of homologous surface proteins with histidine motifs (HxxHxH), known 
as the histidine triad, and include: PhtA, PhtB, PhtD and PhtE [138]. PhtA, PhtB and PhtD 
have been implicated in the progression of pneumococcal infection to lung disease [125]. 
PhtA and PhtB elicit protective immune responses in mice models of sepsis [120, 136]. 
  
1.5.6: Other proteins 
 
High-temperature requirement A (HtrA) has been shown to be a virulence factor in certain 
strains of pneumococci (D39 and TIGR4) and confers them ability to grow under oxidative 
stress in murine models of colonisation and pneumonia [122, 162]. 
 
Efficient development of novel interventions is essential to prevent the global spread of 
invasive pneumococcal disease. Combination of key virulent proteins, as opposed to 
individual virulent protein contributions, is likely to provide optimal immune protection 
against pneumococcal disease [121, 125]. Identification of virulent pneumococcal proteins 
that are essential for IPD and always present in all pneumococci is important for development 
of novel vaccines.  
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1.6: Pneumococcal genomics and reverse vaccinology 
 
1.6.1: Genomics 
 
Pneumococci can be serologically classified in to more than 92 serotypes, based on the 
haplotypes of their polysaccharide capsules [15, 81, 163]. Pneumococci are genetically 
diverse due to their highly recombinogenic nature, which enables them to exchange nucleic 
acid material with other microorganisms in their niche [81]. Despite this genetic diversity the 
genetic structure of pneumococci is well defined and has been resolved using multiple 
housekeeping genes that are always present and play key metabolic roles, also known as 
multi-locus sequence typing (MLST) [39, 42]. MLST exploits the average genetic sequence 
diversity of multiple loci (typically 6-8) to classify bacteria into different lineages based on 
the similarity of the loci used in the typing scheme [36]. This typing scheme can classify 
bacteria that belong to the same lineage if they have exactly similar loci, or as locus variants 
if they differ even at a single locus, due to multiple alleles [36, 39, 42]. These loci are thought 
to be suitable for robustly resolving bacterial populations structure, since they are under 
neutral selection [39]. However, MLST makes use of only a small proportion of the bacterial 
genome providing medium resolution at best [164], and whole genome sequencing 
approaches that are able to address questions that require higher resolution genome 
comparisons of bacterial species are recommended [165, 166]. 
 
The first fully sequenced pneumococcal genome sequence was completed in 2001 and was 
sequenced by The Institute of Genome Research (TIGR, now The John Craig Venter 
Institute) [157].  The genome was of a capsulated serotype 4 clinical pneumococcal isolate, 
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collected from a 30 year-old male patient in Norway [157]. The 2.1 mega-base pairs genome 
sequence had a G+C content of 39.7%, and consisted of 2236 predicted coding regions, with 
only 64% (1440) of these coding regions having assigned biological functions [157]. More 
pneumococcal genomes became available, allowing multiple comparisons of genome-wide 
features [23, 167, 168]. More recent advances in gene sequencing technologies have provided 
large amounts of sequence data accompanied by the development of multiple sequence 
analysis tools that have allowed the genetic diversity in microbial populations to be explored 
at higher resolution [169-172]. Genomics has had a major impact on microbiology, by 
offering better understanding of the genetic diversity within and between species, and is 
widely used for development of diagnostics, antigen identification and functional 
characterisation of infectious diseases [164, 171, 173-175]. Pneumococcal genomes have 
provided a better understanding of the unique gene organisation in S. pneumoniae and how 
this affects their biology [157, 176, 177]. Pneumococcal genomes have helped to unravel the 
mechanisms of antibiotic resistance and, novel genome-based strategies have also been 
exploited for the development of more effective antibiotics and to identify novel vaccine 
candidates [178-181]. Pneumococcal genomics has provided a more in depth understanding 
on the global spread of invasive pneumococcal strains that belong to particular clonal types 
and the important genetic features required for their transmission [182, 183]. The availability 
of genomes has allowed the identification of novel pneumococcal virulence factors. An 
example is the discovery of the pneumococcal pilus in the TIGR4 pneumococcal genome that 
has highlighted its role in enhancing adherence during host-pathogen interactions, promoting 
nasopharyngeal colonisation [24, 184].  Genomics has also been used to identify virulence 
factors used as vaccine targets. An example is the identification of universal potential vaccine 
candidates in the genome of serogroup B Neisseria meningitidis (Men B), which were further 
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assessed for their ability to elicit protective immune responses against diverse Men B strains 
[136, 185-187]. 
 
Some bacterial antigens, for example the pneumococcal polysaccharide capsule, can 
effectively induce protective immunity, and have been used to develop vaccines [3, 20, 115, 
188]. However, only 7 to 23 (PPV, PCV7, PCV9, PCV10, PCV13) of the more than 92 
pneumococcal serotype polysaccharide capsules are incorporated in vaccine formulations, 
and they are only able to protect against the specific vaccine type serotypes and also induce 
cross-protection for serotypes with almost similar polysaccharide virulence determinants. 
These vaccines have been effective at reducing the burden of pneumococcal disease [45]. 
Still, the dynamics of circulating pneumococcal serotypes needs to be monitored after 
vaccine implementation and new serotypes have previously been added to the vaccines to 
avoid changes associated with serotype replacement disease and capsular switching of 
vaccine type capsules for non-vaccine type capsules [53, 114]. Pneumococcal genome 
comparisons have highlighted that these changes are mainly due to purifying selection, 
allowing redundancy in pneumococcal virulence determinants [53, 81, 183, 189].  These 
approaches can be used to identify potential vaccine candidates. Ideal vaccine designs would 
consist of individual antigens or a combination of antigens that elicit protective high immune 
response and are present in all pathogenic bacterial strains of the species under consideration 
[190]. 
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1.6.1.1: The pan-genomic concept 
 
Genomic comparisons within and between various bacterial species genomes, especially 
among clinically important pathogens, have highlighted differences in the distribution of 
structural features, their genetic composition and their varied protein expression patterns, 
providing further details on their population and evolutionary genetics [165, 183, 189, 191]. 
Comparison of multiple bacterial species’ genomes show that these genomes can be 
described as a pan-genome (Figure 1.6), consisting of a “core genome” that is composed of 
all genes present in all strains, and an “accessory genome” composed of genes that are unique 
to certain single strains [192].  
                                      
                                                                                                                                                    
Figure 1.6: The pan-genome concept. A single ring is representative of an entire genome. 
Considering comparative analysis of three genomes (1, 2, and 3). There are those genes that 
will be present in all three genomes, C. These constitute the core genes. There genes that are 
unique to particular bacteria and are not present in all specie genomes, A.  These constitute 
the accessory genes. The accessory genes and the core genes together constitute the pan-
genome. 
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The core genome consists of all genes that are responsible for the basic biology of the 
organism, such as housekeeping genes and those responsible for its important phenotypic 
traits. The genes that constitute the core genome are responsible for housekeeping functions, 
the cell envelope, regulatory functions, transportation, as well as binding proteins. About a 
third of these genes are either hypothetical proteins or proteins of unknown function [192]. 
Accessory genes contribute to the species diversity and encode for those traits that confer 
selective advantages for adaptation to different niches, such as antibiotic resistance genes. 
This is an important concept because virulent antigens that form part of the core genome can 
be exploited for the development of therapeutics and vaccine antigens. 
 
The number of genes in the core genome initially decreases with the addition of each 
subsequent new genome and reaches a constant, which is its minimum, where further 
addition of genomes does not affect the core genome size to a great extent (Figure 1.7). The 
number varies due to presence of paralogs (homologous sequences separated by a duplication 
event, which are discussed in more detail in chapter 3) [192]. 
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Figure 1.7:  The core genome size. The size of the core genome decreases with subsequent 
addition of each new genome until it reaches a constant where further addition of genomes 
does not lead to a reduction in size (reproduced from Tettelin et al. [192]). 
 
Concomitant with the decrease in the size of the core genome, with the addition of each 
subsequent new genome, is the increase in size of the pan-genome (Figure 1.8) [192]. 
 
 
 
Figure 1.8: The pan-genome size. The number of genes in the pan-genome increases with 
the addition of every new genome (reproduced from Tettelin et al. [192]). 
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Some pan-genomes, for example that of Streptococcus pyogenes, are “open”, meaning that 
they increase in size exponentially with the addition of each new genome. Other pan-
genomes, for example that of Bacillus anthracis, are “closed”, and a few genomes are 
sufficient to completely describe the gene content of the species [192]. Streptococcus 
agalactiae has a large pan-genome with little recombination in its core genome, while S. 
pyogenes has a smaller pan-genome with relatively more frequent recombination events in its 
core genome, suggesting that S. agalactiae strains occupy more extensive niches and have 
more genetically diverse strains compared to S. pyogenes [189]. Species pan-genomes are 
generally larger than genera pan-genomes, because bacterial genomes have high 
recombination events both within and across species boundaries [166]. 
 
To understand the global complexity of the pneumococcal species, multiple genomes of 
different pneumococcal isolates from the same species need to be studied. Pneumococci 
exhibit phase variation, that involves the switching on or off of genes, thereby varying their 
gene expression according to external stimuli, their niche and stress conditions. It is possible 
to compare variations in gene presence during a particular disease state, as a consequence of 
phase variation (for example bacteraemia versus meningitis or invasive disease versus 
carriage), with the availability of multiple genomes [192]. These variations may result in 
marked differences in pan-genome size due to differences in niches that the bacteria colonise 
[166]. Defining all the genes present in a species is still challenging, and even with the 
availability of hundreds of genome sequences, more accurate estimates of the pan-genome 
sizes will be possible with a greater number of genomes becoming available in the future 
[192]. Annotation (detailed documentation of genetic information and position) quality also 
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improves with the number of appropriate genomes available for comparison, primarily with 
regards to precise gene prediction [193]. 
 
Setting cut-offs of sequence identity (at least 70% sequence identity) when comparing 
sequences in a pan-genome is of crucial importance as it is provides the criteria by which 
genes or peptides are either included or omitted in the core-genome. This criteria could affect 
the interpretation of results during multiple genome analysis, for example the selection of 
potential therapeutic and vaccine candidates [166]. Thus, entire species genome comparisons 
as opposed to comparative genome hybridisation approaches would be more informative on 
species genetic diversity. Although previous analyses using several genomes indicate that 
gene gain appears to occur more frequently than gene loss in pan-genomes, gene loss events 
could be underestimated, and sample sizes that are more representative of the entire species 
pan-genome are required for this analysis [166]. 
 
Comparative genomic analysis of multiple pneumococcal genomes can be exploited to 
highlight already known and novel therapeutic and vaccine candidates that are present in all 
pneumococcal genomes. Highlights of differentially present or expressed key genes involved 
in pathogenesis will also allow a better understanding of their roles during host-pathogen 
interactions that are associated with different disease outcomes. 
 
1.6.2: Reverse vaccinology 
 
Many new bacterial infections, arising from microbial diversity, are anticipated to emerge in 
the coming decades and the development of vaccines for their control and prevention appears 
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to be the most feasible approach [186]. The diversity may arise from mechanisms that 
promote horizontal gene transfer such as bacteriophage transduction, and up take of 
transformable elements from the environment. 
 
Traditionally, vaccines were produced from live but attenuated forms of microbial pathogens; 
killed, inoperative microbes; purified microbial components; polysaccharide-carrier protein 
conjugates or recombinant proteins, and required large-scale culturing of pathogens under 
certain conditions followed by purification to determine important virulence factors that elicit 
protective host immunity [194-196]. This approach is time consuming typically taking 
between five to fifteen years, and identifies only those antigens that can be purified in 
sufficient quantities. Shortcomings of these methods are that not all immunodominant protein 
antigens induce protective immune responses, there is often antigen diversity due to 
variations in their sequences, and the cost of production is high due to difficulties in scaling-
up protein expression and purification. This approach takes a long time and is only successful 
for those pathogens whose antigens are abundant, and the antigens may or may not elicit 
marked immune responses [194]. Consequently, these methods have failed to provide 
vaccines for some infectious diseases, especially those that cannot be cultured in the 
laboratory. 
 
However, a major discovery in the development of pneumococcal protein vaccines was the 
ability of non-capsulated pneumococci to induce protective immune responses against 
capsulated pneumococci in animal models [197], thus shifting the focus from polysaccharide 
based formulations to those that include surface exposed protein virulence factors as potential 
candidates [132, 133, 136, 153]. More than a hundred pneumococcal surface proteins, with 
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most implicated in pathogenicity and virulence, have been studied for their potential as 
vaccine candidates [136]. 
 
New sequencing technologies have been exploited for the development of new and improved 
vaccines. Bioinformatics techniques have been employed to explore the enormous amounts 
of available microbial sequence data for potential vaccine and therapeutic targets before 
carrying out wet-laboratory experiments [196]. This approach, referred to as “reverse 
vaccinology”, can be used to identify a pathogens entire repertoire of potential vaccine 
antigens without tissue cultures and animal model immunological assays to detect host 
immune responses [194, 196]. It allows the theoretical development of safe and efficacious 
vaccines against any infectious disease.  
Most antigens identified by conventional methods display strain epitope variability or are 
only expressed in some strains. This results in protective immunity in humans against only 
strains with homologous epitopes and not heterologous epitope strains [195]. In reverse 
vaccinology, the candidate antigens are selected from genomes, which are considered 
comprehensive catalogues containing nearly all of the pathogens antigens. With an 
abundance of species genomes, reverse vaccinology offers an abundance of protein antigens 
that could be shortlisted as potential vaccine candidates. Reverse vaccinology has been used 
to identify potential vaccine candidates for group B meningococcus [198]. In 18 months, 85 
new surface-exposed proteins were discovered and 25 of these were shown to induce 
bactericidal antibodies, which is greater than the less than a dozen proteins identified over the 
last four decades [198, 199]. In addition to the number of antigenic proteins identified, they 
were high quality conserved protein antigens, carried multiple protective epitopes and were 
present in most strains [199].  
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Reverse vaccinology identifies the open reading frames (ORF's) coding for all potential 
proteins antigens to be identified in an unbiased manner [195, 199]. A proportion of 
pneumococcal proteins have been successfully identified, expressed and purified and 
screened for their ability to induce bactericidal immune responses. The most promising as 
vaccine candidates are in phases I and II of clinical trials and include pneumolysin, 
pneumococcal surface adhesin A (PsaA), pneumococcal surface protein C (PspC) and 
histidine triad proteins [136]. The ideal protein antigens should be on the cell surface, based 
on the assumption that they are the most accessible by antibodies and will thus elicit the most 
protective immune responses; common to all pneumococci and have well conserved epitopes 
with very limited antigenic diversity. Identification of such high quality antigens provides 
robust foundation for their evaluation as potential vaccine candidates [199]. 
 
A bottleneck to reverse vaccinology is epitope mimicry, also known as "mimetope", where 
there is similarity in a stretch of sequence between parts of the pathogens epitope and those 
of the host, raising the possibility of autoimmune events [200]. Mimetopes have been 
identified in Neisseria meningitidis, which causes meningitis, streptococcal species 
associated with rheumatic fever and Trypanosoma cruzi, causing Chaga's disease [200]. The 
immune system distinguishes self from non-self curbing serious autoimmune problems; 
consequently mimetopes elicit very poor immune responses, rendering antigens with 
mimetopes poor vaccine candidates despite their identification by reverse vaccinology 
methods. Genes encoding candidate vaccine antigens with mimetopes are usually discarded 
during selection, reducing the number of candidates and consequently the time spent in 
immunologically screening poor quality antigens in the laboratory [200]. 
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Information from a single genome is not sufficient to identify potential protein vaccine 
candidates, because it is not representative due to intra-species diversity. An understanding of 
the molecular epidemiology of disease and multiple genomes are required to make a broad 
selection of potential vaccine candidates that are representative of all the strains from a 
particular species. Genomic comparisons highlight genetic differences [136, 187], enabling 
development of a universal vaccine containing a combination of antigens found in all 
pneumococcal strains. Reverse vaccinology identifies protein antigens that are good vaccine 
candidates capable of eliciting a complement-dependent bactericidal immune response in 
murine models during further screening [200]. 
 
1.7: Aim and objectives  
 
1.7.1: Hypothesis  
 
The pneumococcus, a multiple lineage, highly recombinant, genetically diverse pathogen; is 
under strong evolutionary pressure in regions of high disease burden with high frequencies of 
host immunocompromise. This genetic diversity varies for each of the different invasive 
pneumococcal disease outcomes. In this study it was hypothesised that: 
 
! There is a significant difference in the protein antigen diversity between meningitis-
associated and bacteraemia-associated pneumococci from a region of high disease 
burden, and such diversity also exists between HIV infected and non-HIV infected 
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individuals, for each of the two outcomes (bacteraemia and meningitis) of invasive 
pneumococcal disease (IPD).  
 
! There is a significant difference in the rate and extent of gene gain and loss (genetic 
flux), which occurs mainly due to recombination, between meningitis-associated and 
bacteraemia-associated pneumococci that can be resolved using the patterns of gene 
presence or absence (Phyletic patterns).  
 
! There is a significant difference in the prevalence of piliated pneumococci associated 
with invasive pneumococcal disease in Malawi, a region of high disease burden, 
compared to those of other regions. 
 
1.7.2: Aim 
 
The overall aim of this study was to investigate the differences in antigen diversity and 
genetic flux among invasive meningitis-associated and bacteraemia-associated pneumococci 
prior to vaccine introduction from individuals in the Blantyre region of Malawi using whole 
genome sequencing approaches, so as to better understand the biology of this important 
pathogen in an African setting and to inform the design and implementation of existing and 
next generation vaccines. 
 
1.7.2: Objectives 
 
The principle objectives of the study were:  
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1. To develop bioinformatics algorithms and pipelines for analysis of multiple diverse 
pneumococcal datasets to understand pneumococcal population and evolutionary 
genetics. 
 
2.  To establish pneumococcal genetic diversity that determines the propensity to cause 
different outcomes of invasive pneumococcal disease (bacteraemia vs. meningitis). 
 
 
3. To establish whether gene presence and absence profiles (phyletic patterns) can be 
used to resolve pneumococcal population structures, and to investigate the extent by 
which the pneumococcal genome content varies within and across lineages, and in 
different ecological niche (blood and cerebral spinal fluid (CSF)), by examining gene 
gain and gene loss events during invasive pneumococcal disease. 
 
4. To determine the prevalence of pilus among invasive Streptococcus pneumoniae 
isolates prior to pneumococcal conjugate vaccine introduction, in Malawi. 
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CHAPTER 2 
 
Materials and methods 
 
2.1: Study sites, population and pneumococcal isolation 
 
This PhD project formed part of a larger programme of research work focused on 
understanding pneumococcal disease epidemiology, pathogenesis, biology, and immunology 
in Malawi. The work was undertaken at two different sites: The Malawi-Liverpool-Wellcome 
Trust Clinical Research Programme (MLW) in Blantyre, Malawi  (www.mlw.medcol.mw) 
and the Wellcome Trust Sanger Institute (WTSI) (www.sanger.ac.uk) in Hinxton, 
Cambridgeshire, United Kingdom. The MLW microbiology laboratory, based at Queen 
Elizabeth Central Hospital (QECH), has a repository of over 5000 carried and invasive 
pneumococcal isolates obtained from routine invasive bacterial infection surveillance since 
1996 [93]. QECH is one of 4 main central hospitals in Malawi, which covers the southern 
region of the country and provides health services to approximately one million people (7% 
of the Malawian population). QECH is a government-funded hospital with 1250 beds that 
receives up to 1500 adults and children each day, and has an average annual admission rate of 
50,000 patients [93]. All adult general medical admissions (15 years or older) presenting with 
fever or clinical evidence of sepsis had a recommended 5-10 mL of blood drawn for culture. 
Lumbar punctures (LP) were performed when there was a clinical suspicion of meningitis.  
Blood culture (1 mL) or LP were performed on febrile children with a negative thick film for 
malaria parasites and no obvious clinical focus of infection (e.g. pneumonia). Children 
considered severely ill with sepsis or meningitis regardless of thick film result, and patients 
who failed to respond to initial treatment for malaria and remained febrile also underwent 
                                                                                                Chapter 2: Materials and methods 
 41 
blood culture. Cerebral spinal fluid (CSF) and blood cultures (BC) were cultured using 
established isolation methodology and on significant isolates, sensitivity testing was carried 
out according to the British Society for Antimicrobial Chemotherapy (BSAC) guidelines 
[201]. Briefly, blood collected was cultured in blood culture bottles (BioMérieux BacT/Alert 
blood culture bottles, Hazelwood, Mo) for initial growth and detection for 24 hours, using a 
BACTEC machine (Becton Dickinson Microbiology Systems, Sparks, Md.). All bottles that 
were detected as positive were sub-cultured on chocolate agar and blood agar for 
identification of the grown colonies. CSF was centrifuged at 1000 x g for 10 minutes to 
sediment bacteria, and the precipitate was sub-cultured directly on blood agar and chocolate 
agar, and colonies grown identified. Radiologic examination was performed only where 
clinically indicated in patients suspected to have pneumonia. After isolation, the 
pneumococcal isolates were sub-cultured on blood agar and their antibiotic susceptibility 
profiles were determined using Etest strips (AB BioMérieux, Solna, Sweden) according to 
the manufacturer’s recommendation [50], before storage of the pure colonies at -80oC in 
microbank beaded vials (Prolab, Richmond hill, ON, Canada).  
 
2.2: Study isolates 
 
Streptococcus pneumoniae isolates collected between 2002 and 2008 (n =140) were 
randomly selected from the isolate archive (see section 2.4.2 and 2.4.3; and Appendix 1). 
Although isolates were available from the year 1996, isolates from 2002 to 2008 were chosen 
since they had the most recent metadata and were from studies the laboratory staff, currently 
at the MLW, were most conversant with. The pneumococcal isolates used in this study were 
from the CSF (meningitis-associated; n = 70) and blood (bacteraemia-associated; n = 70), and 
were randomly selected using STATA (Appendix 2). HIV status was known in 93 of the 140 
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(66%) individuals (Table 2.1). Two-thirds of the isolates were from adults (66%), who also 
constituted a large proportion of the HIV infected individuals (36.43%) compared to children 
(10%). Overall 46.43% were HIV infected (Table 2.1). Genome sequencing of the isolates 
following DNA isolation was carried out at the WTSI. 
 
Table 2.1: The proportion of isolates obtained from children and adults and their HIV 
status. 
 
HIV 
Status 
Frequency No. of Adults No. of Children Percentage 
(%) 
Cumulative 
percentage  (%) 
Negative 28 16 (11.43) 12 (8.57%) 20 20 
Positive 65 51 (36.43%) 14 (10%) 46.43 66.43 
Unknown* 47 25 (17.86%) 22 (15.71) 33.57 100 
Total 140 92 (66%) 48 (34%) 100   
 
*HIV status was unknown either because the test result had not been recorded or the test was 
not done. 
 
2.3: Ethical considerations 
 
Ethical approval to conduct this work was obtained from the University of Malawi College of 
Medicine Research & Ethics Committee (COMREC), and conformed to institutional 
guidelines. The ethics committee ensured that the study design conformed to national and 
international standards of safety, sample storage and shipment and the protection of the rights 
of individuals from whom samples were obtained in this research. The COMREC protocol 
number for this work was: P.01/08/609. 
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2.4: Laboratory methods 
 
2.4.1: Chemical reagents 
 
All the chemical reagents used in this study were purchased from: Sigma-Aldrich, St Louis, 
MO, USA, unless otherwise stated. 
 
2.4.2: Isolate selection and metadata retrieval 
 
For the purposes of this study, a random sample of the archived S. pneumoniae strains (n = 
140) was selected from a non-redundant database that contains information on all microbial 
isolates processed at MLW. Clinical, microbiologic and demographic metadata for the 
selected isolates was retrieved from the database. Strain information retrieved included: the 
sample number, the date of isolation, the site of isolation (CSF or blood), the study numbers 
of previous studies that collected and archived the isolates, and the antibiotic resistance 
profiles. Patient information retrieved included: HIV status, CD4 counts, age, date of birth, 
ward of admission, the outcome of disease, and the home address. All the patient information 
on antibiotic resistance profiles was not uniform, reflecting changes in laboratory protocols 
used in the MLW laboratory over time. 
 
2.4.3: Pneumococcal strain retrieval and identity confirmation 
 
Two beads were retrieved from each storage vial, transferred under aseptic conditions on to a 
5% gentamicin-sheep blood agar plate (5.5 µg per ml of Gentamicin was used), and streaked 
using a loop to be able to distinguish single colonies. Pneumococcal strains were cultured on 
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gentamicin-sheep blood agar plates with optochin discs at 37oC in 5% CO2 enriched 
atmosphere overnight. Gentamicin is a broad-spectrum antibiotic used to limit or inhibit 
growth of other bacteria on culture media, thereby enhancing the detection and retrieval of 
pneumococcal colonies from culture. S. pneumoniae identity was confirmed by colony 
morphology, α-haemolysis and optochin susceptibility. Pneumococcal colonies have a shiny 
green morphology, and have a flattened and depressed centre when cultured on blood agar for 
24 to 48 hours (Figure 2.1).  
 
 
 
Figure 2.1: The morphology of S. pneumoniae when cultured on blood agar. The 
morphology of pneumococci can be used as a preliminary test to distinguish them from other 
streptococci. However, morphology alone cannot be used for valid identification as 
pneumococci can have other morphologies. In this photograph pneumococci can be 
distinguished morphologically from Streptococcus viridans also growing on the same blood 
agar plate (reproduced from the CDC laboratory manual [202]). 
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Pneumococci cause the destruction of erythrocytes and haemoglobin in blood agar medium 
and result in a greenish clear zone around colonies (Figure 2.2). This is known as α-
haemolysis. This haemolysis is used as preliminary test for the identification of several 
clinically important bacteria [203], including other streptococci that grow on blood agar 
[204]. Thus, α-haemolysis is not used alone as a confirmatory test for pneumococcal 
identification. Pneumococcal growth on blood agar is inhibited by low concentrations of 
ethylhydrocupreine (optochin) [205] (Figure 2.2). The optochin susceptibility test can 
therefore be used to differentiate pneumococci from other α-haemolytic streptococci, which 
are not susceptible. 
 
  
Figure 2.2: α-haemolysis and optochin susceptibility in pneumococci. The arrow shows a 
greenish area surrounding pneumococcal colonies due to haemolytic activity. The green 
colouration is due to haemolysis and thus haemoglobin release in the media. Pneumococci do 
not grow in the area around the optochin disc (P), due to optochin susceptibility (reproduced 
from the CDC laboratory manual [202]). 
 
A single colony from each plate was sub-cultured overnight on a plate of Blood Agar, at 37oC 
in 5% CO2 enriched atmosphere. The pure colonies were transferred into 15mls of Todd-
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Hewitt broth (Oxoid Limited, Basingstoke, Hampshire, England) and cultured overnight at 
37oC and 5% CO2 enriched atmosphere. This significantly increased the number of colonies 
and ensured that enough pneumococcal cells cultured were available for DNA extraction, and 
so the yields were acceptable.  
 
2.4.4: DNA extraction 
 
The overnight culture was pelleted by centrifugation (13,000g for 3.5 mins). Wizard genomic 
DNA purification kits (Promega, Madison, WI, USA) were then used to extract the bacterial 
DNA according to manufacturers’ instructions. In brief, the supernatant was discarded and 
the cells resuspended in 480 µl of 50 mM Tris-EDTA buffer (pH 8.0). EDTA 
(ethylenediamine tetra-acetic acid) is a chelating agent and binds to metallic ions that are 
required as cofactors by enzymes during enzymatic activity. The removal of metallic 
cofactors inhibits enzymes that breakdown DNA and therefore would increase the yield. The 
mixture was incubated at 37oC for 60 mins after the addition of 120 µl of lysozyme. The 
lysozyme was used to digest the bacterial cell wall facilitating cell lysis required for DNA 
extraction. The mixture was centrifuged (13,000g for 3.5 mins) and the supernatant retained. 
The supernatant was mixed with 600 µl nucleic lysis solution (Promega, Madison, WI, USA), 
and incubated at 80oC for 10 mins, and then allowed to cool to room temperature. The 
nucleic lysis solution was used to degrade the nucleic membrane exposing nucleic DNA. 3 µl 
of RNAse solution (Promega, Madison, WI, USA) was then added and the mixture incubated 
at 37oC for 15 mins and then cooled to room temperature. RNAse solution contained 
enzymes (RNAses) that degrade RNA. The mixture was incubated at 37oC to provide optimal 
temperature for RNAse enzymatic activity. The mixture was vortexed at high speed for 20 
secs, after adding 200 µl of Protein precipitation solution (Promega, Madison, WI, USA), and 
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then incubated in ice for 10 mins. Protein precipitation solution was used to separate nucleic 
acids from proteins. The nucleic acid remained in the aqueous phase of the mixture, while the 
proteins were precipitated. The mixture was then pelleted by centrifugation (13,000g for 15 
mins), and 1 ml of the supernatant containing the DNA transferred to a clean eppendorf tube 
containing 600 µl of room temperature isopropanol and centrifuged (13,000g for 15 mins). 
This allowed the concentration of the DNA to a precipitate separating it from impurities in 
the supernatant. DNA is less soluble in isopropanol compared to ethanol, and isopropanol 
was used during the first wash to maximize the amount of DNA in the precipitate. The 
supernatant was poured off and the eppendorf drained on clean absorbent paper. The DNA 
pellet was washed in 600 µl of 70% ethanol and resuspended in 60 µl of Rehydration solution 
(Promega, Madison, WI, USA). Rehydration buffer was used to resolubilize the DNA.  
 
2.4.5: Quantification of DNA extraction products 
 
The presence of DNA was confirmed by analysing DNA extraction product using gel 
electrophoresis in 1% agarose gels (Figure 2.3). Strong bands of DNA when visualised under 
ultra-violet light confirmed the presence of extraction products. Concentrations and quality of 
the DNA extracted were also determined using the Nanodrop ND-1000 spectrophotometer 
system (Nanodrop, Wilmington, DE, USA) and samples were diluted to 2.5 µg in 100 µl 
Tris-EDTA buffer. 
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Figure 2.3: The presence of DNA extraction products confirmed by gel electrophoresis 
analysis. The presence of DNA extraction products was verified by the presence of thick 
bands of DNA when visualised under ultra-violet light. Gel lanes that did not have thick 
bands highlighted DNA extracted samples that had no DNA, and those with very poor quality 
or small amounts of DNA products after extraction. DNA re-extractions were performed for 
samples without or with poor quality DNA extraction products.  
 
2.4.6: Sequencing 
 
Genomic DNA sequencing was performed at WTSI, using Illumina Genome Analyser 
platforms (Illumina, San Diego, California, USA). This first involved the creation of 
sequencing libraries. Library construction was a multi-step procedure that involved (Figure 
2.4): fragmentation of sample DNA; end repair and A-tailing (that is the addition of a single 
DNA strand with multiple adenine nucleic bases); ligation of the sample DNA fragments to 
adapters with T-overhangs (that is fragments of single stranded DNA with multiple thymine 
nucleic bases, which ligate to those with multiple adenine bases to form double stranded 
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DNA), which consisted mainly of primer annealing sequences; and final polymerase chain 
reaction (PCR) amplification of ligated fragments. Adapters were designed to have bases that 
do not allow them to anneal completely to each other, which provide annealing sites for 
primers. PCR amplification was performed to generate adequate amounts of template DNA 
for sequencing, and also resulted in the addition of sequences, known as grafting sequences, 
in the resulting template molecules that allowed them to hybridise with oligonucleotides of 
the sequencing flowcell surface and immobilised them during the sequencing process. Short 
nucleotide sequences know as index tags or barcodes are incorporated in the adapter. 
Sequences tags allow genetic sequences to be distinguished during downstream analysis 
(Figure 2.5).   
 
 
 
Figure 2.4: Sequencing library construction. Fragmented DNA is end-repaired, A-tailed, 
and ligated to adapters with T-overhangs. The resulting template molecules can either be 
amplified by PCR to increase template amounts or hybridised to the flow cell surface for 
                                                                                                Chapter 2: Materials and methods 
 
 50 
sequencing or hybridised directly without performing PCR if the template amounts are 
sufficient (reproduced from Kozarewa et al.[206]). 
 
Libraries can be constructed using one of two strategies for barcoding or indexing (Figure 
2.5): uniplex or in-line index tags, which are incorporated adjacent to the sample DNA, but 
just before the T overhang, and make use of the same primer as the sequence read (Figure 
2.5A); or multiplex index tags that are in the adapter stem arm of the library and require 
independent priming (Figure 2.5B). 
 
 
 
Figure 2.5: Strategies for barcoding sequence libraries. (A) Uniplex or in-line index tags. 
(B) Multiplex index tags. 
 
Multiplex library construction was used for this study, with a 200 bp insertion size, and 54 
nucleotide or 108 nucleotide paired end (adapter) Illumina sequencing, followed by a third 7-
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nucleotide tag read, were performed according to standard protocols [165, 183]. Multiple 
samples were sequenced in parallel on a single run. This significantly reduced the sequencing 
time as samples are run simultaneously, and cost (about 20 times cheaper per 1000 bases) 
when compared to uniplex sequencing techniques. This required the incorporation of sample 
specific index tags into sequencing library adapters that were used as barcodes to identify the 
sample source of each sequence. This made it possible to generate genomic data for multiple 
bacterial isolates on a single sequencer lane providing sequence data scalability for large 
bacterial populations. Multiple libraries were pooled and sequenced in the same region on the 
Illumina Genome Analyser platform. Genomes were distinguished computationally according 
to their barcodes. All samples sequenced had a mean depth of 109.57X (minimum depth 
12X), implying that on average a single nucleotide position on the genome was sequenced up 
to 110 fold and the sequence data integrated (Appendix 1). This provided a very robust 
genomic dataset for downstream analysis. 
 
2.5: Genomic and statistical analysis  
 
Genomic and statistical analysis was performed using the approaches described in chapter 3. 
Briefly, core genes of highly recombinogenic pneumococcal strains of multiple diverse 
lineages were defined using a robust novel reference-free genome analysis pipeline. Core 
genome extrapolations were made with higher precision by fitting a novel double-exponential 
decaying function. The extent of gene gain and gene loss along the genomes of multiple 
diverse lineages in the datasets was evaluated by employing robust probabilistic models that 
are more biologically plausible. In depth discussion of the development and use of methods 
are in chapter 3.
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CHAPTER 3 
 
Bioinformatics methods, pipelines and statistical analysis 
 
3.1: Introduction 
 
Recent advances in next-generation sequencing (NGS) technologies have provided fast, and 
cost-effective means of generating robust, large-scale, sequence data required to unravel the 
broad spectrum of genetic diversity from different organisms [169, 170]. Analysis of such 
datasets can be extremely time-consuming and requires the development of analysis tools 
necessary for data processing, to be able to make correct interpretations of the new genomic 
data. Many tools for analysing NGS data have been developed [207]. While these tools are 
invaluable solutions to specific scientific questions, still, new and bespoke tools are required 
to tackle the gaps in analysis and address new questions that cannot be effectively addressed 
using currently available tools. This chapter gives details on the bioinformatics methods; 
pipelines and statistical analysis approaches used throughout this project, as the basis for the 
result chapters (Chapters 4, 5 and 6).  
 
Contemporary prokaryotic whole-genome studies have employed reference-based approaches 
to study microbial genetic diversity within strains that exhibit small amounts of genetic 
variations [165, 191] or single lineages of highly recombinogenic strains [183]. Reference-
based approaches entail the mapping of draft genome sequences against a completely 
sequenced reference genome. The reference genome is usually from the same or a very 
closely related species in order to allow correlation between similar genes. It is this 
correlation that enables comparisons between genomes to be made, permitting genetic 
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variation to be comprehensively catalogued. Mapping of reads to a reference genome allows 
precise and robust reconstruction of strain phylogenies and provides a better understanding of 
clonal evolution [165, 183]. However, a high quality, complete, well-annotated reference 
chromosome is required, to be able to differentiate between true variation and sequencing 
artefacts, and to resolve the underlying genetic diversity [208]. The mapping process involves 
aligning of individual reads to the reference and there is a high risk of many reads spanning 
gene insertions and deletions being misaligned, and careful analysis using optimal thresholds 
is required. Moreover, application of a reference-based approach would not be ideal for 
analysis of highly recombinogenic, multiple diverse clones, as it would lead to a loss of 
variation, restricted by genes present in the reference [209] (Figure 3.1). It is also difficult to 
assign ancestral clones that can be used as references, since the date of isolation does not 
always correspond with age of a lineage. 
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Figure 3.1: Mapping of draft genomes to an annotated reference. Annotated draft 
genomes B, C and D are mapped to a reference genome A. Although the available genes in 
the draft genomes that are present on the reference will map, the genes that are absent (Gene 
11 and 12) will not and this diversity will not be represented in the downstream analysis. 
 
In this thesis, to study genetic diversity of pneumococci from multiple lineages a clustering 
approach was employed. In the clustering methods, similar genes from multiple genomes are 
classified into the same group if they have sequence similarities and share the same 
biological functions (Chapter 3.5). This allows comparison of genetic variation between 
genomes. For this work, genomes were first subjected to preprocessing, that involved: 
genotype and serotype determination, assembly and annotation. A clustering based pipeline 
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that allowed reference-free analysis of multiple diverse lineage datasets was developed 
(Appendix 2 to 5). 
 
3.2: Serotyping and Multilocus Sequence typing (MLST) 
 
The isolates serotypes and sequence types (STs) were derived from genome sequences using 
established protocols, developed by Croucher et al. [183]. Briefly, the sequences of 94 
pneumococcal capsular loci were concatenated and Illumina sequence reads were 
redundantly aligned against this reference using Burrows-Wheeler aligner (BWA) [210]. The 
capsular locus with the largest segments of its length covered by mapped sequence reads was 
considered to be that encoding the capsule, enabling the serotype to be identified.  
 
The sequences of the seven loci used for sequence typing, along with several hundred base 
pairs of flanking sequence, were obtained either from the genome of S.pneumoniae serotype 
23F ATCC700669 genome (NCBI accession number FM211187) or S. pneumoniae serotype 
3 OXC141 [183], which are two genomes routinely used as reference by the S. pneumoniae 
sequencing group at the Wellcome Trust Sanger Institute (WTSI) [183, 211, 212]. Five 
passes of Illumina read mapping were then used to iteratively transform the reference 
sequences into those of the sequenced isolate using ICORN (iterative correction of reference 
nucleotides) [213]. Once transformed the best alignments between the reference and the 
sequence isolates were used to determine the MLST allele identities and consequently the 
isolates allelic profiles. The allelic profiles were then analysed using www.mlst.net [214], 
which is large MLST database that contains sequence type information from global collection 
of pneumococcal isolates, to establish sequence types. The analysis involved comparison of 
this study’s MLST profiles with those already present in the MLST database to determine 
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their sequence types. There were cases where new sequence types that had not been 
previously reported were observed in this study’s dataset. These isolates sequence types was 
labelled as “Unknown”. 
 
The isolates belong to different serotypes (Figure 3.2) and different clonal types as 
determined by MLST (Figure 3.3), and consequently vary in their potential to cause invasive 
disease [107].  
 
 
 
Figure 3.2: The distribution of serotypes in the dataset. Serotype 1 is the predominant 
serotype associated with severe invasive disease in Malawi, and was also the most common 
serotype in this set of isolates (n =140) that was collected between 2002 an 2008. 
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Figure 3.3: The frequencies of STs in the dataset. Most isolates had novel STs (Unknown) 
that had not been previously reported on the MLST database. ST 217, which is associated 
with serotype 1, had the highest frequency among the known genotypes. 
 
3.3: Draft genome sequence assembly and annotation pipeline 
 
An annotation pipeline was developed that assembled, ordered and annotated sequence data 
in a less labour intensive and less time consuming manner (Appendix 2). De novo sequence 
assembly was performed using Velvet v 0.7.03, a de Bruijn graph-based assembler [215].  In 
the de Bruijn graphs strategy data analysis is not organised around reads but around words of 
k nucleotides (k-mer(s)) [215]. Velvet was optimized to run with the longest k-mer that gave 
an expected coverage value above 20 [183]. The draft genome assemblies were ordered 
against the S. pneumoniae serotype 23F ATCC700669 genome (NCBI accession number 
FM211187) [183, 216] using algorithm-based automatic contiguation of assembled 
sequences (ABACAS) [217] and Artemis comparison tool (ACT) [218]. ACT is part of the 
Artemis genome browser and annotation suite, and is used for visualisation of pairwise 
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comparisons between two or more DNA sequences. The S. pneumoniae serotype 23F 
ATCC700669 genome, a completely sequenced, well-annotated, high quality chromosome 
frequently used pneumococcal genome biology protocols at WTSI [183, 216], was used. 
ABACAS was used to align, order and orient overlapping contigs in the draft assemblies, 
resulting in high quality contiguated draft genome sequences. ACT a comparative genome 
browser, was used to visualize the draft genomes. The draft genomes were then annotated 
using Glimmer3 [219]. Glimmer3 is a gene-finding software used for accurate automated 
identification of genes in bacteria, archaea and viruses. The annotated draft genomes were 
converted to European molecular biology laboratory (EMBL) format using the European 
molecular biology open software suite (EMBOSS) program [220]. The EMBL files were 
used as the input for the clustering process. The analysis performed by the pipeline was 
logged in a file produced by the pipeline, allowing quick detection of any errors. 
 
3.4: Gene clustering pipeline 
 
Orthologs are genes related by common descent, by speciation [221, 222]. Paralogs are 
created by duplication within a genome [222]. Orthologs are likely to retain the same 
function in the course of evolution [222-224]. Paralogs may retain the same function or 
evolve new functions that are related to or different from the original function [223, 224]. 
This is because of lack of the original selective pressure on one or more copies of the 
duplicated genes, therefore making it/them free to mutate and acquire new functions [221, 
223, 224]. Mapping of orthologs against reference genomes helps to identify genes that have 
identical biological functions. A weakness of this approach is that, although the gene 
sequences may be highly similar, they may not be representative of the true orthologs and 
may in reality be functionally different (paralogs), due to the presence of paralogs within 
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protein families. Moreover, the use of a reference genome sequence, on to which other 
genome sequence reads are mapped leads to a tremendous loss of variation, restricted by 
genes present in the reference, based on sequence similarity. An alternative is to use all-
versus-all BLAST comparison of complete proteomes to reveal elementary one-to-one 
ortholog relationships [225]. However, this method is not suitable for the analysis of multiple 
fully sequenced genomes due to time constraints, since this method relies on a sequential 
one-to-one ortholog comparison, and less accurately distinguishes orthologs from paralogs. 
In order to address the question: “Which genes in bacterial genomes share the same 
biological function?” clustering methods have advantages in that they are much faster and 
more accurately distinguish between orthologs and paralogs. However, some of the existing 
clustering methods have two main limitations:  
 
i. they require gene homology similarity data as their initial input data during analysis, 
since applying multiple sequence alignment among all proteins is computationally 
expensive [222].   
ii. most algorithms may be confounded by a local optima in K-means clustering, that is 
they are not implemented to find the “best” starting values during dataset analysis, 
and therefore do not give the best results possible [226].  
 
This is further confounded by extensive gene duplications and functional redundancy (that is 
presence of paralogs), which may result in false positives and mega-clusters. Furthermore, a 
distinction should be made between in-paralogs or recent paralogs (genes duplicated after 
speciation and are likely to retain similar function) and out-paralogs or ancient paralogs 
(genes duplicated before speciation and are likely to acquire new function) (Figure 3.4). 
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Figure 3.4: The concept of orthology and paralogy. (A) Shows homology subtypes of 
orthologs and paralogs. Speciation events result in three species: A, B and C. Speciation and 
gene duplication evolutionary events result in the genes A1, B1, B2, C1, C2, and C3. (B,C) 
Gene duplication of ancestral gene generating paralogs and orthologs followed by a 
speciation event yielding species 1 and 2. Diagram (B) emphasises the final connection 
between paralogs and orthologs. Diagram (C) shows a Fitch representation of the same. The 
events in (B) and (C) are a subset of the four events shown in (A) (gene duplication 1 and 
speciation 2), but using different labels (reproduced from Jensen et al. [224]). 
 
The pneumococcal genome datasets in this thesis (n = 140) were clustered using OrthoMCL 
[222]. OrthoMCL differentiates functional redundancy from divergence, is able to identify 
recent paralogs that are incorporated into ortholog groups within the same genome, and has 
the capacity to resolve many-to-many orthologous relationships, making it useful for multiple 
genome comparisons [222]. A clustering pipeline was therefore developed based on 
OrthoMCL (Appendix 3). 
 
The process of clustering identified orthologous genes, and orthologs found in all the 
genomes in the dataset were used to define the core genome [192]. The clustering of 
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orthologous genes provided a robust basis for comparing and combining data from multiple 
genomes. This method first involved clustering all homologous genes regardless of whether 
they are orthologous or paralogous and then distinguishing them downstream, based on 
annotation from finished reference genomes. This was beneficial when dealing with 
pneumococcal genomes, which are highly recombinant and have a numerous repetitive 
sequences. The use of this approach allowed the extension of the core genome concept, 
which only defines known annotated genes, to include uncharacterised or hypothetical genes 
that are found across the entire dataset and could have important roles (Chapter 4).  
 
The clustering process first involved the computation of pairwise similarities of the annotated 
genomic datasets, which were in EMBL format, using all-versus-all BLASTp comparisons of 
amino acid sequences. Reciprocal best similarity pairs were identified as putative orthologous 
relationships, and a p-value cut-off of 1e-5 recommended from empirical studies was tested, 
and also used during analysis [222]. The BLAST results were then used to generate a 
similarity matrix, which was normalised prior to a Markov clustering process to identify the 
ortholog groups. The MCL graph-clustering algorithm included a parameter that adjusted the 
cluster sizes, also known as the inflation index [222, 227]. The inflation index had a subtle 
impact on results, and a recommended value of 1.5 was applied. Increasing the inflation 
index value would increase the tightness of the cluster, and the opposite is true for lower 
inflation index values. 
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3.5: Definition of the core genome 
 
3.5.1: Annotation transfer from reference to draft genomes 
 
Annotations from 12 publicly available, complete, fully annotated reference genomes (Table 
3.1) were transferred onto the Glimmer3 annotated draft genomes through a process of 
clustering.  
 
Orthologs were determined using OrthoMCL by clustering the draft genomes together with 
the 12 reference genomes, using default parameters (BLASTp E-value cut-off 1e-5 and 
inflation index 1.5) [222]. Once the draft genome datasets were annotated, they were 
clustered without the 12 reference genomes to obtain only orthologous clusters of the draft 
genomes, which constitute the sampled bacterial genomes under investigation. The 
OrthoMCL output was used to establish the core genome for the datasets. 
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3.5.2: Determination of the core genome sizes 
 
A pipeline was developed to organise the clustering analysis results, visualize the results, 
compute the size of the core genome size and identify the core genes (Appendix 4). The 
OrthoMCL ortholog clusters were first organised into a matrix of genome content (Figure 
3.5). The clustered gene results could be divided into three: the core genome that consists of 
single copies of orthologs per genome that constitute mainly housekeeping genes, paralogs 
and the accessory or dispensable genome (Figure 3.5). Poor quality genomes could be 
identified by visualization (Figure 3.6) and excluded from the analysis.  
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Figure 3.5:  Matrix of genome content. The clustered genes were organised into a matrix of 
genome content and visualised. All the genes present (red) were visualised on a blue 
background, and were categorized into three groups: (A) paralogs, (B) core genes and (C) 
accessory genes. 
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Figure 3.6:  Identification of poor quality genomes. All the genes present (red) were 
visualized on a blue background, and were categorized into three groups: (A) paralogs, (B) 
core genes and (C) accessory genes. In this example genomes 5 and 11 were of poor quality 
because they had an overrepresentation of paralogs (genome 5) and accessory genes 
(genomes 5 and 11). Genome 53 also had gene clusters in (B) that was absent in all the other 
genomes. This visualisation technique was used to highlight suspected genome anomalies, 
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and prompted further investigations to ensure that only high quality genomes were used for 
analysis in order to make correct interpretations from the data  
 
The core genome sizes were established conservatively and objectively, by computing the 
number of genes present across all genomes sampled iteratively in an arithmetic progression 
approach. 
 
Only genes that were shared by all the isolates used in the analysis were considered. As 
reported previously, the core genome size was dependent on the number of strains used 
during analysis [192], and gradually decreased with addition of new genomes. The 
OrthoMCL ortholog clusters were organised into a matrix of genome content, using Perl 
scripts, (Appendix 4) with genomes arranged in columns and orthologs in rows. A blank (“-”) 
was inserted where an ortholog was absent. Genomes (the matrix columns) were randomly 
sampled in an arithmetic progression fashion, using the formula: 
 
                          SN = N/2[2a + (N-1) d]. 
 
The number of random sampling events, SN, was established using the least number of 
genome(s) under consideration, a (i.e. 1 genome in this study), the total number of genomes 
under consideration (i.e. the dataset size), N, and the common difference of successive 
genomes, d, (i.e. 1) to be used during sampling. During random sampling, the total number of 
genomes, N, was initialized as 1 genome for the first event, and increased by one unit for 
each of the subsequent events, until it was equivalent to the total number of genomes in the 
dataset in the final event. The random genomes were only sampled once during each event 
and the total number of orthologs shared by all genomes was counted once for each cluster, 
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thereby excluding paralogous counts. This was iterated 100 times resulting in 100 input 
orders for each event; the arithmetic average core genome size was computed for each event 
to enable the average core genome size to be related to the number of genomes sampled. 
Comparisons of core genomes from different sub-datasets were achieved using Perl scripts 
and STATA v 9.2 (Stata Corp, College Station, TX, USA), by matching the core genome 
clusters using their annotations to identify the common core genes.   
 
3.6: Extrapolation of the core genome sizes 
 
To ensure that the core genomes reached plateaus where there would be no further changes in 
their size, the absolute core genome size was extrapolated by fitting exponential-decaying 
functions as previously described by Tettelin et al. [192]. In this thesis, two distinct decay 
phases were identified, so the following double exponential model was fitted to the data using 
the Levenberg-Marquardt iterative estimation method: 
 
y  =  kc1.exp(-n/tc1) + kc2.exp(-n/tc2) + gamma. 
 
In this model, y is the size of the core genome, n is the number of sequenced strains, kc1 and 
tc1 are the exponent and free parameters respectively for the first decay phase, kc2 and tc2 are 
the exponent and free parameters respectively for the second decay phase, and gamma is the 
predicted value of the core genome size with an infinite number of sequenced strains. The 
results of this model are discussed in chapter 4. 
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3.7: Reconstruction of phylogenetic trees 
 
Maximum likelihood phylogenies were reconstructed using the core genes present in the 
dataset under study. Orthologous core gene sets were aligned individually using MUSCLE 
[228]. The individual alignments were concatenated into a single giant alignment. A 
maximum likelihood tree was then generated using RAxML [229]. 
 
3.8: Inference of population structure and genetic flux using phyletic patterns 
 
3.8.1: Determination of genetic population structure using principal component analysis 
(PCA) 
 
Bacteria have intricate population structures, which are further complicated by recombination 
events that might obscure phylogenetic signals [230]. Robust sequence-based approaches that 
determine genetic relatedness are required to explore bacterial population structure and 
evolution. MLST has been used to study the structure of clinically important bacterial 
pathogens [36]. However, MLST makes use of a very small proportion of the genome and 
cannot differentiate closely related isolates [165]. More recently, genome-wide distribution of 
single-nucleotide polymorphisms (SNPs) has been used to resolve population structure [165, 
191]. This approach has also been successfully used to study a single pneumococcal lineage 
(Pneumococcal Molecular Epidemiology Network clone 1 (PMEN1)) [183].  However, the 
high rates of pneumococcal recombination make it difficult to apply this method to 
pneumococcal datasets consisting of multiple lineages. Therefore, a robust, computationally 
efficient principal component analysis (PCA) method was developed to examine whether the 
gene presence and absence profiles (phyletic patterns) could be used to resolve population 
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structures (Appendix 5), using R v 1.40 [231]. The proportion of variance explained by the 
principle components was examined, and it helped to infer the axes that sufficiently 
explained genetic variation in the dataset.  The method allowed the data to be observed from 
different viewpoints (Figure 3.7). The results of this method are discussed in Chapter 5. 
 
 
 
Figure 3.7: The different viewpoints that can be used to observe the data using the PCA 
method. 
 
3.8.2: Inference of genomic flux using the Gain and Loss Mapping Engine 
 
Different genomes have varying number of genes. This variation may be as a result of 
differences in the number of paralogs present from genome-to-genome or dissimilarities in 
the presence of various gene families [232-234]. Studying these genome content variations is 
an important aspect of genome biology, as it helps understand the evolution of different 
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strains and alterations of their functional proteome [235]. Biologically accurate models are 
essential for correct interpretations of research questions addressing speciation, acquisition of 
new functions, and adaptation to different ecological niches. Several computational models 
for studying these genome content variations have been advanced, but they have the 
following limitations [235]: 
 
i. Methods that use compositional disagreements, such as atypical GC content or codon 
usage patterns, to distinguish between the genes under scrutiny and the genomes that 
contain them rely on dissimilarities in traits between them, and fail when these 
differences are subtle or undetectable.  
 
ii. Other methods that use phylogenetic disagreements to estimate recombination are 
limited to the most common genes present in the genomes being studied, and fail in 
cases of extreme sequence divergence or conservation. 
 
iii. Statistical approaches that study phyletic patterns in general have been developed. 
However, some consider an oversimplified description of genome content variations 
and do not account for differing rates of gene gain and loss across gene families.  
 
In this work, a robust statistical framework that implements probabilistic models, Gain and 
Loss Mapping Engine (GLOOME) [235, 236], was used to investigate the degree to which 
pneumococcal genome content varies within and across lineages, and in different ecological 
niche. This method implements probabilistic models, that are more biologically realistic, to 
analyse lineage-specific gene gain and loss dynamics using a mixture model approach. The 
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mixture model accounts for variation in rates of gene gain and loss, which have been shown 
to vary greatly between gene families [235, 237].  
 
This method was used to infer the probability and expectation of transferability for each gene 
along the genomes under examination, and to reliably infer likelihood of gain and loss events 
for gene families across entire datasets. The results of this method are discussed in Chapter 5. 
 
3.8.3: Assessment of agreement using Bland and Altman plots 
 
Agreement between measurement methods can be assessed using Bland and Altman plots 
[238]. In a Bland and Altman plot, the difference between two measurements for each subject 
is plotted against the arithmetic mean of the two measurements (Figure 3.8). The Cartesian 
coordinates of a sample S, with two different measurement values V1 and V2 is: 
 
S(x,y) = ((V1+V2)/2, (V1-V2)). 
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Figure 3.8: Bland and Altman plot used to calculate agreement between two different 
measurement values V1 and V2.  
 
Bland and Altman plots are calculated in log scale when the differences between two 
measurements, (V1-V2), increase with increases of the arithmetic means of the two 
measurements, (V1+V2)/2, (Figure 3.9). The Cartesian coordinates of a sample So, with two 
different measurement values V1 and V2 calculated in log scale is: 
 
So(xo,yo) = ((logV1+logV2)/2, (logV1-logV2)). 
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Figure 3.9: Bland and Altman plot in log scale used to calculate agreement between two 
different measurement values V1 and V2.  
 
Agreements on the extent of genetic flux for gene families between datasets were determined 
using Bland and Altman plots. Log scales were used to calculate agreement because the 
spread of differences increased with increasing means of the observations. This method 
allowed definitive conclusions about the extent of genetic flux. The results of this method are 
discussed in chapter 5. 
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3.9: Discussion  
 
Sophisticated computational algorithms are required to be able to mine relevant biological 
information from immense comparative genomic datasets. A vast repertoire of bioinformatics 
analysis tools exists. However, new and improved bespoke tools are still required to address 
new research questions or to tackle the gaps not addressed by existing tools. Recent 
sequencing technologies that are cheaper and generate high quality sequence data at a faster 
rate have led to a significant increase in the amount of prokaryotic sequence data available. In 
this thesis, various bioinformatics and statistical techniques were employed to explore genetic 
diversity in pneumococcal datasets of multiple diverse lineages. A number of existing 
bioinformatics tools were used to analyse genomic sequence data in order to extract 
meaningful information that could be correctly interpreted. However, bespoke methods were 
also developed to identify and calculate the size of the core genome, to establish the 
population structure. These methods were incorporated into pipelines that were used to 
efficiently mine data (Appendix 2 to 5). 
  
3.9.1: Core genome 
 
Determination of the core genome composition was essential for understanding the 
relationship between meningitic and bloodstream-associated pneumococci, and to establish 
the mechanisms facilitating the tropism for CSF invasion.  
 
Reference-based methods have been developed for core genome analysis, but they are 
suitable for the analysis of genomes from species with low levels of variations. As discussed 
a reference-based method has previously been used to study the pneumococcal PMEN1 
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lineage [183]. However, this method could not be exploited to study multiple diverse 
lineages. A clustering approach was therefore employed to manage multiple diverse lineage 
datasets. The method developed was robust and capable of resolving many-to-many 
orthologous relationships allowing the extension of the core genome concept to include 
uncharacterized or hypothetical genes that might play vital virulence, metabolic and 
regulatory roles. The method also allowed the detection and removal of poor quality genomes 
from downstream analysis, ensuring that only high quality genomes were analysed. This 
ensured that the results could be interpreted robustly and that only accurate conclusions were 
drawn from the analysis. 
 
A double-exponential decaying function that fitted the data more accurately was developed to 
extrapolate the core genome size to infinity. This model was used in Chapter 4 to investigate 
the point at which the core genome plateaus. At the plateau the core genome size was 
constant and additional genomes had no effect on size. This is important because at the 
plateau the pneumococcal species core genome size can be determined. 
 
3.9.2: Genetic flux 
 
Different bacteria are adapted to colonizing different microbial ecologies [239]. The 
pneumococcus is able to colonise a variety of host ecological environments, and this is 
displayed by its ability to colonise the nasopharynx as a commensal and to invade the host’s 
sterile sites, such as the lungs, blood and CSF, causing invasive disease. The genetic 
composition of bacteria varies according to the lifestyle they are adapted to, based on the 
niche they colonise. A PCA analysis method was developed to establish whether the genome 
content could be used to robustly determine the population structure. The proportion of 
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variance explained by the principle components determined the number of principle 
component axes used during the analysis. The least number of PCA axes that sufficiently 
explained variance was three. The results of this analysis are discussed in chapter 5 section 
5.2. Since the method robustly resolved the pneumococcal population structure, the genome 
content matrix was used to infer genomic flux.  
 
A robust probabilistic model, which was biologically feasible, was used to infer the patterns 
of gene gain and loss. The model implemented a mixture model that allowed the rate of 
genetic flux to vary between and within lineages, and across different gene families. The 
extent of gene loss and gain was accurately predicted for meningitic and bloodstream 
pneumococci. The results of this analysis are discussed in chapter 5 sections 5.3 to 5.5. 
 
3.10: Conclusion 
 
A bespoke pipeline was developed to specifically determine the composition of the core 
genome. The pipeline was composed of existing (for example sequence assembly, gene 
annotation, MLST and serotyping programs) and newly developed (for example pipeline for 
clustering pipelines, computationally efficient PCA analysis methods to resolve population 
structure, and a pipeline for genetic flux inference) bespoke bioinformatics tools and 
statistical analysis methods (for example the Bland-Altman plots). The tools were able to 
accurately calculate the size and composition of the core genome. A PCA method that 
robustly determined population structure using phyletic patterns was also developed, after 
establishing that phyletic patterns can be used to resolve the pneumococcal population 
structure. Phyletic patterns were used to infer gene gain and loss events in bloodstream and 
meningitic pneumococcal datasets.  
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CHAPTER 4 
 
Genetic diversity amongst bacteraemia and meningitis causing Streptococcus 
pneumoniae 
 
4.1: Introduction 
 
Nasopharyngeal colonisation is the prerequisite for the complex multistep process that leads 
to pneumococcal blood stream invasion and subsequently meningitis [5]. The blood–brain 
barrier (BBB) normally protects the brain from most bacteria that reach blood stream, 
through very tight cellular junctions that allow very low rates of pinocytosis restricting the 
aetiology of bacterial meningitis to a few, predominantly encapsulated extracellular 
pathogens including the pneumococcus [124]. The ability of the pneumococcus to cross the 
BBB either through host endothelial receptor engagement, cytoskeletal rearrangement and 
transcytosis or by infecting migrating phagocytes is crucial for cerebral spinal fluid (CSF) 
invasion (Figure 4.1) [124, 133, 139, 240]. The avoidance of immune surveillance and the 
capacity of S. pneumoniae to grow and survive in the relatively hostile meningeal space 
facilitate this process [124, 161].  
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Figure 4.1: Pneumococci crossing the blood-brain barrier (BBB). Shows hematogenous 
pneumococcal meningitis. Bacteraemic pneumococci cross the BBB by host endothelial 
receptor engagement (A) and transcytosis (B) (redrawn by Benard Kulohoma, reproduced 
from Mook-Kanamori et al. [124]). 
 
4.1.1: Pathogenesis and pathophysiology of pneumococcal meningitis  
 
Bacterial meningitis is an intense host inflammatory process triggered by bacteria and 
bacterial products that is focused on the subarachnoid space (Figure 4.2) [122, 132, 133, 
139]. Human host factors in addition to HIV have been identified that determine 
susceptibility to and the severity of invasive pneumococcal disease (IPD) in many 
environments. These include extremes of age, splenic dysfunction, sickle cell disease, 
malignancy, chronic liver disease, malnutrition and diabetes [12, 241]. 
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Figure 4.2: Pneumococcal meningitis at the subarachnoid space. Shows hematogenous 
pneumococci associated with meningitis crossing the BBB, thereby triggering host immune 
responses (redrawn by Benard Kulohoma, reproduced from the Qiagen gene-globe pathways 
[242]).  
 
However, the identification of bacterial determinants that explain the tropism of this 
capsulated bacterium for the brain has been elusive. While certain pneumococcal capsule 
serotypes, each with a different propensity to cause IPD, are particularly associated with IPD 
in humans, for example serotype 1 in sub-Saharan Africa [18, 49], there is currently no 
evidence that the serotypes or indeed the sequence types (STs), which are used to classify 
pneumococci into serological and genetic lineages respectively (refer to Chapter 1: 
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Introduction), that cause meningitis are distinct from those that do not [243]. S. pneumoniae 
is highly adapted to colonisation of humans and onward transmission to susceptible hosts [5]. 
This is facilitated both by mutations and by frequent transfers of genetic material (horizontal 
gene transfer), between strains and across bacterial species [53, 81, 183]. This highly active 
process results in considerable redundancy in the range of tools available to S. pneumoniae 
that target host receptors, enabling the pneumococcus to overcome the mucosal barrier and 
survive in the nasopharynx (Figure 4.3) [121, 122, 161, 244].  
 
 
 
Figure 4.3: S. pneumoniae evasion of host barriers to colonisation at the nasopharynx. 
Pneumococci are able to evade mucus entrapment by breaking-down mucus using 
neuraminidase A (NanA), beta-galactosidase A (BgaA), beta-N-acetylglucosaminidase 
(StrH), and neuraminidase B (NanB), while pneumolysin (Ply) hinders mucosal epithelium 
ciliary beating thereby facilitating nasopharyngeal colonisation (A). IgA protease subverts 
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IgA antigen specificity enhancing persistence on the mucosal surface, while N-
acetylglucosamine-deacetylase A (PdgA) and O-acetyltransferase (Adr) deacetylate 
pneumococcal surface peptidoglycan molecules rendering them resistant to lysozyme activity 
(B). Pneumococcal receptors pyruvate oxidase (spxB), Oligopeptide ABC transporter, 
oligopeptide binding protein (ami), macrolide efflux system encoded by mefE/mel (msrA) 
and permease like protein (plpA) facilitate adherence to host mucosal epithelium via GalNac 
receptors enhancing colonisation (C). Pneumococci are transcystosed across the mucosal 
epithelium into the blood through interactions of their surface antigens (phosphocholine 
(ChoP) and choline binding protein A (PspC or CbpA)) with host receptors (platelet-
activating factor (PAFr) and polymeric immunoglobulin receptor (pIgR) respectively) (D). 
Pneumococci translocate across the mucosal epithelium through intercellular and pericellular 
routes antigens-plasminogen complexes that facilitate degradation of inter-epithelial cell 
junctions (E) (redrawn by Benard Kulohoma, reproduced from Mook-Kanamori et al. [124]).  
 
Although meningitis is largely a dead end for the pneumococcus in terms of colonisation and 
onward transmission, meningeal invasion presumably results from the utilisation of one or 
more of the mechanisms evolved for these purposes.  
 
4.1.2: Evolutionary genetics of pneumococcal meningitis 
 
Pneumococci exist as highly diverse genetic lineages that can be serologically classified into 
more than 92 serotypes based on the haplotypes of their polysaccharide capsules [15, 81, 
163]. This genetic diversity is due to recombination events that enable them acquire and 
transfer nucleic acid material with other microorganisms in their niche [81]. Their 
recombinogenic nature enables them to readily avoid the host’s immune surveillance, to 
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escape vaccines by swapping vaccine targets for non-targeted antigens, acquire drug 
resistance determinants, and survive in hostile environments [53, 81, 114, 132]. Although the 
population structure and evolutionary genetics of pneumococci are well defined [42, 81, 157, 
183, 245], there is only limited understanding of the mechanisms that determine these host-
pathogen interactions in humans, which is supported largely by data from tissue culture 
models and animal studies [132, 133, 139]. More specifically, it is not clear whether 
pneumococci that cause meningitis are genetically distinct from those that do not. A single 
meningitis-associated pneumococcal genome would not adequately describe how genetic 
variability influences pathogenesis, because it is not representative of the genetic diversity 
that exists within genetically highly diverse pneumococcal populations. High-throughput 
genome sequencing of large collections of disease-causing strains have provided the 
opportunity to examine the genetic basis of pneumococcal virulence in humans. This study 
explored the possibility that while a range of pneumococcal strains are capable of 
bacteraemia, only strains that possess a distinct minimum set of genes (the meningitis core 
genome) are able to circumvent the blood-brain barrier and survive in an otherwise hostile 
environment to cause meningeal inflammation. Detailed examination of the differences 
between bacteraemic and meningitis causing pneumococcal strains were performed using 
whole genome sequencing (refer to Chapter 2: Materials and methods, and Chapter 3: 
Bioinformatics methods, pipelines and statistical analysis). 
 
4.2: Pneumococcal core genome 
 
This study first set out to define the pneumococcal core genome (Chapter 1.6.1.1), which 
consists of the genes that are common to all the invasive pneumococcal isolates, as opposed 
to the accessory genome which contains the genes that have been identified in at least one 
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and not all invasive pneumococcal isolates. Identification of genes that are always present in 
invasive pneumococcal isolates will highlight key genes required for host invasion, survival 
and immune response evasion, enabling a better understanding of the different combinations 
of mechanisms involved during this processes. In a relatively much smaller study, Hiller and 
colleagues have previously studied this subject by analysing 17 pneumococcal genomes 
(eight from nasopharyngeal isolates from paediatric patients and nine invasive and avirulent 
isolates that were publically available) using a clustering algorithm. They found that 1454 
genes (46%) were conserved among all strains [212]. In the present study, 140 randomly 
selected invasive pneumococcal isolates from Malawian adults and children associated with 
bacteraemia (n = 70) and meningitis (n = 70) (Chapter 2.4) [29, 64, 246] were used to 
establish whether genetic determinants that determine different disease outcomes 
(bacteraemia and meningitis) exist. The isolates belong to different serotypes and clonal types 
as determined by MLST (Chapter 3.2), and consequently vary in their invasive propensity to 
cause invasive disease. The process of clustering was used to identify orthologous genes, and 
the core genome was defined, i.e. the genes universally found in all the genomes [192]. The 
clustering of orthologous genes provided a robust basis for comparing and combining data 
from multiple diverse genomes. Mapping of clones from multiple lineages to a single 
reference genome would result in a tremendous loss of variation, restricted by genes present 
in the reference strain, and would not be ideal for analysis of highly recombinogenic, 
multiple diverse clones of different lineages (Chapter 3.4). To circumvent this problem, 
annotated genomes were clustered using OrthoMCL with default settings (BLASTp E-value 
cut-off 1e-5 and inflation index 1.5) [222], and then organised into a matrix of genome 
content, the core genome size was calculated by computing the number of genes present 
across all genomes sampled iteratively in an arithmetic progression approach (Chapter 3.5). 
The core genome of the entire 140 isolate dataset consisted of 1292 genes (Figure 4.4). This 
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compared favourably with the previously defined pneumococcal core genome and should be 
a more precise estimate than the previous analysis, which used only 17 genomes [212].  
 
 
 
Figure 4.4: The core genome of the entire 140 isolate dataset. It consisted of 1292 genes. 
This comparative genome analysis approach showed that there was a high degree of genetic 
diversity in the pneumococcal genome, with only around 50% and not the entire genome 
being common in all pneumococci. However, despite the high genetic diversity among 
pneumococci a sizeable proportion of their genes are common to all pneumococcal strains. 
Important virulence genes that are always present can be explored as therapeutic and 
diagnostic targets.  
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4.3: Comparison of the core genomes of CSF and blood pneumococcal isolates 
 
This study also examined whether a range of pneumococcal strains that were capable of 
bacteraemia were genetically distinct from those that caused meningeal infection. It is still 
unclear whether pneumococci capable of causing different disease outcomes (bacteraemia 
and meningitis) have the same genes, and consequently employ similar or different invasion 
and survival mechanisms. The entire pneumococcal genomes dataset was first subdivided 
into two subsets: bacteraemia-associated and meningitis-associated based on the assumption 
that pneumococci within these two groups had similar lifestyles. The core genomes of the 
meningitis and bacteraemia subsets were then defined, using the previously described 
clustering method (Chapter 3.5). The two core genomes were then compared to test the 
hypothesis that there are distinct gene sets that are absolutely required for invasion, growth 
and persistence in a particular niche (Chapter 3.5).  
 
Following detailed analysis using the clustering and comparative genomics methods 
described previously (Chapter 3.5) it was determined that the core genome associated with 
meningitis causing isolates was both distinct and slightly larger than that of the bacteraemia 
core genome, 1388 vs. 1378 genes respectively (Figure 4.5). As can been seen in Figure 4.6A 
and Figure 4.7A, the differences between the meningitis and bacteraemia core genomes were 
not accounted for by the absence of large blocks or a large number of genes but usually 
between 1 to 11 genes (Figure 4.6B and Figure 4.7B), except one gene locus of meningitis-
associated core genome that was only present in 4 bacteraemia-associated genomes. Indeed 
some bacteraemia genomes contained the meningitis as well as the bacteraemia core genome; 
and some meningitis genomes contained the bacteraemia as well as the meningitis core 
genome. 
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Figure 4.5: Meningitis and bacteraemia associated pneumococcal core genomes plots 
based on 140 invasive isolates. Both subset core genomes were also markedly larger than 
that of the entire dataset (Figure 4.6). This is because these core genomes consisted of a 
relatively smaller number of genomes (50%, n = 70) compared to that of the entire dataset (n 
= 140), and these subset core genome sizes are expected to reduce with the addition of new 
genomes during analysis. 
   
   
   
C
ha
pt
er
 4
: G
en
et
ic
 d
iv
er
si
ty
 a
m
on
gs
t b
ac
te
ra
em
ia
 a
nd
 m
en
in
gi
tis
 c
au
si
ng
 p
ne
um
oc
oc
ci
  
  
88
 
 
Fi
gu
re
 4
.6
A
: T
he
 n
um
be
r 
ge
ne
s e
ss
en
tia
l f
or
 m
en
in
gi
tis
 m
is
si
ng
 in
 th
e 
ba
ct
er
ae
m
ia
-a
ss
oc
ia
te
d 
pn
eu
m
oc
oc
ca
l d
at
as
et
 (g
en
es
 p
re
se
nt
 a
nd
 
ab
se
nt
 a
re
 r
ep
re
se
nt
ed
 in
 r
ed
 a
nd
 b
lu
e 
re
sp
ec
tiv
el
y)
. S
ho
w
s o
nl
y 
a 
sm
al
l p
ro
po
rti
on
 o
f g
en
e 
is
 a
bs
en
t i
n 
ea
ch
 b
ac
te
ra
em
ia
-a
ss
oc
ia
te
d 
ge
no
m
e.
 
 
   
   
   
C
ha
pt
er
 4
: G
en
et
ic
 d
iv
er
si
ty
 a
m
on
gs
t b
ac
te
ra
em
ia
 a
nd
 m
en
in
gi
tis
 c
au
si
ng
 p
ne
um
oc
oc
ci
  
 
89
 
 
 Fi
gu
re
 4
.6
B
: T
he
 n
um
be
r 
of
 e
ss
en
tia
l g
en
es
 fo
r 
m
en
in
gi
tis
 m
is
si
ng
 in
 th
e 
ba
ct
er
ae
m
ia
-a
ss
oc
ia
te
d 
pn
eu
m
oc
oc
ca
l d
at
as
et
. 
   
   
   
C
ha
pt
er
 4
: G
en
et
ic
 d
iv
er
si
ty
 a
m
on
gs
t b
ac
te
ra
em
ia
 a
nd
 m
en
in
gi
tis
 c
au
si
ng
 p
ne
um
oc
oc
ci
  
  
90
 
 
Fi
gu
re
 4
.7
A
: 
T
he
 n
um
be
r 
ge
ne
s 
es
se
nt
ia
l 
ge
ne
s 
fo
r 
ba
ct
er
ae
m
ia
 m
is
si
ng
 i
n 
th
e 
m
en
in
gi
tis
-a
ss
oc
ia
te
d 
pn
eu
m
oc
oc
ca
l 
da
ta
se
t 
(g
en
es
 
pr
es
en
t 
an
d 
ab
se
nt
 a
re
 r
ep
re
se
nt
ed
 i
n 
re
d 
an
d 
bl
ue
 r
es
pe
ct
iv
el
y)
. S
ho
w
s 
on
ly
 a
 s
m
al
l 
pr
op
or
tio
n 
of
 g
en
e 
is
 a
bs
en
t 
in
 e
ac
h 
m
en
in
gi
tis
-
as
so
ci
at
ed
 g
en
om
e.
 
   
   
   
C
ha
pt
er
 4
: G
en
et
ic
 d
iv
er
si
ty
 a
m
on
gs
t b
ac
te
ra
em
ia
 a
nd
 m
en
in
gi
tis
 c
au
si
ng
 p
ne
um
oc
oc
ci
  
 
91
 
 
 Fi
gu
re
 4
.7
B
: T
he
 n
um
be
r 
of
 e
ss
en
tia
l g
en
es
 fo
r 
ba
ct
er
ae
m
ia
 m
is
si
ng
 in
 th
e 
m
en
in
gi
tis
-a
ss
oc
ia
te
d 
pn
eu
m
oc
oc
ca
l d
at
as
et
. 
   
         Chapter 4: Genetic diversity amongst bacteraemia and meningitis causing pneumococci  
 
 92 
 
 
 
Figure 4.8: Venn diagram of the meningitis-associated and bacteraemia-associated core 
genomes. Shows the number of genes that are common to both of them and those that are 
exclusive to the individual core genomes. 
 
The analysis showed clearly that both the bacteraemia and meningitis core genomes had 
genes that were common to both of them (common core genome) (Figure 4.8), which 
consisted of the all the core genes (n = 1292) of the entire pneumococcal isolates (n = 140) 
used in this study (Chapter 4.2). The finding of a meningitis associated pneumococcal core 
genome with a set of highly conserved genes (n = 96) not always present in pneumococci 
isolated from blood (Figure 4.8) suggested that these genes are necessary for invasion into, 
and then growth or survival within the meningeal compartment but are not essential for 
         Chapter 4: Genetic diversity amongst bacteraemia and meningitis causing pneumococci  
 93 
bacteraemia, defined as recovery of pneumococcus by blood culture. A core genome distinct 
from the meningitis core genome was also identified amongst the bacteraemia isolates (n = 
86). This raised the possibility that there are genes that are necessary for either persistence of 
the pneumococcus in the bloodstream or growth to reach levels sufficient to be detectable by 
routine blood culture but that are not essential for meningeal invasion. These data suggest 
that in the case of both meningitis and bacteraemia, the core genome can be viewed as a key 
that unlocks a pathogenesis pathway. Given that pneumococcal pathogenesis results from a 
complex set of host-pathogen interactions, it is not surprising that in this strain collection, 
there are bacteraemia strains that appear to possess both keys but did not cause clinical 
meningitis in that particular host; and likewise meningitis strains that appear to possess both 
keys but were not recovered from the blood. 
 
4.4: Extrapolation of core genome sizes 
 
In order to derive a more definitive estimate of the difference in core genome size between 
meningitis and bacteraemia strains, core genome size extrapolation using decaying function 
analysis, as previously described by Tettelin and colleagues, was performed [192]. The 
functions were used to determine the size of the core genome until it plateaued, after which 
there would be no significant change in size. However, instead of a single-exponential 
decaying function previously used by Tettelin and colleagues, a novel double-exponential 
decaying function (Chapter 3.6) that fitted the data to a higher degree of precision was used 
to extrapolate the data until it plateaued (Figure 4.9). The extrapolated results were consistent 
with those observed in the analysis of 140 genomes, and the extrapolated meningitis core 
genome reached a minimum of 1371 genes (95% CI 1362 to 1381; R2 = 99.7) and a minimum 
of 1365 genes (95% CI 1357 to 1373; R2 = 99.7) for the bacteraemia-associated core genome 
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when extrapolated to infinity. This suggested that even when the core genomes were 
extrapolated until they plateaued, there were no observable changes in core genome size of 
pneumococcal strains capable of meningeal infection would have a larger core genome size 
that those associated with blood stream infection. This provided strong support that the 
observed difference in core genome sizes persisted even when extrapolated to an infinite 
number of genomes as indicated by the robust R2 values. 
 
 
 
Figure 4.9: Extrapolation of the core genome sizes using the double-exponential model. 
The data was extrapolated by fitting a double exponential decaying function to evaluate the 
absolute number of genes in every meningitis and bacteraemia strain. The meningitis core 
genome reached a minimum of 1371 genes (95% CI 1362 to 1381; R2 = 99.7) versus a 
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minimum of 1365 genes (95% CI 1357 to 1373; R2 = 99.7) for the blood stream-associated 
core genome when extrapolated to infinity.   
 
4.5: Factors influencing the pneumococcal core genome 
 
In order to determine potential factors that might influence our core genome analysis, the 
following factors were assessed: the possibility of imbalanced sampling leading to the 
dominance of a particular clone in the analysis; the potential for the dominance of clones with 
large core genomes in the meningitis dataset; and the likelihood of an over representation of 
prophage and integrative conjugative elements (ICE) in the meningitis core genome dataset. 
 
4.5.1: Dominance of clones with large core genomes 
 
The pneumococcal isolates analysed were randomly selected prior to any form of 
phylogenetic analysis to avoid a selection bias and given the size of the dataset; there should 
be a clonal balance representative of the invasive strains in circulation. However, in many 
SSA countries, serotype 1 (ST217) accounts for over 30% of IPD [18, 49, 247], and in our 
randomly selected Malawian meningitis dataset accounted for 23% of isolates (16/70). It has 
been suggested that highly virulent serotype 1 pneumococcal isolates have genomic regions 
associated with pathogenicity that are absent in others that are intermediately virulent or 
avirulent [51, 243, 248]. Therefore to address the possibility that this meningitis-specific core 
genome is driven by a single serotype 1 clone, an identical analysis to those described 
previously (Chapter 3.5) was carried out with all ST217 isolates excluded. It was found that 
the difference between the meningitis and blood stream core genomes persisted (Figure 4.10).  
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Figure 4.10: Pneumococcal core genome analysis with the serotype 1 (ST217) genomes 
removed.  Sixteen serotype 1 isolates were removed from both the meningitis and the 
bacteria datasets. The number of genomes used in the analysis was 54 for both the meningitis 
and bacteraemia subsets. 
 
This supports the observation that the difference in core genome sizes was not a result of 
dominance of clones with a larger core genome size in the meningitis data subset, but was 
instead a result of other genetic factors that bestow all isolates associated with meningeal 
infection with the capacity to invade the CSF.  
 
The analysis was repeated using the ST217 clones alone, revealing that although the sample 
size was small, a similar core genome difference persisted (Figure 4.11). It was also noted 
that the difference in size exists within a single lineage. 
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Figure 4.11: Serotype 1 (ST217) core genome. Core genomes analysis of a single clone 
(ST217) was performed using the meningitis and bacteraemia datasets and the number of 
genes plotted as a function of the number of genomes used.  The meningitis-associated core 
genome was larger than that associated with bacteraemia even within a single lineage. 
 
4.5.2: Imbalanced sampling leading to the dominance of a particular clone 
 
To determine whether the observation remained robust and were not due to another particular 
clone or clade, the maximum likelihood phylogeny was reconstructed using the core genes 
(Figure 4.12), resulting in a robust phylogenetic trees (Chapter 3.7). The removal of potential 
areas of recombination would result in more robust phylogenetic trees [183], however, this 
was not possible because the dataset used had a diverse set of strains, not a single clone, and 
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did not have an ancestral strain to act as a reference. We noted that the phylogenetic trees 
have multiple distinct branches indicating a high level of genome-wide diversity, with closely 
related clones (clades) on the same ancestral node. This provides further confidence that the 
core genomic differences result from diverse sets of clones.
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4.5.3: Over representation of prophage and integrative conjugative elements 
 
To establish whether the presence of prophage and integrative conjugative elements (ICE) in 
the meningitis core genome made it larger, the entire datasets were mapped against the fully 
annotated reference genome of PMEN1 Spain23F (ST81), which has been shown to contain 
prophage and ICE [183, 216]. The analysis showed that there was no overrepresentation of 
prophage and ICE within the meningitis and bacteraemia core genomes (Figure 4.13) core 
genomes. This provided further confidence that the differences in core genome size were not 
the result of overrepresentation of prophage and ICE within the meningitis core genome. 
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4.6: The influence of HIV on the pneumococcal core genome 
 
SSA countries, such as Malawi, have a disproportionate share of the burden of IPD, which in 
up to 40% of children and 85 - 90% of adults is HIV-associated [64, 246]. Even in the early 
stages when immune response CD4 T cell counts are relatively preserved, HIV-infected 
individuals are 30 to 100 times more likely to develop IPD [64]. The dataset used for this 
thesis had a high proportion of isolates from HIV infected individuals (46%), enabling 
comparisons between isolates from HIV positive (n = 65) and from HIV negative (n = 28) 
individuals. An investigation on the possibility that HIV-mediated immunocompromise 
reduces the selection pressure on pneumococci, therefore influencing genetic diversity and 
thus the core genome size was carried out. The core genomes of the HIV positive and HIV 
negative subsets were first defined. It was found that there was no significant difference in 
their sizes (Figure 4.14). This implied that HIV does not pay a role in diversifying the 
pneumococcal genome. 
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Figure 4.14: Influence of HIV on the pneumococcal core genome. There was no 
significant difference between the HIV negative and HIV positive associated core genomes, 
implying that HIV does not play a role in pneumococcal genetic diversity. 
 
4.7: Composition of the core genomes 
 
4.7.1: Genes involved in overcoming the natural barrier to colonisation and invasion 
 
The core genome common to all 140 pneumococcal isolates (Appendix 6) contains many 
genes that have been implicated in nasopharyngeal colonisation by inhibiting mucus function, 
reducing niche competition by other bacterial species, subverting host cell function and 
facilitating host cell attachment (Chapter 4.1.1 (Figure 4.3)). In animal models, many of these 
virulence genes have also have been shown to facilitate tissue invasion and promote disease. 
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The virulence factors encoded by the overall core genome identified here include: β-
galactosidase (BgaA) and β-N-acetylglucosaminidase (StrH), which deglycosylate mucus 
glycoconjugate to reduce mucus viscosity, thereby limiting mucus entrapment and exposing 
host cell-surface adherence receptors that are exploited by the pneumococcus for attachment 
[124, 140]. Pyruvate oxidase (SpxB) catalyses the production of hydrogen peroxide, which 
kills niche competitors, facilitating pneumococcal colonisation [132, 244]. Bacteriocins 
(small bacterial peptides) kill other bacteria that do not express an immunity factor (blp) 
[140] thus also facilitating pneumococcal colonisation. The overall core genome also encodes 
virulence proteins that enhance colonization either through binding host ligands or subverting 
immune defence including: pneumolysin (Ply) [121, 124, 132], autolysin (LytA) [121], 
choline-binding protein E (CbpE) [122, 139], pneumococcal adhesion and virulence A 
(pavA) [122, 124], pneumococcal surface protein A (pspA) [124], and immunoglobulin A1 
protease (IgA1 protease) [161]. Thus the overall core genome identified here contains 
numerous genes that have been implicated in commensalism of the upper respiratory tract 
and that in animal models have been shown to facilitate tissue invasion. Previous largely 
PCR-based studies have shown that several of these genes, while present in all invasive 
strains in this thesis, are not always present in carriage isolates, therefore highlighting the 
considerable redundancy in the range of tools available to the pneumococcus for survival in 
the nasopharyngeal niche [132, 139, 249, 250]. 
 
4.7.2: Genes involved in blood stream survival and central nervous system invasion  
 
Once the pneumococcus has reached the blood stream, invasion of the meninges is thought to 
require a series of genes that mediate attachment and transcytosis through the BBB, and 
survival within the CSF [124, 132, 133]. The overall core genome identified from human 
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disease isolates includes pneumolysin (Ply; disrupts BBB integrity), pneumococcal adhesion 
and virulence A (pavA; facilitates endothelial fibronectin engagement) and hyaluronidase 
(hyl; degrades endothelial extracellular matrix), which in animal models have been strongly 
implicated in the pathogenesis of meningitis [126, 134, 135]. These genes are all present in 
the overall population core genome, thus supporting their essential role in the pathogenesis of 
meningitis and in general pneumococcal invasion (Appendix 6).  
 
Some of the genes identified in the common core genome encode for putative pneumococcal 
protein antigen vaccine candidates currently under evaluation. The pilin genes that have been 
shown to strongly induce immune responses and have been proposed as vaccine candidates 
were not present in the core genome [24, 27, 251, 252]. However, Neuraminidase (NanA) 
was only present in the bacteraemia core genome (Appendix 7) [5, 121, 124, 132], perhaps 
implying its non-essential role in the pathogenesis of meningitis. Mahdi and colleagues have 
recently conducted a genome-wide in vivo transcriptomic analysis of pneumococci reaching 
the brain after murine intranasal infection [253]. They identified a previously uncharacterized 
protein, alpha-glycerophosphate oxidase (GlpO) that was present in this study’s common 
core genome, which was cytotoxic for human brain microvascular endothelial cells 
(HBMECs) and protected against invasive pneumococcal disease [253]. These common core 
genes are therefore especially attractive as vaccine candidates as they are found in all strains 
that invade the blood stream and those that cause meningitis. 
 
Functionally distinct genes implicated in host cell attachment and invasion, bacterial survival, 
DNA repair and natural competence were observed in the meningitis core genome identified 
by analysis carried out in this thesis (Appendix 8). This meningitis core genome includes 
choline binding protein A (CbpA, SpsA or PspC) a member of a family of surface proteins 
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implicated in colonisation [121], binding to the polymeric immunoglobulin receptor (pIgR) in 
order to cross from the mucosal surface into the blood [124, 254]. In the absence of pIgR on 
the surface of brain endothelium, CbpA binds laminin to initiate contact and translocation 
across the BBB [124, 133]. The meningitis core genome includes genes that enable niche 
adaptation and regulation of metabolism in response to alterations in available carbon 
sources, cations and amino acids, and anaerobic conditions [255]. These include formate 
acetyltransferase (pfl), which is essential for fermentative metabolism, suggesting it’s vital 
role following CSF invasion. Pfl mutants have reduced virulence evidenced by prolonged 
survival times in mice models of bacteraemia. [255].  Fe2+ ABC transporters, which are 
members of the ATP-binding cassette (ABC) transporter superfamily, translocating a variety 
of substrates such as cations, lipids and amino acids, across membranes [256], and have been 
implicated in pneumococcal virulence [257]. Pneumococcal competence genes and their 
expression regulate biofilm formation and are associated with virulence in animal models of 
meningitis [140, 258]. The prominence of DNA repair and regulation genes in the meningitis 
core genome highlights critical nature of gene variation in niche adaptation [81, 259]. Given 
that meningitis is a biological dead end for pneumococcus, because of lack of inter-host 
transmission, it is unlikely that these genes have evolved to facilitate invasion of the brain. 
This suggests that they are important for niche survival elsewhere and as a result explain the 
tropism of these particular pneumococcal strains for the meningeal space.  
 
4.8: Discussion 
 
Previously, tissue culture models and animal studies supported most of the knowledge on the 
pathogenesis of bacterial meningitis [132, 133, 139]. This study has shown how high-
         Chapter 4: Genetic diversity amongst bacteraemia and meningitis causing pneumococci  
 
 110 
throughput genome sequencing of large pneumococcal strain collections together with 
innovative bioinformatics approaches can be used to interrogate human disease.  
 
In this study, a relatively large pneumococcal genomes dataset (n  = 140) was used to define 
the core genome size (1292 genes, 50% of the pneumococcal genome). This provided more 
precise estimates of the pneumococcal core genome size compared to previous studies by 
Hiller and colleagues (1716, 54% of the pneumococcal genome), which considered fewer 
genomes (n = 17). This highlights the high degree of genetic diversity in the pneumococcal 
genome. Still, a sizeable proportion of genes are common to all pneumococcal strains can be 
used to resolve its population structure, and to explore therapeutic and diagnostic targets that 
are always present.    
 
Comparisons of core genome size between meningitis-associated and bacteraemia-associated 
pneumococcal datasets were performed. Interestingly, it was observed that meningitis 
associated pneumococcal isolates had a slightly larger core genome with a different 
composition, compared to bacteraemia-associated isolates. This difference in composition 
consisted of genetic components that were likely to be essential for meningeal invasion and 
survival. Thus, within a highly recombinogenic bacterial population of multiple diverse 
lineages, the core genome was identified supporting evidence of a large, conserved (always 
present) set of genes that can be used to robustly reconstruct phylogenies. The underlying 
patterns of bacterial genomic flux (horizontal gene acquisition and loss), particularly with 
variable rates of recombination in different ecologies, remain largely undefined and are likely 
to be complex [81]. However, despite the highly recombinogenic nature of the multiple 
diverse lineages investigated, this study has identified an overall pneumococcal core genome 
with evidence of a large set of genes that can be used to robustly reconstruct phylogenies. 
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The findings have provided some of the first evidence from human disease that meningitis 
causing pneumococci have a distinct core genome, which encodes for both known and 
previously undescribed proteins that are likely to be essential for meningeal invasion and 
survival. The differences between core genes were not large and not accounted for by the 
absence of large blocks or a large number of genes. The differences are subtle, suggesting 
that in the case of both meningitis and bacteraemia, the core genome can be viewed as a key 
that unlocks pathogenesis pathways, enabling survival in otherwise hostile host 
environments.  
 
The meningitis-associated and bacteraemia-associated core genomes were extrapolated until 
they reached a plateau, where no observable change in core genome size was observed, using 
a novel double-exponential decaying function (Chapter 3.6) that fitted the data to a higher 
degree of precision. It was observed that the meningitis-associated core genome was still 
larger than that associated with bacteraemia. This suggests that even with an infinite number 
of genomes, the meningitis core genome would have a slightly larger core genome that 
consists of genes involved in the evasion of natural immune barriers, invasion and survival in 
the human host.   
 
In this study, factors influencing pneumococcal core genome size were examined. It was 
observed that the difference in composition and size between the meningitis-associated and 
bacteraemia-associated core genomes was not due to dominance of clones with a larger core 
genome in the dataset, imbalanced sampling leading to the dominance of a particular clone, 
or over representation of prophage and integrative conjugative elements in the meningitis-
associated core genome. Moreover, HIV had no influence on the core genome size.    
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These data begin to explain the tropism of some pneumococci for the CSF and not others, 
supporting the considerable in vitro and animal model data that implicate key pneumococcal 
molecules as essential to invasion and survival within the meningeal space. These findings 
also emphasize the considerable redundancy in pneumococcal virulence determinants that 
have been shown to be important in the pathogenesis of pneumococcal meningitis in such 
experiments [124, 132, 133, 139, 255]. Evidence from humans that meningitis causing 
bacteria are genetically distinct has to date been elusive. Specific bacterial phenotypes, for 
example amongst E. coli that have been associated with meningitis [260], encode genetic 
determinants that allow adhesion to the BBB and promote CSF invasion through host 
endothelial receptor engagement. However, until recently the sequencing capacity and 
analytical tools have not been available to provide a comprehensive insight into the genetic 
determinants of bacterial virulence in a human context. Further detailed genomic surveys 
using carefully sampled large longitudinal datasets of carriage and invasive disease isolates 
under different immunological pressures (particularly immunocompromising conditions such 
as HIV) are required. These will undoubtedly generate exciting new insights into the 
pathogenesis of invasive pneumococcal disease providing an in-depth understanding of how 
pneumococcus adaptation to the human host in a largely commensal relationship also enables 
tissue invasion and dissemination. These analyses will also help identify candidate molecules 
that can be exploited as vaccine and therapeutic targets. This study has highlighted a distinct 
minimum conserved set of genes that is necessary for meningeal infection and which begins 
to explain the tropism of some pneumococci for the CSF and not others. 
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CHAPTER 5 
 
Genetic population structure and genomic flux in invasive pneumococci associated with 
bacteraemia and meningitis 
 
5.1: Introduction 
 
Streptococcus pneumoniae (pneumococcus) is the causative bacterial pathogen associated 
with pneumococcal pneumonia, meningitis, acute otitis media and septicaemia [13]. There 
are approximately 15 million episodes of invasive disease worldwide, with the highest burden 
in sub-Saharan Africa (SSA) [13, 241]. SSA also has a distinct distribution of serotypes 
associated with invasive disease [18, 49] and this is true for countries such as Malawi [50, 62, 
63]. In Malawi for example, pneumococcal bacteraemia and meningitis due to serotype 1 
(ST217) is disproportionately high compared to other serotypes [50, 62, 243]. Despite 
pneumococcal conjugate vaccines being available, case management, morbidity and mortality 
remain high [13, 241]. One reason for this is that pneumococci rapidly evolve mechanisms to 
evade clinical interventions by frequent recombination, which gives rise to their mosaic 
chromosome that contains genetic material from different ancestors [53, 81]. Despite the 
large extent of recombination, and the varying amounts, nature and source of incorporated 
genes among lineages that threatens to obscure their evolutionary history; pneumococci 
maintain relatively constant genome sizes (~2.1Kb) and G+C content (~39.49%), suggesting 
gene gains by horizontal transfer are counterbalanced by loss of superfluous genes. This 
enables the construction of robust phylogenies using genes that are rarely transferred [81, 
183], implying that pneumococcal genomes are not simply random collections of genes from 
different backgrounds, but are constituted by a large proportion of more conserved, vertically 
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transmitted genes [261]. Recombination provides bacterial genomes, and particularly 
pneumococci, with a new set of genes encoding virulence factors, used during invasion and 
colonisation of new ecological niches [81, 262]. In pneumococci this is characterised by their 
transition from commensalism at the nasopharynx, to a pathogenic lifestyle in the host by the 
invasion of sterile sites (lungs, blood, CSF and middle ear) [13, 49]. The versatility of their 
genetic make-up enables pneumococci to adapt to different niche changes to facilitate 
nutrients acquisition, host immunity evasion and enhanced virulence.  
 
Detailed comparative genomics analysis of well-sampled ecological data is crucial for 
understanding pneumococcal recombination events [53, 81, 183].  Nonetheless, genome 
comparisons alone do not provide sufficient information to distinguish between insertions, 
deletions and other gene reorganisation events. This requires the use of statistical models that 
describe the underlying niche structure. Statistical models have previously been used to 
understand the role of selection in the emergence [263] and co-existence of bacterial lineages 
in the same niche [264], as well as bacterial genetic and ecological diversity [265-267]. 
 
This study examined whether gene presence and absence profiles (phyletic patterns) can be 
used to resolve bacterial population structures of highly recombinogenic bacteria that have 
clones from multiple lineages. It also investigated the extent by which the pneumococcal 
genome content varies within and across lineages, and in different ecological niche (blood 
and cerebral spinal fluid (CSF)), by examining gene gain and gene loss events in order to 
understand the dynamics of genetic flux (gene gain or loss) during invasive pneumococcal 
disease. 
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5.2: Determination of population structure from phyletic profiles 
 
In this study, to investigate whether pneumococcal phyletic patterns could be used to 
distinctly identify clusters of genetically closely related strains and to effectively resolve their 
population structure. Invasive pneumococcal isolates (bacteraemia, n = 70 and meningitis, n 
= 70) collected from Malawian adults and children, as part our invasive bacterial surveillance 
at a large teaching hospital, were randomly selected and their genomes sequenced (Chapter 
2). The information on serotype and sequence type for each isolate was determined using 
bioinformatics approaches from genome sequences (Chapter 3.2), and the isolates were 
divided into two groups; bacteraemia for those sampled from blood and meningitis for those 
sampled from CSF (refer to Chapter 2.2). This division was based on the biological 
assumption that pneumococci in these subsets adapted to a common lifestyle. The process of 
clustering genes of annotated genomes using OrthoMCL [222] was used to identify 
orthologous genes. The data was transformed into a matrix of genome content, for each 
subset (Chapter 3.3 to 3.5). Clustering of orthologous genes was a reference-free approach 
that allowed robust comparison and integration of data from multiple genomes (Chapter 3.5). 
Alternatively mapping of clones from multiple lineages to a single reference genome could 
be used, but that would lead to a tremendous loss of variation, restricted principally by the 
genes present in the reference, and therefore it would not be ideal for analysing highly 
recombigenic, multiple clones of different lineages (Chapter 3.1). This is further complicated 
by the difficulty in assigning ancestral strains that could be used as references, especially in 
highly divergent bacteria.  
 
In this study, axes of genetic variation within the subsets were inferred using a 
computationally efficient principal component analysis (PCA) method (Chapter 3.7.1), based 
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on phyletic patterns. The dimensions of variation in the phyletic patterns were reduced and 
this variation could be explained by several principal components (Figure 5.1A and 5.2A). 
The cumulative proportion of variance explained by the principal components increased 
exponentially until it reached a constant, where no further variance was explained by the 
principal components. The first three principal components cumulatively explained 25.72% 
and 27.43% of genetic variance in the bacteraemia and meningitis groups respectively 
(Figure 5.1 and 5.2 respectively). 
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This highlights that just a few, and not all, of the principal components are required to 
sufficiently describe the proportions of variance in phyletic patterns. By keeping only 
principal components that explain a large extent of variance, the entire dataset is described 
clearly in a lower dimensional space (Figure 5.3). 
 
 
 
Figure 5.3: Simplified illustration of reduction of dimensionality in data using PCA. 
Shows how PCA can be used to accurately understand multidimensional datasets with a lot of 
variables in lower dimensions. Only 2 axes (axis 1 - the primary principal component and 
axis 2 – the secondary principal component) were used, reducing the data to lower 
dimensions while describing the data with more clarity. 
 
Based on this, the PCA analysis was performed using the first two and three principal 
components. The two principal component analysis indicated a separation into two major 
clusters along the primary axis of variation (PC1) (Figure 5.4). The primary axis explained 
12.85% and 13.21% of the variance in bacteraemia and meningitis respectively. The second 
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principal component axis (PC2) explained 6.89% and 7.8% of the variance in bacteraemia 
and meningitis respectively. This indicates that the second principal component explained 
only about half as much variance explained by the first principal components in both the 
bacteraemia and meningitis groups.  
 
 
Figure 5.4: The principal components analysis using the two principal components. The 
data separated into two major clusters along the primary axis of variation (PC1): the ST217 
cluster (left) and the non-ST217 cluster (right). 
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Specifically, it was noted that all serotype 1 (ST217) isolates clustered closely together, with 
sub-clusters associated with either meningitis or bacteraemia, and clearly separated from 
other pneumococcal clones, suggesting that ST217 isolates possess distinct highly conserved 
phyletic patterns. The three principal component analysis also confirmed this separation. The 
third principal component explained 5.98% and 6.41% of the variance in bacteraemia and 
meningitis respectively. This proportion of variance was slightly lower than that explained by 
the second principal component. However, observations at different planes of view illustrated 
the greater degree of diversity exhibited amongst the non-ST217 cluster, and particularly that 
genetically closely related clones (STs) formed tight clusters in the expanded dimensional 
space (Figure 5.5). 
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Although hyper-recombination results in mosaic chromosomes, a tight cohesion of phyletic 
patterns that delineates lineages still remains. These results indicate that rather than 
widespread dispersion due to sporadic patterns of genome content attributed to simple gene 
presence or absence, clones formed clusters of closely related strains, and as such the 
population structure could therefore be defined. This evidence validates the use of phyletic 
patterns to resolve population structure of a highly divergent bacterial species and suggests 
the existence of a strong phylogenetic signal in pneumococcal phyletic patterns. 
 
5.3: Inference of genomic flux across different population niches 
 
Genetic diversity evolutionarily affects proteome functionality along individual lineages 
[183]. As such, gene gain and loss events make significant contributions to the genetic 
diversity associated with niche adaptation, colonisation, and other alterations in bacterial 
lifestyle [262, 268]. This study examined the extent of this genomic flux at species level (or 
across lineages), and the role of ecology on genome content, by inferred gene gain and loss 
events using a robust statistical framework, the Gain and Loss Mapping Engine (GLOOME) 
[235]. GLOOME is an open source program that implements probabilistic models, that are 
more biologically realistic, to evaluate lineage-specific gain/loss dynamics using a mixture-
model approach [236]. The mixture-model takes into account heterogeneity in the rates of 
gene gain or loss, which have been demonstrated to vary greatly in some gene families that 
show a higher tendency to be transferred [235, 237]. The extent of genomic flux was inferred 
from pneumococcal phyletic patterns (Chapter 3.8.2). 
 
In this study, the transferability for each gene locus along the genome was quantified. 
Quantification of genes likely to be transferred improved the understanding on selection 
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forces that determine whether these newly transferred genes are likely to be fixed in the 
pneumococcal genomes, for each niche under study [235]. It was observed that posterior 
expectations of gene gain exceeded those of gene loss in both the meningitis and bacteraemia 
groups, and that there was a larger genetic flux in the bacteraemia group (Figure 5.6 to Figure 
5.9). This suggests that genes in the bacteraemia group were less conserved compared to 
those associated with meningitis, and that high transfer events of specific genes is important 
during pneumococcal niche adaptation. Less conservation in the bacteraemia-associated 
genomes implies that their genes are under less selection pressure compared to the meningitis 
group, thereby permitting more genetic flux events. It also suggests that a set of conserved 
genes is required by the meningitis-associated group to be able to invade and survive in the 
CSF, causing meningitis. High genetic flux events were observed at loci with high G+C 
content in both the bacteraemia and meningitis groups (Figure 5.6 and 5.7). Bacterial 
genomes show a broad range of variation in their G+C content (approximately 26.5-72.1%), 
and lower genetic diversity has been associated with regions that have high G+C content 
[269].   
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Figure 5.6: Quantification of transferability for each gene locus along the meningitis 
group genome. Overall, the expectations of gene gain appeared to exceed those of gene loss. 
The genomic G+C content is shown above the genetic flux. There were high flux events even 
at loci with high G+C content. 
 
 
Figure 5.7: Quantification of transferability for each gene locus along the bacteraemia 
group genome. Overall, the expectations of gene gain appeared to exceed those of gene loss. 
The genomic G+C content is shown above the genetic flux. There were high flux events even 
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at loci with high G+C content. The extent of genetic flux in the bacteraemia group exceeded 
that of the meningitis group. 
 
 
Figure 5.8: The extent of gene gain events along the genome was more pronounced in 
the bacteraemia group compared to the meningitis group. 
 
 
Figure 5.9: The extent of gene loss events along the genome was more pronounced in the 
bacteraemia group compared to the meningitis group. 
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Comparisons of gain and loss events between the bacteraemia and meningitis groups 
highlighted more pronounced genetic flux events in the bacteraemia group (Figure 5.8 and 
5.9).  
 
This was also true in the ST217 lineage, which was a single lineage with the highest number 
of clones for both the bacteraemia and meningitis groups, with an exception of higher loss 
expectations associated with meningitis compared to bacteraemia (Figure 5.10 and 5.11). 
 
 
Figure 5.10: Quantification of transferability for each gene locus along the bacteraemia 
group genome within a single lineage (ST217). The expectations of gene gain exceeded 
those of gene loss. 
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Figure 5.11: Quantification of transferability for each gene locus along the meningitis 
group genome within a single lineage (ST217). The expectations of gene gain exceeded 
those of gene loss.  
 
This implies that in the ST217 meningitis genomes all genes that are non-essential are lost 
and only a few genes, which are most likely essential for meningitis, are gained. Thus, 
comparisons within a single lineage suggest that pneumococcal genomes associated with 
meningitis are more conserved and have less genetic flux compared to those associated with 
bacteraemia. 
 
The degree of genomic flux within ST217 was lower than that of the entire population, 
providing further support to the observation that phyletic patterns of closely related genomes 
are almost uniform. These closely related single lineage genomes are also likely to contain 
less sequence diversity when compared to each other. Serotype 1, which belongs to the 
ST217 lineage in this Malawian dataset under study, has been associated with high number of 
IPD episodes in sub-Saharan Africa [51, 243], but is rarely found in carriage [51, 248]. This 
higher level of uniformity in phyletic patterns demonstrated by lower extents of 
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transferability in serotype 1 isolates, which were collected at different time points (2002-
2008) in this study. This gives further support that their genomes are have fewer genetic flux 
events. The mean, minimum and maximum expectations of genomic flux were computed to 
compare the extent of genetic flux in the various groups of pneumococci under study (Table 
5.1). 
 
Table 5.1: Summary of the expectations of genomic flux events. The events are either 
gene gain or loss, in the datasets under consideration. The mean expectation is the average 
expectation of the genetic flux events. The minimum and maximum expectations are the 
lowest and highest expectation values in the dataset respectively. The standard deviation is 
the extent by which the mean expectation may vary. 
 
Events 
Mean 
expectation 
Standard 
deviation 
Minimum 
expectation 
Maximum 
expectation 
Meningitis gain 1.83 4.29 0.02 27.62 
Meningitis loss 1.21 2.81 0.02 20.69 
Bacteremia gain 3.57 7.75 0.05 46.51 
Bacteremia loss 3.81 7.70 0.06 31.34 
ST217 meningitis gain 0.11 0.65 0.00 6.39 
ST217 meningitis loss 0.12 0.55 0.00 5.74 
ST217 bacteremia gain 0.21 1.03 0.00 7.02 
ST217 bacteremia loss 0.14 0.56 0.00 4.98 
 
Overall, it was observed on average there were more pronounced genetic flux events in the 
bacteraemia groups. The expectation values of gene gain events exceeded those of gene loss, 
with the exception of the ST217 meningitis group further supporting the previous 
observations.  
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Agreement on the extent of genetic flux between the meningitis and bacteraemia groups was 
further assessed using Bland-Altman plots (Figure 5.12) [238]. Bland-Altman plots are 
graphical methods that were used to compare data measurements from two different groups, 
so as to evaluate agreement on the extent of genetic flux. The two measurements that were 
assessed were the extent of genetic flux and the position along the genome. It was observed 
that there were higher extents of gene loss (Figure 5.12A) and gene gain (Figure 5.12B) 
events in the entire bacteraemia group compared to entire the meningitis group. The extent of 
gene gain for the entire groups exceeded those of gene loss and genetic flux (loss and gain) 
occurred at the same loci (Figure 5.12C).  Similar observations were also made in a single 
lineage (ST217) with the largest number of the pneumococcal genomes from the bacteraemia 
and meningitis groups. Within ST217 lineage, higher extents of gene gain (Figure 5.12D) and 
loss (Figure 5.12E) events were observed in the bacteraemia group, and overall there were 
fewer gene loss events compared to gene gain events (Figure 5.12F). 
 
The spread of differences in the Bland Altman plots (Figure 5.12A to Figure 5.12E) increased 
with increasing mean of the observations. In order to make correct interpretations using the 
Bland-Altman plots, logarithm scales were used to calculate agreement thereby avoiding any 
biased observations due to increase in difference with increasing mean (Figure 5.13A to 
Figure 5.13E). Overall, the extent of both gain (Figure 5.13A) and loss (Figure 5.13B) were 
greater in the entire bacteraemia group compared to that of the entire meningitis group. The 
extent of gene gain for the entire groups exceeded those of gene loss, and genetic flux (loss 
and gain) occurred at the same loci (Figure 5.13C) confirming previously observed results 
using values not in logarithm scale.  Similar observations were made in the ST217 lineage; 
with higher extents of gene gain (Figure 5.13D) events observed in the bacteraemia group. 
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However there were more loss events in the meningitis group compared to the bacteraemia 
group (Figure 5.13E), and overall there were fewer gene loss events compared to gene gain 
events (Figure 5.13F). This was consistent with the previously made observations and further 
supported the finding that there is more gene loss events in the meningitis group of the ST217 
compared to gene gain events.  This was further confirmed using logarithm scaled values 
(Figure 5.13D to Figure 5.13F).
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5.4: Composition of gene loci with large extents of genetic flux 
 
The loci with the highest posterior expectations of gene gain and loss in the bacteraemia 
(Table 5.2) and meningitis (Table 5.3) groups were examined.  
 
Interestingly, important gene families that exhibited high extents of genetic flux were 
observed in both the meningitis and bacteraemia groups, thereby allowing associations to be 
made for different niche under study. High gene flux expectation values were observed in 
both groups for (Table 5.4): iron transport proteins, with high gain events associated with 
bacteraemia and loss in meningitis; high gain events associated with meningitis and loss in 
bacteraemia for cell surface choline binding protein PcpA, putative type I restriction-
modification system S and type I restriction-modification system S proteins; and high loss 
events associated with both bacteraemia and meningitis for the putative Mga-like regulatory 
protein. High gain events exclusively in the bacteraemia group for putative phage 
integrase/recombinase, putative l-lactate oxidase–related protein, putative lantibiotic export 
protein, and group II intron maturase were also observed (Table 5.4). While in the meningitis 
group high gain events were associated with antiholin and mutT/Nudix hydrolase family 
protein; and high loss events for putative sodium:dicarboxylate symporter family protein and 
choline binding protein J (Table 5.4). 
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The key genes gained and lost, which displayed the highest extents of genetic flux, were 
examined to establish their functions and role in pneumococcal adaptation to different niche.  
 
It has long been established that iron-binding proteins play a vital role in the survival of 
pathogenic bacteria [270, 271]. Siderophores, which are small iron chelators for example 
enterobactin, actively enhance bacterial iron acquisition by endocytosis [272]. Siderophores 
chelate either insoluble iron or iron in heme, haemoglobin, transferrin and lactoferrin, which 
is endocytosed using receptor-mediated strategies without compromising cell membrane 
integrity, prior to its cellular processes [270, 273]. Lipoprotein bound iron siderophores have 
been shown to be important in importing iron in Staphylococcus aureus [274], group B 
streptococcus [275], and pathogenic Neisseria, which lack iron siderophores employ 
exogenous iron siderophores and enterobactin homologs enabling them to utilise iron sources 
from other co-colonising organisms [276, 277]. Iron is a crucial nutrient in microbial growth 
and enhances virulence, for example the virulence of Yersinia enterocolitica is enhanced 10 
million-fold by peritoneal injection of ferric desferrioxamine in animal models, and similar 
correlations have been observed during Klebsiella, Salmonella and E. coli [272]. A more 
likely increase in acquisition of iron transport proteins gene in the bacteraemia-associated 
group suggests pneumococcal adaptation to iron nutrient utilisation in the bloodstream, where 
abundant iron sources exists. 
 
High gene flux associated with gene gain in the bacteraemia group was also observed at a 
putative lantibiotic export protein, group II intron maturase putative phage 
integrase/recombinase, and putative l-lactate oxidase–related protein. Gram-positive bacteria 
use lantibiotics to limit competition from other bacteria occupying the same niche or using 
the same nutrient resource [278, 279]. This acquisition of these genes provides the 
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bacteraemia-associated pneumococci with a competitive advantage over other co-colonising 
bacteria. The expectation of lantibiotic gene loss was lower compared to that of gene gain. 
 
Group II intron maturase (GIM), which is a mobile genetic element, encodes a reverse 
transcriptase that also functions as an intron specific splicing factor (maturase), enabling it to 
insert at intron-specific locations in alleles that lack introns (homing) or at other new sites 
(ectopic) but at low frequencies [280, 281]. GIM facilitates direct splicing of intron RNA into 
a DNA target site followed by reverse transcription, and then removes itself by protein-
assisted, autocatalytic RNA splicing [282]. Overall, there were gain events for GIM in the 
bacteraemia-associated dataset. This suggests that the high rate of gene gain events in the 
bacteraemia group might be GIM mediated. In contrast CSF is acellular and lacks single 
stranded RNA and DNA, and there is no circulating nucleic acid content that can be 
incorporated by GIM in meningitis-associated pneumococci.  
 
 In vitro growth experiments show that pneumococci have distinct protein expression when 
grown in media that contains or lacks blood [283]. An example is l-lactate oxidase that is 
involved in the metabolic activity resulting in H2O2 production during aerobic growth, which 
acts as a potential virulence factor by direct host tissue damage and inhibition of other niche 
pathogens [244, 283]. The combined metabolic activity of l-lactate oxidase and pyruvate 
oxidase generates greater amounts of energy during aerobic conditions [284]. High extents of 
gene flux events for the l-lactate oxidase gene were observed in the bacteraemia group, and 
overall there were high expectation of gain events compared to loss events. This suggests that 
the acquisition of l-lactate oxidase gene is associated with a metabolic advantage in the 
bacteraemia group. 
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Phage integrase/recombinase play an active role in the incorporation of homologous or alien 
DNA sequences that may encode resistance determinants and virulence attributes [262]. High 
extents of genetic flux events for putative phage integrase/recombinase were observed in the 
bacteraemia group, implicating them in the acquisition and incorporation of DNA sequences 
in this group. Overall, there was a larger extent gain events in the bacteraemia group, and no 
high extents of flux for this gene loci was observed in the meningitis group.  
 
The bacteraemia group was associated with a high expectation of loss of restriction 
modification systems (RMS). RMS inhibits integration of foreign DNA and bacteriophages 
into bacterial chromosomes. Loss of RMS activity suggests increased uptake and integration 
of DNA and genetic material from the surrounding environment into the genomes of the 
bacteraemia group. On the contrary, in the meningitis group a high expectation of gain was 
observed, thereby counteracting DNA integration, suggesting a larger degree of gene content 
conservation. RMS genes encode a restriction enzyme and a modification methylase, and are 
responsible for the removal of poorly incorporated and modified foreign DNA, restricting 
bacterial chromosomal modifications [285]. RMS can undergo extensive horizontal transfers 
between genomes and they cleave imported DNA sequences that have not been methylated 
by a related or relevant methylase, defending cellular chromosomes from stockpiling foreign 
DNA [285]. Loss of the modification function at certain sequence sites on the chromosome 
intensifies sequence removal resulting in extensive chromosomal degradation, followed by 
SOS response induction and eventually programmed cell death, eliminating the damaged 
cells [285]. RMS are abundant in genomes of Haemophilus influenzae, Neisseria species, and 
Helicobacter pylori, and are almost lacking in the conserved genomes of intracellular 
pathogens such as Rickettsia prowazekii, Trepanoma pallidum, Chlamydia and Buchnera that 
are almost isolated from incoming DNA [285]. 
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Bacteria have specific sets of virulence factors that are appropriate for different niche 
invasion and colonisation (Chapter 4). High gene loss was associated with multiple gene 
activator (Mga) in both bacteraemia and meningitis suggesting its non-essential role in 
promoting onward invasion or its repression and/or elimination to facilitate onward invasion. 
Mga encodes a multiple gene regulator, which activates a core set of virulence genes in group 
A Streptococcus (GAS) [286]. Mga has been shown to control phase variation in GAS, 
thereby altering their virulence capability [287, 288]. A homolog of Mga (mgrA) was 
identified and shown in S. pneumoniae to be necessary for development of pneumonia in 
mice models of nasopharyngeal carriage. It represses the rlrA pathogenicity islet that encodes 
genes mediating adherence, and decreases adherence to epithelial cells in tissue culture, 
suggesting its key role in promoting pneumococcal invasion of the upper respiratory tract 
[289].  
 
There was a high expectation of gain for pneumococcal choline binding protein A (PcpA) in 
the meningitis group, implying the important role of PcpA in meningeal disease. A high 
expectation of loss was observed in the bacteraemia group. PcpA mutants have been shown 
to be less virulent than wild type in mice models of sepsis and pneumonia, and were present 
in pneumococci grown under low-manganese conditions in vitro [290]. PcpA was also one of 
the virulence factors implicated in the induction of phase variation in pneumococci [157]. 
Acquisition of PcpA by the meningitis group and loss by the bacteraemia group suggests its 
essential role during meningitic infection but not bloodstream sepsis. 
 
Choline binding proteins have been shown to be important for initial nasopharyngeal binding 
and colonisation. While, sodium:dicarboxylate symporter exhibits increased expression 
during epithelial cell contact [132]. The high loss expectations for choline binding protein J 
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and sodium:dicarboxylate symporter associated with the meningitis group, implying they are 
non-essential for meningeal invasion. 
 
Elevated gain events were observed for the of antiholins and mutT/NUDIX hydrolase family 
protein in the meningitis group. Holins and antiholins are bacteriophage encoded and 
involved in bacteriophage mediated cell death and lysis. Holins are membrane proteins that 
facilitate the enzymatic activity of bacteriophage-encoded murein hydrolases on 
peptidoglycan. Antiholins antagonise holin activity, and mutations in holin that interrupt the 
gene or prevent expression have been demonstrated to eliminate nearly all extracellular 
murein hydrolase enzymatic action and cell lysis [291, 292]. Nudix hydrolases are nucleoside 
diphosphate pyrophosphatases that are vital for breaking down intracellular compounds and 
are virulence factors in several bacteria [293]. 
 
Quantification of transferability of genes at different positions along the genomes for the 
different groups allowed close examination of the evolutionary forces that determine the 
tendency of a gene to get fixed along the genome. Information on the direction of genomic 
flux improved the understanding of niche adaptation mechanisms employed during disease 
progression in pathogenic bacteria, as well as highlighting important potential therapeutic 
targets.  
 
5.5: Inference of genomic flux along each branch 
 
Adaptation to different niches may involve selection at a small proportion of genome loci 
creating barriers to stockpiling of neutral diversity [265, 266]. Identification of the likelihood 
and direction of genetic fluctuations at these loci across lineages is important, for providing 
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information on their use by nucleic acid based diagnostic techniques and their exploitation by 
therapeutic approaches. In general, conserved loci are preferred for such purposes, because 
they are present in all pneumococcal isolates and rarely undergo genetic changes. However, it 
is more useful to pinpoint sites expected to undergo genomic flux along each branch of a 
phylogeny, because it is more informative with respect to the genetic diversity of each clone, 
as well as within and between lineages. The average extent of genetic flux per loci for each 
branch was examined and it was observed that there were more genome content fluctuations 
of gene loci along the bacteraemia phylogeny (Figure 5.14A and 5.15A). The overall 
percentage expectation of gene transfer by gain or loss for each branch was evaluated and it 
was noted that overall gain and loss events along branches within and across lineages were 
arbitrary (Figure 5.14B and 5.15B). This suggests the extent of gene gain and loss events 
along branches was random in both the bacteraemia and meningitis groups. This was also 
observed when branches of pneumococci within single lineages were compared.
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Genomic flux was especially high at particular loci within lineages, and was more 
pronounced in the bacteraemia group. This suggests that pneumococcal evolution is 
characterised by constant recombinant sampling of genetic material, at different rates at the 
nasopharynx, until they arrive at a combination which provides the requisite gene 
complement to support invasion and survival in a new niche [262]. Selection at certain loci 
may be involved in clearing nearly all of the genetically diverse clones whose specific loci 
are under selective pressure, except for a few individual clones (of each linage) with certain 
characteristics, especially in the population associated with meningitis. This may explain the 
more conserved gene content of the meningitis group compared to the bacteraemia group. 
Although, pneumococci are naturally competent and exhibit no sequence preference, and are 
therefore hyper-recombinogenic [262], they possess mismatch repair mechanisms that detect 
dissimilarities between donor and recipient DNA [262, 265]. A difference in flux could be a 
result of inadequate mechanisms in the case of bacteraemia or conversely very effectual 
mechanisms the meningitis group. Differences in flux might also be a result of enhanced 
competence during bacteraemia, thereby increasing uptake of genetic material from the 
surrounding environment [294, 295].  
 
5.6: Discussion 
 
Gene families can be acquired and lost by horizontal gene transfer and sequence evolution 
processes, resulting in chromosomal reorganisation. Understanding the likelihood, extent and 
directions of gene fluctuations is an important element of understanding genome evolution 
and proteome functionality in clinically relevant bacteria. 
More realistic statistical models for inferring gene gain and loss have progressively been 
developed, to be able to understand genetic flux events. In these approaches, the patterns of 
                Chapter 5: Genetic population structure and genomic flux in invasive pneumococci 
 153 
gene presence and absence (phyletic patterns) are used as input data for analysis [235, 268, 
296, 297]. These models have been successfully employed in primates [298] and prokaryotes 
[235, 268, 296, 297]. The first such statistical model assumed similarity in the rate of gene 
gain and loss, and also that these rates were invariable in gene families [296]. However, there 
is evidence of differing tendencies of gene gain and loss among gene families [235]. 
Recently, mixture-models have been developed, which take into account the differences in 
rates of gene gain and loss among gene families, as well as independent evolution within and 
across lineages [235, 296]. These methods can be used to more accurately infer genetic flux. 
 
Gene content varies within species genomes due to dissimilar acquisition or loss of genes 
within and across lineages. In this study, the use of phyletic patterns to determine the extent 
of genetic flux among multiple diverse pneumococcal lineages, which are highly 
recombinogenic, was evaluated by its ability to resolve the population structure. It was 
observed that phyletic patterns robustly defined the population structure. This suggests the 
existence of a strong phylogenetic signal in phyletic patterns despite extensive recombination 
events. It also suggests that phyletic patterns are often conserved during clonal expansion, 
perhaps due to similar selection pressure at certain gene families within lineages. It also 
validates the use of phyletic patterns to determine genetic flux in highly recombinogenic 
bacteria. 
 
The extent of transferability for each gene locus along the genome was examined across the 
meningitis and bacteraemia groups. A higher extent of genetic flux was observed in the 
bacteraemia group compared to the meningitis group, implying that meningitic genomes are 
more conserved, which is biologically plausible. The extent of gene gain exceeded that of 
gene loss except within a single lineage (ST217) of the meningitic group. This implies that 
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the genes within the ST217 meningitic group are even more conserved, maintaining sets of 
highly essential genes. This implies that all genes that are non-essential for meningeal 
invasion and survival may be lost and that most of the acquired genes play an important role 
during meningitis. Genetic flux within a single lineage was also less pronounced compared to 
that across lineages, suggesting that phyletic patterns within lineages are more conserved. 
There was high genetic flux along the genome regardless of the G+C content. This flux 
appeared to be more pronounced in particular regions along the genome. This suggests that 
gene transfer events can occur at even at loci that are regarded as highly conserved, as 
determined by their high G+C content. It was also suggests that there are regions on 
pneumococcal chromosomes that are likely to undergo gene transfer, supporting to the 
existence of recombination hotspots across multiple lineages [183]. 
 
Pneumococcal meningitis is a dead-end for pneumococci that is most often preceded by 
bacteraemia. Despite clinical case management, bacterial meningitis often results in host 
mortality, thereby preventing further pathogen host-to-host transmission. Both bacteraemia 
and meningitis associated pneumococci are adapted for different niche invasion and survival. 
In this study, genes with high transferability were examined, and gene gain and loss events 
implicated their role as either essential or non-essential for blood and meningeal invasion and 
survival. The blood and cerebral spinal fluid are completely contrasting and separated niche 
environments, with a higher nucleic acid content and iron presence in blood compared to the 
acellular meningeal environment. The availability of nutrients and components required by 
pneumococci from their surrounding environment may play a role on their evolution, and 
consequently gene content. A lower extent of genetic flux was observed in meningitic 
pneumococci, suggesting that a higher degree of genome conservation and implicating the 
role of environment on this conservation. 
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Overall, it was also observed that the extent of gene transfers along phylogenetic branches 
were greater among the bacteraemia group compared to the meningitis group. However, the 
pattern of gene gain or loss was arbitrary within lineages and across groups. 
 
The use of statistical models provided accurate inference of gene gain and loss events 
highlighting pneumococcal gene content fluctuations, and adaptation to different niche.  It 
was observed that despite the high extents of genetic flux within lineages and across groups, 
the meningitis group was more conserved than the bacteraemia group. Several genes had high 
expectation values for gene gain and loss. These genes play important roles in pneumococcal 
niche adaptation, by facilitating nutrient acquisition and genetic diversification, thereby 
offering a selective advantage for niche invasion and survival. It also supports the 
observations made using tissue culture and animal models, which demonstrate that different 
sets of genes are required for tissue-specific invasion and survival (Chapter 4) [132]. This 
analysis has also highlighted the likely direction of fluctuations for some key genes and 
improves the understanding of the role of selection pressure on pneumococcal pathogenesis 
in different niche. 
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CHAPTER 6 
 
Pilus prevalence among invasive Streptococcus pneumoniae isolates prior to 
pneumococcal conjugate vaccine introduction, in Malawi 
 
6.1: Introduction 
 
Streptococcus pneumoniae is capable of invading the host’s sterile sites resulting in invasive 
pneumococcal disease (IPD), and this multistep pathogenesis process is preceded by 
pneumococcal nasopharyngeal colonisation as commensals [5]. Previous studies have 
identified a range of pneumococcal virulence factors that are important in IPD [121]. One 
such example that has attracted a lot of interest is the pilus, which was recently identified in 
S. pneumoniae.  The pilus enhances initial bacterial adhesion and virulence in mice models of 
colonisation, pneumonia and bacteremia [24]. A number of Gram-positive bacteria, for 
example Actinomyces naeslundii, Corynebacterium diphtheriae, Streptococcus parasanguis, 
Group A Streptococcus, Group B Streptococcus, and Mycobacterium tuberculosis, are 
capable of pilus assembly, thereby facilitating colonisation by enhancing their attachment to 
hosts during the initial stages of infection [299-302]. Currently, two types of functional 
pneumococcal pilus have been identified, types I and II pilus (Figure 6.1) [24, 27], and there 
is evidence that these pilus gene loci are acquired through horizontal gene transfer in many 
streptococci and other Gram-positive pathogens [184]. Type I and II pilus may be 
individually or both present in some pneumococci [24, 27]. Type I pilus has been reported to 
be present in approximately 30% of invasive and nasopharyngeal carried pneumococcal 
isolates [25, 26, 303, 304]. Type II pilus has been reported to be present in approximately 
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16% of invasive pneumococci and nasopharyngeal carried pneumococcal isolates [25, 27]. 
Both type I and II pili have been reported to be present in Taiwan19F -14 (ST236) clone [25]. 
 
 
 
Figure 6.1: The genomic organisation of the pilus encoding islets of S. pneumoniae. The 
TIGR4 is an invasive capsulated serotype 4 strain isolated from a 30-year-old male 
Norwegian patient, and was the first pneumococcal isolate to be sequenced [157]. The 
INV104 is an invasive serotype 1 strain collected from Oxford, United Kingdom [212]. (a) 
Shows the type I pilus, which is present in the TIGR4 strain but absent in the INV104 strain. 
(b) Shows the type II pilus, which is absent in the TIGR4 strain but present in the INV104 
strain (reproduced from Bagnoli et al. [27]).  
 
The assembly of three structural proteins (RrgA, RrgB and RrgC), and three transpeptidase 
enzymes (sortases SrtB, SrtC and SrtD also known as SrtC-1, SrtC-2 and SrtC-3 respectively) 
constitutes the type I pilus [305, 306]. The RrgA and RrgB subunits are surface exposed and 
are highly variable compared to RrgC, SrtB, SrtC and SrtD [307]. Host immunity exerts 
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selection pressure on these surface exposed subunits, resulting in sequence variability [307]. 
While RrgB subunits form the middle of the pilus shaft, the RrgA and RrgC subunits are 
present at the distal and proximal ends of the type I pilus (Figure 6.2) [27, 306]. The sortase 
srtB catalyses the formation of covalent complexes between RrgB and RrgC subunits [305, 
306], and anchors RrgC to the peptidoglycan cell wall [306]. The functions of sortases srtC 
and srtD are not clearly defined, but they have been suggested to play roles in RrgA and 
RrgC subunits assembly respectively [305].  
 
 
 
Figure 6.2: The assembled type I pilus subunits. The shaft of the type I pilus is composed 
of RrgA and RrgC on the distal and proximal ends respectively. The RrgB subunits are in the 
middle of the shaft. The RrgC subunit is attached to the peptidoglycan cell wall.  
 
The surface exposed pitB subunits form the backbone of type II pilus (Figure 6.3), and pilus 
assembly requires the sortase SrtG1 and the signal peptidase-related protein sipA [27]. The 
PitA subunit is also surface exposed. 
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Figure 6.3: The assembled type II pilus subunits. The shaft of the type II pilus is 
composed of pitB, which is also attached to the peptidoglycan cell wall. The pitA subunit is 
also surface exposed.  
 
Piliated pneumococcal clones of sequence type (ST) 156 associated with penicillin non-
susceptibility, and irrespective of serotype, have been reported to undergo rapid expansion, 
and notably serotype 14 that increased in prevalence from 40% to 80% [252]. The increase in 
penicillin non-susceptible serotype 14 pneumococci was a result of a capsular switch in the 
variant of the Spain 9v -3 clone, previously shown to spread internationally. Mice models of 
colonisation revealed that piliated ST156 pneumococci outcompeted the non-piliated ST156 
isolates [252]. These piliated isolates have also been suggested to diminish nasopharyngeal 
co-colonisation by Staphylococcus aureus in children aged < 40 months [308], thereby 
outcompeting their niche competitors. Active immunisation with recombinant pneumococcal 
pilus subunits and passive immunisation with antisera raised against pilus has been 
determined as protective in mice models of infection [251]. A previous study on the 
distribution and antigenic variation of pilus, which used IPD isolates collected worldwide, 
resolved the pilus RlrA islets (that consists of the rlrA promoter; RrgA, RrgB and RrgC 
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subunits; and sortases SrtB, SrtC and SrtD) into 3 clade types and highlighted RlrA gene 
presence among antibiotic resistant pneumococci [26]. Investigations after the introduction of 
the 7-valent pneumococcal conjugate vaccine (PCV7) in the USA first illustrated decreased 
type I pilus prevalence, from approximately 23.7% in 2001 to 14.9% in 2004 [309], and more 
recently an increase in prevalence of type I pilus (26.1%) in non-vaccine type pneumococci 
[309]. In the USA, the prevalence of type II pilus, among invasive pneumococcal isolates, 
was also higher in the period after PCV7 introduction period (21%) [310]. The emerging 
piliated non-vaccine type pneumococci were mainly novel clones with a few exceptions, 
suggesting that piliated pneumococci may have a colonisation advantage or are associated 
with genotypes with some beneficial traits, for example antibiotic resistance, compared to 
those without pili [309].   
 
Pilus subunits have been proposed as potential vaccine candidates that could provide 
protection against S. pneumoniae when combined with other immunogenic antigens [27, 
304]. The suitability of the pilus as a vaccine candidate requires further evaluation of the 
prevalence of pili subunits among strains in circulation from different geographic locations. 
In order for pilus subunits to qualify as suitable vaccine candidates, they should be prevalent 
in a significant proportion of circulating pneumococci so as to provide broad coverage among 
the vaccinated population. Malawi, a southern African country, has a high pneumococcal 
disease burden [50, 63], and an ideal vaccine should be able to provide protection against 
pneumococci in circulation to individuals in this region. The 13-valent pneumococcal 
conjugate vaccine (PCV13) was introduced in Malawi in November 2011, in the routine 
childhood immunization schedule for children under the age of 5 with no catch-up 
immunizations. This study examined the prevalence of pilus amongst a set of invasive 
pneumococcal isolates from Malawi, in the period prior to vaccine introduction (2002-2008), 
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to establish prevalence, association with severe disease, age, antibiotic resistance and 
antigenic variation.  
  
6.2: Identification of S. pneumoniae pilus encoding islets 
 
In this study, 140 S. pneumoniae isolates were randomly selected from the invasive isolate 
collection of the Malawi-Liverpool-Wellcome Trust Clinical Research Programme, based at 
Queen Elizabeth Central Hospital in Blantyre Malawi collected between 2002 and 2008 
(Chapter 2.1 and 2.2). They were isolated from cerebral spinal fluid (CSF) and blood of 
children and adults as described earlier (Chapter 2.1 and 2.2). The isolates were subjected to 
whole genome sequencing and the genomes were annotated using Glimmer3 [219] (Chapter 
3.3). Annotations from 12 publicly available, complete, fully annotated reference genomes 
were transferred onto the draft genomes through a process of clustering using OrthoMCL 
[222] with default parameters (p-value cut-off of 1e-5 and inflation index 1.5), thereby 
allowing identification of the pilus encoding islets (Chapter 3.4).  
 
6.3: Prevalence of the pilus operon in S. pneumoniae 
 
The prevalence of piliated pneumococci in the Malawian population was determined by 
confirming the presence of pilus subunits in the pneumococcal genome dataset. Type I pilus 
subunits were detected in 10% (14/140) of the pneumococcal population, while type II 
subunits were detected in 8.57% (12/140) (Figure 6.4). The type I piliated pneumococci were 
labeled strains 1 through 14 (Figure 6.4A), while the type II piliated pneumococci were 
labeled strains 1 through 12 (Figure 6.4B). It was observed that all piliated serotype 19F 
isolates (3/140) had both types I and II pilus subunits and they corresponded to strains labeled 
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3, 4 and 5 in the type I pilus analysis, which were labeled differently as strains 4, 5 and 6 in 
the type II pilus analysis. 
 
Type I pilus was identified in 4 STs (STs 347, 802, 5412 and 5778) covering 6 serotypes 
(19F, 23F, 6A, and 9A) (Figure 6.4A) (Appendix 1). Novel STs (n = 6) that have not yet been 
classified and archived on the multi-locus sequence typing database [214] were labeled as 
“Not assigned”, and covered 5 different serotypes (1, 4, 19F, 23F, and 6A). Strains 1 and 5 of 
the type I pilus analysis did not have complete sets of pilus subunits (Figure 6.4A), and 
therefore were not able to assemble the type I pilus. There were 5 bacteraemia-associated 
(orange) and 9 meningitis-associated (blue) pneumococci with type I pilus subunits (Figure 
6.4A). 
 
 
 
Figure 6.4A: The type I piliated strains showing the subunits present in each strain. The 
type I pilus subunits are flanked by transposes genes (blue). The missing pilus subunits are 
indicated in white colour. Pilus subunits of strains associated with bacteremia are indicated in 
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orange colour and those found in strains associated with meningitis are indicated in light-blue 
colour. 
 
The type II pilus was also identified in a different set of pneumococci, with the exception of 
the serotype 19F isolates, with 4 STs (217, 347, 3544 and 5778) covering 4 different 
serotypes (1, 19F, 7F, and 9A) (Figure 6.4B). Novel STs (n = 7) that have not yet been 
classified and archived on the multi-locus sequence typing database [214] were labeled as 
“Not assigned”, and covered 4 different serotypes (1, 19F, 7A, and 7F). Strains 1 and 3 of the 
type II pilus analysis did not have a complete sets of pilus subunits (Figure 6.4B), and 
therefore were not able to assemble the type II pilus. There were 6 bacteraemia-associated 
(orange) and 6 meningitis-associated (blue) pneumococci with type II pilus subunits (Figure 
6.4B). Overall 16.43% (23/140) of pneumococci in the genomic dataset considered in this 
study were piliated.  
 
 
 
Figure 6.4B: The piliated II strains showing the subunits present in each strain. The type 
II pilus subunits are flanked by PepT and HemH genes (light-green). The missing pilus 
subunits are indicated in white colour. Pilus subunits of strains associated with bacteremia are 
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indicated in orange colour and those found in strains associated with meningitis are indicated 
in light-blue colour. 
 
6.4: Association of pilus operon with serotype, genotype, age, and disease outcome 
 
Pili were present in a minority of strains (16.43%). In this study, it was observed that both 
type I and II pili were present in specific serotypes (1, 4, 6A, 7A, 7F, 9A, 19F and 23F) 
(Figure 6.4). However, no clear association with ST could be made (Figure 6.4). All the 
serotypes of the piliated pneumococci were represented in the PCV13 vaccine except 7A and 
9A, for which cross-protection is provided by vaccine serotypes 7F and 9V respectively. 
PCV13 vaccine contains all the serotype in PCV7 (4, 6B, 9V, 14,18C, 19F and 23F) and in 
addition serotypes 19A, 1, 3, 5, 6A and 7F [311]. 
 
It was observed that there was no association between type I and II pili with either adults (n = 
92) or children (n = 48) (Fisher’s exact p = 0.774 and p = 0.753 respectively).  
 
The association between different disease outcomes, such as bacteremia and meningitis, and 
the types of pilus present was examined. In the type I pilus association analysis, 36% (5/14) 
of pilus were present in bacteraemia-associated pneumococci and 64% (9/14) in the 
meningitis-associated pneumococci. However, there was no significant association between 
type I piliated pneumococci with either bacteraemia or meningitis (Fisher's exact p = 0.257).  
In the 12 type II pilus association analysis, 50% (6/12) of pilus were present in both 
bacteremia-associated and meningitis-associated pneumococci. Similarly, no significant 
association was made between type II piliated pneumococci with either bacteraemia or 
meningitis (Fisher’s exact p = 1.0). 
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6.5: Association of pilus operon with antibiotic resistance  
 
This study examined whether antibiotic resistant pneumococci were likely to carry pilus, and 
considered 3 major commonly used antibiotic compounds: tetracycline, chloramphenicol and 
cotrimoxazole. All pneumococci were tested against these 3 antibiotics, whereas complete 
antibiotic profiles were unavailable for other antibiotics (ampicillin, erythromycin, 
ceftriaxone, and penicillin) used in Malawi for the dataset under study. 
 
Antibiotic susceptibilities were evaluated using Etest strips (Chapter 2.1), and isolates were 
categorised as either antibiotic resistant or susceptible (Figure 6.5). All type I piliated 
pneumococci were resistant to cotrimoxazole (Figure 6.6). There were more cotrimoxazole 
resistant type II piliated pneumococci compared to those susceptible (Figure 6.7).  
 
 
 
Figure 6.5: The proportions of piliated (types I and II), and non-piliated pneumococci 
that were resistant and susceptible to the antibiotics under study (tetracycline, 
cotrimoxazole, and chloramphenicol). 
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Figure 6.6: The proportions of type I piliated pneumococci resistant or susceptible to 
tetracycline, cotrimoxazole, and chloramphenicol.   
 
  
 
Figure 6.7: The proportions of type II piliated pneumococci resistant or susceptible to 
tetracycline, cotrimoxazole, and chloramphenicol.   
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The proportions of piliated and non-piliated pneumococci that were susceptible or resistant to 
the three antibiotics under study were determined. These proportions were determined 
separately for pneumococci with either type I or II pilus (Figure 6.8 and 6.9 respectively). 
The largest proportions of antibiotic resistant piliated pneumococci were observed for the 
antibiotic cotrimoxazole. 
 
 
 
Figure 6.8: The proportions of type I piliated and non-piliated pneumococci resistant or 
susceptible to tetracycline, cotrimoxazole, and chloramphenicol.   
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Figure 6.9: The proportions of type II piliated and non-piliated pneumococci resistant 
or susceptible to tetracycline, cotrimoxazole, and chloramphenicol.   
 
A recent report highlighted the trend of pneumococcal antibiotic resistance to different 
individual antibiotic drugs in Malawi, between 2002 and 2009 [93]. More than 90% of 
pneumococci were resistant to cotrimoxazole compared to > 50% and 20% that were resistant 
to tetracycline and chloramphenicol respectively. Although a large proportion of 
pneumococci circulating in Malawi are antibiotic resistant [93], it was noted that there were 
larger proportions of piliated pneumococcal strains resistant to cotrimoxazole (100% of type I 
and 75% of type II piliated pneumococci respectively) compared to tetracycline (28.6% of 
type I and 16.7% of type II piliated pneumococci respectively) and chloramphenicol (14.3% 
of type I and 8.3% of type II piliated pneumococci respectively) (Figure 6.6 and 6.7 
respectively), raising the possibility that an association exists between piliated pneumococci 
and cotrimoxazole resistance. 
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The probabilities of binomial distribution (95% confidence intervals) were used to establish 
the proportions of piliated antibiotic resistant pneumococci (Table 6.1). This revealed that 
piliated pneumococci, and especially those with type I pilus subunits, were likely to be 
associated with antibiotic drug resistance than susceptibility. This implied that despite the 
existence of more elevated cotrimoxazole resistance compared to tetracycline and 
chloramphenicol in the entire dataset, which is a reflection of the strains in circulation, a 
larger proportion of piliated strains were more likely to be resistant than susceptible to 
cotrimoxazole. However, better-sampled datasets of piliated drug resistant and susceptible 
pneumococci are required to conclusively determine this observation. 
 
Table 6.1: Significance in the proportions of piliated (types I and II) and non-piliated 
pneumococci determined using probabilities of binomial distribution (95% confidence 
interval). Type I piliated pneumococci showed significant association with antibiotic drug 
resistance compared to susceptibilities. 
 
 
 
6.6: Pilus operon sequence diversity 
 
The pilus loci sequences of each the isolates were concatenated into single sequences. 
Multiple sequence alignments were performed using the MUSCLE program [228], followed 
by phylogeny reconstruction of multiple aligned sequences using the PhyML software 
                                    Chapter 6: Pilus prevalence among invasive pneumococci in Malawi 
 170 
(version 3.5) [312]. The sequence diversity of the two types of pili was assessed, and 
compared with well-characterised reference type I pili sequences from the pneumococcal 
molecular epidemiology network (PMEN) collection (GenBank accession numbers EF60625-
EF560637) and a publically available type II pilus sequence (GenBank GU256423). All pilus 
with missing subunits were excluded from analysis (Figure 6.4). The type I pilus sequences 
were associated with 3 main clades (Figure 6.10), while the type II pilus sequences were 
resolved into 2 clades (Figure 6.11). This indicated that the type I pilus in pneumococci 
circulating in Malawi was genetically closely related to those identified in the global 
pneumococcal molecular epidemiology network (PMEN) collection in terms of their 
nucleotide sequence diversity. However, longer branches in the Malawian strains suggest that 
they have more sequence diversity compared to the PMEN collection. 
 
 
 
Figure 6.10: The type I pilus sequences were associated with 3 main clades, shown in 
three colours: blue, green and red. Longer branches in the Malawian strains suggest that they 
have more sequence diversity. 
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Figure 6.11: The type II pilus sequences were associated with 2 main clades, shown in 
two colours: red and black. There was very little sequence diversity between the reference 
strain and the Malawian strains.  
 
6.7: Discussion 
 
The pneumococcal pilus enhances initial adhesion thereby providing a specific colonisation 
advantage [24]. Piliated pneumococci are capable of eliciting protective immune responses 
[24, 251], and have been implicated in diminishing colonisation by other niche competitors 
[308].  
 
Previous studies in Europe, North America and Israel have shown pilus to be prevalent in up 
to 30% of invasive pneumococci [25, 26, 310]. Due to this high prevalence, pili have been 
proposed as potential second-generation protein vaccine candidates that can be used in 
combination with other vaccine candidates. However, introduction of PCV has been 
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suggested to influence the prevalence of piliated pneumococci. The 7-valent pneumococcal 
conjugate vaccine (PCV7) was introduced in the USA routine infant vaccination regime in 
2000 [44, 309].  It was marked by substantial decrease in IPD in vaccinated children, and 
herd immunity in older children and adults [26, 44, 45, 309, 310]. Marked decreases in 
circulating vaccine type (VT) serotypes and proportionate decreases in piliated pneumococci 
were observed followed by an increase of invasive piliated non-vaccine type serotypes 
(NVT) [26, 309]. This raises concern about the impact of PCV introduction on the prevalence 
of piliated pneumococci. An increase in piliated NVT pneumococci, after vaccine 
introduction, which are capable of promoting efficient pneumococcal transmission by 
enhancing initial colonisation, and outcompeting co-colonising niche competitors thereby 
facilitating invasive disease would have serious public health repercussions.  These 
pneumococci would reverse the anticipated effect of the vaccine resulting in an increase of 
more severe invasive disease episodes.  
 
Many countries in Africa have started introducing PCV into their childhood immunisation 
schedules. These countries have a higher disease burden and different distributions of 
invasive disease serotypes compared to those in Europe and North America [18, 49]. The 
PCV formulations being introduced in Africa are different from the one introduced in the 
USA (PCV7), and are able to protect against additional invasive serotypes. An example is the 
13-valent pneumococcal conjugate vaccine (PCV13) that is currently being introduced across 
Malawi, since November 2011. This vaccine in anticipated to provide better coverage (88%) 
for invasive serotypes in Malawi, thereby significantly decreasing invasive pneumococcal 
disease [50]. However, the effect of the vaccine on population structure has to be evaluated 
by studying strains before and after vaccine introduction. 
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In this study, the prevalence of piliated pneumococci prior to PCV13 introduction was 
assessed. These findings provide accurate information that will enable evaluations of the 
vaccine’s impact on pilus. The prevalence of piliated pneumococci (16.43%) was low, and 
lower than those reported elsewhere [308-310]. Pilus subunits were present in certain 
serotypes particularly 1, 4, 6A, 7A, 7F, 9A, 19F, and 23F [304]. There was no association 
between pili presence and age or outcome of disease. This suggests that pili are only required 
for colonisation and are not essential during invasive disease. Although, no pili associations 
with age were observed, a larger dataset is required to definitively examine this association. 
 
Interestingly, an association between pilus presence and cotrimoxazole resistance was 
observed. However, more conclusive future studies with well-sampled pneumococcal 
datasets that more specifically address this question are required. Cotrimoxazole prophylaxis 
was introduced as a routine antibiotic in Malawi in the year 2002 and become a government 
policy in the year 2005, alongside the free national antiretroviral therapy programme among 
HIV-infected individuals [93]. The percentage of invasive pneumococci resistant to 
cotrimoxazole has increased steadily in Malawi, since introduction [93]. This antibiotic 
resistance can also be associated with sulphadoxine pyrimethamine (Fansidar TM), which is a 
drug used to treat malaria, that has the same targets as cotrimoxazole (that is the 
dihydrofolate reductase and dihydropteroate synthase genes) and has resulted in drug 
resistance conferring mutations in Plasmodium falciparum [313]. All type I piliated 
pneumococci were resistant to cotrimoxazole, as well as a large proportion of those with type 
II. This suggests an increase in antibiotic cotrimoxazole resistance among transmitted and 
carried pneumococci in Malawi, since pilus is nonessential but enhances invasive disease. 
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Type I pilus were categorised into 3 main clades, which have previously been observed in a 
global pneumococcal collection [26], whereas 2 clades of type II pilus were observed. This 
implies that pneumococcal pili identified in Malawi, an African country with a high disease 
burden, have the same sequence diversity as those described in other continents. 
Interestingly, type II pili have fewer clades and are therefore more conserved, implying that 
the type II pili subunit genes are less recombinogenic compared to those of type I. There was 
no association between pilus diversity and sequence type, suggesting that pilus sequence 
diversity was not associated with pneumococcal genetic background. 
 
There is currently no report on the prevalence of pilus in Africa, where a large burden of IPD 
exists. In this study, all the pilus serotypes were covered by PCV13, and only a small 
proportion of invasive pneumococcal isolates were piliated. This suggests that pili would not 
provide broad coverage as vaccine candidates in countries such as Malawi. The sequence 
diversity of pili in the PMEN collection is similar to that in pili from Malawian isolates. It is 
unclear what drives the association between piliated pneumococci and cotrimoxazole 
resistance and there is need for continued surveillance after vaccine introduction to fully 
understand its impact on pilus prevalence. 
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CHAPTER 7 
 
General Discussion 
 
7.1: Introduction  
 
This project was designed to investigate the genome-wide diversity of pneumococcal 
antigens among invasive pneumococcal isolates collected from Malawian patients. It focused 
on the diversity of these antigens in pneumococci associated with two disease outcomes: 
bacteraemia (bloodstream infection) and meningitis. Various bioinformatics techniques, some 
of which were newly developed, were used to interrogate the genome sequences of these 
invasive pneumococcal disease isolates. The isolates (n = 140) were obtained from the 
bacterial repository of the Malawi-Liverpool Wellcome Trust Clinical Research Programme 
(MLW), between 2002 and 2008 (Chapter 2.1 and 2.2).  
 
Analysis was performed to characterise differences in the composition of genomic antigen 
diversity among isolates associated with bacteraemia and meningitis, to understand whether 
differences in pneumococcal antigen diversity between meningitis and bacteraemia exist. 
This analysis enabled a better understanding of the tropism for a certain subset of invasive 
pneumococci to cause meningitis, based on their genomic composition. A separate set of 
analyses assessed the ability of phyletic patterns (gene presence and gene absence) to resolve 
the population structure of multiple, diverse, highly recombinogenic bacteria, using 
pneumococcal genomes. These analyses also examined the extents of genetic flux (gene gain 
and gene loss) during bacteraemia and meningitis to determine the likely genes that are 
acquired and lost from samples recovered from bacteraemia and meningitis, which occur in 
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two distinct niches (blood and cerebral spinal fluid respectively), and represent two different 
pneumococcal lifestyles.  A final analysis was performed to determine the prevalence of 
pneumococcal pili in Malawi, in the period before vaccine (PCV13) introduction, as a 
prelude to assessing the impact of PCV13 introduction on pilus prevalence. In this thesis, 
novel bioinformatics software and pipelines were developed (to determine core genome size 
and composition; and to resolve population structure), and were used in combination with 
existing bioinformatics softwares during analysis to yield robust and accurately interpreted 
results (Chapter 3). 
 
This discussion concentrates on the significance of these findings with regards to the diverse 
antigen composition of genomes from pneumococcal bacteraemia and meningitis and how 
they influence the propensity of pneumococci to cause either of the two disease outcomes 
(bacteraemia and meningitis) and identifies antigens that can be used as potential next 
generation vaccine candidates and as therapeutic targets. Future work proceeding from these 
findings will then be discussed. 
 
7.2: Bioinformatics methods, pipelines and statistical analysis 
 
The first objective of this thesis was to develop bioinformatics algorithms and pipelines for 
analysis of multiple diverse pneumococcal datasets to understand pneumococcal population 
and evolutionary genetics. There are more than 92 Streptococcus pneumoniae serotypes [15, 
163], which are genetically diverse, highly recombinogenic and can be genetically 
categorised into multiple lineages based on their sequence types (STs) [35, 42, 81, 183]. In 
this thesis, analyses were based on an extensive dataset of 140 pneumococcal genomes to 
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answer different research questions and required bioinformatics tools capable of exploring 
with very large datasets. High-performance computing clusters, based at the Wellcome Trust 
Sanger Institute, were used as platforms for running the bioinformatics software. There are 
many bioinformatics software applications available for the analysis of different bacterial 
genomic sequence data [207]. These bioinformatics programs are extremely useful solutions 
to specific scientific questions; nonetheless, new and bespoke programs are essential for the 
analysis of new different questions that cannot be effectively addressed using currently 
available specific bioinformatics tools. An example is development of new sequence 
assembly tools capable of correctly assembling enormous amounts short-read sequence data 
generated on the Illumina platform, relative to longer reads previously generated by 454 
sequencing approaches. In this thesis some of the existing bioinformatics tools were used 
successfully to analyse genomic sequence data in order to derive meaningful information that 
could be accurately interpreted. Nonetheless, bespoke methods were also developed to 
identify and calculate the size and composition of the core genome, and to establish the 
population structure. These methods were first validated using test datasets, and allowed 
visualised quality assessment of the data and analysis process, before being integrated into 
pipelines that were used to efficiently analyse data (Appendix 3.1 to 3.4). 
 
In order to understand the mechanisms facilitating the tropism of the pneumococcus for the 
meningeal space, it was important to establish and compare the core genome size and 
composition of meningitis and bacteraemia-associated pneumococci. Reference-based 
methods, which involve mapping of the genome sequences of interest against a selected 
reference genome, have been developed for core genome analysis [165, 183]. However, these 
methods are suitable for the analysis of genomes from bacterial species with low levels of 
                                                                                                                        General discussion 
 178 
genetic variation or the analysis of single lineages of highly recombinogenic bacteria [183]. 
A mapping approach, which involves aligning of query genome sequence reads against a 
single reference genome, would not have been be ideal for this analysis, as mapping highly 
recombinogenic clones from multiple diverse lineages against a single reference genome 
would considerably restrict the degree of variation detected.  These methods could therefore 
not be exploited to study the multiple diverse lineages of highly recombinogenic 
pneumococci that were considered in this thesis.   
 
A clustering approach, using OrthoMCL with default settings (BLASTp E-value cut-off 1e-5 
and inflation index 1.5)  (Chapter 3.5), was therefore employed to analyse the multiple 
diverse lineage datasets. The analysis method developed was robust and capable resolving 
many-to-many orthologous relationships and allowed the extension of the core genome 
concept to include uncharacterised or hypothetical genes that might play key roles in 
pneumococcal virulence, metabolism, as well as regulatory roles. The clustering pipeline also 
enabled the detection and removal of poor quality genome sequences from downstream 
analysis, ensuring that only high quality genomes were analysed. This ensured that the results 
could be interpreted robustly and that only accurate conclusions were drawn from the 
analysis. 
 
During analysis, the core genome sizes in this analysis did not reach a plateau, where there is 
no significant change in the number of core genes with the addition of new genomes. 
Previously, fitting core genome size data to single exponential decaying functions has been 
used to extrapolate core genome sizes [192]. In this thesis a novel double-exponential 
decaying function that fitted the data more accurately was developed. This model was used to 
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extrapolate the core genome size to infinity (Chapter 4.4), to investigate the point at which 
the core genome sizes plateaued. This is important because at the plateau the pneumococcal 
species core genome size could be determined.  
 
Several bacteria are adapted to colonising a wide spectrum of microbial ecologies, and are 
adapted to different lifestyles [239]. Streptococcus pneumoniae is one such bacterium that is 
able to colonise and invade a variety of host ecological environments, as demonstrated by its 
ability to colonise the nasopharynx as a commensal and to invade the host’s sterile sites, such 
as the lungs, blood and CSF, causing life-threatening disease. To achieve this, significant 
genetic variation enabling adaption to their different lifestyles and the niches they colonise 
would be expected. Such variation makes it difficult to robustly and accurately resolve their 
population structures. A computationally efficient principal component analysis (PCA) 
method was developed to investigate whether phyletic patterns (the patterns of gene presence 
or gene absence) could be used to robustly determine the pneumococcal population structure, 
since they are a highly diverse species. This method was applied to the pneumococci 
genomes, which belong to multiple diverse lineages and are highly recombinogenic. 
Resolving the population structure of such highly variant bacterial species is a difficult task, 
because the relatively high rates of recombination greatly obscure their evolutionary history. 
The PCA method developed was able to resolve the pneumococcal population structure, 
suggesting the existence of a strong phylogenetic signal in phyletic patterns. Different 
proportions of variance in the data were explained by the principle components (Chapter 5.2). 
It was determined that two and three principle component axes, which explained most of the 
variance in phyletic patterns, could be used to robustly determine the variance in the data 
(Chapter 5.2). Since the PCA method robustly resolved the pneumococcal population 
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structure, this provided greater confidence for the use of pneumococcal phyletic patterns to 
establish levels of genetic flux (the extent of gene gain and gene loss). 
 
A robust probabilistic model: Gain Loss Mapping Engine (GLOOME) developed by Cohen 
et al. [235, 236], which was more biologically realistic, was then employed to infer the 
patterns of gene gain and loss (Chapter 5.3). Preliminary analysis using GLOOME have been 
performed on datasets from the Clusters of Orthologous Groups (COG) database, which 
consists of orthologs from both eukaryotes and prokaryotes [235, 314]. GLOOME 
implemented a mixture model, which allowed the rate of genetic flux to vary between and 
within lineages, and across different gene families. This enabled accurate prediction and 
interpretation of the extent of gene loss and gain in the pneumococcal datasets. 
 
In summary, a bespoke analytical pipeline, composed of existing and newly developed 
bioinformatics programs that employed a clustering approach, was used to accurately define 
the size and composition of the pneumococcal core genome (Figure 7.1). This enabled core 
genome comparisons between different disease outcomes (meningitis and bacteraemia).  
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Figure 7.1: Summarised core genome analysis pipeline showing the three main steps 
used for quality assessment and analysis. 
 
A computationally robust PCA method (Appendix 3.4), which robustly determines the 
pneumococcal population structure using phyletic patterns, was also developed. After 
establishing that phyletic patterns can be used to robustly resolve the pneumococcal 
population structure, these phyletic patterns were used to infer the extent and direction of 
gene gain and loss events in highly recombinogenic bloodstream and meningitis 
pneumococcal datasets using GLOOME [235, 236]. These methods that were used to analyse 
bacterial genomic data of highly recombinogenic multiple diverse lineages can be used to 
explore other genomic pneumococcal datasets, such as those from carriage; as well as other 
bacterial genomes.  
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7.3: Genetic diversity amongst bacteraemia and meningitis causing Streptococcus 
pneumoniae. 
 
To determine whether there are virulence factors that are associated with the tendency to 
cause meningitis by examining differences in genetic diversity among meningitis and 
bacteraemia associated (bloodstream infection) pneumococci a comparative core genome 
analysis was performed. Most meningitis causing pneumococci arrive in the brain through 
hematogenous spread. Although both pneumococcal bacteraemia and meningitis are life 
threatening, it has long remained unclear whether pneumococci causing meningitis are 
genetically distinct from those that do not. In the past, tissue culture models and animal 
studies supported most of the knowledge on the pathogenesis of bacterial meningitis. High-
throughput genome sequencing of large pneumococcal strain collections together with novel 
innovative bioinformatics approaches was used to study human pneumococcal meningitis.  
 
It was observed that meningitis associated pneumococcal isolates had a slightly larger core 
genome that was also composed of genes distinct from the core genome of the bacteraemia-
associated isolates (Chapter 4.3). This suggested that the meningitis core genome consisted of 
a distinct set of genetic components that were likely to be essential for meningeal invasion 
and survival. Thus, within a highly recombinogenic bacterial population of multiple diverse 
lineages, the overall core genome was identified, supporting evidence of a large, conserved 
(always present) set of genes that can be used to robustly reconstruct phylogenies.  
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These findings have provided some of the first evidence from human disease that meningitis 
causing pneumococci have a distinct core genome, which encodes for both known and 
previously undescribed proteins that are likely to be essential for meningeal invasion and 
survival. The differences between core genes were not large and not accounted for by the 
absence of large blocks or a large number of genes. The differences are subtle, suggesting 
that in the case of both meningitis and bacteraemia, the core genome can be viewed as a key 
that unlocks pathogenesis pathways, enabling survival in otherwise hostile host 
environments. 
 
These data begin to explain the tropism of some pneumococci for the CSF and not others, 
supporting the considerable in vitro and animal model data that implicate key pneumococcal 
molecules as essential to invasion and survival within the meningeal space. These findings 
also emphasise the considerable redundancy in pneumococcal virulence determinants that 
have been shown to be important in the pathogenesis of pneumococcal meningitis in such 
experiments [121, 124, 132, 133, 255]. Evidence from humans that meningitis causing 
bacteria are genetically distinct has to date been elusive. Specific bacterial phenotypes, for 
example amongst E. coli that have been associated with meningitis [260], encode genetic 
determinants that allow adhesion to the BBB and promote CSF invasion through host 
endothelial receptor engagement. However, until recently the sequencing capacity and 
analytical tools have not been available to provide a comprehensive insight into the genetic 
determinants of bacterial virulence in a human context. 
 
This thesis highlighted a distinct minimum conserved set of genes that is necessary for 
meningeal infection, thereby providing a better understanding on the tendency of some 
                                                                                                                        General discussion 
 184 
pneumococci to invade the CSF and cause meningitis (Chapter 4.7). The data also underlines 
the considerable redundancy in pneumococcal virulence determinants that have been shown 
to be important in the pathogenesis of pneumococcal meningitis by in vitro and animal model 
experiments [124, 132, 133, 139, 255]. Analysis showed that the meningitis and bacteraemia-
associated pneumococcal collections used in this thesis belong to diverse genetic lineages; 
and that the distinct size and composition of their core genomes was not due to the presence 
of over-represented clones in the dataset. Further interrogation of the data revealed that the 
slightly larger core genome size of the meningitic pneumococci was not a result of an over-
representation of prophage and integrative conjugate elements (ICE) in meningitis-associated 
genomes. Although it has been unclear whether bacteria causing meningitis in humans are 
genetically distinct from those that do not, specific bacterial phenotypes have been associated 
with meningitis. An example is the Gram-negative bacillus Escherichia coli, which encode 
genetic determinants that allow adhesion to the brain-blood barrier (BBB) and promote CSF 
invasion through host endothelial receptor engagement [260].  
 
Further detailed genomic surveys using carefully sampled large longitudinal datasets of 
carriage and invasive disease isolates under different immunological pressures (particularly 
immunocompromising conditions such as HIV) are required. These will undoubtedly 
generate exciting new insights into the pathogenesis of invasive pneumococcal disease 
providing an in-depth understanding of how pneumococcus adaptation to the human host in a 
largely commensal relationship also enables tissue invasion and dissemination. These 
analyses will also help identify candidate molecules that can be exploited as vaccine and 
therapeutic targets. This study has highlighted a distinct minimum conserved set of genes that 
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is necessary for meningeal infection and which begins to explain the tropism of some 
pneumococci for the CSF and not others. 
 
7.4: Genetic population structure and genomic flux in invasive pneumococci associated 
with bacteraemia and meningitis. 
 
To establish whether gene presence and absence profiles (phyletic patterns) [236] can be used 
to resolve pneumococcal population structures, and to investigate the extent by which the 
pneumococcal genome content varies within and across lineages, and in different ecological 
niche (blood and cerebral spinal fluid (CSF)), gene gain and gene loss events during invasive 
pneumococcal disease was examined [235, 236, 296]. Gene families can be acquired and lost 
by horizontal gene transfer and sequence evolution processes, resulting in chromosomal 
reorganisation [235, 297, 315]. Understanding the likelihood, extent and directions of gene 
fluctuations is an important element of understanding genome evolution and proteome 
functionality in clinically relevant bacteria. These processes remain largely undefined and are 
likely to be complex.  
 
Biologically realistic statistical models for inferring gene gain and loss have progressively 
been developed, to better understand genetic flux events. These models use the patterns of 
gene presence and absence (phyletic patterns) as input data for analysis and have been 
successfully employed in primates [298] and prokaryotes [235, 268, 296, 297]. The initial 
genetic flux inference statistical model assumed similarity in the rate of gene gain and loss, 
and also that these rates were invariable in gene families [296]. However, evidence on 
differing tendencies of gene gain and loss among gene families is now available [235]. 
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Mixture-models that take into account the differences in rates of gene gain and loss among 
gene families, as well as independent evolution within and across lineages have recently been 
developed [235, 296]. Bacterial genomes display varying gene content due to dissimilar rates 
of acquisition or loss of genes within and across lineages, and these statistical models provide 
more accurate inference of these genetic flux. This thesis provides the first evidence of 
genetic flux (gene gain and loss) in S. pneumoniae during invasive disease (bacteraemia and 
meningitis). 
 
In this thesis, genes with high transferability were examined, and gene gain and loss events 
implicated their role as either essential or non-essential for blood and meningeal invasion and 
survival. Blood and CSF are distinct niches, with higher nucleic acid content, numerous 
immune defence proteins and iron presence in blood compared to the acellular meningeal 
environment. The relative abundance of nutrients and components required by pneumococci 
within their niche plays a role on their evolution, especially due to their highly 
recombinogenic nature, and consequently gene content as they adapt from nasopharyngeal 
commensals to invasive pathogens at different host tissue sites. 
 
The ability of phyletic patterns to resolve the pneumococcal population structure, which 
consisted of highly recombinogenic multiple diverse lineages, was used to evaluate their use 
for determining the extent genetic flux among pneumococci. Phyletic patterns robustly 
defined the pneumococcal population structure and validated their use in determining genetic 
flux among highly recombinogenic bacteria (Chapter 5.2). This suggested the existence of a 
strong phylogenetic signal in phyletic patterns, which was used to resolve the pneumococcal 
population structure, despite extensive recombination events. It also suggested that phyletic 
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patterns are often conserved during clonal expansion, perhaps due to similar selection 
pressure at certain gene families within lineages (Chapter 5.2). 
 
For each gene locus along the genome, the extent of transferability was examined for the 
meningitis and bacteraemia groups. A higher extent of genetic flux was observed in the 
bacteraemia group compared to the meningitis group, implying that meningitic genomes are 
more uniform. Overall, the inferred extent of gene gain exceeded that of gene loss in both the 
meningitis and bacteraemia groups, except within a single lineage (ST217) of the meningitic 
group. This implies that the genes within the ST217 meningitic group are more closely 
related and therefore more conserved, maintaining sets of highly essential genes. This also 
suggests that genes that are non-essential for meningeal invasion and survival are more likely 
to be lost or less likely to be acquired. Most of these acquired genes therefore play an 
important role during meningitis, further supporting the findings in the meningitic core 
genome is both larger and distinct from that associated with bacteraemia (Chapter 4). The 
extent of genetic flux within a single lineage was also less pronounced compared to that 
across lineages, supporting the findings that phyletic patterns within lineages are more 
conserved. There was high genetic flux along the genome regardless of the G+C content. 
This flux appeared to be more pronounced in particular regions along the genome. This 
implies that gene transfer events can occur even at loci that are regarded as highly conserved, 
as determined by their high G+C content. It was also suggests that there are regions on 
pneumococcal chromosomes that are more likely to undergo gene transfer, supporting the 
existence of recombination hotspots across multiple lineages [183]. It was also observed that 
the extent of gene transfers along each of the phylogenetic branches were greater among the 
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bacteraemia group compared to the meningitis group (Chapter 5.5). However, the pattern of 
gene gain or loss was arbitrary within lineages and across groups.  
 
Realistic probabilistic models were used to accurately infer pneumococcal gene gain and loss 
events thereby highlighting gene content fluctuations, and adaptation to different niches.  
Despite the high extents of genetic flux within lineages and across groups, the genes in the 
meningitis group genomes displayed lower inferred extents of gene fluctuations and were 
therefore more conserved than to those of the bacteraemia group.  
 
High expectation values for gene gain and loss were observed for several genes (Chapter 
5.4). These genes include:  
• Cell surface choline binding protein PcpA 
• Ferric siderophore ABC transporter proteins  
• Putative type I restriction-modification system S protein  
• Putative Mga-like regulatory protein  
• Putative phage integrase/recombinase  
• Putative L-lactate oxidase-related protein  
• Group II intron maturase  
• Antiholin  
• Putative iron-siderophore binding lipoprotein  
• Putative lantibiotic export protein  
• Choline binding protein J  
• MutT/NUDIX hydrolase family protein  
• Putative sodium:dicarboxylate symporter family protein 
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These genes play important roles in pneumococcal niche adaptation, by facilitating nutrient 
acquisition and genetic diversification, thereby offering a selective advantage for niche 
invasion and survival. These findings also lend further support to significant tissue culture 
and animal model experiments that demonstrate that different sets of genes are required for 
tissue-specific invasion and survival (Chapter 4) [132]. These findings highlighted the likely 
acquisition or loss of key genes during human pneumococcal pathogenesis and improve the 
understanding of the role of selection pressure on pneumococcal pathogenesis. 
 
7.5: Pilus prevalence among invasive Streptococcus pneumoniae isolates prior to 
pneumococcal conjugate vaccine introduction, in Malawi. 
 
Piliated pneumococci exhibit enhanced initial adhesion at the nasopharynx and thus 
potentially have a colonisation advantage [24]. Pneumococcal pili induce protective immune 
responses [24, 251], and are thought to be capable of diminishing nasopharyngeal 
colonisation by other niche competitors, by providing a colonisation advantage [308].  
 
Several African countries have started introducing PCV into their childhood immunisation 
schedules. These countries have a higher disease burden and different distributions of 
invasive disease serotypes compared to those in Europe and North America [18, 49]. The 
PCV formulations being introduced in Africa are different from the one introduced in the 
USA (PCV7), and are able to protect against additional invasive serotypes. An example is the 
13-valent pneumococcal conjugate vaccine (PCV13) that is currently being introduced across 
Malawi, since November 2011. This vaccine in anticipated to provide better coverage (88%) 
for invasive serotypes in Malawi, thereby significantly decreasing invasive pneumococcal 
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disease [50]. However, the impact of these vaccines on the pneumococcal population 
structure of these countries is currently unknown, and has to be evaluated by studying strains 
before and after vaccine introduction.  
 
In this thesis, the prevalence of piliated pneumococci prior to PCV13 introduction in Malawi 
was assessed. The findings will enable evaluations of the vaccine’s impact on the 
pneumococcal strains structure, and more specifically whether it affects the prevalence of 
invasive piliated pneumococci. The prevalence of piliated pneumococci (16.43%) was low, 
compared to those reported in other regions outside Africa (30%). Pili subunits were present 
in certain serotypes, particularly 1, 4, 6A, 7A, 7F, 9A, 19F, and 23F (Chapter 6.3). However, 
there was no association between pili presence and age or outcome of disease (meningitis and 
bacteraemia). The low prevalence of piliated pneumococci suggests that pili are not essential 
for initial colonisation by invasive disease strains. 
 
Interestingly, it was noted that most of the piliated pneumococci were resistant to 
cotrimoxazole. Cotrimoxazole prophylaxis was introduced as a routine antibiotic in Malawi 
in the year 2002 and become widely used for HIV prophylaxis from 2005. Resistance to 
cotrimoxazole among invasive isolates is currently high in Malawi (up to 90%) [93]. 
However, resistance can also be attributed in part to the widespread use of sulphadoxine 
pyrimethamine (Fansidar TM), an antimalarial drug that also has the same targets as 
cotrimoxazole (the dihydrofolate reductase and dihydropteroate synthase genes) that has been 
previously demonstrated to confer drug resistance mutations in Plasmodium falciparum 
[313]. All of the type I and a large proportion of type II piliated pneumococci were resistant 
to cotrimoxazole. This also suggests that an increase in cotrimoxazole resistance exists 
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among transmitted and carried pneumococci in Malawi. However, the low pilus prevalence 
among invasive isolates suggests that the pilus is nonessential during invasive disease 
(Chapter 4). 
 
In Malawi, three main clades of type I pilus were identified, which was consistent with those 
previously described in a global pneumococcal collection. Two clades of type II pilus were 
identified. This implies that pneumococcal pili identified in Malawi, an African country with 
a high disease burden, have the same sequence diversity as those previously described in 
other continents. There was no association between pilus diversity and sequence type, 
suggesting that pilus sequence diversity was not associated with pneumococcal genetic 
background. This provides more support to the possibility of recombinogenic acquisition. 
 
This thesis provides some of the first evidence on pilus prevalence in Africa, where a large 
burden of invasive pneumococcal disease exists. All the pilus serotypes were covered by 
PCV13, and only a small proportion of invasive pneumococcal isolates were piliated. This 
indicates that immunisation with pili would not provide broad coverage against 
pneumococcal disease in countries such as Malawi. The sequence diversity of pili in the 
global collection of the Pneumococcal Molecular Epidemiology Network (PMEN) is similar 
to that in pili from Malawian isolates indicating that pili do not display considerable 
geographic diversity. There is need for continued surveillance after vaccine introduction to 
fully understand its impact on pilus prevalence. 
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7.6: Conclusion 
 
Invasive S. pneumoniae have a distinct set of genes, the core genome, which appear to be 
essential for them to invade and survive in different niches. The findings have suggested that 
the meningitic pneumococci have a slightly larger and distinct core genome composition 
compared to that of bacteraemia-associated pneumococci. Bacteraemia-associated 
pneumococci undergo more genetic flux and are less conserved than meningitis-associated. 
These gene flux events are arbitrary within and across lineages. The findings also imply that 
pneumococcal pili are unsuitable single antigen vaccine candidates in Malawi, a sub-Saharan 
Africa country with a high pneumococcal disease burden, due to their low prevalence and 
non-essential role in invasive disease.  
 
7.7: Future work 
 
The findings from this PhD thesis have provided the basis for other investigations: 
 
7.7.1: Genetic diversity amongst carried and invasive Streptococcus pneumoniae. 
 
Genomic investigations of more detailed, well sampled longitudinal datasets of carriage and 
invasive disease isolates under different immunological pressures (particularly 
immunocomprimising conditions such as HIV) will improve the understanding on the 
pathogenesis of invasive pneumococcal disease. This will help to provide a clear 
understanding of pneumococcal pathogenesis process by elaborating its transition from a 
largely commensal relationship at the nasopharynx to an invasive pathogen at different host 
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tissue sites. This will also help identify candidate molecules that can be exploited as vaccine 
and therapeutic targets.  
 
7.7.2: Immunogenicity of pneumococcal genes that are essential for invasive disease 
(bacteraemia and meningitis) in animal model and tissue culture experiments. 
 
The gene sets identified in this thesis as essential for pneumococcal invasion and survival can 
be investigated for their ability to elicit host immune responses in animal model experiments. 
Universally immunogenic genes and genes that are vital for pneumococcal pathogenesis and 
survival can be proposed as vaccine candidates and therapeutic targets and may undergo 
further downstream examination.  
 
7.7.3: Genetic population structure and genomic flux among carried pneumococcal 
isolates. 
 
Phyletic patterns can be used to determine the population structure of carried pneumococcal 
isolates, which are thought to be less conserved compared to those isolated from invasive 
disease. These phyletic patterns can also be used to infer the patterns of gene acquisition and 
loss in carriage, which can be compared to those of invasive disease presented in this thesis. 
These results will help to determine the dynamic changes associated with genetic transfer 
events when pneumococci transition from a commensal state at the nasopharynx and become 
invasive.   
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7.7.4: Comparison of pilus prevalence among invasive and carriage Streptococcus 
pneumoniae isolates in the period before and after pneumococcal conjugate vaccine 
introduction, in Malawi. 
 
Although pilus prevalence was low in Malawi, piliated pneumococci have been shown to 
have a colonisation advantage. This suggests that perhaps a higher prevalence might be 
associated with carried isolates. Investigations on comparisons between the prevalence of 
pilus among invasive and carried pneumococci, in the periods before and after vaccine 
introduction will help to assess the effect of the vaccine on pilus prevalence.  
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APPENDICES 
 
Appendix 1: Streptococcus pneumoniae isolates used in this thesis.  
 
Sample no. Adult or Child HIV status Year Specimen Genome coverage St Serotype 
Strain 1 Adult Positive 2002 Bacteraemia 84.00 2987 6A 
Strain 2 Adult Unknown 2003 Bacteraemia 84.00 2927 18C 
Strain 3 Adult Negative 2004 Bacteraemia 90.00 289 5 
Strain 4 Adult Positive 2004 Bacteraemia 35.81 63 14 
Strain 5 Adult Positive 2004 Bacteraemia 83.00 Unknown 22A 
Strain 6 Adult Positive 2004 Bacteraemia 72.79 Unknown 10B 
Strain 7 Adult Positive 2004 Bacteraemia 62.76 5902 9A 
Strain 8 Adult Positive 2004 Bacteraemia 75.00 Unknown 18A 
Strain 9 Adult Positive 2004 Bacteraemia 61.97 989 12B 
Strain 10 Adult Positive 2004 Bacteraemia 92.00 217 1 
Strain 11 Adult Positive 2004 Bacteraemia 94.00 217 1 
Strain 12 Child Positive 2004 Bacteraemia 73.57 2987 6A 
Strain 13 Child Unknown 2004 Bacteraemia 76.00 Unknown 6A 
Strain 14 Child Positive 2004 Bacteraemia 68.15 102 18B 
Strain 15 Adult Positive 2005 Bacteraemia 103.79 3548 31 
Strain 16 Adult Negative 2005 Bacteraemia 84.00 Unknown 22F 
Strain 17 Adult Positive 2005 Bacteraemia 106.08 802 23F 
Strain 18 Adult Positive 2005 Bacteraemia 138.11 Unknown 9A 
Strain 19 Adult Positive 2005 Bacteraemia 107.77 2213 4 
Strain 20 Adult Positive 2005 Bacteraemia 91.11 217 1 
Strain 21 Adult Positive 2005 Bacteraemia 131.53 217 1 
Strain 22 Adult Positive 2005 Bacteraemia 182.82 Unknown 1 
Strain 23 Adult Positive 2005 Bacteraemia 138.80 5778 9A 
Strain 24 Adult Positive 2005 Bacteraemia 131.90 4084 33B 
Strain 25 Adult Negative 2005 Bacteraemia 92.00 217 1 
Strain 26 Adult Negative 2005 Bacteraemia 197.97 217 1 
Strain 27 Adult Positive 2005 Bacteraemia 94.00 Unknown 3 
Strain 28 Adult Negative 2005 Bacteraemia 136.68 2062 19A 
Strain 29 Adult Negative 2005 Bacteraemia 198.14 Unknown 1 
Strain 30 Adult Negative 2005 Bacteraemia 97.00 217 1 
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Sample no. Adult or Child HIV status Year Specimen Genome coverage St Serotype 
Strain 31 Adult Positive 2005 Bacteraemia 97.00 Unknown 4 
Strain 32 Child Positive 2005 Bacteraemia 132.46 705 16F 
Strain 33 Child Unknown 2005 Bacteraemia 99.00 Unknown 9A 
Strain 34 Child Negative 2005 Bacteraemia 94.00 Unknown 10B 
Strain 35 Child Positive 2005 Bacteraemia 201.96 Unknown 6A 
Strain 36 Child Negative 2005 Bacteraemia 384.99 Unknown 7A 
Strain 37 Child Negative 2005 Bacteraemia 258.45 Unknown 6A 
Strain 38 Adult Positive 2006 Bacteraemia 114.92 2053 13 
Strain 39 Adult Unknown 2006 Bacteraemia 13.58 Unknown 9A 
Strain 40 Adult Positive 2006 Bacteraemia 41.75 217 1 
Strain 41 Adult Negative 2006 Bacteraemia 96.00 217 1 
Strain 42 Adult Positive 2006 Bacteraemia 41.40 217 1 
Strain 43 Adult Positive 2006 Bacteraemia 33.49 705 16F 
Strain 44 Adult Positive 2006 Bacteraemia 39.56 Unknown 7F 
Strain 45 Adult Negative 2006 Bacteraemia 97.00 217 1 
Strain 46 Adult Positive 2006 Bacteraemia 39.08 63 14 
Strain 47 Adult Positive 2006 Bacteraemia 39.18 Unknown 19F 
Strain 48 Adult Positive 2006 Bacteraemia 42.33 2987 6A 
Strain 49 Adult Positive 2006 Bacteraemia 46.76 217 1 
Strain 50 Adult Negative 2006 Bacteraemia 98.00 Unknown 3 
Strain 51 Adult Positive 2006 Bacteraemia 93.00 Unknown 10B 
Strain 52 Adult Negative 2006 Bacteraemia 92.00 289 5 
Strain 53 Child Positive 2006 Bacteraemia 82.00 Unknown 15B 
Strain 54 Child Positive 2006 Bacteraemia 83.00 Unknown 6A 
Strain 55 Child Negative 2006 Bacteraemia 45.47 Unknown 6B 
Strain 56 Child Positive 2006 Bacteraemia 53.00 2902 6C 
Strain 57 Child Negative 2006 Bacteraemia 87.00 2678 14 
Strain 58 Child Unknown 2006 Bacteraemia 88.00 Unknown 12B 
Strain 59 Child Positive 2006 Bacteraemia 48.88 2053 13 
Strain 60 Adult Unknown 2007 Bacteraemia 98.00 217 1 
Strain 61 Child Unknown 2007 Bacteraemia 95.00 Unknown 9L 
Strain 62 Child Unknown 2007 Bacteraemia 99.00 217 1 
Strain 63 Child Unknown 2007 Bacteraemia 78.00 Unknown 23F 
Strain 64 Adult Unknown 2008 Bacteraemia 83.00 Unknown 7A 
Strain 65 Adult Unknown 2008 Bacteraemia 67.00 Unknown 33A 
Strain 66 Adult Unknown 2008 Bacteraemia 102.64 2062 19A 
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Sample no. Adult or Child HIV status Year Specimen Genome coverage St Serotype 
Strain 67 Child Unknown 2008 Bacteraemia 79.00 Unknown 6B 
Strain 68 Child Negative 2008 Bacteraemia 58.25 Unknown 6A 
Strain 69 Child Unknown 2008 Bacteraemia 85.00 347 19F 
Strain 70 Child Negative 2009 Bacteraemia 23.31 2213 4 
Strain 71 Adult Positive 2004 Meningitis 80.61 5902 9A 
Strain 72 Adult Positive 2004 Meningitis 80.39 2987 6A 
Strain 73 Adult Unknown 2004 Meningitis 201.54 Unknown 23F 
Strain 74 Adult Positive 2004 Meningitis 61.47 Unknown 15B 
Strain 75 Adult Positive 2004 Meningitis 65.29 5396 35B 
Strain 76 Adult Positive 2004 Meningitis 83.24 5604 25F 
Strain 77 Adult Positive 2004 Meningitis 101.81 Unknown 10B 
Strain 78 Adult Negative 2004 Meningitis 78.03 Unknown 12B 
Strain 79 Adult Positive 2004 Meningitis 69.38 1871 9A 
Strain 80 Adult Unknown 2004 Meningitis 371.66 Unknown 37 
Strain 81 Adult Negative 2004 Meningitis 75.15 Unknown 11D 
Strain 82 Child Unknown 2004 Meningitis 86.00 Unknown 7F 
Strain 83 Child Unknown 2004 Meningitis 95.00 63 14 
Strain 84 Child Negative 2004 Meningitis 94.00 217 1 
Strain 85 Child Negative 2004 Meningitis 93.00 989 12B 
Strain 86 Adult Unknown 2005 Meningitis 107.50 Unknown 45 
Strain 87 Adult Positive 2005 Meningitis 162.93 Unknown 12B 
Strain 88 Adult Negative 2005 Meningitis 26.07 217 1 
Strain 89 Adult Negative 2005 Meningitis 190.74 217 1 
Strain 90 Adult Unknown 2005 Meningitis 26.55 217 1 
Strain 91 Adult Unknown 2005 Meningitis 231.09 Unknown 19A 
Strain 92 Adult Positive 2005 Meningitis 152.95 5778 9A 
Strain 93 Adult Unknown 2005 Meningitis 328.88 Unknown 19A 
Strain 94 Adult Unknown 2005 Meningitis 297.45 Unknown 6A 
Strain 95 Adult Unknown 2005 Meningitis 315.68 217 1 
Strain 96 Adult Positive 2005 Meningitis 229.51 63 14 
Strain 97 Adult Positive 2005 Meningitis 64.09 Unknown 4 
Strain 98 Adult Unknown 2005 Meningitis 345.72 2987 6A 
Strain 99 Adult Unknown 2005 Meningitis 48.08 Unknown 12B 
Strain 100 Child Positive 2005 Meningitis 47.56 Unknown 6B 
Strain 101 Child Unknown 2005 Meningitis 269.85 2987 6A 
Strain 102 Child Unknown 2005 Meningitis 234.07 Unknown 18B 
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Sample no. Adult or Child HIV status Year Specimen Genome coverage St Serotype 
Strain 103 Child Positive 2005 Meningitis 121.13 217 1 
Strain 104 Child Positive 2005 Meningitis 235.93 5077 24F 
Strain 105 Child Unknown 2005 Meningitis 98.00 217 1 
Strain 106 Adult Unknown 2006 Meningitis 31.19 217 1 
Strain 107 Adult Unknown 2006 Meningitis 324.22 Unknown 7F 
Strain 108 Adult Unknown 2006 Meningitis 296.28 Unknown 10B 
Strain 109 Adult Positive 2006 Meningitis 48.55 5396 35B 
Strain 110 Adult Positive 2006 Meningitis 59.93 217 1 
Strain 111 Adult Positive 2006 Meningitis 56.82 Unknown 8 
Strain 112 Adult Positive 2006 Meningitis 48.13 802 23F 
Strain 113 Adult Positive 2006 Meningitis 51.43 989 12B 
Strain 114 Child Negative 2006 Meningitis 45.34 Unknown 7C 
Strain 115 Child Negative 2006 Meningitis 98.00 217 1 
Strain 116 Child Negative 2006 Meningitis 48.50 2987 6A 
Strain 117 Child Positive 2006 Meningitis 83.00 Unknown 15C 
Strain 118 Child Positive 2006 Meningitis 96.00 2213 4 
Strain 119 Child Positive 2006 Meningitis 96.00 Unknown 1 
Strain 120 Child Unknown 2006 Meningitis 93.00 289 5 
Strain 121 Child Unknown 2006 Meningitis 84.00 802 23F 
Strain 122 Child Unknown 2006 Meningitis 11.50 289 5 
Strain 123 Adult Negative 2007 Meningitis 40.48 2902 6C 
Strain 124 Adult Positive 2007 Meningitis 28.37 217 1 
Strain 125 Adult Unknown 2007 Meningitis 96.00 Unknown 12B 
Strain 126 Adult Unknown 2007 Meningitis 195.80 5412 6A 
Strain 127 Adult Positive 2007 Meningitis 28.83 2053 13 
Strain 128 Adult Positive 2007 Meningitis 43.16 Unknown 10B 
Strain 129 Child Unknown 2007 Meningitis 490.88 217 1 
Strain 130 Child Unknown 2007 Meningitis 98.00 217 1 
Strain 131 Child Unknown 2007 Meningitis 88.00 347 19F 
Strain 132 Adult Positive 2008 Meningitis 41.40 217 1 
Strain 133 Adult Unknown 2008 Meningitis 98.00 217 1 
Strain 134 Adult Unknown 2008 Meningitis 93.00 989 12B 
Strain 135 Adult Positive 2008 Meningitis 58.69 3544 7F 
Strain 136 Adult Unknown 2008 Meningitis 95.00 Unknown 12B 
Strain 137 Adult Unknown 2008 Meningitis 232.31 Unknown 7F 
Strain 138 Child Unknown 2008 Meningitis 85.00 Unknown 19F 
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Sample no. Adult or Child HIV status Year Specimen Genome coverage St Serotype 
Strain 139 Child Unknown 2008 Meningitis 89.00 Unknown 12A 
Strain 140 Child Unknown 2008 Meningitis 59.00 2285 6A 
 
                                                                                                                               Appendices 
 220 
Appendix 2: STATA commands used to randomly sample pneumococcal isolates from 
the MLW isolate collection 
************************************************ 
* A do file that selects unsequenced 
* clean datasets (from Neil, Micro, Enitan and Elizabeth) 
* from a central database for random sample selection. 
* It also randomly selects isolates for sequencing  
* created by Benard on 24th March 2010 
************************************************ 
 
clear 
set mem 300m 
pause on 
use all_isolates 
keep if Specimen == "csf" 
sample 70, count 
save csf_isolates, replace 
clear 
use all_isolates 
keep if Specimen == "blood" 
sample 70, count 
save blood_isolates, replace 
 
*the end* 
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Appendix 3:  Assembly and annotation pipeline. 
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Appendix 4:  OrthoMCL gene clustering pipeline. 
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Appendix 5: Core genome definition pipeline. 
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Appendix 6: Determination of population structure using PCA. 
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Appendix 7: Entire list of the common core genes to the meningitis and bacteraemia 
dataset. Due to redundancy in naming orthologs several gene names and gene identities are 
provided. All orthologs that belong to the same cluster have the same gene cluster number. 
 
Gene 
no. 
Gene ID Gene 
cluster no. 
Gene name 
1 SPD_1982 1 hypothetical protein 
 SP70585_2280 1 gram-positive signal peptide ysirk family protein 
 SPP_2205 1 conserved hypothetical protein 
2 spr0001 2 DNA biosynthesis initiation binding protein 
 SP70585_0001 2 chromosomal replication initiator protein DnaA 
3 spr0002 3 DNA biosynthesis; sliding clamp subunit required for high processivity; DNA polymerase III 
beta-subunit 
 SPD_0002 3 DNA polymerase III beta subunit 
4 spr0003 4 Hypothetical protein 
 SPD_0003 4 conserved hypothetical protein 
 SP70585_0003 4 conserved domain protein 
5 spr0004 5 Conserved hypothetical protein 
 SPD_0004 5 GTP-binding protein 
 SP70585_0004 5 GTP-binding protein YchF 
6 SP70585_0005 6 peptidyl-tRNA hydrolase 
7 spr0006 7 Transcription-repair coupling factor 
8 SP_0007 8 S4 domain protein 
 spr0007 8 Conserved hypothetical protein 
 SP70585_0007 8 ribosome-associated heat shock protein implicated in the recycling of the 50S subunit 
9 SP_0008 9 hypothetical protein 
 SPD_0008 9 septum formation initiator putative 
 SPJ_0008 9 septum formation initiator 
10 SP_0009 10 hypothetical protein 
 SPJ_0009 10 conserved hypothetical protein 
11 SP_0010 11 conserved domain protein 
 SPD_0010 11 conserved hypothetical protein 
 SPP_0010 11 beta-lactamase class A 
12 SP_0011 12 tRNA (Ile)-lysidine synthetase 
 SPJ_0011 12 tRNA (Ile)-lysidine synthase 
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Gene 
no. 
Gene ID Gene 
cluster no. 
Gene name 
13 SP_0012 13 hypoxanthine-guanine phosphoribosyltransferase 
 spr0011 13 Hypoxanthine guanine phosphoribosyltransferase 
 SP70585_0012 13 hypoxanthine phosphoribosyltransferase 
14 spr0012 14 Cell-division protein / general stress protein class III heat-shock) 
 SPD_0013 14 cell division protein FtsH 
 SP70585_0013 14 ATP-dependent metallopeptidase HflB 
15 spr1819 15 Competence-specific global transcription modulator 
 SPD_0014 15 transcriptional regulator ComX1 
16 SPD_0024 16 adenylosuccinate synthetase 
17 spr0022 17 Conserved hypothetical protein 
 SPD_0025 17 cytidine/deoxycytidylate deaminase family protein 
 SP70585_0081 17 tRNA-specific adenosine deaminase 
18 SP_0021 18 putative deoxyuridine 5'triphosphate nucleotidohydrolase 
 spr0023 18 Deoxyuridinetriphosphatase 
 SPD_0027 18 deoxyuridine 5'-triphosphate nucleotidohydrolase 
19 SP_0022 19 conserved hypothetical protein 
 SPJ_0046 19 phosphoglycerate mutase family protein 
20 spr0026 20 Conserved hypothetical protein 
 SPP_0089 20 carbonate dehydratase 
21 spr0027 21 Hypothetical protein 
 SPJ_0049 21 membrane protein putative 
22 spr0028 22 Phosphoribosylpyrophosphate synthase 
 SPD_0033 22 ribose-phosphate pyrophosphokinase 
23 SPD_0038 23 DNA polymerase I 
 SP70585_0092 23 DNA polymerase I (POL I) 
24 SP_0033 24 conserved hypothetical protein 
 SPJ_0057 24 CoA binding protein 
25 SP_0035 25 aromatic amino acid aminotransferase 
 spr0035 25 Aspartate aminotransferase 
 SPJ_0059 25 putative aminotransferase A 
26 SP_0036 26 conserved hypothetical protein 
 SPP_0100 26 DNA repair protein RecO 
27 SP_0037 27 fatty acid/phospholipid synthesis protein PlsX 
 spr0037 27 Involved in fatty acid/phospholipid synthesis 
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Gene 
no. 
Gene ID Gene 
cluster no. 
Gene name 
28 SP_0038 28 putative acyl carrier protein 
 spr0038 28 Acyl carrier protein 
 SPD_0044 28 acyl carrier protein putative 
 SPJ_0062 28 conserved domain protein 
29 spr0043 29 Transport ATP-binding protein ComA 
 spr0468 29 Conserved hypothetical protein truncation 
 SPD_0049 29 competence factor transporting ATP-binding/permease protein ComA 
30 SPD_0050 30 competence factor transport protein ComB 
 SP70585_0110 30 transport protein ComB 
31 SP_0044 31 phosphoribosylaminoimidazole-succinocarboxamidesynthase 
 spr0045 31 Phosphoribosylaminoimidazole-succinocarboxamidesynthetase 
32 SP_0045 32 putative phosphoribosylformylglycinamidine synthase 
 spr0046 32 Phosphoribosylformylglycinamide synthetase 
 SPD_0052 32 phosphoribosylformylglycinamidine synthase putative 
 SP70585_0112 32 phosphoribosylformylglycinamidine synthase 
33 spr0047 33 Amidophosphoribosyl transferase 
34 SP_0047 34 phosphoribosylformylglycinamide cyclo-ligase 
 spr0048 34 Phosphoribosylaminoimidazole synthetase 
 SP70585_0114 34 phosphoribosylformylglycinamidine cyclo-ligase 
35 spr0049 35 5'-phosphoribosylglycinamide transformylase 1 
 SPD_0055 35 phosphoribosylglycinamide formyltransferase 
36 SP_0049 36 putative vanZ protein 
 SPD_0056 36 vanZ protein putative 
 SP70585_0116 36 teicoplanin resistance protein 
37 SP_0050 37 phosphoribosylaminoimidazolecarboxamide formyltransferase/IMP cyclohydrolase 
 spr0051 37 Phosphoribosylaminoimidazolecarboxamideformyltransferase 
 SPD_0057 37 bifunctional purine biosynthesis protein PurH 
38 spr0052 38 Phosphoribosylglycinamide synthetase 
 SPJ_0083 38 phosphoribosylamine--glycine ligase 
39 spr0053 39 Phosphoribosylaminoimidazole carboxylase catalytic subunit 
40 spr0054 40 Phosphoribosyl glucinamide formyltransferase 
 SPD_0060 40 phosphoribosylaminoimidazole carboxylase ATPase subunit 
41 SP_0055 41 hypothetical protein 
 SPD_0061 41 conserved hypothetical protein 
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Gene 
no. 
Gene ID Gene 
cluster no. 
Gene name 
42 SP_0056 42 adenylosuccinate lyase 
43 spr0057 43 Beta-N-acetyl-hexosaminidase precursor 
 SPJ_0088 43 beta-N-acetylhexosaminidase 
44 spr0058 44 Conserved hypothetical protein 
 SPD_0064 44 transcriptional regulator GntR family protein 
45 SP_0060 45 glycosyl hydrolase family 35 
 SPD_0065 45 Beta-galactosidase 3 
 SP70585_0126 45 beta-galactosidase 
 SPJ_0090 45 beta-galactosidase (Lactase) 
46 SPD_0066 46 PTS system IIB component 
 SP70585_0127 46 phosphotransferase system sugar-specific eiib component 
47 spr0061 47 Phosphotransferase system sugar-specific EIIC component 
 SP70585_0128 47 PTS system IIC component 
48 SP_0063 48 PTS system IID component 
 spr0062 48 Phosphotransferase system sugar-specific EIID component 
49 spr0063 49 Phosphotransferase system sugar-specific EII component 
 SPD_0069 49 PTS system IIA component 
50 SP_0065 50 sugar isomerase domain protein AgaS 
 spr0064 50 Tagatose-6-phosphate ketose/aldose isomerase 
 SP70585_0131 50 putative tagatose-6-phosphate ketose/aldose isomerase 
51 spr0065 51 Aldose-1-epimerase (mutarotase) 
 SPT_0103 51 aldose 1-epimerase 
52 SP_0071 52 zinc metalloprotease ZmpC 
 SP_1154 52 immunoglobulin A1 protease 
 SPD_1018 52 immunoglobulin A1 protease precursor 
 SPJ_1073 52 IgA1 protease 
53 spr0066 53 Conserved hypothetical protein 
 SPD_0072 53 glyoxalase family protein 
54 SPD_0076 54 potassium uptake protein Trk family protein 
 SP70585_0140 54 Trk transporter membrane-spanning protein-K+ transport 
55 spr0071 55 Trk transporter NAD+ binding protein-K+ transport 
 SPD_0077 55 potassium uptake protein Trk family protein 
56 SP_0083 56 DNA-binding response regulator 
 spr0076 56 Response regulator 
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 SP70585_0146 56 response regulator SaeR 
57 SP_0084 57 sensor histidine kinase 
 SPP_0146 57 histidine kinase 
58 spr0078 58 30S Ribosomal protein S4 
 SPJ_0111 58 ribosomal protein S4 
59 spr0080 59 Hypothetical protein 
 SPP_0149 59 conserved hypothetical protein 
60 spr0081 60 ABC transporter membrane-spanning permease-sugar transport 
 SP70585_0151 60 ABC transporter permease protein 
61 spr0082 61 ABC transporter membrane spanning permease-sugar transport 
 SPD_0089 61 ABC transporter permease protein 
 SPP_0152 61 protein LplC 
62 spr0083 62 ABC transporter solute binding protein-sugar transport 
 SPD_0090 62 ABC transporter substrate-binding protein 
63 SP70585_0154 63 conserved hypothetical protein 
 SPJ_0118 63 rhodanese-like domain protein 
64 SP_0096 64 hypothetical protein 
 SPD_0092 64 conserved hypothetical protein 
65 SP_0098 65 hypothetical protein 
 SP70585_0157 65 conserved hypothetical protein 
66 spr0088 66 Hypothetical protein 
 SPJ_0122 66 conserved hypothetical protein 
67 SP_0100 67 conserved hypothetical protein 
 SPD_0096 67 transcriptional regulator PadR family protein 
 SPJ_0123 67 transcription regulator 
68 SP_0101 68 putative transporter 
 spr0090 68 Conserved hypothetical protein 
 SPD_0097 68 transporter putative 
 SPT_0135 68 cyanate permease 
69 SP_0102 69 glycosyl transferase 
 spr0091 69 Conserved hypothetical protein 
 SPD_0098 69 glycosyl transferase group 2 family protein 
70 SP_0103 70 putative capsular polysaccharide biosynthesis protein 
 spr0092 70 CapD protein required for the biosynthesis of type 1 capsular polysaccharide 
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 SPD_0099 70 capsular polysaccharide biosynthesis protein 
71 SP_0104 71 hydrolase haloacid dehalogenase-like family 
 SPD_0101 71 hydrolase haloacid dehalogenase-like family protein 
 SPJ_0127 71 phosphoglycolate phosphatase 
72 SP_0105 72 L-serine dehydratase iron-sulfur-dependent alpha subunit 
 spr0094 72 L-serine dehydratase alpha subunit 
73 SP_0106 73 L-serine dehydratase iron-sulfur-dependent beta subunit 
 spr0095 73 L-serine dehydratase beta subunit 
74 spr0096 74 Hypothetical protein 
 SPT_0141 74 LysM domain protein 
75 SP_0118 75 tRNA (5-methylaminomethyl-2-thiouridylate)-methyltransferase 
76 spr0123 76 Conserved hypothetical protein 
 SPD_0128 76 MutT/nudix family protein 
77 SP_0120 77 glucose-inhibited division protein A 
 SPD_0129 77 tRNA uridine 5-carboxymethylaminomethyl modification enzyme gidA (glucose-inhibited 
division protein A) 
78 SP_0122 78 conserved hypothetical protein 
 SPJ_0156 78 conserved domain protein 
79 SP_0124 79 hypothetical protein 
 spr0127 79 orf51 
 SPD_0132 79 conserved hypothetical protein 
 SPJ_0157 79 bacteriocin-type signal sequence domain protein 
80 SP_0125 80 hypothetical protein 
 SPP_0194 80 conserved hypothetical protein 
81 spr0129 81 Conserved hypothetical protein 
 SP70585_0205 81 glycoprotein endopeptidase 
82 SP_0128 82 putative ribosomal-protein-alanine acetyltransferase 
 spr0130 82 Ribosomal protein alanine acetyltransferase 
83 SP_0129 83 glycoprotease family protein 
 spr0131 83 Secreted metalloendopeptidase Gcp 
 SP70585_0207 83 O-sialoglycoprotein endopeptidase (Glycoprotease) 
84 SP_0144 84 hypothetical protein 
 SPD_0147 84 CAAX amino terminal protease family protein 
 SPJ_0173 84 caax amino protease family 
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85 spr0144 85 Conserved hypothetical protein 
 SPD_0148 85 transporter major facilitator family protein 
86 SP_0148 86 ABC transporter substrate-binding protein 
 spr0146 86 ABC transporter substrate-binding protein-amino acid transport 
87 spr0147 87 ABC transporter solute-binding protein-unknown substrate 
 SPT_0196 87 lipoprotein 
88 spr0148 88 Succinyl-diaminopimelic descuccinlyase (ArgE/DapE/Acy1 family protein) 
 SPD_0152 88 peptidase M20/M25/M40 family protein 
89 spr0149 89 ABC transporter ATP-binding protein-unknown substrate 
 SPD_0153 89 ABC transporter ATP-binding protein 
 SP70585_0225 89 methionine import ATP-binding protein MetN 
90 SP_0152 90 putative ABC transporter permease protein 
 spr0150 90 ABC transporter membrane-spanning permease-unknown substrate 
 SP70585_0226 90 ABC transporter permease protein 
91 spr0151 91 Hypothetical protein 
 SPD_0155 91 membrane protein putative 
 SPJ_0182 91 membrane-bound protein 
92 SP_0154 92 hypothetical protein 
 spr0152 92 Conserved hypothetical protein 
 SPD_0156 92 membrane protein putative 
 SP70585_0228 92 protein of unknown function 
93 SP_0155 93 putative sensor histidine kinase 
 spr0153 93 Histidine kinase 
 SPJ_0184 93 sensor histidine kinase putative 
94 SP70585_0230 94 DNA-binding response regulator 
 SPP_0225 94 response regulator 
95 SP_0158 95 NrdI family protein 
 spr0156 95 Conserved hypothetical protein 
 SPD_0160 95 nrdI protein putative 
 SPJ_0187 95 ribonucleotide reductase 
96 spr0157 96 Conserved hypothetical protein 
 SPD_0161 96 membrane protein putative 
 SP70585_0233 96 mn2+ and fe2+ transporter of the nramp family 
97 SP_0161 97 conserved domain protein 
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 spr0159 97 Conserved hypothetical protein 
 SP70585_0235 97 response regulator of the LytR/AlgR family 
98 spr0160 98 DNA mismatch repair protein 
 SPD_0165 98 DNA mismatch repair protein HexB 
 SP70585_0237 98 MutL 
 SPJ_0191 98 DNA mismatch repair protein MutL 
99 spr0161 99 Riboflavin synthase beta chain 
 SP70585_0238 99 67-dimethyl-8-ribityllumazine synthase 
100 SP_0176 100 34-dihydroxy-2-butanone 4-phosphate synthase/GTP cyclohydrolase II 
 spr0162 100 Riboflavin biosynthesis; GTP-cyclohydrolase II 
101 SP_0177 101 riboflavin synthase alpha subunit 
 spr0163 101 Riboflavin synthase alpha-chain 
102 SP_0178 102 riboflavin biosynthesis protein RibD 
 spr0164 102 Riboflavin biosynthese; a deaminase 
103 spr0165 103 Holliday junction DNA helicase 
 SPD_0170 103 Holliday junction DNA helicase RuvA 
104 spr0166 104 3-Methyladenine DNA glycosylase I constitutive 
 SPD_0171 104 DNA-3-methyladenine glycosylase I 
 SPJ_0197 104 DNA-3-methyladenine glycosylase 1 
105 SP_0181 105 conserved hypothetical protein 
 SPD_0172 105 CAAX amino terminal protease family protein 
 SPJ_0198 105 caax amino protease family 
106 spr0168 106 Conserved hypothetical protein 
 SPT_0219 106 MccC family protein 
107 SP_0185 107 magnesium transporter CorA family 
 SPD_0175 107 magnesium transporter CorA family protein 
 SPJ_0201 107 magnesium and cobalt transporter 
108 SP_0186 108 excinuclease ABC subunit A 
 SPP_0242 108 excinuclease ABC A subunit 
109 SP_0187 109 peptidase M24 family protein 
 spr0172 109 Aminopeptidase P 
 SPP_0243 109 Xaa-Pro dipeptidase 
110 SP_0189 110 conserved hypothetical protein 
 spr0173 110 Arsenate reductase putative 
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 SP70585_0250 110 regulatory protein spx 
111 SP_0191 111 hypothetical protein 
 SPJ_0205 111 lipoprotein putative 
112 SP_0192 112 conserved hypothetical protein 
 spr0175 112 Hypothetical protein 
113 spr0177 113 Conserved hypothetical protein 
114 SP_0197 114 putative dihydrofolate synthetase 
 SPD_0183 114 folylpolyglutamate synthase 
 SP70585_0255 114 dihydrofolate:folylpolyglutamate synthetase 
115 SP_0198 115 hypothetical protein 
 SPD_0184 115 lipoprotein putative 
 SPJ_0210 115 conserved hypothetical protein 
116 SPD_0185 116 cardiolipin synthetase 
 SPJ_0211 116 cardiolipin synthase 
117 spr0182 117 Hypothetical protein 
 SP70585_0258 117 competence-induced protein Ccs4 
118 spr0183 118 Ribonucleotide reductase class III anaerobic 
 SP70585_0259 118 anaerobic ribonucleoside-triphosphate reductase 
119 SP_0203 119 hypothetical protein 
 SPT_0251 119 conserved hypothetical protein 
120 spr0184 120 Hypothetical protein 
 SPD_0189 120 acetyltransferase GNAT family protein 
121 SP_0205 121 anaerobic ribonucleoside-triphosphate reductase activating protein 
 spr0185 121 NrdD activating enzyme generating glycyl radical 
122 SP_0207 122 conserved domain protein 
 spr0186 122 Hypothetical protein 
 SPD_0191 122 conserved hypothetical protein 
 SP70585_0263 122 phosphoribulokinase / Uridine kinase family 
123 spr0187 123 30S Ribosomal protein S10 
 SPD_0192 123 ribosomal protein S10 
124 spr0188 124 50S Ribosomal protein L3 
 SPD_0193 124 ribosomal protein L3 
125 SP_0210 125 ribosomal protein L4 
 spr0189 125 50S Ribosomal protein L4 
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 SPP_0261 125 ribosomal protein L4/L1 family 
126 spr0190 126 50S Ribosomal protein L23 
 SPD_0195 126 ribosomal protein L23 
127 spr0191 127 50S Ribosomal protein L2 
 SPT_0259 127 ribosomal protein L2 
128 spr0192 128 30S Ribosomal protein S19 
 SPJ_0223 128 ribosomal protein S19 
129 spr0194 129 50S Ribosomal protein L22 
 SP70585_0270 129 ribosomal protein L22 
130 spr0195 130 30S Ribosomal protein S3 
 SPP_0266 130 ribosomal protein S3 
131 spr0196 131 50S Ribosomal protein L16 
 SPJ_0226 131 ribosomal protein L16 
132 spr0197 132 50S Ribosomal protein L29 
 SPP_0268 132 ribosomal protein L29 
133 spr0198 133 30S Ribosomal protein S17 
 SPJ_0228 133 ribosomal protein S17 
134 spr0199 134 50S Ribosomal protein L14 
 SPP_0270 134 ribosomal protein L14 
135 spr0200 135 50S Ribosomal protein L24 
 SPJ_0230 135 ribosomal protein L24 
136 SP_0221 136 ribosomal protein L5 
 spr0201 136 50S Ribosomal protein L5 
 SP70585_0277 136 50S ribosomal protein L5(BL6) 
137 SP_0224 137 ribosomal protein S8 
 spr0203 137 30S Ribosomal protein S8 
138 SP_0225 138 ribosomal protein L6 
 SP70585_0280 138 50S ribosomal protein L6 
139 SP_0226 139 ribosomal protein L18 
 spr0205 139 50S Ribosomal protein L18 
140 spr0206 140 30S Ribosomal protein S5 
 SPD_0210 140 ribosomal protein S5 
141 spr0207 141 50S Ribosomal protein L30 
 SPT_0274 141 ribosomal protein L30 
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142 spr0208 142 50S Ribosomal protein L15 
 SPJ_0238 142 ribosomal protein L15 
143 spr0209 143 Multispanning membrane protein translocator of proteins 
 SP70585_0285 143 preprotein translocase SecY subunit 
144 SP_0231 144 adenylate kinase 
 spr0210 144 Adenylate kinase (ATP-AMP transphosphorylase) 
145 SP70585_0287 145 translation initiation factor IF-1 
146 SP_0234 146 ribosomal protein S13 
 spr0213 146 30S Ribosomal protein S13 
 SPJ_0243 146 ribosomal protein S13p/S18e 
147 SP_0235 147 ribosomal protein S11 
 spr0214 147 30S Ribosomal protein S11 
148 spr0215 148 RNA polymerase alpha subunit 
 SP70585_0291 148 DNA-directed RNA polymerase alpha subunit 
149 spr0216 149 50S Ribosomal protein L17 
 SP70585_0292 149 ribosomal protein L17 
150 SP_0238 150 ACT domain protein 
 SPD_0220 150 conserved hypothetical protein 
151 spr0218 151 Conserved hypothetical protein 
152 SP_0240 152 phosphoglycerate mutase family protein 
 spr0219 152 Phosphoglycerate mutase 2 paralog 
153 SP_0250 153 PTS system IIC component 
 spr0231 153 Phosphotransferase system sugar-specific EIIC component 
 SP70585_0312 153 lichenan permease iic component (pts system lichenan-specific eiiccomponent) (eiic-lic) 
154 SP_0251 154 putative formate acetyltransferase 
 spr0232 154 Formate acetyltransferase 3 
 SPD_0235 154 pyruvate formate-lyase 
155 SP_0252 155 transaldolase family protein 
 spr0233 155 Transaldolase C 
 SPD_0236 155 transaldolase putative 
 SPJ_0264 155 fructose-6-phosphate aldolase 
156 SP_0253 156 glycerol dehydrogenase 
 spr0234 156 Glycerol dehydrogenase NAD+ dependent 
 SPJ_0265 156 glycerol dehydrogenase (gldh) 
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157 SPT_0302 157 leucyl-tRNA synthetase 
158 spr0236 158 Conserved hypothetical protein 
 SPD_0239 158 acetyltransferase GNAT family protein 
 SP70585_0317 158 acetyltransferase gnat family 
159 spr0237 159 Conserved hypothetical protein 
 SPD_0240 159 acetyltransferase GNAT family protein 
160 SP_0259 160 Holliday junction DNA helicase RuvB 
 spr0238 160 Branch migration of Holliday structures 
161 spr0239 161 Hypothetical protein 
 SP70585_0320 161 conserved hypothetical protein 
162 spr0240 162 Undecaprenyl diphosphate synthase 
 SPJ_0271 162 di-transpoly-cis-decaprenylcistransferase 
163 SPJ_0272 163 phosphatidate cytidylyltransferase 
164 SP_0263 164 eep protein 
 spr0242 164 Determinant for enhanced expression of pheromone 
 SPD_0245 164 zinc metalloprotease Eep 
 SP70585_0323 164 RIP metalloprotease RseP 
165 SPT_0311 165 prolyl-tRNA synthetase 
166 SPD_0247 166 glycosyl hydrolase family protein 1 
 SP70585_0325 166 glycosyl hydrolase family 1 
 SPP_0315 166 6-phospho-beta-glucosidase 
167 SP_0266 167 glucosamine--fructose-6-phosphate aminotransferase isomerizing 
 spr0245 167 L-glutamine-D-fructose-6-phosphateamidotransferase 
168 SP_0267 168 putative oxidoreductase 
 spr0246 168 Conserved hypothetical protein 
 SPP_0318 168 oxidoreductase 
169 SP_0268 169 putative alkaline amylopullulanase 
 spr0247 169 Alkaline amylopullulanase 
 SP70585_0328 169 pullulanase extracellular 
170 spr0248 170 30S Ribosomal protein S12 
 SPT_0316 170 ribosomal protein S12 
171 SP_0272 171 ribosomal protein S7 
 spr0249 171 30S Ribosomal protein S7 
172 SP_0273 172 translation elongation factor G 
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 spr0250 172 Elongation factor G 
173 spr0251 173 DNA polymerase III alpha subunit 
 SP70585_0332 173 DNA polymerase III alpha subunit Gram-positive type 
174 SP_0275 174 conserved hypothetical protein 
 spr0252 174 Hypothetical protein 
 SPD_0255 174 addiction module antitoxin RelB/DinJ family protein putative 
 SP70585_0333 174 addiction module antitoxin RelB/DinJ family 
175 SP_0276 175 conserved hypothetical protein 
 SPD_0256 175 conserved hypothetical protein TIGR00053 
 SPJ_0284 175 DNA damage inducible protein 
176 spr0254 176 Aminopeptidase 
 SPT_0323 176 aminopeptidase PepS 
177 SP_0280 177 ribosomal small subunit pseudouridine synthase A 
178 spr0258 178 Aminopeptidase C 
 SPJ_0289 178 aminopeptidase C (Bleomycin hydrolase) 
179 SP_0282 179 PTS system mannose-specific IID component 
 spr0259 179 Phosphotransferase system mannose-specific EIID 
 SPD_0262 179 PTS system mannose/fructose/sorbose family protein IID component 
180 SP_0283 180 PTS system mannose-specific IIC component 
 spr0260 180 Phosphotransferase system mannose-specific EIIC 
 SP70585_0342 180 PTS system sorbose-specific IIC component 
181 SP_0284 181 PTS system mannose-specific IIAB components 
 spr0261 181 Phosphotransferase system mannose-specific EIIAB 
 SP70585_0343 181 mannose-specific phosphotransferase system component iiab 
182 spr0264 182 Conserved hypothetical protein 
 SPD_0267 182 xanthine/uracil permease family protein 
183 spr0265 183 Conserved hypothetical protein 
 SPD_0268 183 CAAX amino terminal protease family protein 
 SP70585_0347 183 caax amino protease family protein 
184 SP_0289 184 dihydropteroate synthase 
185 SP_0290 185 dihydrofolate synthetase 
 SPD_0270 185 folylpolyglutamate synthase 
186 spr0268 186 GTP cyclohydrolase 
 SPT_0337 186 GTP cyclohydrolase I 
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187 spr0269 187 Aldolase-pyrophosphokinase 
 SP70585_0351 187 bifunctional folate synthesis protein 
188 spr0271 188 50S Ribosomal protein L13 
 SP70585_0353 188 ribosomal protein L13 
189 SP_0295 189 ribosomal protein S9 
 spr0272 189 30S Ribosomal protein S9 
190 spr0284 190 Alpha-xylosidase 
 SPD_0285 190 glycosyl hydrolase family protein 31 
 SPP_0348 190 glycosyl hydrolase family 31 
191 spr0285 191 Gluthatione peroxidase 
 SP70585_0378 191 peroxiredoxin Hyr1 (hydrogen peroxide resistanceprotein 1) (oxidant receptor peroxidase 1) 
(glutathione peroxidase 3) 
192 SP_0314 192 hyaluronidase 
 spr0286 192 Hyaluronate lyase precursor (hyaluronidase/hyase) 
 SPD_0287 192 hyaluronate lyase precursor 
 SP70585_0379 192 hyaluronate lyase 
193 SP_0317 193 4-hydroxy-2-oxoglutarate aldolase/2-dehydro-3-deoxyphosphogluconate aldolase 
 spr0287 193 2-keto-3-deoxy-6-phosphogluconate aldolase 
194 SPD_0290 194 carbohydrate kinase PfkB family protein 
 SPJ_0313 194 2-keto-3-deoxygluconate kinase 
195 SP_0319 195 conserved domain protein 
 spr0289 195 Hypothetical protein 
 SPD_0291 195 ribose 5-phosphate isomerase putative 
 SP70585_0383 195 ribose 5-phosphate isomerase RpiB 
196 spr0290 196 5-keto-D-gluconate 5-reductase 
 SPD_0292 196 oxidoreductase short chain dehydrogenase/reductase family protein 
197 SP_0321 197 PTS system IIA component 
 spr0291 197 Phosphotransferase system sugar-specific EII component 
198 SP_0322 198 glucuronyl hydrolase 
 spr0292 198 Unsaturated glucuronyl hydrolase 
 SP70585_0386 198 unsaturated glucuronyl hydrolase (UGL) (Glycuronidase) (Unsaturated uronic acid hydrolase) 
(Glycosaminoglycan hydrolase) 
199 SP_0323 199 PTS system IIB component 
 spr0293 199 Phosphotransferase system sugar-specific EII component 
200 SP_0324 200 PTS system IIC component 
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 SP70585_0388 200 phosphotransferase system sugar-specific EII component 
201 spr0295 201 Phosphotransferase system sugar-specific EII component 
 SPD_0297 201 PTS system IID component 
202 spr0296 202 Conserved hypothetical protein 
 SPD_0298 202 preprotein translocase YajC subunit 
203 SP_0327 203 hypothetical protein 
 SPD_0300 203 conserved hypothetical protein 
 SPP_0362 203 oligohyaluronate lyase 
204 spr0298 204 Transcription regulator member of GalR family 
 SPD_0301 204 sugar binding transcriptional regulator RegR 
205 spr0302 205 YllC protein 
 SPD_0304 205 S-adenosyl-methyltransferase MraW 
206 spr0303 206 Cell division protein 
 SPJ_0328 206 cell division protein FtsL 
207 SPD_0306 207 penicillin-binding protein 2X 
 SPJ_0329 207 penicillin binding protein 2x 
208 SP_0337 208 phospho-N-acetylmuramoyl-pentapeptide-transferase 
 spr0305 208 Undecaprenyl-phosphate-UDP-MurNAc-pentapeptide phospho-MurNAc-pentapeptide 
transferase 
209 SP_0338 209 putative ATP-dependent Clp protease ATP-binding subunit 
 spr0307 209 ATP-dependent protease ATP-binding subunit 
 SPD_0308 209 ATP-dependent Clp protease ATP-binding subunit 
210 spr0309 210 Hypothetical protein 
 SP70585_0405 210 conserved hypothetical protein 
211 spr0310 211 Alpha 1-6-glucosidase 
 SPD_0311 211 glucan 16-alpha-glucosidase 
 SP70585_0406 211 trehalose-6-phosphate hydrolase (Alphaalpha-phosphotrehalase) 
212 SP_0346 212 capsular polysaccharide biosynthesis protein Cps4A 
 spr0314 212 The type 2 capsule locus of Streptococcus pneumoniae 
 SPD_0315 212 integral membrane regulatory protein Cps2A 
 SP70585_0413 212 integral membrane regulatory protein Wzg 
213 SP_0347 213 capsular polysaccharide biosynthesis protein Cps4B 
 SPP_0384 213 tyrosine-protein phosphatase CpsB 
214 SP_0348 214 capsular polysaccharide biosynthesis protein Cps4C 
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 SPD_0317 214 chain length determinant protein/polysaccharide export protein MPA1 family protein 
 SP70585_0415 214 capsular polysaccharide biosynthesis protein Wzd 
215 SP_0349 215 capsular polysaccharide biosynthesis protein Cps4D 
 SPD_0318 215 tyrosine-protein kinase Cps2D cytosolic ATPase domain 
 SP70585_0416 215 tyrosine-protein kinase CpsD 
216 SP_0366 216 oligopeptide ABC transporter oligopeptide-binding protein AliA) 
217 SP_0368 217 cell wall surface anchor family protein 
 spr0328 217 Conserved hypothetical protein 
 SP70585_0439 217 endo-alpha-N-acetylgalactosaminidase 
218 SP70585_0440 218 penicillin-binding protein 1A 
219 SPT_0413 219 recombination protein U 
220 SPD_0338 220 conserved hypothetical protein 
221 SPD_0339 221 conserved hypothetical protein 
 SP70585_0443 221 cell division initiation protein 
222 spr0333 222 Conserved hypothetical protein 
 SPD_0341 222 RNA methylase family protein UPF0020 putative 
 SPJ_0359 222 methyltransferase 
223 SP_0374 223 hypothetical protein 
 SPD_0342 223 conserved hypothetical protein 
224 spr0335 224 6-phosphogluconate dehydrogenase 
 SPD_0343 224 6-phosphogluconate dehydrogenase decarboxylating 
225 spr0336 225 Response regulator 
 SPJ_0362 225 DNA-binding response regulator 
226 SPP_0419 226 mevalonate kinase 
227 spr0339 227 diphosphomevalonate decarboxylase 
228 SPP_0421 228 phosphomevalonate kinase 
229 SP_0384 229 FMN-dependent dehydrogenase family protein 
 spr0341 229 Isopentenyl diphosphate isomerase 
 SPD_0349 229 isopentenyl-diphosphate delta-isomerase type 2 
230 spr0342 230 Conserved hypothetical protein 
231 SP_0386 231 putative sensor histidine kinase 
 SPD_0351 231 sensor histidine kinase putative 
 SPT_0431 231 histidine kinase 
232 SP_0387 232 DNA-binding response regulator 
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 SPJ_0374 232 response regulator 
233 SP_0400 233 trigger factor 
234 SP_0401 234 putative helicase 
 spr0363 234 Exonuclease V 
 SPD_0366 234 helicase RecD/TraA family protein 
 SPP_0433 234 helicase RecD/TraA family 
235 SPJ_0390 235 signal peptidase I 
236 SPD_0368 236 ribonuclease HIII 
237 SP_0404 237 hypothetical protein 
 SPP_0436 237 conserved hypothetical protein 
238 SP_0405 238 conserved hypothetical protein 
 SPP_0437 238 CvpA family protein 
239 spr0368 239 DNA mismatch repair protein 
 SPT_0444 239 MutS2 family protein 
240 SPD_0372 240 sodium:alanine symporter family protein 
 SPJ_0395 240 D-alanine glycine permease 
241 SPD_0373 241 conserved hypothetical protein 
 SP70585_0480 241 macrophage infectivity potentiator protein 
242 SP_0410 242 putative exfoliative toxin 
 SPD_0374 242 exfoliative toxin putative 
 SPJ_0397 242 exfoliative toxin A 
243 SPP_0442 243 seryl-tRNA synthetase 
244 SPD_0376 244 conserved hypothetical protein 
 SPH0520 244 ManO 
245 SPP_0444 245 aspartate kinase 
246 SP_0415 246 enoyl-CoA hydratase/isomerase family protein 
 spr0375 246 Enoyl-CoA hydratase II 
 SPJ_0401 246 enoyl-CoA hydratase 
247 SP_0416 247 transcriptional regulator MarR family 
 spr0376 247 Conserved hypothetical protein 
 SPD_0379 247 transcriptional regulator MarR family protein 
 SPJ_0402 247 transcriptional regulator 
248 SP_0417 248 3-oxoacyl-(acyl-carrier-protein) synthase III 
 spr0377 248 3-oxoacyl-acyl-carrier-protein synthase III 
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 SPD_0380 248 3-oxoacyl-acyl-carrier-protein) synthase III 
 SP70585_0488 248 beta-ketoacyl-acyl carrier protein synthase III 
249 spr0378 249 Acyl carrier protein 
 SP70585_0489 249 conserved domain protein 
250 SP_0419 250 enoyl-(acyl-carrier-protein) reductase 
 spr0379 250 Enoyl-acyl carrier protein (ACP) reductase 
 SPD_0382 250 trans-2-enoyl-ACP reductase II 
 SP70585_0490 250 putative enoyl-(acyl-carrier-protein) reductase II 
251 spr0380 251 Malonyl acyl carrier protein transacylase 
 SP70585_0491 251 malonyl CoA-acyl carrier protein transacylase 
252 spr0381 252 3-ketoacyl-acyl carrier protein reductase 
 SP70585_0492 252 3-oxoacyl-(acyl-carrier-protein) reductase 
253 SP_0422 253 3-oxoacyl-(acyl-carrier-protein) synthase II 
 spr0382 253 Beta ketoacyl-acyl carrier protein synthase 
 SP70585_0493 253 3-oxoacyl-[acyl-carrier-protein] synthase 2 
254 SP_0423 254 acetyl-CoA carboxylase bitoin carboxyl carrier protein 
 spr0383 254 Biotin carboxyl carrier protein of acetyl-CoA carboxylase 
255 spr0384 255 Hydroxymyristoyl-(acyl carrier protein) dehydratase 
 SPD_0387 255 beta-hydroxyacyl-(acyl-carrier-protein) dehydratase FabZ 
256 spr0385 256 Biotin carboxylase a subunit of acetyl-CoA carboxylase (ACC) 
 SPD_0388 256 acetyl-CoA carboxylase biotin carboxylase 
257 SP_0426 257 acetyl-CoA carboxylase carboxyl transferase beta subunit 
 spr0386 257 Acetyl-coenzyme A carboxylase carboxyl transferase subunit beta 
258 spr0387 258 Acetyl-coenzyme A carboxylase carboxyl transferase subunit alpha 
 SPD_0390 258 acetyl-CoA carboxylase carboxyl transferase alpha subunit 
259 spr0391 259 Conserved hypothetical protein 
 SP70585_0503 259 general stress protein Gls24 family 
260 spr0392 260 Elongation factor P 
 SP70585_0504 260 translation elongation factor P 
261 SP_0436 261 glutamyl-tRNA (Gln) amidotransferase B subunit 
 spr0393 261 Glutamyl tRNA-Gln amidotransferase subunit B 
 SPD_0396 261 glu-trnagln amidotransferase subunit b 
262 SP_0437 262 glutamyl-tRNA (Gln) amidotransferase A subunit 
 spr0394 262 Glu-tRNAGln amidotransferase subunit A 
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 SPD_0397 262 glutamyl-tRNA (Gln) amidotransferase subunit A 
 SP70585_0506 262 glutamyl-tRNA (Gln) amidotransferase subunit A (Glu-ADTsubunit A) 
263 spr0395 263 Glutamyl tRNA-Gln amidotransferase subunit C 
 SPD_0398 263 glutamyl-tRNA (Gln) amidotransferase C subunit 
264 SPJ_0423 264 peptide chain release factor 3 
265 spr0398 265 50S Ribosomal protein L28 
 SPD_0401 265 ribosomal protein L28 
266 SP_0442 266 conserved hypothetical protein 
 SP70585_0512 266 alkaline shock protein 
267 spr0400 267 Conserved hypothetical protein 
 SP70585_0513 267 dihydroxyacetone kinase family protein 
268 spr0401 268 Acetolactate synthase large subunit 
 SPD_0404 268 acetolactate synthase large subunit biosynthetic type 
269 spr0402 269 Acetolactate synthase small subunit 
270 SP70585_0516 270 ketol-acid reductoisomerase 
271 spr0405 271 Hypothetical protein 
 SPD_0408 271 conserved hypothetical protein 
272 spr0406 272 Threonine desaminase 
 SPP_0480 272 threonine dehydratase 
273 spr0409 273 ABC transporter substrate binding protein-glutamine transport 
 SPD_0412 273 amino acid ABC transporter amino acid-binding protein/permease protein 
274 SP_0454 274 hypothetical protein 
 SPD_0414 274 membrane protein putative 
 SPP_0486 274 conserved hypothetical protein 
275 SP_0479 275 potassium uptake protein Trk family 
 SPD_0429 275 potassium uptake protein Trk family protein 
 SP70585_0542 275 Trk transporter membrane-spanning protein-K+ transport 
276 SP_0480 276 potassium uptake protein Trk family 
 spr0427 276 Trk transporter NAD+ binding protein-K+ transport 
 SPD_0430 276 potassium uptake protein Trk family protein 
277 SPD_0431 277 conserved hypothetical protein 
 SP70585_0544 277 protein of unknown function 
278 SP_0483 278 ABC transporter ATP-binding protein 
 spr0430 278 ABC transporter ATP-binding protein-cobalt transport 
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 SP70585_0547 278 putative ABC transporter ATP-binding protein 
279 SP_0484 279 cobalt transport protein 
 spr0431 279 ABC transporter membrane-spanning permease-unknown substrate 
 SPD_0435 279 membrane protein putative 
 SP70585_0548 279 cobalt transport family protein 
280 SP_0486 280 RNA methyltransferase TrmH family 
 spr0432 280 rRNA methylase 
 SPD_0436 280 TrmH family RNA methyltransferase 
 SP70585_0549 280 CspR 
 SPT_0527 280 RNA methyltransferase TrmH family group 2 
281 spr0434 281 Conserved hypothetical protein 
 SPT_0529 281 PAP2 family protein 
282 spr0435 282 Hypothetical protein 
 SP70585_0552 282 conserved hypothetical protein 
283 SP_0492 283 conserved domain protein 
 spr0436 283 Hypothetical protein 
 SPJ_0461 283 conserved hypothetical protein 
284 SP_0493 284 putative DNA-directed RNA polymerase delta subunit 
 spr0437 284 RNA polymerase (delta subunit) 
 SPD_0441 284 DNA-directed RNA polymerase delta subunit putative 
 SP70585_0554 284 DNA-directed RNA polymerase delta subunit 
285 spr0438 285 CTP synthetase 
 SPT_0533 285 CTP synthase 
 SPG_0448 285 CTP synthase (UTP-ammonia lyase) 
286 SP_0496 286 Na/Pi cotransporter II-related protein 
 spr0439 286 Conserved hypothetical protein 
 SPD_0443 286 Na/Pi-cotransporter II-related protein 
 SPP_0519 286 sodium-dependent phosphate transporter 
287 SP_0498 287 putative endo-beta-N-acetylglucosaminidase 
 spr0440 287 Hypothetical protein 
 SPD_0444 287 endo-beta-N-acetylglucosaminidase putative 
 SP70585_0558 287 endo-beta-N-acetylglucosaminidase D 
288 SP_0499 288 phosphoglycerate kinase 
289 SP_0500 289 conserved domain protein 
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 spr0442 289 Hypothetical protein 
 SPD_0446 289 membrane protein putative 
 SPP_0522 289 conserved hypothetical protein 
290 SP_0501 290 transcriptional regulator MerR family 
 spr0443 290 Transcriptional repressor of the glutamine synthetase gene 
 SPD_0447 290 transcriptional regulator MerR family protein 
 SP70585_0561 290 HTH-type transcriptional regulator GlnR 
291 spr0444 291 Glutamine synthetase type 1 
 SPP_0524 291 glutamine synthetase type I 
292 SP_0505 292 putative type I restriction-modification system S subunit 
 spr0445 292 type I restriction enzyme 
 spr0448 292 Type I site-specific deoxyribonuclease chain S 
293 SP_0510 293 type I restriction-modification system R subunit 
 spr0450 293 EcoA type I restriction-modification enzyme R subunit 
294 spr0453 294 Heat inducible transcription repressor 
 SPD_0458 294 heat-inducible transcription repressor HrcA 
295 spr0454 295 Heat-shock protein (activation of DnaK) 
 SPD_0459 295 heat shock protein GrpE 
 SP70585_0572 295 co-chaperone GrpE 
296 SP_0517 296 dnaK protein 
 spr0455 296 Class I heat-shock protein (molecular chaperone) 
 SPD_0460 296 chaperone protein DnaK 
297 SP_0521 297 HIT family protein 
 spr0458 297 Conserved hypothetical protein 
 SPD_0463 297 Hit-like protein involved in cell-cycle regulation putative 
 SP70585_0578 297 histidine triad domain protein 
298 SP_0522 298 ABC transporter ATP-binding protein 
 spr0459 298 ABC transporter ATP-binding protein-unknown substrate 
 SP70585_0579 298 ABC-type transporter ATP-binding protein EcsA 
299 SP_0523 299 putative ABC transporter permease protein 
 spr0460 299 ABC transporter membrane-spanning permease-unknown substrate 
 SPD_0465 299 ABC transporter permease protein putative 
 SP70585_0580 299 ABC transporter permease protein 
300 SP_0525 300 BlpS protein 
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 spr0462 300 Regulatory protein 
301 spr0466 301 Conserved hypothetical protein truncation 
 SPJ_0495 301 BlpC ABC transporter 
302 SPP_0564 302 BlpY protein 
 SPG_0493 302 immunity protein BlpY 
303 SP_0547 303 conserved domain protein 
 spr0474 303 ABC transporter ATP binding protein-unknown substrate 
 SPD_0475 303 CAAX amino terminal protease family protein 
304 spr0475 304 Conserved hypothetical protein 
 SPD_0476 304 phosphotransferase enzyme family protein 
 SP70585_0610 304 phosphotransferase enzyme family 
305 spr0476 305 Conserved hypothetical protein 
 SP70585_0611 305 tRNA (guanine-N(7)-)-methyltransferase 
306 SP_0552 306 SP14.3 protein 
 spr0477 306 Conserved hypothetical protein 
307 SP_0553 307 N utilisation substance protein A 
 spr0478 307 Transcription termination 
 SPJ_0513 307 transcription termination factor NusA 
308 spr0479 308 Conserved hypothetical protein 
 SP70585_0614 308 putative chain a hypothetical cytosolic protein coded by gene from nusainfb ylxr homologue 
309 SP_0555 309 ribosomal protein L7A family 
 spr0480 309 Conserved hypothetical protein 
 SPD_0481 309 ribosomal protein L7A family protein 
 SPP_0572 309 ribosomal protein HS6-type 
310 spr0481 310 Initiation factor IF2 
 SPD_0482 310 initiation factor IF-2 
 SPJ_0516 310 translation initiation factor IF-2 
311 spr0482 311 Ribosome binding factor A 
 SP70585_0617 311 ribosome-binding factor A 
312 SPD_0484 312 conserved hypothetical protein 
313 SP_0561 313 conserved domain protein 
 spr0485 313 Hypothetical protein 
 SPJ_0521 313 conserved hypothetical protein 
314 spr0486 314 Conserved hypothetical protein 
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 SP70585_0627 314 hemerythrin HHE cation binding domain subfamily putative 
315 SP_0563 315 hypothetical protein 
 SPJ_0523 315 conserved hypothetical protein 
316 SP_0564 316 hypothetical protein 
 SPJ_0524 316 superfamily II helicase 
 SPP_0581 316 conserved hypothetical protein 
317 spr0490 317 Conserved hypothetical protein 
 SPD_0492 317 acetyltransferase GNAT family protein 
 SPJ_0527 317 acetyltransferase gnat family 
318 SPP_0585 318 valyl-tRNA synthetase 
319 spr0507 319 Phenylalanyl-tRNA synthetase alpha chain 
 SPD_0504 319 phenylalanyl-tRNA synthetase alpha subunit 
320 SP_0580 320 acetyltransferase GNAT family 
 spr0508 320 Conserved hypothetical protein 
 SPD_0505 320 acetyltransferase GNAT family protein 
 SP70585_0644 320 protease synthase and sporulation negative regulatory protein PAI 1 
321 spr0509 321 Phenylalanyl-tRNA synthetase beta chain 
 SPD_0506 321 phenylalanyl-tRNA synthetase beta subunit 
322 spr0510 322 Hypothetical protein 
 SPD_0507 322 conserved hypothetical protein 
 SP70585_0646 322 endonuclease/exonuclease/phosphatase family 
323 SP_0584 323 putative transcriptional regulator) 
 spr0513 323 Conserved hypothetical protein 
 SP70585_0649 323 helix-turn-helix domain protein 
324 SP_0585 324 5-methyltetrahydropteroyltriglutamate--homocysteinemethyltransferase 
 spr0514 324 Tetrahydropteroyltriglutamate methyltransferase 
 SPD_0510 324 5-methyltetrahydropteroyltriglutamate--homocysteineS-methyltransferase 
325 SP_0586 325 putative 510-methylenetetrahydrofolate reductase 
 spr0515 325 510-methylenetetrahydrofolate reductase 
326 SP_0588 326 polyribonucleotide nucleotidyltransferase 
327 spr0517 327 Serine acetyltransferase 
 SPJ_0543 327 serine O-acetyltransferase 
328 spr0518 328 Hypothetical protein 
 SPD_0514 328 acetyltransferase GNAT family protein 
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 SP70585_0654 328 acetyltransferase gnat family 
329 spr0519 329 Cysteinyl-tRNA synthetase 
330 spr0520 330 Conserved hypothetical protein 
 SP70585_0656 330 ribonuclease III family protein 
331 SPD_0517 331 conserved hypothetical protein 
 SPP_0610 331 leucine-rich protein 
332 SP_0599 332 transmembrane protein Vexp1 
 spr0524 332 ABC transporter membrane-spanning permease-Pep export 
 SPD_0521 332 ABC transporter transmembrane protein Vexp1 
333 spr0525 333 ABC transporter ATP-binding protein-Pep export 
 SPD_0522 333 ABC transporter ATP-binding protein Vexp2 
334 SP_0601 334 transmembrane protein Vexp3 
 spr0526 334 ABC transporter membrane-spanning permease-Pep export 
 SPD_0523 334 ABC transporter transmembrane protein Vexp3 
335 SP_0603 335 DNA-binding response regulator VncR 
 SP70585_0665 335 VncR response regulator 
336 spr0529 336 VncS histidine kinase 
 SPD_0525 336 sensor histidine kinase VncS 
337 spr0530 337 Fructose-bisphosphate aldolase 
 SP70585_0667 337 fructose-16-bisphosphate aldolase class II 
338 SP_0606 338 putative oxidoreductase 
 spr0531 338 Hypothetical protein 
 SPD_0527 338 oxidoreductase putative 
 SPT_0632 338 oxidoreductase NAD-binding 
339 SP_0608 339 amino acid ABC transporter permease protein 
 spr0533 339 ABC transporter membrane-spanning permease-glutamine transport 
340 SP_0609 340 amino acid ABC transporter amino acid-binding protein 
 spr0534 340 ABC transporter substrate-binding protein-glutamine transport/Major cell binding factor 
precursor 
341 SP_0611 341 single-stranded-DNA-specific exonuclease RecJ 
 spr0537 341 Single-stranded DNA-specific exonuclease 5'-3' 
342 SP_0613 342 metallo-beta-lactamase superfamily protein 
 spr0538 342 Conserved hypothetical protein 
 SP70585_0674 342 metallo-beta-lactamase family protein 
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343 spr0539 343 tributyrin esterase 
344 SP_0615 344 beta-lactam resistance factor 
 spr0540 344 Serine/alanine adding enzyme 
 SPD_0535 344 serine/alanine-adding enzyme MurM 
345 SPD_0536 345 beta-lactam resistance factor 
 SPP_0630 345 alanine adding enzyme 
346 SP_0617 346 conserved domain protein 
 spr0542 346 Hypothetical protein 
 SPD_0537 346 matrixin family protein 
 SPJ_0568 346 matrixin family 
347 SP_0618 347 excinuclease ABC subunit C 
 spr0543 347 Exonuclease ABC-subunit C 
 SPP_0632 347 excinuclease ABC C subunit 
348 spr0544 348 Conserved hypothetical protein 
 SPP_0633 348 Ser/Thr protein phosphatase family protein 
349 SP_0623 349 dipeptidase 
 SPT_0647 349 dipeptidase PepV 
350 SP_0626 350 branched-chain amino acid transport system II carrier protein 
 spr0551 350 Branched-chain amino acid transport system carrier protein 
351 SP_0627 351 conserved hypothetical protein 
 SPJ_0579 351 peptidase M42 
352 spr0553 352 Hypothetical protein 
 SPP_0643 352 HIT family protein 
353 spr0554 353 Conserved hypothetical protein 
 SPD_0549 353 lipoprotein putative 
 SP70585_0690 353 D-alanyl-D-alanine carboxypeptidase 
354 spr0555 354 50S Ribosomal protein L11 
 SPJ_0582 354 ribosomal protein L11 
355 SP_0631 355 ribosomal protein L1 
 spr0556 355 50S Ribosomal protein L1 
356 spr0557 356 ABC transporter ATP-binding protein-role in polysaccharide efflux 
 SP70585_0696 356 ABC transporter ATP-binding protein 
357 spr0558 357 Conserved hypothetical protein 
 SPD_0555 357 membrane protein putative 
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 SPJ_0589 357 membrane protein 
358 spr0559 358 Conserved hypothetical protein 
 SPD_0556 358 membrane protein putative 
 SPJ_0590 358 ABC transporter permease protein 
359 SPG_0583 359 conserved domain protein 
 SPCG_0598 359 hypothetical protein 
 HMPREF0837_
10931 
359 acetyltransferase 
 SPN23F05780 359 putative uncharacterised protein 
360 SP_0647 360 putative PTS system IIC component 
 SPD_0561 360 PTS system IIC component putative 
 SP70585_0705 360 phosphotransferase system sugar-specific EII component 
361 spr0565 361 beta-galactosidase precursor 
 SPD_0562 361 beta-galactosidase precursor putative 
 SPJ_0596 361 beta-galactosidase 
362 spr0571 362 Conserved hypothetical protein 
 SPD_0567 362 rRNA methylase putative 
 SPT_0677 362 SAM-dependent methyltransferase 
363 SP_0653 363 hypothetical protein 
 SP70585_0714 363 conserved hypothetical protein 
364 SP_0657 364 putative ribonuclease BN 
 spr0574 364 Conserved hypothetical protein 
 SPD_0570 364 ribonuclease BN putative 
 SPH0752 364 ribonuclease BN 
365 SPD_0571 365 cytochrome c-type biogenesis protein CcdA 
 SP70585_0717 365 cytoChrome c-type biogenesis protein 
366 SP_0659 366 thioredoxin family protein 
 spr0576 366 Conserved hypothetical protein 
367 SP_0660 367 peptide methionine sulfoxide reductase 
 spr0577 367 Peptide methionine sulfoxide reductase paralog 
 SPD_0573 367 peptide methionine sulfoxide reductase msrA/msrB 2 
 SP70585_0719 367 peptide methionine sulfoxide reductase MsrA/msrB 
368 SPD_0574 368 DNA-binding response regulator 
 SPJ_0610 368 response regulator 
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369 SP_0662 369 putative sensor histidine kinase 
 spr0579 369 Histidine kinase 
 SPD_0575 369 sensor histidine kinase putative 
370 SPD_0576 370 conserved hypothetical protein TIGR01440 
 SP70585_0722 370 conserved hypothetical protein 
371 spr0581 371 Zinc metalloprotease 
 SP70585_0723 371 zinc metalloprotease ZmpB 
372 spr0582 372 Para-aminobenzoate synthetase 
 SPD_0578 372 para-aminobenzoate synthase component I 
 SPJ_0615 372 chorismate binding enzyme 
373 SP_0667 373 putative pneumococcal surface protein 
 spr0583 373 Hypothetical protein 
 SPD_0579 373 pneumococcal surface protein putative 
 SP70585_0726 373 conserved hypothetical protein 
374 SP_0668 374 glucokinase 
 spr0584 374 Glucose kinase 
 SPJ_0619 374 glucokinase (Glucose kinase) 
375 spr0585 375 Thymidylate synthase 
376 SP_0671 376 tRNA isopentenylpyrophosphate transferase 
 SPD_0583 376 tRNA delta (2)-isopentenylpyrophosphate transferase 
377 spr0589 377 Conserved hypothetical protein 
 SPD_0584 377 GTP-binding protein HflX 
378 spr0590 378 Hypothetical protein 
 SPD_0585 378 conserved hypothetical protein 
 SPP_0694 378 cystathionine beta-lyase 
379 SP_0674 379 metallo-beta-lactamase superfamily protein 
 spr0591 379 Conserved hypothetical protein 
 SPT_0698 379 ribonuclease Z 
380 SP_0675 380 oxidoreductase short chain dehydrogenase/reductase family 
 spr0592 380 Conserved hypothetical protein 
 SPD_0587 380 oxidoreductase short chain dehydrogenase/reductase family protein 
 SPJ_0626 380 oxidoreductase 
381 SP_0676 381 putative transcriptional regulator 
 SPD_0588 381 transcriptional regulator putative 
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 SP70585_0735 381 regulatory function on capsule expression 
382 SPD_0589 382 conserved hypothetical protein 
383 SP_0678 383 conserved hypothetical protein 
 SPD_0590 383 rhodanese-like domain 
 SP70585_0737 383 rhodanese family protein 
384 SP_0680 384 ribosomal small subunit pseudouridine synthase A 
385 SP_0681 385 elongation factor Tu family protein 
 spr0598 385 GTP-binding protein TypA/BipA (tyrosine phosphorylated protein A) 
 SP70585_0740 385 GTP-binding protein TypA/BipA 
386 spr0601 386 Conserved hypothetical protein 
 SPD_0596 386 membrane protein putative 
 SPP_0705 386 bacteriocin-associated integral membrane protein 
387 SP_0687 387 ABC transporter ATP-binding protein 
 spr0602 387 ABC transporter ATP-binding protein-sodium transport 
388 spr0603 388 UDP-N-acetylmuramoyl-L-alanine--D-glutamateligase 
 SP70585_0745 388 UDP-N-acetylmuramoylalanine--D-glutamate ligase 
389 SP_0689 389 UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol 
N-acetylglucosamine transferase 
 spr0604 389 Undecaprenyl-PP-MurNAc-pentapeptide-UDPGlcNAc GlcNAc transferase 
390 SP_0690 390 cell division protein DivIB 
391 spr0613 391 Orotidine-5'-decarboxylase 
 SPD_0608 391 orotidine 5'-phosphate decarboxylase 
392 SP_0702 392 orotate phosphoribosyltransferase PyrE 
 SP70585_0749 392 orotate phosphoribosyltransferase 
393 SP_0710 393 amino acid ABC transporter permease protein 
 spr0623 393 ABC transporter membrane-spanning permease-glutamine transport 
394 spr0627 394 Lactate oxidase 
 SP70585_0761 394 L-lactate oxidase 
395 SP_0716 395 putative transcriptional regulator 
 spr0628 395 Conserved hypothetical protein 
 SPD_0622 395 transcriptional regulator TENA/THI-4 family protein putative 
 SPJ_0656 395 tena/thi-4 family 
396 SPD_0623 396 hydroxyethylthiazole kinase 
397 spr0630 397 Thiamin-phosphate pyrophosphorylase 
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 SPJ_0658 397 thiamine-phosphate pyrophosphorylase 
398 spr0631 398 Conserved hypothetical protein 
 SPD_0625 398 membrane protein putative 
 SP70585_0766 398 ABC-type cobalt transport system permease component 
399 spr0632 399 ABC transporter ATP-binding protein-cobalt or other cation transport 
 SPD_0626 399 ABC transporter ATP-binding protein 
400 spr0633 400 Conserved hypothetical protein 
 SPD_0627 400 membrane protein putative 
401 SP_0722 401 transcriptional activator TenA 
 spr0634 401 Transcriptional regulator of extracellular enzyme genes 
 SPD_0628 401 transcriptional activator TenA TENA/THI-4 family protein 
 SPJ_0662 401 tena/thi-4 family 
402 spr0635 402 Hypothetical protein 
 SPJ_0663 402 ThiW protein 
403 SP_0724 403 putative hydroxyethylthiazole kinase 
 SPD_0630 403 hydroxyethylthiazole kinase putative 
 SPJ_0664 403 hydroxyethylthiazole kinase 
404 SP_0725 404 thiamine-phosphate pyrophosphorylase 
 spr0637 404 Thiamine phosphate pyrophosphorylase 
405 SP_0727 405 putative transcriptional repressor 
 spr0639 405 COPAB ATPases metal-fist type repressor 
 SPD_0633 405 transcriptional regulator putative 
 SP70585_0774 405 copper transport repressor CopY/TcrY family 
406 SP_0728 406 hypothetical protein 
 SP70585_0775 406 conserved hypothetical protein 
407 SP_0729 407 cation-transporting ATPase E1-E2 family 
 spr0641 407 P-type ATPase-probable copper transporter 
 SPD_0635 407 cation-transporting ATPase E1-E2 family protein 
 SP70585_0776 407 copper-translocating P-type ATPase 
408 SPT_0746 408 pyruvate oxidase 
409 spr0647 409 Mannose-6-phosphate isomerase 
 SPJ_0675 409 mannose-6-phosphate isomerase class I 
410 spr0651 410 Conserved hypothetical protein 
411 SPJ_0681 411 conserved hypothetical protein 
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412 spr0654 412 dCMP deaminase 
 SPD_0648 412 cytidine and deoxycytidylate deaminase family protein 
 SP70585_0790 412 ComE operon protein 2 
413 spr0655 413 Uracil phosphoribosyltransferase 
414 SP_0746 414 ATP-dependent Clp protease proteolytic subunit 
 SPD_0650 414 ATP-dependent Clp protease proteolytic subunit ClpP 
 SP70585_0792 414 Clp protease 
415 SP_0748 415 conserved hypothetical protein 
416 SP_0749 416 branched-chain amino acid ABC transporter amino acid-binding protein 
 spr0659 416 ABC transporter substrate-binding protein-branched chain amino acid transport 
417 SP_0750 417 branched-chain amino acid ABC transporter permease protein 
 spr0660 417 ABC transporter membrane-spanning permease-branched chain amino acid transport 
418 SP_0751 418 branched-chain amino acid ABC transporter permease protein 
 spr0661 418 ABC transporter membrane-spanning permease-branched chain amino acid transport 
419 SP_0752 419 branched-chain amino acid ABC transporter ATP-binding protein 
 spr0662 419 ABC transporter ATP-binding protein-branched chain amino acid transport 
420 spr0663 420 ABC transporter ATP-binding protein-branched chain amino acid transport 
 SPD_0656 420 branched-chain amino acid ABC transporter ATP-binding protein 
421 SP_0754 421 putative acetoin utilisation protein AcuB 
 spr0664 421 Conserved hypothetical protein 
 SPD_0657 421 acetoin utilisation protein AcuB putative 
 SPP_0765 421 AcuB family protein 
422 SP_0755 422 peptide chain release factor 2 programmed frameshift 
 SP70585_0800 422 peptide chain release factor 2 
423 SP_0756 423 cell division ABC transporter ATP-binding protein FtsE 
 spr0666 423 ABC transporter ATP-binding protein & cell division protein 
 SPD_0659 423 cell division ATP-binding protein FtsE 
424 spr0667 424 Cell division protein FtsX 
 SPD_0660 424 cell division ABC transporter permease protein FtsX 
425 spr0668 425 PTS glucose-specific enzyme IIABC component 
 SPD_0661 425 PTS system IIABC components 
 SP70585_0803 425 pts system iibc component 
426 SP_0760 426 hypothetical protein 
 SPD_0662 426 endonuclease/exonuclease/phosphatase family protein 
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 SPP_0770 426 metal-dependent hydrolase 
427 SP_0761 427 ATP-dependent RNA helicase DEAD/DEAH box family 
 spr0670 427 ATP-dependent RNA helicase 
 SPD_0663 427 ATP-dependent RNA helicase DEAD/DEAH box family protein 
 SP70585_0805 427 superfamily II DNA and RNA helicase 
428 SP_0762 428 S-adenosylmethionine synthetase 
 SPJ_0699 428 methionine adenosyltransferase 
429 spr0672 429 Dihydroorotate dehydrogenase 
 SPD_0665 429 dihydroorotate dehydrogenase A 
 SP70585_0807 429 dihydroorotate dehydrogenase (dihydroorotate oxidase) (dhodehase) (dhodase) (dhod) 
430 SPJ_0702 430 DNA polymerase III delta subunit 
431 SP_0766 431 superoxide dismutase manganese-dependent 
 spr0674 431 Manganese co-factored superoxide dismutase 
 SP70585_0809 431 superoxide dismutase [Mn] (General stress protein 24) (GSP24) 
432 spr0675 432 Hypothetical protein 
 SPD_0668 432 conserved hypothetical protein 
 SPP_0776 432 transcriptional regulator 
433 SP_0768 433 conserved hypothetical protein 
 SPD_0669 433 radical SAM enzyme Cfr family protein 
 SP70585_0811 433 radical SAM enzyme Cfr family 
434 SP_0770 434 ABC transporter ATP-binding protein 
 spr0678 434 ABC transporter ATP-binding protein-unknown substrate 
435 SP_0771 435 peptidyl-prolyl cis-trans isomerase cyclophilin-type 
 spr0679 435 Peptidyl-prolyl cis-trans isomerase 
436 SP_0775 436 ribosomal protein S16 
 spr0682 436 30S Ribosomal protein S16 
437 SP_0776 437 KH domain protein 
 SPD_0675 437 conserved hypothetical protein 
 SPJ_0713 437 conserved domain protein 
438 spr0684 438 Hypothetical protein 
 SPD_0676 438 conserved hypothetical protein 
 SPJ_0714 438 hydrolase alpha/beta fold family putative 
439 SP70585_0820 439 16S rRNA processing protein RimM 
440 SP70585_0821 440 tRNA (guanine-N1)-methyltransferase 
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441 SP_0780 441 ribonucleoside-diphosphate reductase alpha subunit truncation 
 spr0688 441 Hypothetical protein 
 SPD_0680 441 conserved hypothetical protein 
 SP70585_0822 441 oxygen-sensitive ribonucleoside-triphosphate reductase 
442 SP_0783 442 conserved hypothetical protein 
 SPD_0684 442 biotin synthase (BioY family protein) putative 
 SPT_1417 442 biotin synthase 
443 SP_0784 443 glutathione reductase 
 spr0692 443 Glutathione oxidoreductase 
 SPD_0685 443 glutathione-disulfide reductase 
444 SP_0785 444 conserved hypothetical protein 
 SPD_0686 444 efflux transporter RND family protein MFP subunit 
 SPJ_0727 444 membrane-fusion protein 
445 SP_0786 445 ABC transporter ATP-binding protein 
 spr0694 445 ABC transporter ATP-binding protein-unknown substrate 
 SP70585_0829 445 macrolide export ATP-binding/permease protein MacB 
446 SP_0787 446 conserved hypothetical protein 
 SPD_0688 446 efflux ABC transporter permease protein 
 SP70585_0830 446 ABC-type antimicrobial peptide transport system permease component 
447 SPP_0797 447 methionyl-tRNA synthetase 
448 spr0697 448 Conserved hypothetical protein 
 SPD_0691 448 transcriptional regulator PadR family protein 
 SP70585_0833 448 transcriptional regulator PadR family 
449 SP_0790 449 conserved domain protein 
 spr0698 449 Conserved hypothetical protein 
 SPP_0799 449 membrane protein putative 
450 spr0699 450 Conserved hypothetical protein 
 SPD_0693 450 oxidoreductase aldo/keto reductase family protein 
 SP70585_0835 450 oxidoreductase aldo/keto reductase family 
451 SP_0792 451 hypothetical protein 
 SPP_0801 451 conserved hypothetical protein 
452 SP_0793 452 oxidoreductase short chain dehydrogenase/reductase family 
 spr0701 452 3-Ketoacyl-ACP reductase 
 SPD_0695 452 oxidoreductase short chain dehydrogenase/reductase family protein 
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 SP70585_0837 452 3-ketoacyl-(acyl-carrier-protein) reductase 
453 spr0702 453 Conserved hypothetical protein 
 SP70585_0838 453 MutT/nudix family protein 
454 SP_0795 454 PEP-utilizing enzymes family protein 
 spr0704 454 Hypothetical protein 
 SPD_0698 454 conserved hypothetical protein 
 SP70585_0840 454 PEP-utilizing enzyme family protein 
455 SPJ_0741 455 conserved hypothetical protein 
456 SP_0797 456 aminopeptidase N 
457 spr0707 457 Response regulator transcriptional regulatory protein 
 SPD_0701 457 DNA-binding response regulator CiaR 
 SP70585_0843 457 transcriptional regulatory protein CiaR 
458 SP_0799 458 sensor histidine kinase CiaH 
 spr0708 458 Sensor protein CiaH histide kinase 
 SPP_0808 458 sensor protein CiaH 
459 SP_0800 459 hypothetical protein 
 SP70585_0845 459 conserved hypothetical protein 
460 SP_0801 460 conserved hypothetical protein 
 SP70585_0846 460 protease 
461 SP_0802 461 DNA polymerase III epsilon subunit/ATP-dependent helicase DinG 
 spr0711 461 ATP-dependent DNA helicase 
 SPD_0705 461 DnaQ family exonuclease/DinG family helicase putative 
462 SP_0803 462 putative rod shape-determining protein RodA 
 spr0712 462 Rod shape determining protein 
 SPD_0706 462 rod shape-determining protein RodA putative 
 SPT_1396 462 RodA 
463 SP_0804 463 putative 4-methyl-5 (b-hydroxyethyl)-thiazole monophosphate biosynthesis protein 
 spr0713 463 4-methyl-5 (b-hydroxyethyl)-thiazole monophosphate biosynthesis protein 
464 SP_0805 464 hydrolase haloacid dehalogenase-like family 
 SPD_0708 464 hydrolase haloacid dehalogenase-like family protein 
 SP70585_0850 464 phosphoglycolate phosphatase 
465 SP_0806 465 DNA gyrase subunit B 
 spr0715 465 DNA gyrase 
 SPT_1393 465 DNA gyrase B subunit 
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466 SP_0807 466 putative septation ring formation regulator EzrA 
 spr0716 466 Cell division regulator negative regulator of FtsZ ring formation 
 SP70585_0852 466 septation ring formation regulator EzrA 
467 SPD_0718 467 conserved hypothetical protein 
468 spr0727 468 ABC transporter membrane-spanning permease-glutamine transport 
 SPD_0719 468 amino acid ABC transporter permease protein 
469 SP_0824 469 amino acid ABC transporter ATP-binding protein 
 spr0728 469 ABC transporter ATP-binding protein-glutamine transport 
 SP70585_0861 469 glutamine transport ATP-binding protein GlnQ 
470 SP_0825 470 methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase 
 spr0729 470 Fold bifunctional protein; includes: methylenetetrahydrofolate dehydrogenase 
methenyltetrahydrofolate cyclohydrolase 
471 SP_0828 471 ribose 5-phosphate isomerase 
 spr0731 471 Ribose-5-phosphate epimerase 
 SP70585_0864 471 ribose 5-phosphate isomerase A 
472 spr0732 472 phosphodeoxyribomutase 
 SPP_0835 472 phosphopentomutase 
473 spr0733 473 Hypothetical protein 
 SPJ_0768 473 conserved hypothetical protein 
474 SP_0831 474 purine nucleoside phosphorylase family 2 
 spr0734 474 Purine nucleoside phosphorylase (inosine phosphorylase) 
 SPD_0726 474 purine nucleoside phosphorylase family protein 2 
475 SPD_0727 475 conserved hypothetical protein 
 SP70585_0870 475 hypothetical protein 
476 spr0737 476 Conserved hypothetical protein truncation 
 SPD_0729 476 hemolysin-related protein 
 SPP_0840 476 conserved hypothetical protein 
477 SP_0835 477 purine nucleoside phosphorylase family 1 
 spr0738 477 Purine nucleoside phosphorylase (inosine phosphorylase) 
 SPD_0730 477 purine nucleoside phosphorylase 
478 SP_0837 478 putative DNA topology modulation protein FlaR 
 spr0739 478 Modulates DNA topology 
 SPD_0731 478 DNA topology modulation protein FlaR putative 
 SPJ_0774 478 topology modulation protein 
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479 SPJ_0776 479 pantothenate kinase 
480 spr0744 480 Pyrimidine nucleoside phosphorylase 
 SP70585_0878 480 pyrimidine-nucleoside phosphorylase (pynp) 
 SPJ_0779 480 pyrimidine-nucleoside phosphorylase 
481 spr0745 481 Deoxyribose-phosphate aldolase 
482 SPT_1359 482 cytidine deaminase 
483 spr0747 483 Conserved hypothetical protein 
 SPD_0739 483 probable membrane lipoprotein TmpC precursor 
 SPP_0851 483 lipoprotein 
484 spr0748 484 ABC transporter ATP-binding protein-ribose/galactose transport 
 SPD_0740 484 sugar ABC transporter ATP-binding protein 
 SP70585_0882 484 ribose import ATP-binding protein RbsA 
485 SP_0847 485 putative sugar ABC transporter permease protein 
 spr0749 485 ABC transporter membrane-spanning permease-ribose/galactose transport 
 SPD_0741 485 sugar ABC transporter permease protein putative 
486 SP_0848 486 putative sugar ABC transporter permease protein 
 spr0750 486 ABC transporter membrane-spanning permease-ribose/galactose transport 
 SPD_0742 486 sugar ABC transporter permease protein putative 
487 spr0755 487 Conserved hypothetical protein 
 SPP_0859 487 membrane protein putative 
488 spr0756 488 Topoisomerase IV subunit B 
 SP70585_0888 488 DNA topoisomerase IV B subunit 
489 SPD_0747 489 conserved hypothetical protein 
 SP70585_0889 489 hypothetical protein 
490 SP_0855 490 topoisomerase IV subunit A 
 SPP_0862 490 DNA topoisomerase IV A subunit 
491 spr0758 491 Branched-chain-amino-acid transaminase 
 SPD_0749 491 branched-chain amino acid aminotransferase 
492 SP_0858 492 putative membrane protein 
 spr0760 492 Conserved hypothetical protein 
 SPD_0751 492 membrane protein putative 
 SPP_0865 492 permease 
493 SP_0859 493 membrane protein 
 spr0761 493 Conserved hypothetical protein 
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 SPD_0752 493 membrane protein putative 
 SPH0958 493 permease 
 SPG_0779 493 hypothetical protein 
494 SP_0860 494 pyrrolidone-carboxylate peptidase 
 spr0762 494 Pyrrolidone-carboxylate peptidase (5-oxoprolyl-peptidase) 
 SP70585_0895 494 pyroglutamyl-peptidase I 
495 spr0764 495 30S Ribosomal protein S1 
 SPD_0757 495 ribosomal protein S1 
 SP70585_0899 495 putative 30S ribosomal protein S1 homolog 
496 SPD_0759 496 conserved hypothetical protein 
 SPP_0872 496 GAF domain-containing protein 
497 SP_0865 497 DNA polymerase III gamma and tau subunits 
 spr0769 497 DNA-directed DNA polymerase III chain 
 SP70585_0903 497 DNA polymerase III subunit gamma/tau 
498 spr0770 498 Hypothetical protein 
 SPD_0761 498 conserved hypothetical protein 
499 SP_0867 499 ABC transporter ATP-binding protein 
 spr0771 499 ABC transporter ATP-binding protein-unknown substrate 
 SP70585_0905 499 FeS assembly ATPase SufC 
500 SP_0868 500 conserved hypothetical protein 
 SPP_0876 500 FeS assembly protein SufD 
501 SP_0869 501 aminotransferase class-V 
 spr0773 501 Conserved hypothetical protein 
 SPD_0764 501 cysteine desulfurases SufS subfamily protein 
 SP70585_0907 501 cysteine desulfurase (Selenocysteine lyase) (Selenocysteine reductase) (Selenocysteine beta-
lyase) 
502 SP_0870 502 NifU family protein 
 spr0774 502 NifU protein 
 SPD_0765 502 SUF system FeS assembly protein NifU family protein 
 SP70585_0908 502 SUF system FeS assembly protein NifU family 
503 spr0775 503 Conserved hypothetical protein 
 SP70585_0909 503 FeS assembly protein SufB 
504 SP_0872 504 D-alanyl-D-alanine carboxypeptidase 
 SPD_0767 504 penicillin-binding protein 3/D-alanyl-D-alanine carboxypeptidase 
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505 SP_0875 505 lactose phosphotransferase system repressor 
 spr0778 505 Transcriptional repressor of the fructose operon 
506 SP_0876 506 putative 1-phosphofructokinase 
 spr0779 506 Fructose-1-phosphate kinase 
 SPD_0772 506 1-phosphofructokinase putative 
 SPP_0884 506 1-phosphofructokinase 
507 spr0780 507 Fructose specific-phosphotransferase system IIBC component 
 SPD_0773 507 PTS system fructose specific IIABC components 
 SP70585_0915 507 iiabc fructose/xylitol-pts 
508 SP_0878 508 SpoE family protein 
 spr0781 508 Cell division protein 
 SP70585_0916 508 DNA translocase ftsk 
509 SP_0880 509 aminotransferase class-V 
 spr0783 509 Probable pyridoxal-phosphate dependent aminotransferase 
 SPD_0776 509 aminotransferase class V 
 SP70585_0918 509 cysteine desulfurase 
 SPJ_0822 509 cysteine desulphurase 
510 SP_0881 510 thiazole biosynthesis protein ThiI 
 spr0784 510 Thiamin biosynthesis protein 
 SP70585_0919 510 thiamine biosynthesis/tRNA modification protein ThiI 
511 SP_0882 511 conserved hypothetical protein 
 spr0785 511 Hypothetical protein 
 SPH0987 511 putative esterase superfamily 
512 SP_0884 512 hypothetical protein 
 SPD_0780 512 conserved hypothetical protein 
 SPP_0890 512 putative esterase superfamily 
513 SP_0885 513 hypothetical protein 
 SPD_0781 513 conserved hypothetical protein 
 SP70585_0923 513 carbamoylphosphate synthase large subunit 
514 SP_0886 514 putative type I restriction-modification system M subunit 
 spr0790 514 Type I restriction modification enzyme methylase subunit 
 SPD_0782 514 type I restriction-modification system M subunit putative 
515 SP_0892 515 putative type I restriction-modification system R subunit 
 spr0792 515 Type 1 restriction modification system endonuclease R 
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 SPD_0784 515 type I restriction-modification system R subunit putative 
516 SP_0893 516 putative transcriptional repressor 
 SPD_0786 516 transcriptional regulator of arginine metabolism expression putative 
 SPJ_0834 516 arginine repressor 
517 SP_0894 517 X-pro dipeptidyl-peptidase 
 spr0794 517 Xaa-pro dipeptidyl-peptidase 
 SPD_0787 517 Xaa-Pro dipeptidyl-peptidase PepX 
 SP70585_0933 517 Xaa-pro dipeptidyl-peptidase (x-pro dipeptidyl-peptidase) (x-prolyl-dipeptidyl 
aminopeptidase) (x-pdap) 
518 SP_0895 518 DNA polymerase III alpha subunit 
 spr0795 518 DNA-polymerase III alpha-chain 
 SP70585_0934 518 DNA polymerase III subunit alpha 
519 spr0796 519 6-phosphofructokinase I 
 SPJ_0837 519 6-phosphofructokinase 
520 spr0797 520 Pyruvate kinase I; fructose-stimulated 
 SPD_0790 520 pyruvate kinase 
521 spr0799 521 Hypothetical protein 
 SP70585_0937 521 lipoprotein putative 
 SPJ_0839 521 conserved hypothetical protein 
522 SP_0905 522 conserved hypothetical protein 
 SPD_0798 522 membrnae protein puative 
523 SP_0908 523 putative transcriptional regulator 
 spr0808 523 Toxin expression-transcriptional accessory protein 
 SPD_0802 523 S1 RNA binding domain 
 SPJ_0847 523 S1 RNA binding domain protein 
524 spr0810 524 Hypothetical protein 
 SPD_0803 524 conserved hypothetical protein 
 SP70585_0948 524 PspC domain family 
525 SP_0913 525 putative ABC transporter permease protein 
 spr0813 525 ABC transporter membrane-spanning permease-unknown substrate 
 SPD_0805 525 transporter permease protein putative 
526 SPP_0926 526 spermidine synthase 
527 SP_0919 527 conserved hypothetical protein 
 SPP_0927 527 saccharopine dehydrogenase 
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528 SP70585_0959 528 carboxynorspermidine decarboxylase 
529 SP_0921 529 conserved hypothetical protein 
 SPJ_0862 529 agmatine deiminase 
530 SP_0922 530 carbon-nitrogen hydrolase family protein 
 spr0823 530 Beta-alanine synthase or beta-ureidopropionase 
 SPD_0815 530 hydrolase carbon-nitrogen family protein 
 SP70585_0961 530 N-carbamoylputrescine amidase 
531 SP_0925 531 conserved hypothetical protein 
 spr0826 531 Hypothetical protein 
 SPD_0817 531 CAAX amino terminal protease family protein 
 SP70585_0964 531 caax amino protease family 
532 SP_0927 532 transcriptional regulator LysR family 
 spr0828 532 Regulatory function on capsule expression in group B streptococci 
 SPD_0818 532 transcriptional regulator LysR family protein 
533 spr0829 533 Signal peptidase type II; lipoprotein signal peptidase 
 SPD_0819 533 signal peptidase II 
534 SP_0929 534 ribosomal large subunit pseudouridine synthase D 
 spr0830 534 23S rRNA pseudouridine synthase supresses ftsH (ts) mutants 
535 spr0831 535 Teichoic acid phosphorylcholine esterase/choline binding protein E (cbpE) 
 SPD_0821 535 choline binding protein E 
536 spr0832 536 Gamma-glutamyl kinase 
 SPP_0938 536 glutamate 5-kinase 
537 SPD_0823 537 gamma-glutamyl phosphate reductase 
 SPJ_0872 537 glutamate-5-semialdehyde dehydrogenase 
538 SP70585_0972 538 pyrroline-5-carboxylate reductase 
539 SPP_0941 539 thymidylate kinase 
540 SP_0936 540 DNA polymerase III delta prime subunit 
 spr0836 540 DNA polymerase III delta' subunit 
 SP70585_0974 540 DNA polymerase III subunit delta 
541 SPD_0827 541 conserved hypothetical protein 
 SPJ_0876 541 initiation-control protein YabA 
542 SP_0938 542 tetrapyrrole methylase family protein 
 spr0838 542 Conserved hypothetical protein 
 SPD_0828 542 conserved hypothetical protein TIGR00096 
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543 SP_0943 543 Gid protein 
 spr0844 543 Glucose inhibited division protein 
 SPD_0833 543 tRNA uridine 5-carboxymethylaminomethyl modification enzyme gid 
 SP70585_0982 543 tRNA:M (5)U-54 methyltransferase 
544 SP_0944 544 uridylate kinase 
 SPH1048 544 UMP kinase 
545 SP70585_0984 545 ribosome recycling factor 
546 spr0847 546 Conserved hypothetical protein 
 SPP_0953 546 s1 RNA binding domain protein 
547 spr0848 547 Conserved hypothetical protein 
 SPP_0954 547 conserved domain protein 
548 spr0849 548 PhoH-like protein 
 SPT_1255 548 PhoH family protein 
549 spr0855 549 Conserved hypothetical protein 
 SPD_0842 549 acetyltransferase GNAT family protein 
 SPJ_0894 549 acetyltransferase gnat family 
550 SP70585_0994 550 competence protein 
 SPP_0961 550 competence protein CelA 
551 SP_0955 551 DNA internalisation-related competence protein ComEC/Rec2 
 spr0857 551 Competence protein 
 SPD_0844 551 competence protein CelB 
552 spr0859 552 Hypothetical protein 
 SP70585_0997 552 ABC transporter ATP-binding protein 
553 SP_0958 553 hypothetical protein 
 SP70585_0998 553 membrane protein putative 
554 SPD_0847 554 translation initiation factor IF-3 
555 spr0862 555 50S Ribosomal protein L35 
 SPP_0966 555 ribosomal protein L35 
556 spr0863 556 50S Ribosomal protein L20 
 SP70585_1001 556 ribosomal protein L20 
557 SP_0962 557 lactoylglutathione lyase 
558 SPD_0851 558 dihydroorotate dehydrogenase electron transfer subunit 
559 SP_0964 559 dihydroorotate dehydrogenase B 
 spr0866 559 Dihydroorotate dehydrogenase 
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 SPD_0852 559 dihydroorotate dehydrogenase catalytic subunit 
 SP70585_1004 559 dihydroorotate dehydrogenase B catalytic subunit 9dihydroorotate oxidase b) (dhodehase b) 
560 spr0867 560 Endo-beta-N-acetylglucosaminidase 
 SPD_0853 560 endo-beta-N-acetylglucosaminidase precursor putative 
561 SP_0966 561 adherence and virulence protein A 
 spr0868 561 Fibronectin-binding protein-like protein A 
 SP70585_1006 561 fibronectin/fibrinogen binding protein 
562 SPD_0855 562 conserved hypothetical protein TIGR00043 
 SPJ_0908 562 conserved hypothetical protein 
563 spr0870 563 Diacylglycerol kinase 
 SP70585_1008 563 diacylglycerol kinase (dagk) (diglyceride kinase) (dgk) 
564 spr0871 564 GTPase/GTP-binding protein 
 SPJ_0910 564 GTP-binding protein Era 
565 SP70585_1010 565 formamidopyrimidine-DNA glycosylase 
566 SP_0971 566 putative kinase 
 spr0873 566 Conserved hypothetical protein 
 SP70585_1011 566 dephospho-CoA kinase 
567 spr0875 567 Major facilitator superfamily multi-drug resistance efflux pump 
 SPD_0860 567 multi-drug resistance efflux pump 
 SP70585_1012 567 multidrug resistance protein MdtG 
568 SP_0974 568 putative preprotein translocase SecG subunit 
 spr0877 568 Protein-export membrane protein secG 
 SP70585_1014 568 preprotein translocase SecG subunit 
569 SP_0975 569 exoribonuclease VacB/Rnb family 
 spr0878 569 Exoribonuclease R 
 SPD_0862 569 ribonuclease R 
570 SP_0976 570 SsrA-binding protein 
 spr0879 570 Small protein B 
571 spr0880 571 Tellurite resistance 
 SPJ_0918 571 tellurite resistance protein TehB 
572 SPD_0865 572 competence protein CoiA 
 SPJ_0919 572 competence protein 
573 spr0882 573 Group B oligopeptidase 
 SPJ_0920 573 oligoendopeptidase F 
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574 spr0883 574 Conserved hypothetical protein 
 SPD_0867 574 O-methyltransferase 
 SP70585_1020 574 O-methyltransferase family protein 
575 SP_0981 575 putative protease maturation protein 
 spr0884 575 Proteinase maturation protein 
 SPD_0868 575 protease maturation protein putative 
 SPJ_0922 575 foldase protein PrsA 
576 SP_0985 576 putative regulatory protein 
 SPD_0871 576 regulatory protein putative 
 SP70585_1026 576 regulatory protein 
577 SP_0986 577 conserved hypothetical protein 
 SPD_0872 577 membrane protein putative 
 SPJ_0927 577 integral membrane protein 
578 SP_0987 578 hypothetical protein 
 SPD_0873 578 conserved hypothetical protein 
 SPT_1217 578 lyzozyme M1 
579 spr0891 579 UDP-N-acetylglucosamine pyrophosphorylase 
580 SP_0989 580 MutT/nudix family protein 
 spr0892 580 Conserved hypothetical protein 
 SPD_0875 580 hydrolase NUDIX family protein 
 SP70585_1030 580 ADP-ribose pyrophosphatase 
581 SP_0991 581 5'-methylthioadenosine/S-adenosylhomocysteinenucleosidase 
 spr0894 581 5'-methylthioadenosine / S-adenosylhomocysteine nucleosidase 
 SP70585_1032 581 MTA/SAH nucleosidase 
582 SPD_0878 582 conserved hypothetical protein 
 SP70585_1033 582 protein of unknown function 
583 SP_0993 583 exonuclease 
 spr0896 583 DNA polymerase III epsilon chain 
 SPJ_0934 583 DNA polymerase III subunit epsilon 
584 SP_0994 584 hypothetical protein 
 SPD_0880 584 glycerophosphoryl diester phosphodiesterase family protein 
585 SP_0997 585 hypothetical protein 
 SPJ_0938 585 conserved hypothetical protein 
586 spr0902 586 Hypothetical protein 
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 SPJ_0939 586 conserved hypothetical protein 
587 spr0903 587 Cytochrome c-type biogenesis protein 
 SPD_0885 587 cytochrome c-type biogenesis protein CcdA 
588 SP_1000 588 thioredoxin family protein 
 spr0904 588 Conserved hypothetical protein 
589 spr0905 589 Cationic amino acid transporter-APC Superfamily 
 SPJ_0942 589 amino acid permease family protein 
590 spr0906 590 Lipoprotein 
 SPD_0888 590 adhesion lipoprotein 
 SPJ_0943 590 zinc-binding lipoprotein AdcA 
591 SP_1003 591 conserved hypothetical protein 
 spr0907 591 Pneumococcal histidine triad protein D precursor 
 spr1060 591 Histidine Motif-Containing protein 
592 SP_1007 592 hypothetical protein 
 SPJ_0947 592 conserved hypothetical protein 
593 spr0913 593 Aminotripeptidase; tripeptidase 
 SPH1110 593 peptidase T 
594 SPT_1062 594 ferrochelatase 
595 SP_1012 595 conserved hypothetical protein 
 spr0917 595 citrulline cluster-linked gene 
 SPD_0898 595 membrane protein putative 
 SP70585_1051 595 citrulline cluster-linked protein 
596 spr0918 596 Aspartate beta-semialdehyde dehydrogenase 
 SPD_0900 596 aspartate-semialdehyde dehydrogenase 
597 SPJ_0955 597 dihydrodipicolinate synthase 
598 SP_1016 598 thiophene and furan oxidation protein ThdF 
 spr0920 598 Thiophene and furan oxidation protein 
 SP70585_1055 598 tRNA modification GTPase TrmE 
599 SPD_0904 599 thymidine kinase 
600 spr0924 600 Peptide chain release factor I 
 SPD_0906 600 peptide chain release factor 1 
601 spr0925 601 HemK protein homolog; possible protoporphyrinogen oxidase 
 SPD_0907 601 HemK protein 
 SP70585_1060 601 protein-(glutamine-N5) methyltransferase release factor-specific 
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602 SP_1022 602 Sua5/YciO/YrdC family protein 
 spr0926 602 Conserved hypothetical protein 
 SPD_0908 602 Sua5/YciO/YrdC/YwlC family protein 
603 spr0927 603 Conserved hypothetical protein 
 SP70585_1062 603 acetyltransferase gnat family 
 SPJ_0962 603 acetyltransferase gnat family protein 
604 SP_1024 604 serine hydroxymethyltransferase 
605 SP_1025 605 hypothetical protein 
 SPP_1031 605 conserved hypothetical protein 
606 spr0930 606 Conserved hypothetical protein 
 SPJ_0965 606 pneumococcal vaccine antigen A 
607 SP70585_1066 607 conserved hypothetical protein 
608 SP_1029 608 RNA methyltransferase TrmA family 
 spr0932 608 Conserved hypothetical protein 
 SP70585_1067 608 23S rRNA 9uracil-5-)-methyltransferase RumA 
609 SP_1067 609 putative cell division protein FtsW 
 SPD_0952 609 cell division protein FtsW putative 
 SPJ_1005 609 cell division protein FtsW 
610 SPD_0953 610 phosphoenolpyruvate carboxylase 
611 SP_1069 611 conserved hypothetical protein 
 spr0975 611 ABC transporter substrate-binding protein-unknown substrate 
 SP70585_1143 611 ABC transporter substrate binding protein 
612 SP_1070 612 conserved hypothetical protein 
 spr0976 612 ABC transporter membrane-spanning permease-unknown substrate 
 SPD_0955 612 amino acid or sugar ABC transport systems permease protein 
 SP70585_1144 612 ABC-type transporter 
613 SP_1071 613 ABC transporter ATP-binding protein 
 spr0977 613 ABC transporter ATP-binding protein-unknown substrate 
614 SPP_1078 614 DNA primase 
615 SP_1073 615 RNA polymerase sigma-70 factor 
 spr0979 615 RNA polymerase sigmA FACTOR 70 
 SP70585_1147 615 RNA polymerase sigma factor RpoD (Sigma-A) (Sigma-43) 
616 spr0980 616 Conserved hypothetical protein 
 SP70585_1148 616 N-6 Adenine-specific DNA methylase YitW 
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617 spr0981 617 Glycosyltransferase 
 SPP_1081 617 glycosyl transferase CpoA 
618 SP_1076 618 glycosyl transferase group 1 
 spr0982 618 Conserved Hypothetical protein 
619 spr0983 619 Hypothetical protein 
 SPD_0962 619 conserved hypothetical protein 
 SP70585_1151 619 conserved domain protein 
620 SP_1079 620 GTP-binding protein GTP1/Obg family 
 spr0984 620 GTP-binding protein 
 SPD_0964 620 GTP1/Obg family GTP-binding protein 
 SPJ_1017 620 Spo0B-associated GTP-binding protein 
621 SP_1081 621 UDP-N-acetylglucosamine1-carboxyvinyltransferase 
622 spr0990 622 Conserved hypothetical protein 
 SP70585_1156 622 acetyltransferase gnat family protein 
 SPJ_1020 622 acetyltransferase gnat family 
623 SP_1083 623 conserved hypothetical protein 
 SP70585_1157 623 cytosolic protein containing multiple CBS domains 
624 SP_1084 624 methionine aminopeptidase type I 
 spr0992 624 Methionine aminopeptidase 
625 SP_1087 625 ATP-dependent DNA helicase PcrA 
 spr0995 625 ATP-dependent DNA helicase 
626 SP_1088 626 DNA repair protein RadC 
 spr0996 626 DNA repair protein 
627 spr0997 627 Conserved hypothetical protein 
 SPD_0974 627 class I glutamine amidotransferase putative 
 SPJ_1026 627 glutamine amidotransferase class I 
628 spr0998 628 Conserved hypothetical protein 
 SP70585_1164 628 redox-sensing transcriptional repressor rex 
629 spr0999 629 Hypothetical protein 
 SPJ_1029 629 conserved hypothetical protein 
630 spr1002 630 Ribose-phosphate pyrophosphokinase 
 SP70585_1168 630 ribose-Phosphate pyrophosphokinase (rppk) (phosphoribosylpyrophosphate synthetase) 
631 spr1003 631 Conserved hypothetical protein 
 SPD_0981 631 adenylate cyclase putative 
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 SP70585_1169 631 adenylate cyclase 
632 SP_1097 632 conserved hypothetical protein 
 spr1004 632 Similar to GTP pyrophosphokinase 
 SPD_0982 632 pyrophosphokinase family protein 
 SP70585_1170 632 GTP pyrophosphokinase 
633 SP_1098 633 conserved hypothetical protein 
 SPD_0983 633 inorganic polyphosphate/ATP-NAD kinase putative 
 SP70585_1171 633 probable inorganic polyphosphate/ATP-NAD kinase (Poly P)/ATP NAD kinase) 
634 SP_1099 634 ribosomal large subunit pseudouridine synthase RluD subfamily 
 spr1006 634 23S rRNA pseudouridine synthase 
 SPD_0984 634 ribosomal large subunit pseudouridine synthase RluD subfamily protein 
635 SP_1100 635 phosphate acetyltransferase 
636 SPD_0987 636 conserved hypothetical protein TIGR00103 
 SP70585_1174 636 conserved hypothetical protein 
637 SP_1104 637 putative membrane protein 
 spr1011 637 Conserved hypothetical protein 
 SPD_0988 637 integral membrane protein 
 SPT_1150 637 membrane protein putative 
638 spr1012 638 50S Ribosomal protein L21 
 SP70585_1176 638 ribosomal protein L21 
639 SP70585_1177 639 conserved hypothetical protein 
640 spr1014 640 50S Ribosomal protein L27 
 SP70585_1178 640 ribosomal protein L27 
641 spr1017 641 Macrolide-efflux protein 
 SP70585_1181 641 riboflavin biosynthesis protein RibF 
642 spr1018 642 Conserved hypothetical protein 
 SPD_0995 642 membrane protein putative 
643 SP_1112 643 degV family protein 
 SPJ_1050 643 conserved hypothetical protein 
644 SP_1113 644 DNA-binding protein HU 
 spr1020 644 Histone-like DNA-binding protein 
 SP70585_1184 644 DNA-binding protein HU 1 (DNA-binding protein II) HB) 
645 SP_1114 645 ABC transporter ATP-binding protein 
 spr1021 645 ABC transporter ATP-binding protein-unknown substrate 
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 SP70585_1185 645 ATPase component of ABC transporter with duplicated ATPase domains 
646 SP_1116 646 putative transporter 
 SPD_1000 646 transporter major facilitator family protein 
 SP70585_1187 646 ABC transporter membrane-spanning permease-macrolide efflux 
647 spr1024 647 DNA ligase 
 SPD_1001 647 DNA ligase NAD-dependent 
648 SP_1118 648 putative pullulanase 
 spr1025 648 Thermostable pullulanase 
 SP70585_1189 648 pullulanase type I 
649 spr1029 649 14-alpha-glucan branching enzyme 
650 SP_1122 650 glucose-1-phosphate adenylyltransferase 
651 SP_1123 651 glycogen biosynthesis protein GlgD 
 spr1031 651 Required for glycogen biosynthesis 
 SP70585_1193 651 glucose-1-phosphate adenylyltransferase GlgD subunit 
652 SP_1124 652 glycogen synthase 
 SPD_1008 652 glycogen/starch synthases ADP-glucose type 
 SP70585_1194 652 glycogen synthase (Starch [bacterial glycogen]synthase) 
653 SP_1126 653 conserved hypothetical protein TIGR00045 
 SPD_1011 653 glycerate kinase 
654 spr1035 654 Hypothetical protein 
 SPP_1131 654 conserved hypothetical protein 
655 SP_1128 655 enolase 
 SPJ_1066 655 phosphopyruvate hydratase 
656 SP_1151 656 exonuclease RexB 
 spr1039 656 Second subunit of major exonuclease 
 SPD_1015 656 ATP-dependent exonuclease RexB 
 SPP_1137 656 ATP-dependent nuclease subunit B 
657 SP_1152 657 exonuclease RexA 
 spr1040 657 First subunit of major exonuclease 
 SPJ_1071 657 recombination helicase AddA 
658 spr1041 658 Hypothetical protein 
 SPP_1139 658 conserved hypothetical protein 
659 spr1044 659 Ribonuclease H 
 SPD_1020 659 ribonuclease HII 
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 SPT_1183 659 ribonuclease HII (RNase HII) 
660 SP_1157 660 voltage-gated chloride channel family protein 
 spr1045 660 Conserved hypothetical protein 
661 SP_1159 661 integrase/recombinase phage integrase family 
 spr1046 661 Integrase/recombinase 
 SPD_1023 661 integrase/recombinase phage integrase family protein 
 SP70585_1211 661 tyrosine recombinase XerC 
662 SP_1160 662 putative lipoate-protein ligase 
 SPD_1024 662 lipoate-protein ligase putative 
 SPP_1203 662 lipoate protein ligase A 
663 SP_1161 663 putative acetoin dehydrogenase complex E3 component dihydrolipoamide dehydrogenase 
 spr1048 663 Dihydrolipoamide dehydrogenase 
 SP70585_1213 663 dihydrolipoyl dehydrogenase 
664 SP_1162 664 putative acetoin dehydrogenase complex E2 component dihydrolipoamide acetyltransferase 
 spr1049 664 Dihydrolipoamide S-acetyltransferase 
 SPD_1026 664 acetoin dehydrogenase complex E2 component dihydrolipoamide acetyltransferase putative 
665 SP_1163 665 putative acetoin dehydrogenase E1 component beta subunit 
 spr1050 665 TPP-dependent acetoin dehydrogenase beta chain 
 SPD_1027 665 acetoin dehydrogenase E1 component beta subunit putative 
666 SP_1164 666 putative acetoin dehydrogenase E1 component alpha subunit 
 spr1051 666 TPP-dependent acetoin dehydrogenase alpha chain 
 SPD_1028 666 TPP-dependent acetoin dehydrogenase alpha-subunit 
667 spr1052 667 Conserved hypothetical protein 
 SPJ_1084 667 mate efflux family protein 
668 SP_1167 668 dihydroorotase multifunctional complex type 
 spr1053 668 Dihydroorotase 
 SPJ_1085 668 dihydroorotase (DHOase) 
669 SP_1168 669 mutator MutT protein 
 spr1054 669 8-oxodGTP nucleoside triphosphatase 
 SPD_1031 669 Mutator mutT protein (78-dihydro-8-oxoguanine-triphosphatase) (8-oxo-dGTPase) 
670 spr1055 670 DNA-uracil glycosylase 
 SPP_1211 670 uracil-DNA glycosylase 
671 spr1062 671 PTS enzyme I 
 SPD_1039 671 phosphoenolpyruvate-protein phosphotransferase 
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672 spr1063 672 Histidine-containing phosphocarrier protein of the PTS 
 SPD_1040 672 phosphocarrier protein HPr 
 SP70585_1230 672 phosphocarrier protein HPr (Histidine-containing protein)) 
673 SP_1178 673 NrdH-redoxin 
 spr1064 673 Glutaredoxin-like protein involved in electron transport system for ribonucleotide reductase 
system NrdEF 
 SPD_1041 673 glutaredoxin-like protein NrdH 
 SPJ_1097 673 glutaredoxin 
674 SP_1179 674 ribonucleoside-diphosphate reductase 2 alpha subunit 
 spr1065 674 Ribonucleoside-diphosphate reductase (major subunit) 
 SPD_1042 674 ribonucleoside-diphosphate reductase alpha subunit 
675 SP_1180 675 ribonucleoside-diphosphate reductase 2 beta subunit 
 spr1066 675 Nonessential ribonucleoside-diP reductase 2 subunit beta class I function unknown 
 SPD_1043 675 ribonucleoside-diphosphate reductase beta subunit 
676 spr1069 676 Phospho-beta-D-galactosidase 
 SPP_1227 676 6-phospho-beta-galactosidase 
677 SP_1185 677 PTS system lactose-specific IIBC components 
 spr1070 677 PTS system lactose-specific IIBC component 
 SP70585_1237 677 PTS system lactose-specific IIC component 
678 SP70585_1240 678 tagatose 16-diphosphate aldolase 
679 SPP_1232 679 tagatose-6-phosphate kinase 
680 SP_1192 680 galactose-6-phosphate isomerase LacB subunit 
681 SPJ_1118 681 GTP-binding protein LepA 
682 SPJ_1119 682 serine/threonine protein phosphatase 
683 spr1084 683 DNA repair and genetic recombination 
 SPP_1243 683 DNA repair protein RecN 
684 SP_1203 684 putative transcriptional repressor 
 spr1085 684 Transcriptional regulator of arginine metabolism expression 
 SPD_1063 684 transcriptional regulator of arginine metabolism expression putative 
685 SP_1204 685 putative hemolysin A 
 spr1086 685 Conserved hypothetical protein 
 SPD_1064 685 hemolysin A putative 
 SPJ_1122 685 hemolysin A 
686 spr1087 686 Farnesyl diphosphate synthase 
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 SPD_1065 686 geranyltranstransferase 
 SP70585_1255 686 geranyltranstransferase (Farnesyl-diphosphate synthase) (FPP synthase) 
687 spr1088 687 Exodeoxyribonuclease small subunit 
 SPD_1066 687 exodeoxyribonuclease VII small subunit 
688 spr1089 688 Exodeoxyribonuclease large subunit 
 SP70585_1257 688 exodeoxyribonuclease VII large subunit 
689 SPP_1249 689 uridine kinase 
690 SP_1210 690 hypothetical protein 
 SPJ_1127 690 conserved hypothetical protein 
691 SP_1213 691 conserved domain protein 
 SPD_1072 691 conserved hypothetical protein 
692 SP_1215 692 putative transporter FNT family 
 SPD_1075 692 transporter FNT family protein putative 
 SP70585_1264 692 formate-nitrate transporter 
693 SP_1219 693 DNA gyrase A subunit 
 spr1099 693 DNA gyrase subunit A 
694 SPD_1078 694 L-lactate dehydrogenase 
695 SP_1224 695 conserved domain protein 
 spr1104 695 Hypothetical protein 
 SPD_1082 695 conserved hypothetical protein 
696 SPG_1116 696 VicX protein 
697 spr1106 697 Histidine kinase 
 SPD_1084 697 sensory box sensor histidine kinase 
 SPP_1263 697 sensor protein YycG 
698 spr1107 698 Response regulator 
 SPD_1085 698 DNA-binding response regulator 
 SP70585_1273 698 alkaline phosphatase synthesis transcriptional regulatory proteinphoP 
699 SP_1229 699 formate--tetrahydrofolate ligase 
700 SP_1230 700 conserved hypothetical protein 
 spr1110 700 Similar to C-terminal region of the Dfp protein 
 SPD_1088 700 phosphopantothenate--cysteine ligase 
701 SP_1231 701 flavoprotein 
 spr1111 701 Similar to N-terminal region of the Dfp protein 
 SP70585_1277 701 phosphopantothenoylcysteine decarboxylase 
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702 SP_1232 702 membrane protein 
 spr1112 702 Conserved hypothetical protein 
 SPD_1090 702 membrane protein putative 
 SPJ_1146 702 integral membrane protein 
703 SP_1233 703 hypothetical protein 
 SPD_1091 703 membrane protein putative 
 SP70585_1279 703 conserved hypothetical protein 
704 SP_1234 704 transcriptional regulator biotin repressor family 
 spr1114 704 Conserved hypothetical protein 
 SPD_1093 704 transcriptional regulator biotin repressor family protein 
705 SP_1237 705 acetyltransferase GNAT family 
 spr1117 705 Conserved hypothetical protein 
706 SP_1238 706 excinuclease ABC subunit B 
 spr1118 706 Exonuclease ABC-subunit B 
 SPP_1276 706 excinuclease ABC B subunit 
707 SP_1240 707 conserved hypothetical protein 
 SPD_1097 707 CAAX amino terminal protease family protein 
 SPJ_1153 707 caax amino protease family 
708 SP_1241 708 amino acid ABC transporter amino acid-binding protein/permease protein 
 spr1120 708 ABC transporter membrane spanning permease-glutamine transport 
709 SP_1243 709 glucose-6-phosphate 1-dehydrogenase 
 SPJ_1156 709 glucose-6-phosphate dehydrogenase 
710 spr1124 710 Conserved hypothetical protein 
 SPT_0984 710 Cof family protein 
711 spr1125 711 Conserved hypothetical protein 
 SPT_0983 711 Cof family protein 
712 SP_1247 712 conserved hypothetical protein 
 spr1126 712 chromosome condensation and segregation SMC protein 
 SPJ_1160 712 chromosome segregation protein SMC 
713 SPJ_1161 713 ribonuclease III 
714 spr1128 714 GMP reductase 
 SPJ_1163 714 guanosine monophosphate reductase 
715 SP_1258 715 putative 2-isopropylmalate synthase 
 spr1136 715 2-isopropylmalate synthase truncation 
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 SP70585_1321 715 2-isopropylmalate synthase (Alpha-isopropylmalatesynthase) (Alpha-IPM synthetase) 
716 spr1138 716 Hypothetical protein 
 SPJ_1174 716 conserved hypothetical protein 
717 SP_1260 717 copper homeostasis protein CutC 
 spr1139 717 Copper sensitivity 
718 SP70585_1325 718 conserved hypothetical protein 
719 SP_1263 719 DNA topoisomerase I 
720 SP_1266 720 putative DNA processing protein DprA 
 spr1144 720 DNA processing Smf protein 
 SPD_1122 720 DNA processing protein DprA putative 
 SPJ_1180 720 DNA protecting protein DprA 
721 SP_1268 721 licB protein 
 SPD_1124 721 protein LicB 
 SP70585_1331 721 homologous to LicB which regulates expression of LPS epitopes in H. influenzae 
722 SPP_1307 722 choline kinase 
723 spr1148 723 Conserved hypothetical protein 
 SPD_1126 723 alcohol dehydrogenase zinc-containing 
 SPJ_1184 723 xylitol dehydrogenase 
724 SP_1271 724 putative 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase 
 spr1149 724 Conserved hypothetical protein 
 SPD_1127 724 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase 
725 SP_1272 725 putative polysaccharide biosynthesis protein 
 spr1150 725 Conserved hypothetical protein 
 SPD_1128 725 polysaccharide biosynthesis protein putative 
 SP70585_1335 725 virulence factor mvin superfamily 
726 spr1153 726 Carbamoylphosphate synthase (ammonia) heavy subunit 
 SPD_1131 726 carbamoyl-phosphate synthase large subunit 
727 spr1154 727 Carbamoylphosphate synthase (glutamine-hydrolysing) light subunit 
 SPD_1132 727 carbamoyl-phosphate synthase small subunit 
728 spr1155 728 Aspartate carbamoyltransferase 
729 SP_1278 729 pyrimidine operon regulatory protein 
 spr1156 729 Transcriptional attenuation of the pyrimidine operon / uracil phosphoribosyltransferase 
activity 
 SPD_1134 729 pyrimidine operon regulatory protein/uracil phosphoribosyltransferase 
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730 spr1157 730 endonuclease III (DNA repair) 
 SP70585_1342 730 endonuclease III 
731 SPD_1136 731 Uncharacterised ACR 
 SPJ_1194 731 conserved hypothetical protein 
732 spr1161 732 ABC transporter ATP-binding protein-unknown substrate 
 SPD_1137 732 ABC transporter ATP-binding protein 
733 spr1162 733 Heat shock protein 
 SPD_1138 733 heat shock protein HtpX 
 SPP_1322 733 putative protease HtpX homolog 
734 SP_1284 734 lemA protein 
 SPJ_1199 734 cytoplasmic membrane protein 
735 SP_1285 735 glucose-inhibited division protein B 
 spr1164 735 Glucose inhibited division protein B 
 SPP_1324 735 methyltransferase GidB 
736 SP_1286 736 uracil permease 
 SPD_1141 736 uracil-xanthine permease 
 SP70585_1351 736 uracil permease (Uracil transporter) 
737 SP_1287 737 signal recognition particle protein 
 spr1166 737 Signal recognition particle (Fifty four homolog) 
738 SP_1288 738 conserved hypothetical protein 
 SP70585_1353 738 HTH DNA binding domain protein 
739 spr1169 739 Conserved hypothetical protein 
 SP70585_1355 739 dGTP triphosphohydrolase 
 SPP_1329 739 HD superfamily phosphohydrolase 
740 SP_1291 740 Cof family protein 
 spr1170 740 Conserved hypothetical protein 
 SPP_1330 740 phosphatase YidA 
741 spr1171 741 50S Ribosomal protein L19 
 SP70585_1358 741 ribosomal protein L19 
742 SP_1294 742 crcB protein 
 SPJ_1210 742 putative Protein CrcB homolog 1 
743 SPP_1337 743 flavodoxin 
744 spr1176 744 Conserved hypothetical protein 
 SP70585_1363 744 DHH subfamily 1 protein 
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745 spr1177 745 50S ribosomal protein L31 
 SPD_1154 745 ribosomal protein L31 
746 SPD_1158 746 NADP-specific glutamate dehydrogenase 
 SP70585_1369 746 NAD (p)-specific glutamate dehydrogenase 
747 spr1211 747 50S Ribosomal protein L12 
 SPD_1187 747 ribosomal protein L7/L12 
748 spr1212 748 50S Ribosomal protein L10 
 SPD_1188 748 ribosomal protein L10 
749 SP_1356 749 amidohydrolase family protein 
 spr1214 749 N-ethylammeline chlorohydrolase 
 SPD_1190 749 Atz/Trz family protein 
 SPJ_1256 749 chlorohydrolase 
750 SP_1357 750 ABC transporter ATP-binding/permease protein 
 spr1215 750 ABC transporter ATP-binding/membrane-spanning protein-unknown substrate 
751 SP_1358 751 ABC transporter ATP-binding/permease protein 
 spr1216 751 ABC transporter ATP-binding/membrane-spanning protein-unknown substrate 
752 spr1217 752 Peptide methionine sulfoxide reductase 
 SPD_1193 752 peptide methionine sulfoxide reductase msrA/msrB 1 
 SP70585_1398 752 peptide methionine sulfoxide reductase MsrA/msrB 
753 spr1219 753 Homoserine dehydrogenase 
 SPP_1381 753 homoserine dehydrogenase (HDH) 
754 SP_1362 754 putative transcriptional regulator MecA 
 spr1220 754 Negative regulator of genetic competence 
 SPJ_1262 754 adapter protein MecA 
755 SP_1363 755 conserved domain protein 
 spr1221 755 Hypothetical protein 
 SP70585_1402 755 conserved hypothetical protein 
756 SP_1364 756 hypothetical protein 
 SPD_1198 756 membrane protein putative 
757 spr1224 757 Conserved hypothetical protein 
 SPD_1200 757 glycosyl transferase group 1 family protein 
 SPJ_1266 757 glycosyl transferase group 1 
758 SPD_1201 758 phosphotransferase LicD3 
 SP70585_1406 758 licD3 protein 
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 SPT_0906 758 LicD1 paralog 
759 spr1227 759 Prephenate dehydratase 
 SP70585_1408 759 prephenate dehydratase (PDT) 
760 SPP_1390 760 shikimate kinase 
761 spr1229 761 3-Enolpyruvylshikimate-5-phosphate synthetase 
 SP70585_1410 761 3-phosphoshikimate 1-carboxyvinyltransferase 
762 SPJ_1272 762 conserved hypothetical protein 
763 SPP_1393 763 prephenate dehydrogenase 
764 SPP_1394 764 chorismate synthase 
765 SPD_1209 765 3-dehydroquinate synthase 
766 spr1234 766 Shikimate dehydrogenase 
 SPD_1210 766 shikimate 5-dehydrogenase 
767 SP_1377 767 3-dehydroquinate dehydratase 
 SP70585_1416 767 3-dehydroquinate dehydratase type I 
768 SP_1378 768 conserved hypothetical protein 
 SPT_0895 768 methyltransferase 
769 spr1237 769 Hypothetical protein 
 SPD_1213 769 membrane protein putative 
770 SP_1381 770 ABC transporter ATP-binding protein 
 spr1238 770 ABC transporter ATP-binding protein-unknown substrate 
771 spr1239 771 Alpha-amylase precursor 
 SPD_1215 771 alpha-amylase 
 SPJ_1281 771 alpha-amylase (14-alpha-D-glucanglucanohydrolase) 
772 SP70585_1421 772 alanyl-tRNA synthetase 
773 spr1241 773 Conserved hypothetical protein 
774 SP_1386 774 spermidine/putrescine ABC transporter spermidine/putrescine-binding protein 
 spr1243 774 ABC transporter substrate-binding protein-spermidine/putrescine transport 
775 SP_1387 775 spermidine/putrescine ABC transporter permease protein 
 spr1244 775 ABC transporter membrane-spanning permease-spermidine/putrescine transport 
776 spr1245 776 ABC transporter membrane-spanning permease-spermidine/putrescine transport 
 SPD_1220 776 spermidine/putrescine ABC transporter permease protein 
777 SP_1389 777 spermidine/putrescine ABC transporter ATP-binding protein 
 spr1246 777 ABC transporter ATP-binding protein-spermidine/putrescine transport 
778 SPD_1222 778 UDP-N-acetylenolpyruvoylglucosamine reductase 
                                                                                                                                   Appendices 
 299 
Gene 
no. 
Gene ID Gene 
cluster no. 
Gene name 
779 spr1248 779 Conserved hypothetical protein 
 SPP_1410 779 membrane protein putative 
780 spr1249 780 Alpha-acetolactate decarboxylase 
781 spr1250 781 Conserved hypothetical protein 
 SP70585_1432 781 transcriptional regulator GntR family 
782 SP_1394 782 amino acid ABC transporter amino acid-binding protein 
 spr1251 782 ABC transporter substrate-binding protein-glutamine-binding protein 
783 SP_1395 783 putative phosphate transport system regulatory protein PhoU 
 spr1252 783 Phosphate transport system regulatory protein 
 SPD_1227 783 phosphate transport system regulatory protein PhoU putative 
784 SP_1396 784 putative phosphate ABC transporter ATP-binding protein 
 spr1253 784 ABC transporter ATP-binding protein-phosphate transport 
 SPD_1228 784 phosphate ABC transporter ATP-binding protein putative 
785 SP_1397 785 putative phosphate ABC transporter ATP-binding protein 
 spr1254 785 ABC transporter ATP-binding protein-phosphate transport 
 SPD_1229 785 phosphate ABC transporter ATP-binding protein putative 
786 SP_1398 786 putative phosphate ABC transporter permease protein 
 spr1255 786 ABC transporter membrane-spanning permease-phosphate transport 
 SPD_1230 786 phosphate ABC transporter permease protein putative 
787 SP_1399 787 putative phosphate ABC transporter permease protein 
 spr1256 787 ABC transporter membrane-spanning permease-phosphate transport 
 SPD_1231 787 phosphate ABC transporter permease protein putative 
788 SP_1400 788 putative phosphate ABC transporter phosphate-binding protein 
 spr1257 788 ABC transporter substrate-binding protein-phosphate transport 
 SPD_1232 788 phosphate ABC transporter phosphate-binding protein putative 
789 spr1259 789 Conserved hypothetical protein 
 SPD_1233 789 NOL1/NOP2/sun family protein 
790 SPD_1235 790 conserved hypothetical protein 
791 SP_1405 791 conserved hypothetical protein 
 SPD_1236 791 regulatory protein Spx 
792 SP_1407 792 hydrolase haloacid dehalogenase-like family 
 spr1264 792 N-acetyl-glucosamine matabolism 
 SPD_1238 792 hydrolase haloacid dehalogenase-like family protein 
 SP70585_1446 792 HAD-superfamily subfamily IIA hydrolase 
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793 SP_1408 793 putative acyl-ACP thioesterase 
 spr1265 793 Hypothetical protein 
 SPD_1239 793 acyl-ACP thioesterase putative 
 SPJ_1307 793 acyl-acyl-carrier protein thioesterase 
794 SP_1409 794 putative oxygen-independent coproporphyrinogen III oxidase 
 spr1266 794 Coproporphyrinogen III oxidase 
 SPD_1240 794 oxygen-independent coproporphyrinogen III oxidase putative 
795 SP70585_1449 795 conserved hypothetical protein 
796 SPD_1242 796 conserved hypothetical protein 
797 spr1269 797 Prolipoprotein diacylglycerol transferase 
 SPD_1243 797 prolipoprotein diacylglyceryl transferase 
798 spr1270 798 Hpr (Ser) kinase/phosphatase 
 SPT_0861 798 HPr 
799 spr1271 799 30S Ribosomal protein S21 
 SPJ_1313 799 ribosomal protein S21 
800 SP_1415 800 glucosamine-6-phosphate isomerase 
 spr1272 800 N-acetylglucosamine-6-phosphate isomerase 
 SP70585_1454 800 glucosamine-6-phosphate deaminase (glucosamine-6-phosphate isomerase) (gnda) 
801 spr1273 801 S-adenosylmethionine:tRNAribosyltransferase-isomerase 
802 spr1275 802 Conserved hypothetical protein 
 SPD_1249 802 hypothetical acetyltransferase 
 SP70585_1457 802 acetyltransferase gnat family 
803 SP_1421 803 conserved hypothetical protein 
 SPD_1251 803 nicotinate phosphoribosyltransferase putative 
 SP70585_1459 803 putative nicotinate phosphoribosyltransferase 
804 spr1282 804 Hypothetical protein 
 spr1284 804 Protease 
 SPD_1256 804 peptidase U32 family protein 
 SP70585_1467 804 peptidase U32 family 
805 SP_1445 805 GMP synthase 
 spr1300 805 Glutamine amidotransferase 
 SPD_1274 805 GMP synthase C-terminal domain 
 SP70585_1485 805 GMP synthase [glutamine-hydrolyzing] (Glutamineamidotransferase) (GMP synthetase) 
806 SP_1446 806 transcriptional regulator GntR family 
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 spr1301 806 Conserved hypothetical protein 
 SPD_1275 806 transcriptional regulator GntR family protein 
807 spr1303 807 Hypothetical protein 
 SPD_1277 807 conserved hypothetical protein 
 SPT_0826 807 beta-lactamase 
808 spr1304 808 C3-degrading proteinase 
 SP70585_1489 808 CppA protein 
809 SP_1450 809 putative platelet activating factor 
 spr1305 809 Hypothetical protein 
 SPD_1279 809 GDSL-like lipase/acylhydrolase putative 
 SP70585_1490 809 conserved hypothetical protein 
 SPJ_1349 809 conserved hypothetical protein putative 
810 spr1306 810 Conserved hypothetical protein 
 SPD_1280 810 Cof family protein 
 SP70585_1491 810 hydrolase 
 SPP_1472 810 conserved hypothetical protein putative 
811 spr1310 811 Peptide deformylase N-formylmethionylaminoacyl-tRNA deformylase 
 SPJ_1355 811 peptide deformylase 
812 SP_1457 812 RNA methyltransferase TrmH family group 3 
 spr1311 812 tRNA (guanosine-2'-O-)-methyltransferase TrmH family 
 SPD_1286 812 TrmH family RNA methyltransferase group 3 
813 SP_1458 813 thioredoxin reductase 
 SP70585_1499 813 thioredoxin-disulfide reductase 
814 spr1313 814 Hypothetical protein 
 SP70585_1500 814 conserved hypothetical protein 
815 SP_1460 815 amino acid ABC transporter ATP-binding protein 
 spr1314 815 ABC transporter ATP-binding protein-aspartate/glutamate transport 
816 spr1315 816 ABC transporter membrane-spanning permease-aspartate/glutamate transport 
 SPD_1290 816 amino acid ABC transporter permease protein 
817 SP_1462 817 conserved hypothetical protein 
 SPD_1291 817 ArsC family protein 
 SPJ_1361 817 arsenate reductase 
818 SP_1463 818 methylated-DNA--protein-cysteineS-methyltransferase 
 SP70585_1504 818 O6-methylguanine-DNA methyltransferase 
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819 spr1318 819 Hypothetical protein 
 SPD_1293 819 acetyltransferase GNAT family protein 
 SP70585_1505 819 acetyltransferase gnat family 
820 spr1319 820 Hypothetical protein 
 SPJ_1364 820 conserved hypothetical protein 
821 spr1320 821 Conserved hypothetical protein 
 SPD_1295 821 hemolysin 
 SP70585_1507 821 hemolysin-3 (Hemolysin III) (Hly-III) 
822 SP_1467 822 conserved hypothetical protein 
 SPD_1296 822 glutamine amidotransferase SNO family protein putative 
 SP70585_1508 822 SNO glutamine amidotransferase family superfamily 
823 spr1322 823 Pyridoxine biosynthesis protein 
824 SPD_1298 824 NADH oxidase 
 SPH1585 824 NADH oxidase (noxase) 
825 SP_1470 825 putative thiamine biosynthesis protein ApbE 
 spr1324 825 Thiamine biosynthesis lipoprotein 
 SPD_1300 825 thiamine biosynthesis protein ApbE putative 
826 SP_1471 826 putative oxidoreductase 
 spr1325 826 Conserved hypothetical protein 
 SPD_1301 826 NADPH-dependent FMN reductase 
 SPJ_1371 826 NADPH-dependent fmn reductase domain protein 
827 SP_1472 827 putative oxidoreductase 
 spr1326 827 Hypothetical protein 
 SPD_1302 827 oxidoreductase putative 
 SP70585_1514 827 NADPH-dependent fmn reductase domain protein 
828 spr1328 828 Glycyl-tRNA synthetase beta chain 
 SPJ_1374 828 glycyl-tRNA synthetase beta subunit 
829 spr1329 829 Glycyl-tRNA synthetase alpha chain 
 SPD_1305 829 glycyl-tRNA synthetase alpha subunit 
830 SP_1479 830 peptidoglycan N-acetylglucosamine deacetylase A 
 spr1333 830 Peptidoglycan GlcNAc deacetylase 
831 SP_1482 831 oxidoreductase Gfo/Idh/MocA family 
 SPD_1311 831 oxidoreductase Gfo/Idh/MocA family protein 
 SPP_1502 831 oxidoreductase 
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832 SP_1483 832 ATP-dependent RNA helicase DEAD/DEAH box family 
 SPD_1312 832 ATP-dependent RNA helicase DEAD/DEAH box family protein 
 SPJ_1381 832 DEAD/DEAH box helicase 
 SPP_1503 832 DEAD RNA helicase 
833 SPJ_1388 833 translation elongation factor Tu 
834 SP_1491 834 putative glycerol uptake facilitator protein 
 spr1344 834 Glycerol uptake facilitator protein paralog 
 SPD_1320 834 glycerol uptake facilitator protein putative 
835 SP_1492 835 cell wall surface anchor family protein 
 spr1345 835 Hypothetical protein 
 SP70585_1531 835 MucBP domain family 
836 SPD_1322 836 conserved hypothetical protein 
 SPJ_1394 836 hypothetical protein 
837 SP_1496 837 transposase IS630-Spn1 related Orf2 
 spr1349 837 Degenerate transposase 
 SPD_1324 837 IS630-Spn1 transposase Orf2 
 SP70585_1534 837 transposase 
 SPG_1419 837 IS630-Spn1 transposase 
838 spr1351 838 Phosphoglucomutase 
 SPD_1326 838 phosphoglucomutase/phosphomannomutase family protein 
 SP70585_1536 838 phosphomannomutase 
839 SPD_1327 839 bacterocin transport accessory protein 
840 spr1354 840 ABC transporter ATP-binding protein-glutamine transport 
 SPD_1329 840 amino acid ABC transporter ATP-binding protein 
 SP70585_1539 840 glutamine transport ATP-binding protein GlnQ 
841 spr1355 841 ABC transporter membrane-spanning permease-glutamine transport 
 SP70585_1540 841 amino acid ABC transporter permease protein 
842 SP_1504 842 TPR domain protein 
 spr1356 842 Conserved hypothetical protein 
843 SP_1505 843 membrane protein 
 spr1357 843 Conserved hypothetical protein 
 SPD_1332 843 membrane protein putative 
 SPP_1524 843 transport protein 
844 SP_1506 844 conserved hypothetical protein 
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 SPJ_1406 844 3-carboxymuconate cyclase 
845 spr1359 845 Proton-translocating ATPase F1 sector epsilon-subunit 
 SPJ_1409 845 ATP synthase F1 epsilon subunit 
846 spr1360 846 Proton-translocating ATPase F1 sector beta-subunit 
 SPD_1335 846 ATP synthase F1 beta subunit 
847 spr1361 847 Proton-translocating ATPase F1 sector gamma-subunit 
 SPJ_1411 847 ATP synthase F1 gamma subunit 
848 spr1362 848 Proton-translocating ATPase F1 sector alpha-subunit 
 SPD_1337 848 ATP synthase F1 alpha subunit 
849 spr1363 849 Proton-translocating ATPase F1 sector delta-subunit 
 SPD_1338 849 ATP synthase F1 delta subunit 
850 SP_1512 850 ATP synthase F0 B subunit 
 spr1364 850 Proton-translocating ATPase F0 sector subunit b 
851 spr1365 851 Proton-translocating ATPase F0 sector subunit a 
 SPD_1340 851 ATP synthase F0 A subunit 
852 SP_1518 852 conserved hypothetical protein 
 spr1370 852 Hypothetical protein 
 SPD_1346 852 Uncharacterised BCR putative 
 SPT_1456 852 aminodeoxychorismate lyase 
853 spr1371 853 Conserved hypothetical protein 
 SPD_1347 853 acetyltransferase GNAT family protein 
 SPJ_1422 853 acetyltransferase gnat family 
854 spr1372 854 Hypothetical protein 
 SPD_1348 854 acetyltransferase GNAT family protein 
 SP70585_1559 854 acetyltransferase gnat family 
855 spr1373 855 UDP-N-acetylmuramate-alanine ligase 
 SPJ_1424 855 UDP-N-acetylmuramate--alanine ligase 
856 SP_1522 856 conserved domain protein 
 spr1374 856 Hypothetical protein 
 SPD_1350 856 conserved hypothetical protein 
857 spr1375 857 SWF/SNF family ATP-dependent RNA helicase 
 SPD_1351 857 Snf2 family protein 
858 SP_1524 858 aminotransferase class II 
 spr1376 858 Aminotransferase 
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 SPJ_1428 858 putative aminotransferase B 
859 SP_1525 859 transulfuration enzyme family protein 
 spr1377 859 Cystathionine gamma-synthase 
 SPD_1353 859 Cys/Met metabolism PLP-dependent enzyme putative 
 SP70585_1564 859 cystathionine gamma-synthase (CGS) (O-succinylhomoserine)(thiol)-lyase) 
860 SP_1529 860 putative polysaccharide biosynthesis protein 
 SPD_1358 860 polysaccharide biosynthesis protein putative 
 SP70585_1568 860 polysaccharide transporter 
861 spr1384 861 UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysineLigase 
 SPD_1359 861 UDP-N-acetylmuramoylalanyl-D-glutamate--2 6-diaminopimelate ligase 
862 SP_1533 862 conserved domain protein 
 spr1388 862 Hypothetical protein 
 SPD_1362 862 conserved hypothetical protein 
863 SP_1534 863 inorganic pyrophosphatase manganese-dependent 
 spr1389 863 Manganese-dependent inorganic pyrophosphatase 
 SPD_1363 863 manganese-dependent inorganic pyrophosphatase putative 
864 SP70585_1574 864 conserved hypothetical protein 
865 spr1391 865 Conserved hypothetical protein 
 SPP_1559 865 methyltransferase 
866 SP_1537 866 putative general stress protein 13 
 spr1392 866 Conserved hypothetical protein 
 SPD_1366 866 general stress protein 13 putative 
 SP70585_1576 866 S1-type RNA-binding domain protein 
867 SP_1538 867 Cof family protein/peptidyl-prolyl cis-trans isomerase cyclophilin type 
 spr1393 867 Hypothetical protein 
868 spr1394 868 30S Ribosomal protein S18 
 SPD_1368 868 ribosomal protein S18 
869 SP_1540 869 single-strand binding protein 
 spr1395 869 Single stranded binding protein 
 SP70585_1579 869 single-stranded DNA-binding protein (SSB)(Helix-destabilizingprotein) 
870 spr1396 870 30S Ribosomal protein S6 
 SPP_1564 870 ribosomal protein S6 
871 spr1397 871 Asparaginyl-tRNA synthetase (asparagine--tRNA ligase) 
 SPJ_1446 871 asparaginyl-tRNA synthetase 
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872 SPD_1373 872 aspartate aminotransferase 
 SP70585_1583 872 aspartate aminotransferase (transaminase a) (aspat) 
873 SPD_1374 873 conserved hypothetical protein 
 SP70585_1584 873 peptidase propeptide and ypeb domain protein 
874 SP_1546 874 conserved domain protein 
 spr1402 874 Hypothetical protein 
 SPD_1375 874 NADPH-dependent FMN reductase putative 
 SP70585_1586 874 oxidoreductase 
875 SP_1547 875 conserved hypothetical protein 
876 spr1408 876 Formylmethionine deformylase 
 SPD_1381 876 polypeptide deformylase 
877 spr1409 877 Conserved hypothetical protein 
 SPD_1382 877 glutathione S-transferase family protein 
878 SP_1551 878 cation-transporting ATPase E1-E2 family 
 spr1410 878 P-type ATPase-calcium transporter 
 SPD_1383 878 cation-transporting ATPase E1-E2 family protein 
879 spr1411 879 Conserved hypothetical protein 
 SPD_1384 879 cation efflux family protein 
880 spr1412 880 ABC transporter ATP-binding protein-unknown substrate 
 SPD_1385 880 ABC transporter ATP-binding protein 
881 SP_1554 881 polyA polymerase family protein 
 spr1413 881 tRNA nucleotidyltransferase 
 SP70585_1597 881 tRNA nucleotidyltransferase/poly A polymerase family protein 
882 SPD_1387 882 dihydrodipicolinate reductase 
883 SP_1558 883 hypothetical protein 
 SPJ_1465 883 conserved hypothetical protein 
884 spr1418 884 Conserved hypothetical protein 
 SPD_1391 884 YbbR-like lipoprotein putative 
 SPP_1584 884 lipoprotein putative 
885 spr1419 885 Conserved hypothetical protein 
 SPD_1392 885 conserved hypothetical protein TIGR00159 
886 SP_1563 886 pyridine nucleotide-disulphide oxidoreductase family protein 
 spr1421 886 Thioredoxin reductase 
887 SPD_1394 887 Uncharacterised BCR 
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 SPJ_1470 887 conserved hypothetical protein 
888 spr1423 888 Conserved hypothetical protein 
 SPP_1588 888 transporter 
889 SPD_1396 889 conserved hypothetical protein 
 SP70585_1607 889 P-loop ATPase protein family 
890 spr1426 890 Conserved hypothetical protein 
 SPJ_1474 890 GTP-binding protein 
891 SP_1569 891 ATP-dependent Clp protease ATP-binding subunit ClpX 
 spr1427 891 ATP-dependent Clp protease ATP-binding subunit (class III heat-shock protein) 
892 SP_1570 892 hypothetical protein 
 SPD_1400 892 conserved hypothetical protein 
893 SPD_1403 893 14-beta-N-acetylmuramidase putative 
 SPJ_1479 893 14-beta-N-acetylmuramidase 
 SPT_1513 893 lysozyme 
894 spr1432 894 Triose phosphate isomerase 
 SPD_1404 894 triosephosphate isomerase 
 SP70585_1615 894 triose-phosphate isomerase 
895 spr1433 895 Conserved hypothetical protein 
 SP70585_1616 895 DNA replication protein DnaD 
896 spr1434 896 Homoserine O-succinyltransferase 
897 SP_1578 897 putative methyltransferase 
 SPD_1408 897 conserved hypothetical protein 
 SPJ_1485 897 SAM-dependent methyltransferase 
898 spr1437 898 ABC transporter ATP-binding protein-multiple sugar transport 
 SPD_1409 898 sugar ABC transporter ATP-binding protein 
899 SP_1583 899 isochorismatase family protein 
 SPT_1522 899 isochorismatase 
900 spr1439 900 Transcriptional pleiotropic repressor 
 SP70585_1624 900 GTP-sensing transcriptional pleiotropic repressor CodY 
901 SP_1586 901 putative ATP-dependent RNA helicase 
 spr1440 901 Conserved hypothetical protein 
 SPD_1413 901 ATP-dependent RNA helicase putative 
 SP70585_1625 901 cold-shock DEAD box protein A 
 SPJ_1491 901 ATP-dependent RNA helicase DEAD/DEAH box family 
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902 SPD_1414 902 oxalate:formate antiporter 
 SPJ_1492 902 major facilitator:Oxalate:Formate Antiporter 
903 SPD_1415 903 oxidoreductase pyridine nucleotide-disulfide class I 
904 spr1443 904 Conserved hypothetical protein 
 SPJ_1494 904 Mur ligase family protein 
905 SP_1590 905 conserved hypothetical protein 
 SPT_1528 905 cobyric acid synthase 
906 SP_1591 906 proline dipeptidase 
 spr1445 906 Dipeptidase 
 SPD_1418 906 proline dipeptidase PepQ 
 SP70585_1633 906 Xaa-Pro dipeptidase (X-Pro dipeptidase) (Prolinedipeptidase) (Prolidase) (Imidodipeptidase) 
907 SP_1598 907 putative phosphomethylpyrimidine kinase 
 spr1450 907 Pyridoxine kinase 
 SPD_1423 907 phosphomethylpyrimidine kinase putative 
 SPJ_1502 907 phosphomethylpyrimidine kinase 
908 spr1451 908 tRNA pseudouridine synthase A 
909 SP_1600 909 putative membrane protein 
 spr1453 909 Major facilitator superfamily transporter-efflux 
 SPD_1425 909 transporter major facilitator family protein 
 SP70585_1639 909 major facilitator superfamily transporter 
910 SP_1602 910 phnA protein 
 spr1455 910 Required for expression of the phosphonate utilisation phenotype in E. coli 
 SP70585_1642 910 alkylphosphonate utilisation operon protein PhnA 
911 SP70585_1643 911 cytidylate kinase 
912 spr1457 912 Hypothetical protein 
 SPD_1429 912 conserved hypothetical protein 
913 SP_1605 913 ferredoxin 
914 SPJ_1513 914 UDP-glucose 4-epimerase 
915 SP_1609 915 conserved hypothetical protein 
 SPD_1434 915 conserved hypothetical protein TIGR00486 
916 SP_1610 916 SAM-dependent methyltransferase 
 spr1463 916 Conserved hypothetical protein 
 SPJ_1517 916 Bcl-2 family protein 
917 SP_1615 917 transketolase 
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918 spr1465 918 Conserved hypothetical protein 
 SPD_1437 918 acyltransferase domain protein 
 SP70585_1665 918 acyltransferase family protein 
919 spr1467 919 30S Ribosomal protein S15 
 SPT_1565 919 ribosomal protein S15 
920 SPD_1440 920 conserved hypothetical protein 
 SP70585_1668 920 YwnB 
921 spr1470 921 Hypothetical protein 
 SP70585_1670 921 conserved hypothetical protein 
922 spr1472 922 Threonyl-tRNA synthetase 1 
 SP70585_1672 922 threonyl-tRNA synthetase 
923 SPD_1445 923 sensor histidine kinase 
 SP70585_1673 923 histidine kinase 
924 SP_1633 924 DNA-binding response regulator 
 SPT_1572 924 response regulator 
925 spr1475 925 Hypothetical protein 
 SPJ_1527 925 conserved hypothetical protein 
926 spr1477 926 Conserved hypothetical protein 
 SPP_1655 926 Rrf2 family protein 
927 SP_1637 927 conserved hypothetical protein 
 SPJ_1530 927 metallophosphoesterase 
928 SP_1638 928 iron-dependent transcriptional regulator 
 spr1480 928 Metalloregulator 
929 SP_1645 929 GTP pyrophosphokinase 
 SP70585_1686 929 guanosine-35-bis (diphosphate)3-pyrophosphohydrolase 
930 spr1490 930 Conserved hypothetical protein 
 SP70585_1687 930 metallo-beta-lactamase superfamily protein 
931 SPH1756 931 endopeptidase O 
932 spr1492 932 ABC transporter ATP-binding protein-manganese transport 
 SPD_1461 932 manganese ABC transporter ATP-binding protein 
 SP70585_1689 932 manganese transport system ATP-binding protein MntA 
933 SP_1649 933 putative manganese ABC transporter permease protein 
 spr1493 933 ABC transporter membrane-spanning permease-manganese transport 
 SPD_1462 933 manganese ABC transporter permease protein putative 
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934 SP_1650 934 manganese ABC transporter manganese-binding adhesion liprotein 
 spr1494 934 ABC transporter substrate-binding protein-manganese transport 
 SPD_1463 934 ABC transporter substrate binding lipoprotein 
935 spr1495 935 Thioredoxin-linked thiol peroxidase 
 SPP_1670 935 thiol peroxidase (Scavengase P20) 
 SPT_1591 935 thiol peroxidase 
936 SP_1652 936 putative membrane protein 
 spr1496 936 Hypothetical protein 
 SPD_1465 936 efflux ABC transporter permease protein 
937 SP_1653 937 ABC transporter ATP-binding protein 
 spr1497 937 ABC transporter ATP-binding protein-unknown substrate 
 SP70585_1694 937 macrolide export ATP-binding/permease protein MacB 
938 SPD_1467 938 conserved hypothetical protein 
 SP70585_1695 938 alpha-fucosidase 
939 spr1499 939 Phosphoglyceromutase 
 SPD_1468 939 phosphoglycerate mutase 
 SP70585_1696 939 23-bisphosphoglycerate-dependent phosphoglycerate mutase (phosphoglyceromutase) (pgam) 
(bpg-dependent pgam) (dpgm) 
940 SPJ_1554 940 isoleucyl-tRNA synthetase 
941 spr1507 941 Conserved hypothetical protein 
 SPD_1476 941 YlmG protein 
 SP70585_1703 941 yggt family putative 
942 spr1508 942 Conserved hypothetical protein 
 SPP_1682 942 YlmF protein 
943 spr1509 943 Conserved hypothetical protein 
 SPD_1478 943 YlmE protein 
 SPP_1683 943 pyridoxal phosphate enzyme YggS family 
944 SPP_1684 944 cell division protein FtsZ 
945 SPP_1685 945 cell division protein FtsA 
946 SP_1670 946 UDP-N-acetylmuramoylalanyl-D-glutamyl-2 6-diaminopimelate--D-alanyl-D-alanyl ligase 
 spr1514 946 UDP-N-acetylmuramoylalanine-D-glutamyl-lysine-D-alanyl-D-alanineligase 
947 SP_1671 947 D-alanine--D-alanine ligase 
 SPD_1484 947 D-alanine-D-alanine ligase 
 SP70585_1711 947 D-alanine--D-alanine ligase (D-alanylalanine synthetase) (D-Ala-D-Ala ligase) 
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948 SPJ_1567 948 recombination protein RecR 
949 SPJ_1568 949 penicillin-binding protein 2B 
950 SP_1674 950 putative phosphosugar-binding transcriptional regulator 
 spr1518 950 Conserved hypothetical protein 
 SPD_1487 950 phosphosugar-binding transcriptional regulator putative 
 SP70585_1714 950 transcriptional regulator RpiR family 
951 SPT_1614 951 glucokinase 
 SPCG_1647 951 ROK family protein 
952 SP_1676 952 putative N-acetylneuraminate lyase 
 spr1186 952 N-acetylneuraminate lyase subunit truncation 
 SPD_1163 952 N-acetylneuraminate lyase putative 
953 SP70585_1719 953 conserved hypothetical protein 
954 spr1526 954 ABC transporter membrane-spanning permease-sugar transport 
 SPD_1494 954 sugar ABC transporter permease protein 
955 SP_1683 955 sugar ABC transporter sugar-binding protein 
 spr1527 955 ABC transporter substrate-binding protein-sugar transport 
956 SP_1684 956 PTS system IIBC components 
 spr1528 956 Phosphotransferase system sugar-specific EII component 
 SP70585_1723 956 pts system maltose-and glucose-specific eiicb component 
957 SP_1685 957 conserved hypothetical protein 
 spr1529 957 N-acetylmannosamine-6-P epimerase 
 SPD_1172 957 N-acetylmannosamine-6-phosphate 2-epimerase 2 putative 
958 SP_1686 958 oxidoreductase Gfo/Idh/MocA family 
 spr1530 958 Conserved hypothetical protein 
 SPD_1498 958 putative oxidoreductase 
 SPJ_1580 958 putative oxidoreductase YjhC 
959 SP_1689 959 ABC transporter permease protein 
 SP70585_1728 959 ABC transporter membrane-spanning permease-sugar transport 
960 SP_1690 960 ABC transporter substrate-binding protein 
 SP70585_1729 960 ABC transporter substrate-binding protein-sugar transport 
961 spr1535 961 Hypothetical protein 
 SPJ_1585 961 conserved hypothetical protein 
962 SP_1695 962 putative acetyl xylan esterase 
 spr1538 962 Xylan esterase 1 
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 SPD_1506 962 acetyl xylan esterase putative 
963 spr1539 963 Branch migration of Holliday junctions junction-specific DNA helicase 
 SPD_1507 963 ATP-dependent DNA helicase RecG 
964 SPJ_1591 964 alanine racemase 
965 spr1541 965 Acyl Carrier protein synthase 
 SPJ_1592 965 holo-(acyl-carrier protein) synthase 
966 spr1542 966 Phospho-2-dehydro-3-deoxyheptonate aldolase (DAHP synthatase); possibly tyr-sensitive 
 SPD_1510 966 phospho-2-dehydro-3-deoxyheptonate aldolase 
967 SP_1701 967 phospho-2-dehydro-3-deoxyheptonate aldolase 
 spr1543 967 phospho-2-dehydro-3-deoxyheptonate aldolase (DAHP synthatase isozyme)-possibly phe 
sensitive 
968 SPJ_1595 968 preprotein translocase SecA subunit 
969 spr1553 969 Phosphoglycerate dehydrogenase 
 SPD_1519 969 phosphoglycerate dehydrogenase-related protein 
 SP70585_1747 969 GTP-binding protein EngA 
 SPJ_1604 969 ribosome-associated GTPase EngA 
970 spr1554 970 Homologue of NADPH-flavin oxidoreductase 
 SPJ_1605 970 nitroreductase family protein 
971 spr1555 971 Primosome component (helicase loader) 
 SPD_1521 971 primosomal protein DnaI 
972 spr1557 972 Conserved hypothetical protein 
 SPD_1523 972 transcriptional regulator NrdR family protein 
 SP70585_1752 972 transcriptional regulator NrdR 
973 spr1558 973 Conserved hypothetical protein 
 SPD_1524 973 transcriptional regulator GntR family protein 
 SP70585_1753 973 transcriptional regulator GntR family 
974 spr1559 974 ABC transporter ATP-binding protein-unknown substrate 
 SPD_1525 974 ABC transporter ATP-binding protein 
975 SP_1716 975 conserved hypothetical protein 
 spr1561 975 ABC transporter membrane-spanning permease-Na+ export 
 SPD_1527 975 membrane protein putative 
976 SPD_1528 976 ABC transporter ATP-binding protein 
 SP70585_1757 976 ABC transporter ATP-binding protein-Na+ export 
977 SP_1720 977 conserved hypothetical protein 
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 spr1564 977 Hypothetical protein 
 SPD_1530 977 membrane protein putative 
 SPJ_1615 977 snare associated golgi protein 
978 SPCG_1693 978 fructokinase 
979 SP_1722 979 PTS system IIABC components 
 spr1566 979 Phosphotransferase system enzyme II 
 SP70585_1761 979 pts system sucrose-specific iibc component 
980 SPD_1534 980 sucrose-6-phosphate hydrolase 
 SP70585_1763 980 sucrose-6-phosphate hydrolase (Sucrase) (Invertase) 
981 SP_1726 981 3-hydroxy-3-methylglutaryl-CoA reductase 
 spr1570 981 3-hydroxy-3-methylglutaryl-coenzyme a reductase 
 SPD_1536 981 hydroxymethylglutaryl-CoA reductase degradative 
982 spr1572 982 Hypothetical protein 
 SPP_1745 982 conserved hypothetical protein 
983 SPD_1541 983 membrane protein putative 
 SP70585_1771 983 conserved hypothetical protein 
984 spr1577 984 Eukaryotic-type serine/threonine kinase 
 SPD_1542 984 serine/threonine protein kinase 
 SP70585_1772 984 Stk1 
985 SP_1733 985 putative phosphatase 
 spr1578 985 Phosphoprotein phosphatase 
 SPD_1543 985 phosphatase putative 
 SP70585_1773 985 protein phosphatase PrpC 
986 SP_1734 986 rRNA methyltransferase RsmB 
 spr1579 986 rRNA methylase 
 SP70585_1774 986 ribosomal RNA small subunit methyltransferase B 
987 SP70585_1775 987 methionyl-tRNA formyltransferase 
988 SP_1736 988 primosomal protein N' 
 spr1581 988 Primosomal replication factor Y 
 SP70585_1776 988 primosomal protein N' (ATP-dependent helicase PriA) (Replication factor Y) 
989 SP_1737 989 putative DNA-directed RNA polymerase omega subunit 
 spr1582 989 Hypothetical protein 
 SPD_1547 989 DNA-directed RNA polymerase omega chain putative 
 SP70585_1777 989 DNA-directed RNA polymerase omega chain 
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990 SPH1847 990 guanylate kinase 
991 SP_1739 991 KH domain protein 
 SPP_1757 991 conserved hypothetical protein 
992 spr1589 992 Conserved hypothetical protein 
 SPD_1554 992 iojap-related protein 
 SPT_1682 992 putative iojap homolog 
993 SP_1745 993 isochorismatase family protein 
 spr1590 993 Conserved hypothetical protein 
994 spr1592 994 Conserved hypothetical protein 
 SPD_1557 994 nicotinate (nicotinamide) nucleotide adenylyltransferase 
995 SPD_1558 995 conserved hypothetical protein TIGR00253 
 SP70585_1787 995 conserved hypothetical protein 
996 SP_1749 996 GTP-binding protein 
 spr1594 996 Conserved hypothetical protein 
997 SP_1751 997 putative transporter CorA family 
 spr1596 997 CorA-magnesium and cobalt transporter 
 SPD_1561 997 magnesium transporter CorA family protein putative 
998 SP_1752 998 putative mechanosensitive ion channel 
 spr1597 998 Hypothetical protein 
 SPD_1562 998 small conductance mechanosensitive ion channel (MscS) family protein 
 SP70585_1791 998 small conductance mechanosensitive ion channel 
999 SP_1754 999 conserved hypothetical protein 
 SPP_1772 999 integral membrane protein 
1000 SP_1774 1000 putative transcriptional regulator 
 spr1600 1000 Conserverd hypothetical protein 
 SP70585_1819 1000 transcriptional regulator putative 
1001 SP_1775 1001 conserved domain protein 
 spr1601 1001 Hypothetical protein 
 SP70585_1820 1001 conserved hypothetical protein 
1002 spr1602 1002 Thioredoxin reductase 
 SPJ_1673 1002 thioredoxin 
1003 spr1603 1003 Conserved hypothetical protein 
 SPD_1568 1003 GTP cyclohydrolase putative 
 SP70585_1822 1003 NADPH-dependent 7-cyano-7-deazaguanine reductase 
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1004 SP_1779 1004 hypothetical protein 
 SPD_1570 1004 conserved hypothetical protein 
1005 SP_1780 1005 putative oligoendopeptidase F 
 spr1606 1005 Similar to oligoendopeptidase 
 SPD_1571 1005 oligoendopeptidase F putative 
 SPJ_1679 1005 oligoendopeptidase F 
1006 SP_1781 1006 conserved hypothetical protein 
 SPD_1572 1006 conserved hypothetical protein TIGR00046 
 SPJ_1680 1006 protein YqeU 
1007 spr1608 1007 Ribosomal protein methyltransferase 
 SPD_1573 1007 ribosomal protein L11 methyltransferase 
1008 spr1611 1008 Hypothetical protein 
 SPJ_1687 1008 conserved hypothetical protein 
1009 SP70585_1832 1009 conserved hypothetical protein 
1010 spr1616 1010 Chromosome segregation helicase 
 SPD_1580 1010 ATPase AAA family protein 
 SPT_1717 1010 ATPase AAA family 
1011 SP_1804 1011 putative general stress protein 24 
 spr1625 1011 Conserved hypothetical protein 
 SPD_1590 1011 general stress protein 24 putative 
 SPP_1802 1011 Gls24 protein 
1012 spr1626 1012 Hypothetical protein 
 SPP_1803 1012 conserved hypothetical protein 
1013 SP_1808 1013 putative type IV prepilin peptidase 
 SPD_1593 1013 type IV prepilin peptidase putative 
 SP70585_1869 1013 type 4 prepilin peptidase 
1014 spr1632 1014 Tryptophan synthase beta chain 
 SPD_1597 1014 tryptophan synthase beta subunit 
1015 SP_1813 1015 N-(5'-phosphoribosyl)-anthranilate isomerase 
 spr1633 1015 Phosphoribosylanthranilate isomerase 
1016 SPD_1600 1016 anthranilate phosphoribosyltransferase 
1017 SP_1816 1017 anthranilate synthase component II 
 spr1636 1017 Anthranilate synthase component II (glutamine amido-transferase) 
1018 SPD_1602 1018 anthranilate synthase component I 
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1019 SP_1837 1019 putative capsular polysaccharide biosynthesis protein 
 spr1654 1019 Conserved hypothetical protein 
 SPD_1619 1019 capsular polysaccharide biosynthesis protein putative 
 SPJ_1742 1019 Cps7G 
1020 SP_1838 1020 putative glycosyl transferase 
 spr1655 1020 Conserved hypothetical protein 
 SPD_1620 1020 glycosyl transferase putative 
 SPJ_1743 1020 bacterial sugar transferase family protein 
1021 spr1656 1021 ABC transporter ATP-binding/membrane spanning protein-unknown substrate 
 SPD_1621 1021 ABC transporter ATP-binding/permease protein 
1022 spr1657 1022 ABC transporter ATP-binding/membrane spanning protein-unknown substrate 
 SPD_1622 1022 ABC transporter ATP-binding/permease protein 
1023 SPD_1624 1023 conserved hypothetical protein 
 SPJ_1747 1023 hypothetical protein 
1024 SP_1845 1024 exodeoxyribonuclease 
 SPT_1761 1024 exodeoxyribonuclease III 
1025 SP70585_1901 1025 xanthine phosphoribosyltransferase 
1026 spr1663 1026 Nucleobase:cation symporter for xanthine 
 SP70585_1902 1026 xanthine permease 
1027 SP_1852 1027 galactose-1-phosphate uridylyltransferase 
1028 SP_1853 1028 galactokinase 
1029 SP_1854 1029 galactose operon repressor 
 spr1669 1029 GalR member of GalR-LacI family of transcriptional regulators binds DNA; regulator of gal 
operon 
1030 spr1677 1030 ABC transporter membrane-spanning permease-choline transporter 
 SPD_1642 1030 choline transporter (glycine betaine transport system permease protein) 
 SP70585_1916 1030 choline transporter 
1031 SP_1861 1031 choline transporter 
 spr1678 1031 ABC transporter ATP-binding protein-choline transporter 
 SP70585_1917 1031 choline transport ATP-binding protein opuBA 
1032 SP_1862 1032 hypothetical protein 
 SPD_1644 1032 conserved hypothetical protein 
1033 spr1680 1033 Hypothetical protein 
 SPD_1645 1033 transcriptional regulator MarR family protein 
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 SPJ_1769 1033 transcriptional regulator MarR family 
1034 spr1681 1034 Hypothetical protein 
 SPJ_1770 1034 conserved hypothetical protein 
1035 SP_1865 1035 glutamyl-aminopeptidase 
 SPD_1647 1035 glutamyl aminopeptidase PepA 
 SPP_1866 1035 glutamyl aminopeptidase 
1036 SP_1867 1036 NAD-dependent epimerase/dehydratase family protein 
 spr1683 1036 UDP-galactose 4-epimerase truncation 
1037 spr1684 1037 ABC transporter membrane-spanning permease-ferric iron transport 
 SPD_1649 1037 iron-compound ABC transporter permease protein 
1038 spr1685 1038 ABC transporter membrane-spanning permease-ferric iron transport 
 SPD_1650 1038 iron-compound ABC transporter permease protein 
1039 spr1686 1039 ABC transporter ATP-binding protein-ferric iron transport 
 SPD_1651 1039 iron-compound ABC transporter ATP-binding protein 
1040 spr1687 1040 ABC transporter substrate-binding protein-ferric iron transport 
 SPD_1652 1040 iron-compound ABC transporter iron-compound-binding protein 
1041 spr1688 1041 Conserved hypothetical protein 
 SPD_1653 1041 conserved hypothetical protein TIGR00278 
1042 SPD_1654 1042 ribosomal large subunit pseudouridine synthase B 
1043 spr1690 1043 Conserved hypothetical protein 
 SPD_1655 1043 segregation and condensation protein B 
1044 SP_1876 1044 segregation and condensation protein A 
 spr1691 1044 Conserved hypothetical protein 
 SP70585_1931 1044 ScpA/B protein 
1045 SP_1877 1045 integrase/recombinase phage integrase family 
 spr1692 1045 Recombinase site specific 
 SPD_1657 1045 integrase/recombinase phage integrase family protein 
 SP70585_1932 1045 tyrosine recombinase 
1046 spr1693 1046 Conserved hypothetical protein 
 SP70585_1933 1046 CBS domain protein 
1047 SP_1879 1047 conserved hypothetical protein 
 SPD_1659 1047 phosphodiesterase MJ0936 family protein 
 SPJ_1784 1047 phosphodiesterase family 
1048 SP_1880 1048 HAM1 protein 
                                                                                                                               Appendices 
 318 
Gene 
no. 
Gene ID Gene 
cluster no. 
Gene name 
 spr1695 1048 Hypothetical protein 
 SPD_1660 1048 non-canonical purine NTP pyrophosphatase rdgB/HAM1 family protein 
1049 SPH1997 1049 glutamate racemase 
1050 spr1697 1050 Hypothetical protein 
 SPD_1662 1050 conserved hypothetical protein 
1051 SP_1885 1051 trehalose operon transcriptional repressor 
 SPD_1665 1051 trehalose operon repressor 
1052 spr1703 1052 ABC transporter ATP-binding protein-oligopeptide transport 
 SPD_1667 1052 oligopeptide ABC transporter ATP-binding protein AmiF 
1053 spr1704 1053 ABC transporter ATP-binding protein-oligopeptide transport 
 SPD_1668 1053 oligopeptide ABC transporter ATP-binding protein AmiE 
1054 spr1705 1054 ABC transporter membrane-spanning permease-oligopeptide transport 
 SPD_1669 1054 oligopeptide ABC transporter permease protein AmiD 
1055 SP_1890 1055 oligopeptide ABC transporter permease protein AmiC 
 spr1706 1055 ABC transporter membrane-spanning permease-oligopeptide transport 
1056 spr1711 1056 ABC transporter membrane-spanning permease-multiple sugars 
 SPD_1676 1056 sugar ABC transporter permease protein 
1057 SP_1897 1057 sugar ABC transporter sugar-binding protein 
 spr1712 1057 ABC transporter substrate-binding protein-multiple sugars 
1058 SP_1899 1058 msm operon regulatory protein 
 spr1714 1058 MSM (multiple sugar metabolism) operon regulatory protein 
 SPD_1679 1058 msm operon regulatory protein MsmR 
1059 SP_1900 1059 BirA bifunctional protein 
 SPD_1680 1059 biotin--acetyl-CoA-carboxylase ligase 
 SP70585_1958 1059 biotin-[acetyl-CoA-carboxylase] ligase 
1060 SP_1901 1060 RNA methyltransferase TrmA family 
 spr1717 1060 Conserved hypothetical protein 
 SP70585_1982 1060 23S rRNA (uracil-5-)-methyltransferase RumA 
1061 spr1718 1061 Conserved hypothetical protein 
 SPD_1705 1061 regulatory protein RecX 
 SPP_1931 1061 RecA regulator RecX 
1062 spr1719 1062 Conserved hypothetical protein 
1063 SP_1906 1063 chaperonin 60 kDa 
 spr1722 1063 Chaperonin GroEL 
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 SPT_1855 1063 chaperonin GroL 
1064 SP_1907 1064 chaperonin 10 kDa 
 spr1723 1064 Cochaperonin GroES 
 SPT_1856 1064 chaperonin GroS 
1065 SP_1909 1065 oxidoreductase short chain dehydrogenase/reductase family 
 spr1725 1065 Oxidoreductase 
 SPD_1712 1065 oxidoreductase short chain dehydrogenase/reductase family protein 
1066 spr1726 1066 Conserved hypothetical protein 
 SPJ_1905 1066 putative tRNA binding domain protein 
1067 SP_1911 1067 putative thioredoxin 
 spr1727 1067 Conserved hypothetical protein 
 SPD_1714 1067 thioredoxin family protein 
1068 SP_1912 1068 hypothetical protein 
 SPD_1715 1068 conserved hypothetical protein 
1069 spr1732 1069 Conserved hypothetical protein 
 SPD_1719 1069 PAP2 family protein 
1070 SP_1922 1070 conserved hypothetical protein 
 SPD_1725 1070 conserved hypothetical protein TIGR01033 
1071 SP_1923 1071 pneumolysin 
 spr1739 1071 Pneumolysin (sulfhydryl-activated toxin that lyses cholesterol containing membranes) 
 SP70585_2003 1071 pneumolysin (Thiol-activated cytolysin) 
1072 SP_1924 1072 hypothetical protein 
 SPJ_1921 1072 conserved hypothetical protein 
1073 spr1741 1073 Hypothetical protein 
 SPP_1955 1073 conserved hypothetical protein 
1074 SP70585_2006 1074 hypothetical protein 
 SPP_1956 1074 conserved hypothetical protein 
1075 SP_1937 1075 autolysin 
 spr1754 1075 Autolysin (N-acetylmuramoyl-L-alanine amidase) 
 SPD_1737 1075 autolysin/N-acetylmuramoyl-L-alanine amidase 
 SP70585_0079 1075 lytic amidase (N-acetylmuramoyl-L-alanine amidase) 
1076 SP_1939 1076 MATE efflux family protein DinF 
 spr1756 1076 DNA-damage-inducible protein 
1077 spr1757 1077 DNA recombination/repair 
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 SPD_1739 1077 recA protein 
 SPT_1898 1077 protein RecA 
1078 SP_1941 1078 competence/damage-inducible protein CinA 
 spr1758 1078 Competence induced protein 
 SPD_1740 1078 competence-damage protein (Exported protein 10) putative 
 SP70585_2020 1078 competence/damage-inducible protein CinA N-domain putative 
1079 SP_1943 1079 acetyltransferase GNAT family 
 spr1760 1079 Conserved hypothetical protein 
 SPD_1742 1079 acetyltransferase GNAT family protein 
1080 SP_1944 1080 conserved hypothetical protein TIGR00150 
 SP70585_2023 1080 conserved hypothetical protein 
1081 spr1762 1081 Hypothetical protein 
 SP70585_2024 1081 lipoprotein putative 
1082 SP_1956 1082 hypothetical protein 
 spr1772 1082 Hypothetical protein truncation 
 SP70585_2027 1082 bacteriocin-associated integral membrane protein 
 SPJ_1949 1082 conserved hypothetical protein 
1083 spr1773 1083 ABC transporter ATP-binding protein-unknown substrate 
 SPD_1755 1083 ABC transporter ATP-binding protein 
 SP70585_2028 1083 ABC-type antimicrobial peptide transport system ATPase component 
1084 spr1775 1084 Nucleoside diphosphate kinase 
 SP70585_2030 1084 nucleoside diphosphate kinase (NDK) (NDP kinase)(Abnormal wing disks protein)(Killer of 
prune protein)) 
1085 spr1776 1085 DNA-dependent RNA polymerase 
 SP70585_2031 1085 DNA-directed RNA polymerase beta' subunit 
1086 SP_1961 1086 DNA-directed RNA polymerase beta subunit 
 spr1777 1086 DNA-dependent RNA polymerase subunit beta 
1087 SP_1963 1087 CBS domain protein 
 SPD_1761 1087 CBS domain membrane protein 
 SPJ_1956 1087 hemolysin 
1088 SP_1964 1088 DNA-entry nuclease 
 SPJ_1957 1088 DNA-entry nuclease (competence-specific nuclease) 
1089 SP_1965 1089 hypothetical protein 
 SPD_1763 1089 conserved hypothetical protein 
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 SPT_1944 1089 conserved domain protein 
1090 spr1781 1090 UDP-N-acetylglucosamine1-carboxyvinyltransferase 
1091 SPD_1765 1091 conserved hypothetical protein 
 SPP_1988 1091 ATP-dependent protease La 
1092 SP_1969 1092 putative type II DNA modification methyltransferase 
 spr1784 1092 Conserved hypothetical protein 
 SPD_1767 1092 type II DNA modification methyltransferase putative 
 SP70585_2042 1092 N6-adenine-specific methylase 
1093 spr1785 1093 Aspartate--ammonia ligase (asparagine synthetase A) 
 SPD_1768 1093 aspartate--ammonia ligase 
1094 spr1787 1094 Conserved hypothetical protein 
 SPD_1769 1094 membrane protein putative 
 SPP_1993 1094 membrane protein 
1095 SPD_1771 1095 SpoU rRNA Methylase family protein 
 SPP_1994 1095 possible rRNA/tRNA methylase 
1096 spr1789 1096 Acylphosphate phosphohydrolase 
 SPD_1772 1096 acylphosphatase putative 
 SPJ_1967 1096 acylphosphatase 
1097 SP_1975 1097 SpoIIIJ family protein 
 spr1790 1097 Conserved hypothetical protein 
 SP70585_2047 1097 membrane protein OxaA 2 
1098 SP_1976 1098 pyruvate formate-lyase-activating enzyme 
 spr1791 1098 Pyruvate-formate lyase activating enzyme 
 SPD_1774 1098 pyruvate formate-lyase activating enzyme 
 SP70585_2048 1098 pyruvate formate-lyase 1-activating enzyme 
1099 SPD_1775 1099 diaminopimelate decarboxylase 
1100 spr1793 1100 Activator of purine biosynthetic genes 
 SPD_1776 1100 pur operon repressor PurR 
 SP70585_2050 1100 pur operon repressor 
1101 SPD_1777 1101 cmp-binding-factor 1 
 SP70585_2051 1101 3'-5' exoribonuclease YhaM 
1102 SPD_1778 1102 conserved hypothetical protein 
 SP70585_2052 1102 competence-induced protein Ccs50 
1103 spr1796 1103 Conserved hypothetical protein 
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 SPJ_1974 1103 thiamine pyrophosphokinase 
1104 spr1797 1104 Pentose-5-phosphate-3-epimerase 
 SPJ_1975 1104 ribulose-phosphate 3-epimerase 
1105 SP_1984 1105 ribosome small subunit-dependent GTPase A 
 spr1798 1105 Conserved hypothetical protein 
1106 SPJ_1977 1106 dimethyladenosine transferase 
1107 SP_1988 1107 putative immunity protein 
 spr1802 1107 Conserved hypothetical protein 
 SPJ_1980 1107 immunity protein putative 
1108 SP_1990 1108 primase-related protein 
 spr1804 1108 Conserved hypothetical protein 
 SPP_2013 1108 putative primase homolog 
1109 SP_1991 1109 putative hydrolase 
 spr1805 1109 Conserved hypothetical protein 
 SPD_1788 1109 hydrolase TatD family protein 
 SP70585_2063 1109 deoxyribonuclease TatD family 
 SPJ_1984 1109 hydrolase TatD family 
1110 spr1806 1110 Hypothetical protein 
 SP70585_2064 1110 cell wall surface anchor family protein 
1111 spr1807 1111 50S Ribosomal protein L34 
 SPJ_1986 1111 ribosomal protein L34 
1112 spr1808 1112 Potential aminotransferase 
 SPD_1791 1112 aminotransferase class I 
 SPP_2017 1112 aspartate aminotransferase 
1113 spr1810 1113 Conserved hypothetical protein 
 SPD_1793 1113 universal stress protein family protein 
 SPJ_1989 1113 universal stress protein family 
1114 SP_1998 1114 putative L-asparaginase 
 spr1812 1114 L-asparaginase (L-asparagine amidohydrolase) 
 SPD_1796 1114 L-asparaginase putative 
 SPP_2022 1114 L-asparaginase 
1115 SPJ_1993 1115 catabolite control protein A 
1116 spr1814 1116 Response regulator 
 SPD_1798 1116 DNA-binding response regulator 
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1117 SP_2001 1117 putative sensor histidine kinase 
 SPD_1799 1117 sensor histidine kinase putative 
 SPP_2025 1117 histidine kinase 
1118 spr1817 1118 ABC transporter ATP binding protein-unknown substrate 
 SPD_1801 1118 ABC transporter ATP-binding protein 
1119 SP_2007 1119 transcription antitermination protein NusG 
 spr1820 1119 Transcription antitermination factor 
 SP70585_2094 1119 transcription termination/antitermination factor NusG 
1120 SP_2008 1120 putative preprotein translocase SecE subunit 
 spr1821 1120 Preprotein translocase secE component 
 SPD_1820 1120 preprotein translocase SecE subunit 
1121 SP70585_2097 1121 penicillin-binding protein 2A 
1122 SP_2011 1122 ribosomal large subunit pseudouridine synthase RluD subfamily 
 spr1824 1122 Ribosomal large subunit pseudouridine synthase D 
 SPD_1822 1122 ribosomal large subunit pseudouridine synthase RluD subfamily protein 
1123 SP_2012 1123 glyceraldehyde 3-phosphate dehydrogenase 
 spr1825 1123 Glyceraldehyde 3-phosphate dehydrogenase (phosphorylating) 
 SPD_1823 1123 glyceraldehyde-3-phosphate dehydrogenase type I 
1124 spr1826 1124 Conserved hypothetical protein 
 SP70585_2100 1124 efflux ABC transporter permease protein 
1125 SP_2016 1125 nicotinate-nucleotide pyrophosphorylase 
 spr1829 1125 Probable nicotinate-nucleotide pyrophosphorylase 
 SP70585_2103 1125 nicotinate-nucleotide diphosphorylase (carboxylating) 
1126 spr1830 1126 Conserved hypothetical protein 
 SPD_1827 1126 membrane protein putative 
 SPT_2014 1126 membrane protein 
1127 SP_2021 1127 glycosyl hydrolase family 1 
 SP70585_2107 1127 beta-glucosidase 
 SPP_2058 1127 glycosyl hydrolase family protein 1 
1128 spr1834 1128 Phosphotransferase system system cellobiose-specific IIC component 
 SPD_1831 1128 PTS system IIC component 
1129 SP_2023 1129 PTS system IIB component 
 spr1835 1129 Phosphotransferase system system cellobiose-specific IIB component 
1130 spr1837 1130 Alcohol-acetaldehyde dehydrogenase 
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 SPD_1834 1130 alcohol dehydrogenase iron-containing 
 SPJ_2031 1130 aldehyde-alcohol dehydrogenase 2 
1131 spr1838 1131 Hypothetical protein 
 SPD_1836 1131 conserved hypothetical protein 
 SPP_2063 1131 morn motif family protein 
1132 spr1839 1132 Conserved hypothetical protein 
 SPJ_2034 1132 phosphotyrosine protein phosphatase 
1133 spr1840 1133 Conserved hypothetical protein 
 SP70585_2115 1133 preprotein translocase YajC subunit 
1134 spr1842 1134 Conserved hypothetical protein 
 SP70585_2117 1134 probable L-ascorbate-6-phosphate lactonase UlaG (L-ascorbate utilisation protein G) 
1135 SP_2032 1135 transcriptional regulator BglG family 
 spr1843 1135 Conserved hypothetical protein 
 SPD_1841 1135 transcriptional regulator BglG family protein 
1136 SP_2033 1136 putative L-ribulose 5-phosphate 4-epimerase AraD 
 spr1844 1136 L-ribulose 5-phosphate 4-epimerase 
 SPD_1842 1136 L-ribulose-5-phosphate 4-epimerase 
 SP70585_2119 1136 L-ribulose-5-phosphate 4-epimerase (Phosphoribuloseisomerase) 
1137 SP_2034 1137 putative hexulose-6-phosphate isomerase 
 spr1845 1137 Hexulose-6-phosphate isomerase 
 SP70585_2120 1137 hexulose-6-phosphate isomerase putative 
1138 SP_2035 1138 putative hexulose-6-phosphate synthase 
 spr1846 1138 Hexulose-6-phosphate synthase (HumpS) 
 SPD_1844 1138 hexulose-6-phosphate synthase putative 
 SP70585_2121 1138 orotidine 5'-phosphate decarboxylase / humps family putative 
1139 SP_2036 1139 PTS system IIA component 
 spr1847 1139 Phosphotransferase system sugar-specific EII component 
 SP70585_2122 1139 ascorbate-specific phosphotransferase enzyme iia component 
1140 spr1848 1140 Phosphotransferase system sugar-specific EII component 
 SPD_1846 1140 PTS system IIB component 
 SP70585_2123 1140 ascorbate-specific phosphotransferase enzyme iib component 
1141 SP_2038 1141 putative PTS system membrane component 
 spr1849 1141 Phosphotransferase system sugar-specific EII component 
 SPD_1847 1141 PTS system membrane component putative 
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 SP70585_2124 1141 ascorbate-specific PTS system enzyme IIC 
1142 SP_2040 1142 putative jag protein 
 spr1851 1142 Hypothetical protein 
 SPD_1849 1142 protein jag (SpoIIIJ-associated protein ) putative 
 SPT_2035 1142 jag protein 
1143 spr1852 1143 Conserved hypothetical protein 
 SPD_1850 1143 SpoIIIJ family protein 
 SPJ_2047 1143 membrane protein OxaA 1 
1144 spr1853 1144 Ribonuclease P-protein component 
 SPJ_2048 1144 ribonuclease P protein component 
1145 spr1854 1145 Acetate kinase (acetokinase) 
 SPT_2039 1145 acetate kinase 
1146 spr1855 1146 Conserved hypothetical protein 
 SPJ_2051 1146 adenine-specific DNA methylase 
1147 SP70585_2137 1147 conserved hypothetical protein 
1148 spr1863 1148 Competence protein 
 SPJ_2058 1148 competence protein CglB 
1149 spr1864 1149 Competence protein 
 SPD_1863 1149 competence protein CglA 
 SPJ_2059 1149 putative ABC transporter subunit ComYA 
1150 spr1866 1150 Putative alcohol dehydrogenase 
 SPD_1865 1150 alcohol dehydrogenase zinc-containing 
1151 spr1867 1151 N-acetylglucosamine-6-phosphate deacetylase 
1152 SP_2057 1152 conserved hypothetical protein 
 spr1868 1152 Hypothetical protein 
 SPD_1867 1152 membrane protein putative 
 SPP_2095 1152 acyltransferase 
1153 spr1869 1153 tRNA-guanine transglycosylase (guanine insertion enzyme) 
 SPD_1868 1153 queuine tRNA-ribosyltransferase 
1154 spr1870 1154 Hypothetical protein 
 SPD_1869 1154 membrane protein putative 
 SPJ_2065 1154 conserved hypothetical protein 
1155 SPD_1871 1155 conserved hypothetical protein 
1156 spr1875 1156 Conserved hypothetical protein 
                                                                                                                               Appendices 
 326 
Gene 
no. 
Gene ID Gene 
cluster no. 
Gene name 
 SPD_1874 1156 LysM domain protein 
 SPJ_2069 1156 LysM domain-containing protein 
1157 SP_2064 1157 hydrolase haloacid dehalogenase-like family 
 spr1876 1157 Hypothetical protein 
 SPD_1875 1157 hydrolase haloacid dehalogenase-like family protein 
 SPJ_2070 1157 HAD-superfamily hydrolase subfamily IA variant 1 
1158 SP_2065 1158 MATE efflux family protein 
 spr1877 1158 Multi antimicrobial extrusion (MATE) family transporter 
 SP70585_2156 1158 multi antimicrobial extrusion 
1159 SPJ_2072 1159 threonine synthase 
1160 SP_2067 1160 hypothetical protein 
 SPJ_2073 1160 conserved hypothetical protein 
1161 SP_2068 1161 cytidine/deoxycytidylate deaminase family protein 
 spr1880 1161 Conserved hypothetical protein 
1162 spr1881 1162 Glutamyl-tRNA synthetase (glutamate--tRNA ligase)) 
 SPJ_2091 1162 glutamyl-tRNA synthetase 
1163 SP70585_2177 1163 glucose-6-phosphate isomerase 
1164 SP_2072 1164 glutamine amidotransferase class-I 
 SPD_1899 1164 glutamine amidotransferase class 1 
 SP70585_2179 1164 glutamine amidotransferase 
1165 spr1885 1165 ABC transporter ATP-binding/membrane spanning protein-unknown substrate 
 SPD_1900 1165 ABC transporter ATP-binding/permease protein 
1166 SP_2075 1166 ABC transporter ATP-binding/permease protein 
 spr1887 1166 ABC transporter ATP-binding/membrane spanning protein-unknown substrate 
1167 spr1890 1167 Arginyl-tRNA synthetase (arginine--tRNA ligase) (ARGRS) 
 SP70585_2185 1167 arginyl-tRNA synthetase 
1168 SPD_1907 1168 conserved hypothetical protein 
1169 SP_2082 1169 response regulator 
 SP70585_2188 1169 alkaline phosphatase synthesis transcriptional regulatory proteinphoP 
1170 SP_2083 1170 sensor histidine kinase PnpS 
 spr1894 1170 Histidine kinase 
 SP70585_2189 1170 histidine kinase PnpS 
1171 spr1895 1171 ABC transporter substrate-binding protein-phosphate transport 
 SPD_1910 1171 phosphate ABC transporter phosphate-binding protein 
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1172 SP_2085 1172 phosphate ABC transporter permease protein 
 spr1896 1172 ABC transporter membrane-spanning permease-phosphate transport 
 SPD_1911 1172 phosphate ABC transporter permease protein PstC 
1173 SP_2086 1173 phosphate ABC transporter permease protein 
 spr1897 1173 ABC transporter membrane-spanning permease-phosphate transport 
 SPD_1912 1173 phosphate ABC transporter permease protein PstA 
1174 spr1898 1174 ABC transporter ATP-binding protein-phosphate transport 
 SPD_1913 1174 phosphate ABC transporter ATP-binding protein 
1175 spr1899 1175 Negative regulator of pho regulon for phosphate transport 
 SPD_1914 1175 phosphate transport system regulatory protein PhoU 
1176 SP_2091 1176 Glycerol-3-phosphate dehydrogenase NAD(P)+) 
1177 SPD_1919 1177 UTP-glucose-1-phosphate uridylyltransferase 
1178 SP_2095 1178 5-formyltetrahydrofolate cyclo-ligase family protein 
 spr1905 1178 Conserved hypothetical protein 
 SP70585_2201 1178 5-formyltetrahydrofolate cyclo-ligase 
1179 SP_2096 1179 peptidase M20/M25/M40 family 
 spr1906 1179 Similar to several hippurate hydrolases and amino acid amidohydrolases; can be a peptidase 
too 
 SPD_1922 1179 peptidase M20/M25/M40 family protein 
1180 SP_2097 1180 putative 2345-tetrahydropyridine-2-carboxylate N-succinyltransferase 
 spr1907 1180 2345-tetrahydropyridine-2-carboxylate N-succinyltransferase-related protein 
1181 spr1908 1181 Conserved hypothetical protein 
 SPD_1924 1181 membrane protein putative 
 SPJ_2118 1181 membrane protein 
1182 SPJ_2119 1182 penicillin-binding protein 1B 
1183 spr1910 1183 Tyrosyl-tRNA synthetase 1 
 SP70585_2206 1183 tyrosyl-tRNA synthetase 
1184 SP_2101 1184 cation-transporting ATPase EI-E2 family 
 SPD_1927 1184 cation-transporting ATPase E1-E2 family protein 
 SP70585_2207 1184 P-type ATPase-metal/cation transport 
1185 spr1912 1185 Hypothetical protein 
 SP70585_2208 1185 conserved hypothetical protein 
1186 SP_2103 1186 rRNA (guanine-N1-)-methyltransferase 
 SP70585_2209 1186 23S rRNA m1G745 methyltransferase 
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1187 spr1915 1187 Hypothetical protein 
 SP70585_2210 1187 conserved hypothetical protein 
1188 spr1917 1188 4-alpha-glucanotransferase (amylomaltase) 
 SPD_1933 1188 4-alpha-glucanotransferase 
1189 SP_2108 1189 maltose/maltodextrin ABC transporter maltose/maltodextrin-binding protein 
 spr1918 1189 ABC transporter substrate-binding protein-maltose/maltodextrin 
1190 spr1919 1190 ABC transporter membrane-spanning permease-maltose/maltodextrin 
 SPD_1935 1190 maltodextrin ABC transporter permease protein 
1191 SP_2110 1191 maltodextrin ABC transporter permease protein 
 spr1920 1191 ABC transporter membrane-spanning permease-maltose/maltodextrin 
1192 SP_2111 1192 malA protein 
 SPJ_2132 1192 maltodextrose utilisation protein MalA 
1193 spr1922 1193 Maltose operon transcriptional repressor 
1194 spr1924 1194 Aspartyl-tRNA synthetase (aspartate-tRNA ligase) 
 SP70585_2220 1194 aspartyl-tRNA synthetase 
1195 SP_2116 1195 conserved domain protein 
 spr1926 1195 Hypothetical protein 
 SPD_1944 1195 CAAX amino terminal protease family protein 
 SPP_2171 1195 caax amino protease family 
1196 spr1927 1196 Hypothetical protein 
 SPP_2172 1196 membrane protein putative 
1197 SP_2119 1197 putative transcriptional regulator 
 spr1929 1197 Conserved hypothetical protein 
 SPD_1947 1197 transcriptional regulator putative 
 SPP_2174 1197 conserved domain protein 
1198 SP_2122 1198 conserved hypothetical protein 
 SPD_1951 1198 transporter major facilitator family protein 
 SP70585_2247 1198 membrane protein putative 
 SPJ_2145 1198 transporter major facilitator family 
1199 spr1935 1199 Dihydroxyacid dehydratase 
 SPP_2182 1199 dihydroxy-acid dehydratase 
1200 spr1936 1200 Putative transketolase c-terminal section 
 SPD_1957 1200 transketolase C-terminal subunit 
 SP70585_2253 1200 transketolase C-subunit 
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1201 SP_2128 1201 transketolase N-terminal subunit 
 spr1937 1201 Putative transketolase n-terminal section 
 SP70585_2254 1201 transketolase thiamine disphosphate-binding subunit 
1202 SP_2129 1202 putative PTS system IIC component 
 spr1938 1202 Conserved hypothetical protein 
 SPD_1959 1202 PTS system IIC component putative 
 SPJ_2154 1202 ascorbate-specific PTS system enzyme IIC 
1203 SP_2130 1203 putative PTS system IIB component 
 spr1939 1203 Hypothetical protein 
 SPD_1960 1203 PTS system IIB component putative 
 SP70585_2256 1203 phosphotransferase system galactitol-specific IIB component 
1204 SP_2131 1204 transcriptional regulator BglG family 
 spr1940 1204 Conserved hypothetical protein 
 SP70585_2257 1204 transcriptional regulator BglG family protein 
1205 spr1941 1205 Hypothetical protein 
 SPD_1962 1205 conserved hypothetical protein 
 SPP_2188 1205 integral membrane protein 
1206 spr1943 1206 50S Ribosomal protein L32 
 SPJ_2159 1206 ribosomal protein L32 
1207 spr1944 1207 50S Ribosomal protein L33 
 SPJ_2160 1207 ribosomal protein L33 
1208 spr1950 1208 Conserved hypothetical protein 
 SP70585_2270 1208 ROK family protein 
1209 SP_2143 1209 conserved hypothetical protein 
 SPD_1971 1209 glycosyl hydrolase-related protein 
 SPJ_2169 1209 glycosyl hydrolase family 38 
1210 SP70585_2272 1210 conserved hypothetical protein 
1211 spr1953 1211 Conserved hypothetical protein 
 SPD_1973 1211 alpha-12-mannosidase putative 
 SPJ_2171 1211 antigen cell wall surface anchor family 
1212 SP_2146 1212 conserved hypothetical protein 
 spr1954 1212 Hypothetical protein 
 SP70585_2274 1212 putative alpha-L-fucosidase 1 9Alpha-L-fucoside fucohydrolase) 
 SPJ_2172 1212 FucA 
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1213 spr1955 1213 Arginine deiminase truncation 
 SPH2340 1213 arginine deiminase 
1214 spr1957 1214 Ornithine transcarbamoylase 
 SPP_2200 1214 ornithine carbamoyltransferase 
1215 SP_2151 1215 carbamate kinase 
1216 SP_2152 1216 conserved hypothetical protein 
 spr1959 1216 Conserved hypothetical integral membrane protein 
 SPD_1978 1216 membrane protein putative 
 SPJ_2176 1216 arginine-ornithine antiporter 
1217 SP_2153 1217 peptidase M20/M25/M40 family 
 spr1960 1217 Conserved hypothetical protein 
 SPD_1979 1217 peptidase M20/M25/M40 family protein 
 SPJ_2177 1217 putative dipeptidase 
1218 spr1963 1218 Probable alcohol dehydrogenase 
 SPD_1985 1218 alcohol dehydrogenase iron-containing 
 SP70585_2283 1218 NAD-dependent methanol dehydrogenase (medh) 
1219 SP_2158 1219 L-fucose isomerase 
1220 SP_2167 1220 putative L-fuculose kinase fucK 
 spr1973 1220 Fucose kinase 
 SPD_1995 1220 L-fuculose kinase FucK putative 
 SPJ_2193 1220 rhamnulokinase (Rhamnulose kinase) 
1221 SP_2168 1221 putative fucose operon repressor 
 spr1974 1221 Regulator of fucose operon 
 SPD_1996 1221 fucose operon repressor putative 
1222 SP_2169 1222 zinc ABC transporter zinc-binding lipoprotein 
 spr1975 1222 ABC transporter substrate-binding protein-Zinc (Zn2+) transport 
 SP70585_2295 1222 zinc-binding lipoprotein AdcA 
1223 spr1976 1223 ABC transporter membrane-spanning permease-Zinc (Zn2+) transport 
 SPD_1998 1223 zinc ABC transporter permease protein 
 SP70585_2296 1223 ABC transporter membrane-spanning permease-Zinc 
1224 SP_2171 1224 zinc ABC transporter ATP-binding protein 
 spr1977 1224 ABC transporter ATP-binding domain-Zinc (Zn2+) permease 
 SP70585_2297 1224 zinc transport system ATP-binding protein AdcC 
1225 spr1978 1225 Transcriptional repressor for Zn (2+)-responsive expression 
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 SPD_2000 1225 adc operon repressor AdcR 
 SP70585_2298 1225 putative transcriptional repressor 
1226 SP_2173 1226 dltD protein 
 spr1979 1226 D-alanine transfer from undecaprenol-phosphate to the poly (glycerophosphate) chain 
 SPD_2002 1226 undecaprenol-phosphate-poly (glycerophosphate subunit) D-alanine transfer protein 
1227 spr1980 1227 D-alanyl carrier protein 
 SPD_2003 1227 D-alanine--poly (phosphoribitol) ligase subunit 2 
1228 SP_2175 1228 dltB protein 
 spr1981 1228 D-alanine transfer from Dcp to undecaprenol-phosphate 
 SPH2371 1228 protein DltB 
1229 SP_2176 1229 D-alanine-activating enzyme 
 spr1982 1229 D-alanine-D-alanyl carrier protein ligase 
 SPD_2005 1229 D-alanine--poly (phosphoribitol) ligase subunit 1 
1230 SP_2185 1230 hypothetical protein 
 spr1990 1230 Glycerol-3-phosphate dehydrogenase truncation 
 SPD_2012 1230 alpha-glycerophosphate oxidase 
 SP70585_2311 1230 alpha-glycerophosphate oxidase (Glycerol-3-phosphateoxidase) 
1231 SPG_2127 1231 glycerol kinase 
1232 SP_2187 1232 conserved domain protein 
 spr1992 1232 Hypothetical protein 
 SPD_2014 1232 conserved hypothetical protein 
 SP70585_2313 1232 M protein trans-acting positive regulator (MGA) 
1233 SP_2188 1233 chaperonin 33 kDa 
 spr1993 1233 Chaperonin (heat shock protein 33) 
 SPT_2203 1233 chaperonin HslO 
1234 SP_2189 1234 putative TIM-barrel protein NifR3 family 
 spr1994 1234 Conserved hypothetical protein 
 SPD_2016 1234 TIM-barrel protein nifR3 family protein putative 
 SPJ_2216 1234 tRNA-dihydrouridine synthase B 
1235 SP_2191 1235 conserved hypothetical protein 
 SPD_2018 1235 isoprenylcysteine carboxyl methyltransferase (ICMT) family protein 
 SP70585_2317 1235 membrane protein putative 
1236 SP_2193 1236 DNA-binding response regulator 
 spr1998 1236 Response regulator 
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1237 SPJ_2222 1237 transcriptional regulator CtsR 
1238 SP_2196 1238 ABC transporter ATP-binding protein 
 spr2002 1238 ABC transporter ATP-binding protein-anion transport 
1239 SP_2197 1239 putative ABC transporter substrate-binding protein 
 spr2003 1239 Conserved hypothetical protein 
 SPD_2025 1239 ABC transporter substrate-binding protein putative 
 SP70585_2325 1239 ABC transporter substrate-binding protein 
1240 spr2004 1240 ABC transporter membrane-spanning permease-unknown substrate 
 SP70585_2326 1240 ABC transporter permease protein 
1241 SP70585_2327 1241 conserved hypothetical protein 
1242 SP70585_2329 1242 conserved hypothetical protein 
1243 SP70585_2330 1243 replicative DNA helicase 
1244 spr2009 1244 50S Ribosomal protein subunit L9 
 SPD_2031 1244 ribosomal protein L9 
1245 spr2010 1245 Conserved hypothetical protein 
 SPP_2258 1245 DHH subfamily 1 protein 
1246 spr2011 1246 Conserved hypothetical protein 
 SPD_2033 1246 ribosomal subunit interface protein 
 SP70585_2333 1246 ribosome-associated protein Y 
1247 spr2012 1247 Involved in transformation (competence for DNA uptake) 
 SPD_2034 1247 competence protein ComF putative 
 SP70585_2334 1247 transformation-related protein 
 SPJ_2233 1247 putative competence protein ComF 
1248 SP_2208 1248 putative helicase 
 spr2013 1248 Involved in transformation; required for DNA uptake but not for binding; Related to ATP-
dependent RNA/DNA helicases 
 SPD_2035 1248 helicase putative 
1249 SPD_2036 1249 conserved hypothetical protein TIGR00257 
 SP70585_2336 1249 conserved hypothetical protein 
1250 SP_2210 1250 cysteine synthase 
 spr2015 1250 Cysteine synthase O-acetylserine sulfhydrylase 
 SPT_2228 1250 cysteine synthase A 
1251 spr2019 1251 Elongation factor TS 
 SP70585_2341 1251 translation elongation factor Ts 
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1252 spr2020 1252 30S Ribosomal protein S2 
 SPP_2267 1252 ribosomal protein S2 
1253 SP_2216 1253 secreted 45 kd protein 
 SPD_2043 1253 secreted 45 kDa protein precursor 
 SP70585_2343 1253 general stress protein GSP-781 
1254 SP_2217 1254 putative rod shpae-determining protein MreD 
 spr2022 1254 Cell-shape determining protein MreD 
 SPD_2044 1254 rod shpae-determining protein MreD putative 
 SP70585_2344 1254 rod shape-determining protein MreD 
1255 spr2023 1255 Cell shape determining protein MreC 
 SPJ_2244 1255 rod shape-determining protein MreC 
1256 SP_2219 1256 conserved hypothetical protein 
 spr2024 1256 ABC transporter membrane-spanning permease-unknown substrate 
 SPD_2046 1256 cobalt ABC transporter permease protein 
 SP70585_2346 1256 ABC transporter permease protein 
1257 SP_2220 1257 ABC transporter ATP-binding protein 
 spr2025 1257 ABC transporter ATP-binding protein-unknown substrate 
 SPD_2047 1257 cobalt ABC transporter ATP-binding protein CbiO1 
 SP70585_2347 1257 cobalt import ATP-binding protein CbiO 1 
1258 SP_2221 1258 ABC transporter ATP-binding protein 
 spr2026 1258 ABC transporter ATP-binding protein-unknown substrate 
 SPD_2048 1258 cobalt ABC transporter ATP-binding protein CbiO2 
 SP70585_2348 1258 cobalt import ATP-binding protein CbiO 2 
1259 spr2027 1259 Phosphotidylglycerophosphate synthase 
 SPD_2049 1259 CDP-diacylglycerol--glycerol-3-phosphate3-phosphatidyltransferase 
1260 SPD_2050 1260 conserved hypothetical protein 
1261 spr2029 1261 Conserved hypothetical protein 
 SPD_2051 1261 peptidase M16 family protein 
 SP70585_2351 1261 peptidase M16 family 
1262 SPD_2052 1262 conserved hypothetical protein 
 SP70585_2352 1262 peptidase M16 family 
1263 SP_2226 1263 conserved hypothetical protein 
 SP70585_2353 1263 S4 domain protein YaaA putative 
1264 spr2032 1264 Recombination protein RecF 
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 SPD_2054 1264 recF protein 
 SP70585_2354 1264 DNA replication and repair protein RecF 
1265 SP70585_2355 1265 inosine-5'-monophosphate dehydrogenase 
1266 SPP_2281 1266 tryptophanyl-tRNA synthetase 
1267 SP_2230 1267 ABC transporter ATP-binding protein 
 spr2035 1267 ABC transporter ATP-binding protein-unknown substrate 
 SP70585_2357 1267 ATPase component of ABC transporters with duplicated ATPase domains 
1268 SP_2231 1268 putative ABC transporter permease protein 
 spr2036 1268 Conserved hypothetical protein 
 SPD_2058 1268 ABC transporter permease protein putative 
 SP70585_2358 1268 ABC transporter permease component 
1269 SP_2233 1269 hypothetical protein 
 spr2039 1269 Conserved hypothetical protein truncation 
 SPJ_2260 1269 conserved hypothetical protein 
1270 SP_2235 1270 response regulator ComE 
 SPJ_2264 1270 response regulator 
1271 SP_2236 1271 putative sensor histidine kinase ComD 
 SPP_2291 1271 ComD 
 SPT_2256 1271 histidine protein kinase 
1272 SPD_2068 1272 serine protease 
 SPP_2295 1272 trypsin domain protein 
1273 SP_2240 1273 spspoJ protein 
 spr2046 1273 Chromosome segregation protein 
 SPD_2069 1273 SpoJ protein 
 SPJ_2270 1273 stage 0 sporulation protein J 
1274 spr0025 1274 DNA repair: sensitivity to gamma and UV radiation 
 SP70585_0084 1274 DNA repair protein RadA 
1275 spr0072 1275 Conserved hypothetical protein 
 SPD_0078 1275 glycosyl transferase group 2 family protein 
 SP70585_0143 1275 glycosyltransferases involved in cell wall biogenesis 
 SPG_0081 1275 glycosyl transferase family 2 truncation 
1276 SPD_0079 1276 conserved hypothetical protein 
 SP70585_0144 1276 glycosyltransferases involved in cell wall biogenesis 
 SPG_0082 1276 glycosyl transferase family 2 
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 SPCG_0078 1276 hypothetical protein 
1277 spr0133 1277 Degenerate transposase (orf2) 
 SP70585_0209 1277 transposase 
 SPCG_0134 1277 degenerate transposase 
 HMPREF0837_
10439 
1277 IS1167 transposase 
 SPN23F01430 1277 putative transposase 
1278 SPD_0181 1278 conserved hypothetical protein TIGR00250 
 SPJ_0207 1278 conserved hypothetical protein 
1279 spr0567 1279 Hypothetical protein 
 SP70585_0709 1279 transposase 
 SPCG_0605 1279 degenerate transposase 
1280 spr0569 1280 Hypothetical protein 
 SPD_0565 1280 conserved hypothetical protein 
1281 spr0570 1281 Hypothetical protein 
 SPD_0566 1281 conserved hypothetical protein 
 SPCG_0608 1281 Predicted Fe-S oxidoreductase 
 HMPREF0837_
10945 
1281 radical SAM family protein 
1282 spr0730 1282 Conserved hypothetical protein 
 SPD_0722 1282 YjeF-like protein 
 SPP_0833 1282 putative YjeF homolog C-terminus 
1283 spr0759 1283 ABC transporter substrate-binding protein-oligopeptid transport internal deletion 
 SPJ_0794 1283 conserved hypothetical protein 
1284 spr0910 1284 Pneumococcal histidine triad protein E precursor truncation 
 SPJ_0946 1284 hypothetical protein 
 SPP_1011 1284 pneumococcal histidine triad protein E 
1285 spr1095 1285 O-acetylhomoserine sulfhydrylase truncation 
 SPD_1073 1285 O-acetylhomoserine aminocarboxypropyltransferase/cysteine synthase 
 SP70585_1262 1285 O-acetylhomoserine (thiol)-lyase (O-acetylhomoserinesulfhydrylase) (OAH sulfhydrylase) 
(Homocysteine) 
1286 spr1096 1286 O-acetylhomoserine sulfhydrylase truncation 
 SP70585_1263 1286 O-acetylhomoserine sulfhydrylase 
 SPG_1108 1286 conserved hypothetical protein 
1287 spr1381 1287 ABC transporter truncation 
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 SPD_1355 1287 conserved hypothetical protein 
 SP70585_1294 1287 ABC transporter NBP/MSD fusion protein 
 SPP_1546 1287 ABC transporter 
1288 SPJ_1436 1288 conserved hypothetical protein 
 SPP_1555 1288 hypothetical protein 
1289 spr1560 1289 Hypothetical protein 
 SP70585_1755 1289 ABC transporter ATP-binding protein 
 SPT_1654 1289 membrane protein putative 
1290 SPD_1563 1290 Dicarboxylate/amino acid:cation (Na+ or H+) symporter 
 SP70585_1792 1290 inner membrane symporter YgjU 
1291 HMPREF0837_
12068 
1291 conserved hypothetical protein 
 SPN23F18610 1291 hypothetical protein 
1292 spr1933 1292 Positive transcriptional regulator of glucosyltransferase and Spp phenotype 
 SPD_1952 1292 transcriptional activator Rgg/GadR/MutR family protein C-terminal domain 
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1 SPD_1473 1 Hypothetical protein 
 SP70585_1700 1 Conserved hypothetical protein 
2 SPG_1043 2 Phosphoserine phosphatase 
 SPN23F10460 2 Putative hydrolase (pseudogene) 
3 SP_0097 3 Conserved domain protein 
 spr0086 3 Hypothetical protein 
 SPD_0093 3 Membrane protein putative 
4 SP_0157 4 Hypothetical protein 
 SPD_0159 4 Membrane protein putative 
 SP70585_0231 4 Conserved hypothetical protein 
5 SP_0222 5 Ribosomal protein S14 
 spr0202 5 30S Ribosomal protein S14 
6 SP_0285 6 Alcohol dehydrogenase zinc-containing 
 spr0262 6 Alcohol dehydrogenase propanol-preferring 
7 SP_0340 7 Autoinducer-2 production protein 
 SPD_0309 7 S-ribosylhomocysteine lyase (autoinducer-2 production protein luxS) AI-2 synthesis 
protein 
 SP70585_0404 7 S-ribosylhomocysteinase LuxS 
8 SP_0488 8 Conserved hypothetical protein 
 SPD_0437 8 Membrane protein putative 
9 SP_0514 9 Hypothetical protein 
 SPD_0457 9 Conserved hypothetical protein 
10 SP_0519 10 DnaJ protein 
 spr0456 10 Heat-shock protein (activation of DnaK) 
 SPD_0461 10 Chaperone protein DnaJ 
11 SP_0526 11 Response regulator BlpR 
 spr0463 11 Response regulator 
12 SP_0527 12 Putative sensor histidine kinase BlpH 
 spr0464 12 Histidine kinase 
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13 SP_0622 13 Nitroreductase family protein 
 spr0546 13 Nitroreductase 
 SP70585_0682 13 Oxidoreductase 
14 SP_0645 14 Putative PTS system IIA component 
 spr0562 14 Phosphotransferase system sugar-specific EII component 
 spr1081 14 Hypothetical protein 
15 SP_0655 15 Transporter monovalent cation:proton antiporter-2(CPA2) family 
 spr0573 15 Na+/H+ antiporter 
 SPD_0569 15 Sodium/hydrogen exchanger family protein 
16 SP_0709 16 Amino acid ABC transporter ATP-binding protein 
 spr0622 16 ABC transporter ATP-binding protein-glutamine transport 
 SPJ_0649 16 Glutamine transport ATP-binding protein GlnQ 
17 SP_0737 17 Sodium-dependent transporter 
18 SP_0769 18 VanZF-related protein 
 spr0677 18 Hypothetical protein 
 SPD_0670 18 Conserved hypothetical predicted membrane protein 
 SP70585_0812 18 VanZ family protein 
19 SP_0820 19 ATP-dependent Clp protease ATP-binding subunit ClpE 
 spr0725 19 ATP dependent protease 
20 SP_0841 20 Conserved hypothetical protein 
 SPD_0735 20 Methyltransferase small domain putative 
 SP70585_0877 20 Methyltransferase small domain superfamily 
21 SP_0912 21 ABC transporter ATP-binding protein 
 spr0812 21 ABC transporter ATP-binding protein-unknown substrate 
 SP70585_0949 21 Bacitracin export ATP-binding protein BceA 
22 SP_0915 22 Putative IS1239 transposase 
 spr0511 22 Degenerate transposase 
 spr1367 22 Transposase 
 SPD_0807 22 IS1239 transposase putative 
23 SP_1004 23 Conserved hypothetical protein 
 spr0908 23 Pneumococcal histidine triad protein E precursor 
24 SP_1043 24 Hypothetical protein 
 SPD_0924 24 Conserved hypothetical protein 
25 SP_1044 25 Putative hydrolase 
                                                                                                                                   Appendices 
 339 
Gene 
no. 
               Gene 
ID 
Gene 
cluster 
Gene name 
 spr0946 25 Conserved hypothetical protein 
 SPD_0925 25 Hydrolase putative 
 SP70585_1123 25 ADP-ribosylglycohydrolase superfamily 
 SPJ_0981 25 ADP-ribosylation/Crystallin J1 
26 SP_1045 26 Conserved hypothetical protein TIGR00147 
 spr0947 26 Conserved hypothetical protein 
27 SP_1078 27 Hypothetical protein 
 SPD_0963 27 Conserved hypothetical protein 
28 SP_1094 28 Aminotransferase class-V 
 spr1001 28 Pyridoxal-phosphate dependent aminotransferase 
 SP70585_1167 28 Putative cysteine desulfurase (NifS protein homolog) 
29 SP_1115 29 Putative transcriptional regulator MutR 
 spr1022 29 Transcriptional regulator 
 SPD_0999 29 Transcriptional regulator MutR putative 
30 SP_1193 30 Galactose-6-phosphate isomerase LacA subunit 
31 SP_1228 31 A/G-specific adenine glycosylase 
 spr1108 31 Similar to A/G-specific adenine glycosylase 
32 SP_1235 32 MutT/nudix family protein 
 spr1115 32 Conserved hypothetical protein 
 SP70585_1298 32 NTP pyrophosphohydrolase including oxidative damage repair enzymes 
33 SP_1244 33 Signal recognition particle-docking protein FtsY 
 spr1123 33 Cell division protein FtsY 
34 SP_1250 34 Conserved domain protein 
 spr1129 34 Hypothetical protein 
 SPD_1108 34 Conserved hypothetical protein 
35 SP_1254 35 Hypothetical protein 
 SPD_1112 35 Conserved hypothetical protein 
36 SP_1255 36 Putative 3-isopropylmalate dehydratase small subunit 
 SPD_1113 36 3-isopropylmalate dehydratase small subunit putative 
37 SP_1256 37 Conserved hypothetical protein 
38 SP_1267 38 LicC protein 
 spr1145 38 Homologous to LicC which regulates expression of LPS epitopes in H. influenzae 
 SPD_1123 38 CTP:phosphocholine cytidylyltransferase 
39 SP_1403 39 Inositol monophosphatase family protein 
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 spr1260 39 Conserved hypothetical protein 
40 SP_1406 40 Hypothetical protein 
 SPD_1237 40 Membrane protein putative 
 SP70585_1445 40 Integral membrane protein 
41 SP_1420 41 NH (3)-dependent NAD+ synthetase 
 spr1276 41 NAD synthetase ammonia dependent 
 SPD_1250 41 NAD+ synthetase 
42 SP_1452 42 Hypothetical protein 
 SPD_1281 42 Conserved hypothetical protein 
43 SP_1453 43 Conserved domain protein 
 spr1308 43 Hypothetical protein 
44 SP_1485 44 IS3-Spn1 transposase 
 spr0352 44 Degenerate transposase (orf2) 
45 spr1347 45 Hypothetical protein 
 SPD_1323 45 Conserved hypothetical protein 
46 SP_1500 46 Amino acid ABC transporter amino acid-binding protein 
 spr1353 46 ABC transporter substrate-binding protein-glutamine transport 
47 SP_1514 47 ATP synthase F0 C subunit 
 spr1366 47 Proton-translocating ATPase F0 sector subunit c 
 SP70585_1551 47 Conserved domain protein 
48 SP_1516 48 Acetyltransferase GNAT family 
 spr1368 48 Hypothetical protein 
 SPD_1343 48 Acetyltransferase GNAT family protein 
49 SP_1531 49 Hypothetical protein 
 SPD_1360 49 Conserved hypothetical protein 
50 SP_1567 50 Endoribonuclease L-PSP 
 spr1425 50 Transcription regulator 
51 SP_1571 51 Dihydrofolate reductase 
52 SP_1596 52 IS3-Spn1 hypothetical protein interruption 
 spr0355 52 Degenerate transposase (orf1) 
53 SP_1623 53 Cation-transporting ATPase E1-E2 family 
 spr1464 53 P-type ATPase-metal cation transport 
54 SP_1661 54 Cell division protein DivIVA 
 spr1505 54 Cell-division initiation protein (septum placement) 
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55 SP_1668 55 Hypothetical protein 
 SPD_1481 55 Membrane protein putative 
 SP70585_1708 55 Conserved hypothetical integral membrane protein 
56 SP_1681 56 Sugar ABC transporter permease protein 
 spr1525 56 ABC transporter membrane-spanning permease-sugar transport 
57 SP_1703 57 Conserved domain protein 
 spr1545 57 Hypothetical protein 
 SPJ_1596 57 Conserved hypothetical protein 
58 SP_1727 58 Hydroxymethylglutaryl-CoA synthase 
 spr1571 58 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase 
59 SP_1730 59 Hypothetical protein 
 SPD_1540 59 Membrane protein putative 
 SP70585_1770 59 Conserved hypothetical protein 
60 SP_1746 60 Conserved hypothetical protein 
 SPD_1556 60 Conserved hypothetical protein TIGR00488 
61 SP_1750 61 Conserved hypothetical protein 
 SPD_1560 61 HAD superfamily protein (subfamily IIIA) phosphatase 
62 SP_1778 62 Aquaporin 
 spr1604 62 Aquaporin Z-water channel protein 
63 SP_1783 63 MutT/nudix family protein 
 spr1609 63 78-dihydro-8-oxoguanine-triphosphatase 
64 SP_1851 64 Conserved hypothetical protein 
 SP70585_1906 64 Thioesterase family protein 
65 SP_1883 65 Putative dextran glucosidase DexS 
 spr1698 65 Dextran glucosidase 
 SPD_1663 65 Alphaalpha-phosphotrehalase 
66 SP_1942 66 Putative transcriptional regulator 
 spr1759 66 Regulator of lytRABC operon 
 SPD_1741 66 Transcriptional regulator putative 
67 SP_1968 67 Phosphopantetheine adenylyltransferase 
 spr1783 67 Lipopolysaccharide core biosynthesis protein 
 SPD_1766 67 Pantetheine-phosphate adenylyltransferase 
68 SP_1986 68 Hypothetical protein 
 SPD_1783 68 Conserved hypothetical protein 
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69 SP_1997 69 Cof family protein 
 spr1811 69 Conserved hypothetical protein 
70 SP_2050 70 Competence protein CglD 
 spr1861 70 Competence protein 
71 SP_2054 71 Conserved hypothetical protein 
72 SP_2071 72 Hypothetical protein 
 SPD_1898 72 Conserved hypothetical protein 
73 SP_2077 73 Putative transcriptional repressor 
 spr1889 73 Arginine repressor 
74 SP_2089 74 Transposase IS1380-Spn1 related truncation 
75 SP_2120 75 Hypothetical protein 
76 SP_2125 76 Conserved hypothetical protein 
 SP70585_2250 76 Domain of unknown function protein 
77 SP_2201 77 Choline binding protein D 
78 spr0324 78 Transposase uncharacterised truncation 
79 spr0814 79 Conserved hypothetical protein 
 SP70585_0951 79 Integral membrane protein 
80 spr0885 80 Degenerate transposase (orf2) 
81 spr0948 81 Neopullulanase 
82 spr1135 82 3-isopropylmalate dehydrogenase 
83 spr1274 83 Choline binding protein 
 SPD_1248 83 Conserved hypothetical protein 
84 spr1398 84 Conserved hypothetical protein 
 SPD_1372 84 Glyoxalase family protein 
85 SPD_1504 85 Sialidase A precursor 
 SP70585_1731 85 Neuraminidase 
86 SPD_1903 86 DNA mismatch repair protein MutS 
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Gene 
no. 
Gene ID Gene 
cluster 
Gene name 
1 HMPREF0837_1
0825 
1 Possible transport/processing ATP-binding protein ComA 
2 SPJ_0042 2 Lytic amidase (N-acetylmuramoyl-L-alanine amidase) pseudo 
 SPN23F00360 2 Putative peptidoglycan hydrolytic amidase (pseudogene) 
3 SP_0075 3 Phosphorylase Pnp/Udp family 
 spr0068 3 Conserved hypothetical protein 
 SPD_0074 3 Phosphorylase Pnp/Udp family protein putative 
 SP70585_0138 3 Phosphorylase Pnp/Udp family 
4 SP_0082 4 Cell wall surface anchor family protein 
 spr0075 4 Conserved hypothetical protein 
5 SP_2190 5 Choline binding protein A 
6 SP_0141 6 Transcriptional regulator 
 spr0140 6 Positive transcriptional regulator of mutA 
 SP70585_0215 6 MutR 
 SPG_0143 6 Transcriptional regulator 
7 SP_0248 7 PTS system IIA component 
 spr0229 7 Phosphotransferase system sugar-specific EIIA component 
8 SP_0249 8 PTS system IIB component 
 spr0230 8 Phosphotransferase system sugar-specific EIIB component 
9 SP_0277 9 Hypothetical protein 
 SPD_0257 9 Conserved hypothetical protein 
10 SP_0390 10 Choline binding protein G 
11 SP_0430 11 Hypothetical protein 
 SPD_0392 11 Conserved hypothetical protein 
12 SP_0448 12 Hypothetical protein 
 SPD_0407 12 Conserved hypothetical protein 
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13 SP_0457 13 Bacitracin resistance protein 
 spr0413 13 A lipid kinase; may confer bacitracin resistance by phosphorylation of 
undecaprenol 
 SPD_0417 13 Bacitracin resistance protein/undecaprenol kinase putative 
 SP70585_0528 13 Undecaprenyl-diphosphatase 
14 SP_0458 14 DNA-damage inducible protein P 
15 SP_0459 15 Formate acetyltransferase 
 spr0415 15 Pyruvate formate-lyase 
16 SP_0509 16 Type I restriction-modification system M subunit 
 spr0449 16 EcoE type I restriction modification enzyme M subunit 
 SPD_0454 16 Type I restriction-modification system M subunit 
 SP70585_0567 16 Type I restriction enzyme 
17 SP_0513 17 Hypothetical protein 
 SPD_0457 17 Conserved hypothetical protein 
18 SP_0565 18 Conserved domain protein 
 spr0489 18 Hypothetical protein 
 SPD_0491 18 Conserved hypothetical protein 
 SP70585_0630 18 Conserved protein/domain typically associated with flavoprotein oxygenase 
Dim6/ntab family 
19 SP_0577 19 PTS system beta-glucosides-specific IIABC components 
 spr0505 19 Phosphotransferase system sugar-specific EII component 
20 SP_0578 20 6-phospho-beta-glucosidase 
 SP70585_0642 20 beta-glucosidase (Gentiobiase) (Celloiase) (Beta-D-glucoside glucohydrolase) 
(Amygdalase) 
21 SP_0595 21 Hypothetical protein 
 SPD_0518 21 Conserved hypothetical protein 
22 SP_0610 22 Amino acid ABC transporter ATP-binding protein 
 spr0535 22 ABC transporter ATP-binding protein-glutamine truncation 
 SP70585_0672 22 Glutamine transport ATP-binding protein GlnQ 
23 SP_0624 23 Conserved hypothetical protein 
 SP70585_0684 23 Uracil DNA glycosylase family protein 
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24 SP_0641 24 Serine protease subtilase family 
 spr0561 24 Cell wall-associated serine proteinase precursor PrtA 
 SPD_0558 24 Cell wall-associated serine protease PrtA 
 SP70585_0702 24 Serine protease 
25 SP_0650 25 Hypothetical protein 
 SPD_0564 25 Conserved hypothetical protein 
 SP70585_0710 25 Integral membrane protein 
26 SP_0670 26 Hypothetical protein 
 SPD_0582 26 Conserved hypothetical protein 
27 SP_0682 27 Hypothetical protein 
 SPD_0594 27 Conserved hypothetical protein 
28 SP_0703 28 Hypothetical protein 
 SPD_0610 28 Conserved hypothetical protein 
29 SP_0713 29 Lysyl-tRNA synthetase 
 spr0626 29 Lysyl-tRNA synthetase (lysine--tRNA ligase) (LYSRS) 
30 SP_0726 30 Phosphomethylpyrimidine kinase 
31 SP_0743 31 Transcriptional regulator TetR family 
 spr0653 31 Conserved hypothetical protein 
32 SP_0816 32 Hypothetical protein 
 SPD_0714 32 Conserved hypothetical protein 
33 SP_0838 33 Ribosomal protein S20 
 spr0740 33 30S Ribosomal protein subunit S20 
34 SP_0887 34 Putative type I restriction-modification system S subunit 
 spr0791 34 Type I restriction-modification enzyme 1 S subunit 
 SPD_0783 34 Type I restriction-modification system 
35 SP_0902 35 Hypothetical protein 
 SPD_0796 35 Conserved hypothetical protein 
36 SP_0923 36 Cof family protein 
 spr0824 36 Conserved hypothetical protein 
37 SP_0984 37 Phosphoglycerate mutase family protein 
 spr0887 37 Phosphoglycerate mutase 
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38 SP_0990 38 Hypothetical protein 
 SPD_0876 38 Conserved hypothetical protein 
39 SP_1010 39 Large conductance mechanosensitive channel protein MscL 
40 SP_1093 40 Hypothetical protein 
 SPD_0978 40 Conserved hypothetical protein 
41 SP_1119 41 Glyceraldehyde-3-phosphate dehydrogenase NADP-dependent 
 spr1028 41 NADP-dependent glyceraldehyde-3-phosphate dehydrogenase 
 SP70585_1190 41 NADP-dependent glyceraldehyde-3-p 
42 SP_1182 42 Lactose phosphotransferase system repressor 
43 SP_1186 43 PTS system lactose-specific IIA component 
 SP70585_1238 43 Lactose-specific phosphotransferase enzyme iia component 
44 SP_1212 44 tRNA pseudouridine synthase B 
 spr1092 44 tRNA pseudouridine 5S synthase 
45 SP_1218 45 Conserved hypothetical protein 
 spr1098 45 Sortase 
46 SP_1223 46 Conserved hypothetical protein 
 spr1103 46 Hypothetical protein 
47 SP_1273 47 LicD1 protein 
 spr1151 47 Required for phosphorylcholine incorporation in teichoic and lipoteichoic acids 
 SPD_1129 47 Phosphotransferase LicD1 
 SP70585_1336 47 Phosphotransferase 
48 SP_1300 48 Hypothetical protein 
 SPD_1155 48 Conserved hypothetical protein 
 SP70585_1365 48 High-affinity Fe2+/Pb2+ permease 
49 SP_1365 49 Glycosyl transferase family 2 
 spr1223 49 Galactosyl transferase paralog 
50 SP_1422 50 Hypothetical protein 
 SPD_1252 50 Membrane protein putative 
 SP70585_1460 50 Conserved hypothetical protein 
51 SP_1447 51 Membrane protein 
 spr1302 51 Conserved hypothetical protein 
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52 SP_1478 52 Oxidoreductase aldo/keto reductase family 
 spr1332 52 Conserved hypothetical protein 
 SP70585_1519 52 25-diketo-D-gluconic acid reductase A 
53 SP_1517 53 Transcription elongation factor GreA 
54 SP_1557 54 DegV family protein 
 spr1415 54 Conserved hypothetical protein 
55 SP_1559 55 Phosphoglucomutase/phosphomannomutase family protein 
56 SP_1572 56 Non-heme iron-containing ferritin 
 spr1430 56 DNA binding protein starved cells-like peroxide resistance protein 
57 SP_1577 57 Adenine phosphoribosyltransferase 
58 SP_1606 58 Glycosyl transferase family 2 
 spr1459 58 Glycosil transferase 
 SPD_1431 58 Glycosyl transferase group 2 family protein 
 SP70585_1646 58 Bactoprenol glucosyl transferase 
59 SP_1625 59 Putative cadmium resistance transporter 
 spr1466 59 Confers low level cadmium resistance in Staphylococcus aureus 
 SPD_1438 59 Cadmium resistance transporter putative 
 SP70585_1666 59 CadD 
60 SP_1677 60 Hypothetical protein 
61 SP_1688 61 ABC transporter permease protein 
 spr1532 61 ABC transporter membrane-spanning permease-sugar transport 
62 SP_1694 62 Hypothetical protein 
 SPD_1505 62 Conserved hypothetical protein 
63 SP_1712 63 Hypothetical protein 
 spr1556 63 Chromosome replication initiation protein/membrane attachment protein 
Putative 
 SPD_1522 63 Conserved hypothetical protein 
 SP70585_1751 63 Replication initiation and membrane attachment protein 
64 SP_1725 64 Sucrose operon repressor 
 spr1569 64 Sucrose regulon regulatory protein 
65 SP_1743 65 Conserved hypothetical protein 
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 SP70585_1782 65 SAM-dependent methyltransferase 
66 SP_1802 66 Hypothetical protein 
 SPD_1588 66 Conserved hypothetical protein 
67 SP_1803 67 Conserved hypothetical protein 
 SPD_1589 67 Lipoprotein putative 
68 SP_1814 68 Indole-3-glycerol phosphate synthase 
69 SP_1823 69 MgtC/SapB family protein 
 spr1641 69 Mg (2+) transport ATPase/permease 
 SPD_1606 69 MgtC/SapB family protein 
 SP70585_1883 69 putative Mg2+ transporter-C (MgtC) family protein 
70 SP_1824 70 ABC transporter permease protein 
 spr1643 70 ABC transporter membrane-spanning permease-unknown substrate 
71 SP_1825 71 ABC transporter ATP-binding protein 
 spr1644 71 ABC transporter ATP-binding protein-unknown substrate 
 SP70585_1885 71 Spermidine/putrescine import ATP-binding protein PotA 
72 SP_1893 72 Hypothetical protein 
 SPD_1672 72 Membrane protein putative 
 SP70585_1950 72 O-antigen polymerase family 
73 SP_1894 73 Sucrose phosphorylase 
 spr1709 73 Dextransucrase (sucrose 6-glucosyltransferase) 
74 SP_1898 74 Alpha-galactosidase 
 spr1713 74 Alpha-galactosidase (melibiase) 
 SPD_1678 74 alpha-galactosidase AgaN 
75 SP_1914 75 Hypothetical protein 
 SPD_1717 75 Membrane protein putative 
 SP70585_1995 75 Conserved hypothetical protein 
76 SP_1917 76 Hypothetical protein 
 SPD_1720 76 Conserved hypothetical protein 
77 SP_1958 77 Hypothetical protein 
 SPD_1756 77 Conserved hypothetical protein 
78 SP_1987 78 ABC transporter ATP-binding protein 
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 spr1801 78 ABC transporter ATP-binding protein-unknown substrate 
 SP70585_2058 78 ABC-type antimicrobial peptide transport system ATPase component 
79 SP_1989 79 Putative transcriptional regulator PlcR 
 spr1803 79 Transcriptional activator 
80 SP_2002 80 Conserved hypothetical protein 
 SPD_1800 80 Membrane protein putative 
 SP70585_2075 80 ABC-type multidrug transport system permease component 
81 SP_2005 81 Hypothetical protein 
 SPD_1803 81 Conserved hypothetical protein 
82 SP_2020 82 Transcriptional regulator GntR family 
 spr1832 82 Conserved hypothetical protein 
83 SP_2024 83 PTS system IIA component 
 spr1836 83 Phosphotransferase system system cellobiose-specific IIA component 
84 SP_2039 84 Conserved hypothetical protein 
 spr1850 84 Hypothetical protein 
85 SP_2043 85 Hypothetical protein 
 SPD_1852 85 Conserved hypothetical protein 
86 SP_2048 86 Conserved hypothetical protein 
 SP70585_2136 86 Competence protein ComGF 
87 SP_2051 87 Competence protein CglC 
 spr1862 87 Competence protein 
88 SP_2090 88 Transcriptional regulator 
 spr1901 88 Hypothetical protein 
89 SP_2094 89 Conserved hypothetical protein 
 SP70585_2200 89 Peptidase S54 
90 SP_2113 90 Conserved hypothetical protein 
 SPD_1940 90 Membrane protein putative 
 SP70585_2219 90 YitT family protein 
91 SP_2115 91 Hypothetical protein 
 SPD_1943 91 Conserved hypothetical protein 
92 SP_2159 92 fucolectin-related protein 
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 spr1965 92 Hypothetical protein 
 SP70585_2286 92 blood group A-and B-cleaving endo-beta-galactosidase 
93 SP_2192 93 Sensor histidine kinase 
 spr1997 93 Histidine kinase 
94 SP_2234 94 Transcriptional regulator TetR family 
 spr2040 94 Conserved hypothetical protein 
95 spr0549 95 Hypothetical protein 
 SPD_0544 95 Conserved hypothetical protein 
96 spr0620 96 ABC transporter substrate-binding protein-unknown substrate truncation 
 SP70585_0755 96 ABC-type amino acid transport/signal transduction system periplasmic 
component/domain protein 
 
 
 
